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IN-VITRO PK/PD PROFILING AND MODELING OF THE ANTI-SICKLING AGENTS, 5-
HYDROXYMETHYL FURFURAL (5-HMF) AND NOVEL SYNTHETIC ALLOSTERIC 
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Introduction. 5-HMF and novel INN-compounds are left-shifting AEH, shown to have 
anti-sickling action by forming transiently covalent Schiff-base adducts with hemoglobin (Hb), 
thereby increasing the Hb O2-affinity. They are hypothesized to be substrates for aldehyde 
dehydrogenase (ALDH) in the liver and red blood cells (RBC).  
 
Methods. Biopharmaceutical assessments were made for AEH, using calculated 
physicochemical properties. Their in-vitro hepatic metabolism (mediated by ALDH) was 
xl 
 
 
characterized using hepatic cytosol, and in-vitro-in-vivo extrapolations (IVIVE) were made. 
Inter-species differences in hepatic cytosolic ALDH activity were investigated using 
acetaldehyde as a model substrate in different mammalian species. Time- and concentration-
dependent in-vitro disposition of 5-HMF in human whole blood was fully characterized and 
quantitatively modeled. In-vitro time- and concentration-dependent pharmacodynamic (PD) 
profiling of AEH (0.5 – 5 mM) was carried out in normal whole blood. 5-HMF binding to 
(normal) HbA and (sickle) HbS was studied in systematic time- and concentration-dependency 
studies using isolated Hb solutions. Quantitative PK/PD models were developed to fit the 
experimental data by nonlinear regression (Scientist
®
). 
 
Results. 5-HMF and the two INN-compounds were classified as BCS-I and BCS-II, 
respectively. All AEH were substrates for hepatic ALDH, with predicted low/intermediate 
hepatic extraction. Intrinsic ALDH activity varied significantly between mammalian species. In 
whole blood, 5-HMF plasma concentrations declined rapidly (t1/2 of 0.8 – 4 hrs), with nonlinear 
kinetics, due to saturable Hb-binding. AEH showed a time-dependent, biphasic PD effect in 
whole blood, suggesting transiently covalent Hb binding, with slow recovery to the baseline, 
corresponding to dissociation from Hb and subsequent metabolism by RBC-ALDH. Binding 
studies with HbA and HbS demonstrated slight differences in binding affinity, but sustained 
adduct formation - with slow dissociation t1/2. A novel semi-mechanistic target-site drug 
disposition (TSDD)/PD model was developed, integrating the information, for simultaneous 
modeling of 5-HMF concentrations in plasma, and its effect in whole blood.  
 
xli 
 
 
Conclusions. This translational research investigated in detail the in-vitro PK/PD of 
AEH, and systematically compared findings with older generation compounds. A (generic) novel 
TSDD/PD model was developed for disposition of AEH, identifying k-1 (dissociation constant of 
AEH from Hb) and kmet (RBC-ALDH metabolism rate constant) as key properties for the time 
course of PD effect.  
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    CHAPTER 1 
1 INTRODUCTION 
 
 
 
1.1 Sickle Cell Disease (SCD) 
SCD is a congenital hemoglobinopathy that primarily manifests as severe vaso-occlusive 
pain crises and hemolytic anemia in individuals with homozygous trait; it is the most common 
inherited hematologic disorder in the US and affects 20-25 million people in the world (Ashley-
Koch et al., 2000; Quinn et al. 2004; Aliyu et al., 2008). Nearly 300,000 babies were born 
worldwide with sickle cell anemia in the year 2010, based on estimates by the Malaria Atlas 
Project (MAP; http://www.map.ox.ac.uk), and, in the U.S., nearly 2000 babies are born with 
SCD every year (Brawley et al, 2008). The disease is most prevalent among those of African, 
Latin American, Mediterranean, Middle-eastern and Indian origin. In the U.S., 9% of the African 
American populations have the sickle cell trait (heterozygotes); 1 in 600 African Americans 
suffer from homozygous SCD (Wood & Steinberg, 1999; Quinn et al. 2004; Brawley et al, 
2008). 
It is primarily a pediatric disease with significant SCD-related morbidities appearing in 
children; it is known to be associated with decreased life expectancy (Platt et al., 1994; Quinn et 
al. 2004; Yanni et al., 2009). In 1960 and early 1970, the median life expectancy was 14.3 years 
with 20% of deaths occurring in the first two years of life (Platt et al., 1994). Life expectancy has 
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improved over decades with decreased death rates in children; median survival for individuals 
with homozygous SCD estimated as 42 years for men and 48 years for women (during the 
1980’s), primarily owing to improved medical interventions and health care (Platt et al., 1994; 
Quinn et al. 2004). However, although mortality rates in black children with SCD significantly 
decreased from 1980 – 2002, the observed lack of significant reduction in the mortality rate for 
older children (> 4 – 10 years) suggests the need for newer approaches for disease management 
in the older children with SCD (Yanni et al., 2009). 
 
1.1.1 Pathophysiology 
SCD was one of the first diseases understood at the molecular level (Epstein & Bunn, 
1997; Serjeant, 2001): A point mutation on the β-globin gene due to which β6-glutamic acid is 
replaced with valine, a neutral amino acid, results in the formation of abnormal (sickle) HbS. 
HbS differs from normal adult Hb (HbA) in that it polymerizes with other HbS molecules upon 
deoxygenation owing to hydrophobic interactions. Aggregation of HbS polymers results in 
distortion, “sickling”, dehydration and loss of flexibility of red blood cells (RBC), which leads to 
vaso-occlusion of the micro-vasculature, resulting in the vaso-occlusive pain crises, the hallmark 
of the disease, and tissue injury. Additional features that lead to vaso-occlusive events are 
endothelial dysfunction, imbalance between vasodilators and vasoconstrictors and altered 
rheological properties of the (sickle) RBC (SS cells) (Epstein & Bunn, 1997; Wood & Steinberg, 
1999; Kato et al., 2009). Nitric oxide (NO), a vasodilator, is critical for maintaining normal 
endothelial function. Hemolysis of SS cells releases free Hb in the plasma that potentially 
scavenges NO, resulting in endothelial dysfunction and NO resistance (Kato et al., 2009).  
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1.1.2 Clinical manifestations 
Several clinical manifestations are major health concerns due to limited available and 
satisfactory treatment options (Epstein & Bunn, 1997; Okpala et al., 2006; Kato et al., 2009). 
The primary clinical features of SCD are hemolytic anemia, vaso-occlusion, pulmonary 
hypertension and severe infections. Complications of hemolytic anemia include jaundice, gall 
stones due to increased bilirubin excretion and aplastic crisis or sudden cessation of bone marrow 
activity (Wood & Steinberg, 1999; Serjeant, 2001). Vaso-occlusive complications include 
severe, painful episodes, stroke, acute chest syndrome, osteonecrosis, multi-organ (spleen, liver, 
and kidney) dysfunction and chronic end organ damage. Sepsis due to infections by S. 
pneumoniae, E. coli and S.aureus may be potentially life-threatening in young patients (Wood & 
Steinberg, 1999; Serjeant, 2001). There have also been several reports on priapism, effect on 
growth and pregnancy (Serjeant, 2001). 
 
1.1.3 SCD Management  
There is no current treatment for SCD by itself, but therapy is directed towards effective 
management and relief of the symptoms or prevention of complications of the disease (Wood & 
Steinberg, 1999). SCD is a multi-organ disease, for which specialty and comprehensive care 
have been shown to reduce the number of hospitalizations and the length of stay for patients 
suffering from this disease (Okpala, 2004). An approach to provide relief during acute severe 
pain episodes is by parenteral opioid administration, which may also be accompanied by 
adjunctive therapy or non-steroidal anti-inflammatory agents (NSAIDS). Chronic or mild-to-
moderate pain may be treated by fentanyl patches or non-opioid analgesics like acetaminophen 
and NSAIDS (Wood & Steinberg, 1999). Opioid use requires cautious and judicious 
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administration by health care providers, while chronic high dose NSAID and acetaminophen 
therapy may lead to renal, cardiovascular and hepatotoxicity. Furthermore the use of these drugs 
in children is poses a concern due to these toxicities (Stuart & Nagel, 2004).  
Hydration and supplemental oxygen (O2) therapy may be provided during pain episodes 
and acute chest syndrome, and antibiotics are often given for the treatment and prevention of 
infections in SCD (Stuart & Nagel, 2004). 
Simple blood transfusion is life-saving and is indicated for severe episodes of acute and 
chronic anemia, splenic sequestration, aplastic crises, strokes in children and hypoxia due to 
acute chest syndrome. Transfusions help rapidly reduce the HbS concentration to less than 30% 
of the total Hb concentration to reduce/relieve the complications of the disease (Wood & 
Steinberg, 1999; Serjeant, 2001). Chronic simple transfusion or exchange transfusion may be 
used for prevention of strokes, in heart and renal failure, and other conditions. The duration of 
transfusion for prevention of stroke is unclear, and intracerebral hemorrhage, which may occur 
years after the stroke, cannot be prevented by prophylactic transfusions (Wood & Steinberg, 
1999). Alloimmunization, infection transmission and iron overload, which require chelation 
therapy, are among the adverse events due to blood transfusion (Wood & Steinberg, 1999).  
Hematopoietic stem cell transplantation has been performed in children, and found to 
provide a cure to the disease. It has been found a high risk approach in adults; however, recent 
medical interventions have proven successful (Hsieh et al., 2009). Bone marrow transplantation 
may be considered most effective treatment for the disease by replacing the diseased bone 
marrow with healthy bone marrow from a genetically-matched donor to produce normal HbA in 
the SCD patient (Epstein & Bunn, 1997). However there are specific criteria for such transplants, 
and include requirement of a genetically-matched donor for patients with severe symptoms but 
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no long term organ damage. Additionally, such transplantation is associated with high risks, such 
as infections, graft-versus-host-disease, a 10% risk of graft failure, complications as a result of 
the drugs used during the transplant, and veno-occlusive disease (St. Jude Children’s Research 
Hospital, 2009).  
Hydroxyurea (HU), originally an anti-cancer agent, is the only medication currently 
approved by the U.S. Food and Drug Administration (FDA) for prevention of severe pain 
episodes in adults with SCD (Brawley et al., 2008). HU has been shown to stimulate the 
production of fetal hemoglobin (HbF) in RBC, and dilutes the HbS containing RBC. HbF also 
has high O2 affinity, compared to HbS and HbA (discussed further under section 1.2), which 
helps prevent the RBC from sickling. Sickle cells have a right-shifted oxygen equilibrium curve 
(OEC), likely as a physiological compensatory mechanism to promote more O2 delivery to the 
tissues, however, the deoxygenation of HbS results in polymerization and RBC sickling. HbF has 
high affinity for O2 (see section 1.2.3), and HbF induction in SS cells results in a left-shift in the 
OEC, which prevents HbS deoxygenation and sickling of RBC. High grade evidence backs 
improved blood markers, decreased pain crises and hospitalizations, and some low-grade 
evidence on decreased mortality, with HU therapy. However, evidence for the efficacy of HU 
therapy is inadequate in infants (Brawley et al., 2008). Furthermore, decreased HU adherence 
has been observed among patients, and 3 – 6 months of therapy required for a clinical response 
in addition to concerns of long-term usage of the anti-cancer agent in a non-malignant disease 
may be possible explanations (Epstein & Bunn, 1997; Brawley et al., 2008). HU also has 
significant adverse effects associated with its therapy. Short-term dose-related side effects 
include lowered blood count (leukopenia, thrombocytopenia, anemia), pneumonitis, skin rashes 
and nausea, while long term adverse effects include hyperpigmentation, risk for skin cancer, 
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decreased sperm count in males and reproductive defects in females (Brawley et al., 2008). 
Therefore other (safer) alternative options that may induce or modulate HbF production are 
being considered for investigation (Epstein & Bunn, 1997). Furthermore, the improved SCD 
outcomes owing to left-shifted OEC provide a therapeutic proof of concept for the 
investigational compounds (AEH) described in section 1.4, and forms the basis of this research 
project. 
 
1.1.4 Newer therapeutic interventions for SCD 
Due to lack of safe and effective therapy for SCD, researchers have investigated several 
approaches for the potential treatment of the disease. Some such investigational strategies 
include ion channel blockers, anti-adhesion agents, use of nitric oxide, gene therapy, etc. (Stuart 
& Nagel, 2004; Okpala, 2006).  
Decitabine, also an anti-cancer drug, is known for its effectiveness in increasing HbF 
levels like HU, and is thought to be less cytotoxic than HU. The primary side effects observed 
are reflected by decreased blood counts, with no major toxicities. The agent is still under 
development as an orphan drug for the treatment of SCD (Okpala, 2006). Short-chain fatty acids 
such as butyric acid and arginine butyrate are known to induce HbF levels, and early clinical 
investigations on these potential treatments are ongoing (Wood & Steinberg, 1999). 
Another orphan drug under clinical investigation is Niprisan, the mechanism of action for 
which is not clear. It has been shown to reduce the sickling of RBC and prolong survival in 
transgenic (Tg) sickle mice in a dose-dependent manner. In SCD patients, Phase II double-blind 
trials have demonstrated safety and tolerability of Niprisan, which also successfully reduced pain 
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episodes compared to placebo, and Phase III investigational studies are being carried out in the 
U.S (Okpala, 2006).  
Preclinical and some clinical studies have shown anti-adhesion and anti-inflammatory 
therapy may be useful in the treatment of the activated, adhesive endothelium, responsible for 
vaso-occlusion in SCD. Monoclonal antibodies are under (preclinical) investigation for anti-
adhesion therapy, but may be limited by non-specific effects and costs for treatment in humans 
(Stuart & Nagel, 2004; Okpala, 2006). Purified poloxamer 188 is an anti-inflammatory agent 
found to reduce the viscosity and adhesiveness in blood and improve micro-vascular blood flow 
(Orringer et al., 2001). It has been shown to decrease the duration of pain episodes by a small but 
significant extent in SCD adults and children (Orringer et al., 2001; Stuart & Nagel, 2004). 
Other approaches involve ion channel blockers that prevent dehydration (or promote 
hydration) of sickle cells (SS cells) (Okpala, 2006). ICA-17043, a derivative of the anti-fungal 
clotrimazole, with less hepatotoxicity and nephrotoxicity, has been shown to prevent SS cell 
dehydration and significantly reduce hemolysis in SCD patients, but its effect on vaso-occlusive 
pain episodes is not known. More extensive (Phase III) clinical trials are underway (Okpala, 
2006). 
Newer anti-sickling agents that fall into the class of benzaldehydes are considered potential 
breakthrough in the treatment of SCD (Safo et al., 2004; Okpala, 2006; Nnamani et al., 2008), 
and are further discussed in detail under section 1.4. 
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1.2 Hemoglobin (Hb) 
 
1.2.1 HbA  
1.2.1.1 Structure  
HbA is a tetrameric allosteric protein composed of two α- and β-subunits, or globin 
chains, each containing an iron-heme, capable of  cooperative binding of O2 (Perutz et al., 1987). 
The α-chain consists of 141 amino acids in linear sequence, while the β-chain, slightly longer 
than the α-chain, consists of 146 amino acids (Bunn & Forget, 1986). These subunits exist as α-
helices, stabilized by hydrogen bonding, and form a tetrahedral structure of Hb molecule, with a 
two-fold axis of symmetry and a central water cavity (Bunn & Forget, 1986). The heme groups 
in the four subunits are approximately equidistant from one another and the four subunits interact 
with one other by means of relatively weak Van der Waals forces and hydrogen bonds (Bunn & 
Forget, 1986). Hb exists in two conformations, the oxygenated (relaxed, R-state) and the 
deoxygenated (tense, T-state); the deoxy-state is stabilized by inter-subunit and intra-subunit 
salt-bridges (Bunn & Forget, 1986). The deoxy-conformation is further stabilized by organic 
phosphates such as 2,3-diphosphoglycerate (2,3-DPG).  
 
1.2.1.2 Function  
Oxygen can be transported in blood in two forms; (poorly) dissolved in plasma (~2%) 
and bound to Hb (~98%). HbA has high solubility and is known for its O2-carrying capacity in 
blood (~20 ml O2 in 100 ml blood). Its physiological role includes O2 loading in the lungs and its 
delivery to the tissues. The cooperative mechanism between the four heme subunits in Hb in 
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binding to O2, i.e. binding to one O2 enhances the affinity of the remaining sites; enables 
efficient O2 delivery by Hb to the tissues. This phenomenon is represented by the classic OEC, 
and the sigmoidal shape of the OEC reflects the cooperativity of Hb in binding to O2, (see 
section 1.2.2). At the O2 tension or partial pressure (pO2) in the alveoli (pulmonary pO2 of ~120 
mmHg), the Hb in RBC is virtually completely saturated with O2 (SO2). The pO2 at the tissues is 
~25 – 30 mmHg (which falls in the “steep portion” of the OEC); the Hb releases some O2 and 
becomes ~50% saturated with O2, delivering sufficient O2 to the tissues for utilization. The steep 
portion of the OEC facilitates more O2 unloading and delivery, with slight reduction in tissue 
pO2 from the normal (e.g., during exercise). Once the venous blood returns to the lungs, it 
equilibrates with the alveolar pO2 of about 95 – 100 mmHg and results in rapid re-oxygenation 
of Hb (Bunn & Forget, 1986).  
As the four heme groups get oxygenated, the inter- and intra-subunit salt bridges 
stabilizing the deoxy-state are successively broken, which forms the basis of the cooperativity of 
the Hb molecule. The fully oxygenated Hb molecule therefore, has fewer constraints than deoxy-
Hb (Bunn & Forget, 1986). 
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1.2.2 OEC 
The sigmoidal OEC for Hb represents its SO2 at varying pO2. The pO2 at 50% saturation of 
Hb (p50) describes the O2-affinity for Hb (normal value 26 ± 1 mmHg), and allows for effective 
loading and unloading of O2 from Hb (Bunn & Forget, 1986). Figure 1.1 (A) shows a 
representation of a typical OEC for normal HbA (reproduced from Rhoades and Tanner, 2003). 
A left-shift in the OEC reduces the p50, and increases the binding affinity of Hb for O2, while a 
right shift in the OEC increases the p50 and reduces the binding affinity of Hb for O2. The p50 is 
sensitive to changes in pH and CO2, known as the Bohr effect, 2,3-DPG, and temperature, and 
may be seen from Figure 1.1 (B) (Bunn & Forget, 1986; Eaton et al., 1999; Rhoades and Tanner, 
2003). Increased hydrogen ions, CO2, 2,3-DPG and temperature shift the OEC (and p50) to the 
right, resulting in more O2 unloading to the tissues (during increased metabolic activity). The 
cooperativity of the subunits of the Hb molecule is described by the Hill coefficient, n, and has a 
normal value of 2.8 – 3.0 (Bunn & Forget, 1986; Rhoades and Tanner, 2003). 
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Figure 1.1. (A) Typical OEC for normal HbA in whole blood and (B) factors that right-shift 
the OEC (Reproduced from Rhoades and Tanner, 2003). 
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1.2.3 HbF  
HbF is an embryonic Hb and predominant in fetal RBC. It is present in high levels in 
newborns (~80%) and decreases in the first 6 months of life. Adult RBC contain only small 
levels of HbF (0.1 – 7%), and levels may increase in pregnancy and in genetic disorders (Bunn & 
Forget, 1986).  
HbF is composed of two α-subunits as normal HbA and ϒ-subunits, which are analogous 
to the β-subunits and differ in 39 of the 146 amino acid residues (Bunn & Forget, 1986). HbF 
containing (fetal) RBC have higher O2-affinity (p50 ~20 mmHg) than normal adult HbA 
containing RBC.  
 
1.2.4 HbS  
HbS is a variant of Hb, and differs from normal HbA by only a single base substitution of 
A  T on the 6th codon of the β-globin gene. This point mutation results in the substitution of 
the (polar) β-glutamic acid by a neutral amino acid, valine. The α-globin chains of HbS are 
identical to HbA, and the β-globin chains with this substitution result in abnormal HbS.  
HbS is less soluble than HbA and polymerizes on deoxygenation to long-chain insoluble 
Hb fibers. Deoxy HbS has solubility of about 16 g/dl, compared to other forms that have 
solubility greater than 50 g/dl (Noguchi et al, 1981). Therefore, on deoxygenation, the solubility 
of HbS is exceeded and (reversible) polymerization, aggregation and precipitation takes place. 
The polymer fibers damage the RBC membrane, altering their rheological properties, i.e., 
increasing viscosity, compared to HbA containing RBC, which further result in the vaso-
occlusive events (Bunn & Forget, 1986).  
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Dilute HbS solutions have normal OECs, but sickle blood (containing HbS) have 
decreased O2-affinity. The OECs are right-shifted and p50 values are higher than HbA containing 
RBC, varying between 30 – 45 mmHg (Bunn & Forget, 1986). Among several factors that are 
responsible for the right-shifted OECs, higher 2,3-DPG levels in homozygous SCD patients 
lower the O2 affinity directly, and also by lowering the pH (Bunn & Forget, 1986). Additionally, 
the intracellular polymerization of HbS also results in a right shift in the OEC, and the 
polymerization of HbS further increases the p50 proportionately (Bunn & Forget, 1986; Steinberg 
et al., 2009). The reduced O2-affinity provides an advantage to SCD patients for more O2 
unloading in the tissues, but also favors further polymerization after deoxygenation.  
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1.3 Abnormalities and heterogeneity of SS cells  
SS cells are more heterogeneous than HbA-containing RBC and vary in size, shape, color 
and intra-cellular composition. They also have several structural and functional abnormalities 
due to the abnormal HbS. Changes in the morphological shape of the SS cells with long 
filamentous projections depend considerably on the rate of deoxygenation; slow deoxygenation 
primarily results in banana-shaped cells, rapid deoxygenation results in a granular appearance, 
while a “holly leaf” shape is considered an intermediate between the two (Bunn & Forget, 1986). 
SS cells generally have higher and more variable density and Hb concentration as 
compared to normal RBCs due to dehydration after repetitive polymerization on deoxygenation 
and depolymerization on oxygenation (Bunn & Forget, 1986; Agre and Parker, 1989). The 
dehydration is a result of water loss from the cells, as well as cation movements (net gain of Na 
and loss of K) that occur likely due to mechanical stress on the SS cell membrane by the HbS 
polymers, and depend on the HbF content (Bunn & Forget, 1986; Agre and Parker, 1989). 
Several other hypotheses have been reported in the literature, investigating the likely 
mechanisms responsible for dehydration of SS cells (Agre and Parker, 1989). HbF is distributed 
in SS cells with high variability (in certain populations), and is primarily responsible for 
inhibition of polymerization. SS cells that contain HbF, contain proportionately less HbS, and 
have prolonged survival time from sickling compared to irreversibly sickled cells that have less 
HbF (Bunn & Forget, 1986; Akinsheye et al., 2011). SS cells also contain higher and variable 
levels of 2,3-DPG depending on differences in intracellular enzyme and metabolic intermediate 
levels.   
The structural abnormalities of SS cells are thought to be a consequence of presence of 
denatured HbS that binds to the inner cell membrane (with higher affinity than HbA) and/or 
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stretching and deformation of the membrane on repetitive polymerization and depolymerization 
during the deoxygenation-oxygenation cycles. It has been shown that SS cells have high levels of 
oxidants such as superoxide, peroxide and hydroxyl radicals, and may be responsible for oxidant 
stress in these cells (Bunn & Forget, 1986; Agre and Parker, 1989). Several membrane 
abnormalities also cause adhesiveness of these cells to the vascular endothelium, and contribute 
towards the vaso-occlusion (Agre and Parker, 1989). 
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1.4 Allosteric Effectors of Hb (AEH) 
 
1.4.1 Molecular Pharmacology  
Aromatic aldehydes (and aliphatic aldehydes, to a lesser extent) are known to form 
reversible, covalent imine linkages, also known as Schiff base adducts, with amino terminals of 
Hb (Zaugg et al., 1977; Safo et al., 2004). The Schiff base formation occurs between the 
carbonyl group and free amino residues. This binding to Hb shifts the dynamic equilibrium 
between the low O2-affinity deoxygenated (tense, T-) conformational state and the high affinity 
oxygenated (relaxed, R-) conformational state, towards the R-state (Perutz et al., 1987; Safo et 
al., 2004). This increases the O2-affinity of Hb and, for HbS, maintains the soluble fraction, 
prevents its polymerization, and thus inhibits sickling of the RBC in-vitro (Beddell et al. 1984; 
Safo et al., 2004). 
Figure 1.2 shows the chemical structures of various investigational AEH; as can be 
observed, all compounds have a common structural scaffold, namely benzaldehyde (aromatic 
aldehyde). Valeresol and Tucaresol may be considered among the “first generation” AEH (FGE), 
and were the first AEH administered to man. The newer, “second generation” AEH (SGE) 
consist of naturally occurring compounds, Vanillin and 5-Hydroxymethyl furfural (5-HMF), and 
novel synthetic derivatives, that were discovered and synthesized (respectively) at the Virginia 
Commonwealth University Department of Medicinal Chemistry.        
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Figure 1.2. Chemical structures of AEH: Valeresol, Tucaresol, Vanillin, 5-HMF, INN-312 and INN-298. The Schiff-base 
forming aldehyde-group is circled in red dotted lines. 
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1.5 First Generation AEH (FGE)  
 
1.5.1 Valeresol  
1.5.1.1 Physicochemical Characteristics 
Valeresol (BW12C), chemically 5[2-formyl-3- hydroxyphenoxy] pentanoic acid, is a 
small molecule with molecular weight of 238.2 Da. It is relatively lipophilic, with a clogP of 
2.43, and has an acidic pKa value of 4.67 (SciFinder Scholar
®
). It is expected to primarily exist 
in its ionized form at the physiological pH (7.4). It is sparingly soluble in the acidic pH range, 
and very soluble at pH > 7.0.  
 
1.5.1.2 In-vitro findings 
The in-vitro anti-sickling action of Valeresol was studied by Kneen and White (1981) and 
Beddell et al. (1984): In-vitro pharmacodynamic (PD) studies demonstrated a concentration-
dependent left-shift in p50 after incubating valeresol with isolated human HbA solutions and 
normal whole blood for 30 min. It resulted in modification of HbA, determined mathematically 
from the OEC profiles as %MOD (fraction of Hb modified, i.e., Hb-adduct) (Beddell et al. 
1984). In sickle whole blood, valeresol showed a reduction in the count of sickled cells, and an 
increase in normal cells suggesting promising anti-sickling action in-vivo (Beddell et al. 1984). 
Further information about its in-vitro metabolism or disposition in whole blood has not been 
discussed or reported in the literature.  
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1.5.1.3 Clinical Pharmacokinetics 
The first-in-human (FIH) safety and tolerability studies for valeresol were carried out by 
Fitzharris et al. (1985), in 7 healthy male volunteers. Valeresol was administered at doses of 2, 5, 
10, 15 (to 2 volunteers each) and 20 mg/kg (to 5 volunteers) doses by IV infusion over 1 hour. 
The dose of 20 mg/kg was previously projected to result in Hb modification of 15-30%, which 
was thought adequate for therapeutic benefit, i.e., inhibition of sickling. Plasma and whole blood 
hemolysates were assayed by a relatively non-specific HPLC-UV assay for the quantification of 
valeresol, where in a metabolite of valeresol was reported to undergo extraction from plasma and 
hemolysate, in addition to parent valeresol, during the extraction procedure, and was detected 
along with the parent compound (Fitzharris et al, 1985). 
 The pharmacokinetic profile for valeresol in whole blood was analyzed using a bi-
exponential decline, to estimate the hybrid rate constants, α and β, the respective half-lives (t1/2
α
 
and t1/2
β
), total clearance (CLtot) and area under the concentration-time curve, AUC (assuming 
AUC ~ AUCoo). RBC concentrations of valeresol were calculated from the measured plasma, 
corresponding whole blood concentrations and the hematocrit (Hct) (Fitzharris et al., 1985). 
From our current knowledge of possible elimination mechanisms in the RBC (see Chapter 6), 
concurrent metabolism of valeresol by aldehyde dehydrogenase (ALDH) may take place in RBC. 
Therefore, the calculated RBC concentrations may not entirely reflect the true RBC 
concentrations, and their validity is questionable. 
 At the end of the infusion, 80% of the administered dose was estimated to be present in 
the RBC, while 20% of the dose was accounted for in the plasma (Fitzharris et al., 1985).  For the 
administered doses of 2 – 20 mg/kg valeresol, (nonlinear) supra-proportional increase in Cmax 
and AUCoo, along with a decrease in CLtot, was observed. This was attributed to ‘saturable 
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elimination’ at higher doses. The t1/2
α
 and t1/2
β
 were estimated to be 2.2 hrs and 8.5 hrs, 
respectively, in whole blood after a dose of 20 mg/kg. The α-phase was thought to represent the 
dissociation of valeresol from the Hb adduct (considered as the rate-limiting step), as the rate of 
decline of the left-shifting effect was similar to the α-phase rate constant; and the β-phase was 
considered to represent the loss of metabolite (which was detected along with the parent 
valeresol) from the body (Fitzharris et al., 1985).  
 From a pilot mass balance study, carried out using 
14
C-labelled drug (10 mg/kg), 
followed by urine and feces sample-collection for analysis, only 67% of the total radioactivity 
was accounted for, after 5 days. About 65% of the radioactive dose was found to be in the urine, 
of which only 2.2% was excreted as the unchanged parent drug (fraction excreted unchanged in 
the urine, fe ~ 0.01) (Fitzharris et al., 1985). The t1/2 of radioactivity was estimated as 22 hrs. 
This provides evidence valeresol is extensively metabolized, and likely bound to Hb in RBC (the 
known mechanism of action) and other tissues. However, no metabolic studies have been 
reported in the literature. The prolonged t1/2 of radioactivity (22 hrs), followed by undetectable 
concentrations of unchanged drug in the urine after 24 hrs (7-fold longer than the PD effect half-
life, likely corresponding to RBC binding and dissociation), and unaccounted radioactivity 
further suggest extensive tissue binding and metabolism (Fitzharris et al., 1985). 
The total clearance of valeresol from whole blood was estimated between 20 – 45 ml/min 
(Fitzharris et al., 1985). Assuming hepatic metabolism primarily comprises the nonrenal 
clearance pathway for valeresol, this estimate is considerably lower than the hepatic blood flow 
(~1500 ml/min), suggesting it may undergo low hepatic extraction possibly due to high protein 
binding. A rapid decline in PD effect of valeresol was observed from these studies (see section 
1.5.1.4), presumably owing to its dissociation from Hb-adduct. In such a case, free valeresol is 
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expected to re-distribute from RBC to the plasma to achieve an equilibrium, which was not 
attained in the study, suggesting loss of valeresol in RBC itself, likely due to ALDH-metabolism.  
The FIH studies were followed by Phase II studies, where valeresol was administered at 
doses of 7.5 – 20 mg/kg over 1 hr IV infusion to 8 homozygous SCD patient volunteers (Keidan 
et al., 1986). Detailed PK analysis has not been reported for these studies. The investigators 
demonstrated the specific Hb-binding ability of valeresol from the high RBC:plasma ratio (=14). 
The t1/2
α
 and t1/2
β
 were estimated to be 1.7±0.4 hrs and 9.3±3.1 hrs, and the ‘elimination half-life’ 
was not found to be dose-dependent (Keidan et al., 1986).  
 
1.5.1.4 Clinical Pharmacodynamics 
The effect of valeresol on OEC was measured using the Hem-O-Scan apparatus, which 
records the SO2 of whole blood as a continuous function of the pO2. The percent of Hb modified 
(%MOD) was calculated based on a method by Beddell et al, 1984. A dose-dependent left-shift 
in p50 and modification of Hb (%MOD) was observed, with peak effect (left-shift in p50 and 
modification of Hb, %MOD) observed immediately at the end of the 1 hr infusion of 2 – 20 
mg/kg of valeresol to healthy volunteers. The average %MOD for 20 mg/kg valeresol was 15.5% 
(range 12.3-18.2%). A mono-exponential decline in the post-infusion pharmacological effect (or 
loss of %MOD) was estimated to occur with a half-life of 3.1±0.5 hrs, comparable to the α-phase 
(see section 1.5.1.3) (Fitzharris et al., 1985). 
When 7.5 – 20 mg/kg valeresol was administered over 1 hr IV infusion to SCD patients, 
no significant benefit in rheological properties and deformability (or filterability) of RBC could 
be established (Keidan et al., 1986). Instead, increased sickling after 4 hrs after the short-term 
infusion was observed, possibly owing to a short pharmacological effect half-life of ~3 hrs, or 
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rebound sickling with treatment withdrawal (Keidan et al., 1986). Therefore, any further studies 
on valeresol were terminated.  
 
1.5.2 Tucaresol  
1.5.2.1 Physicochemical Characteristics 
Tucaresol (589C80) is chemically 4[2-formyl-3-hydroxyphenoxymethyl]benzoic acid, 
and has a molecular weight of 272.3 Da. Like valeresol, it is a lipophilic molecule with a clogP 
of 2.75, and has an acidic pKa value of 4.17 (SciFinder Scholar
®
). It is expected to primarily 
exist in its ionized form at the physiological pH (7.4). It is sparingly soluble in the acidic pH 
range, and soluble at pH > 7.0.  
 
1.5.2.2 Pre-clinical findings 
Tucaresol was developed as a close analogue of valeresol with replacement of the 
tetramethylene chain by a benzyl group; it was determined to be a more potent left-shifter of p50 
for Hb than valeresol in-vitro (White and Wootton, 1989). Comparative in-vivo PD studies 
between valeresol and tucaresol were carried out in rats by White and Wootton (1989), to assess 
the potency and duration of action of tucaresol. The peak effect (%MOD) in groups of 5 rats 
administered IV doses of valeresol and tucaresol (87.5 and 100 mg/kg respectively), was 
achieved within 15 min, however, a difference in duration of effect was observed. The PD effect 
half-life in rats was 2.8 hrs for valeresol and 16 hrs for tucaresol. A delayed peak effect, followed 
by a longer duration of action was also observed for tucaresol after P.O. administration (White 
and Wootton, 1989). In-vitro metabolism or disposition studies for tucaresol are not reported in 
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the literature. The fraction unbound (fu) for tucaresol has been reported as < 0.02 from 
(unpublished) in-vitro plasma protein binding studies (Rolan et al., 1993). In-vitro pharmacology 
and toxicology studies and inter-species in-vivo studies for tucaresol have been referred to, but 
are also not reported in the literature (Rolan, 1995). 
 
1.5.2.3 Clinical Pharmacokinetics 
The safety, tolerance and clinical PK for tucaresol were assessed from FIH dose-
escalation studies, following administration of single oral doses of 200, 400, 800 (2 subjects 
each), 1200, 2000, 2800 and 3600 mg (4 subjects each) to 9 healthy volunteers (Rolan et al., 
1993). Tucaresol present in plasma and lysates from whole blood samples up to 540 hrs post-
dose was analyzed using HPLC-UV and non-compartmental PK analysis of the concentration-
time profiles was carried out to determine the AUCoo, oral clearance (CLoral, or CLtot/Foral) and 
terminal half-life. RBC concentrations of tucaresol were calculated from the measured plasma, 
whole blood concentrations and the Hct, similar to the method for valeresol (Rolan et al., 1993). 
Again, the validity of the calculated RBC concentrations for tucaresol may be questionable due 
to intraerythrocytic ALDH metabolism.  
 The oral bioavailability for tucaresol was thought to be high, since 70% of the orally 
administered dose could be accounted for - from peak levels in whole blood (Rolan et al., 1993). 
Linear PK was observed for 200-3600 mg doses of tucaresol; the Cmax in plasma and RBC, and 
AUCoo were found to increase proportionally with dose. The RBC:plasma concentration ratio 
ranged from 3.8 – 11.2  with increasing doses. The average time to peak concentration (tmax) was 
about 5.8 hrs in the plasma and about 10-24 hrs in the RBC (for the low and high doses, 
respectively), with inter-individual variation. The plasma concentrations were found to follow a 
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biexponential decline with terminal half-lives of 8 – 12 days, while concentrations in the RBC 
declined monoexponentially, with half-lives of 5-6 days. The terminal half-life of tucaresol in the 
plasma was found to increase with dose, showing some evidence of decreased clearance, but this 
has not been investigated further (Rolan et al., 1993). The long terminal half-life in the plasma 
was attributed to extensive plasma protein binding with very slow dissociation, owing to the 
ability of tucaresol to form ‘reversible’, highly stable, covalent adducts with plasma proteins 
other than Hb, thought to function as a deep compartment (Rolan et al., 1993). 
A second study in healthy volunteers was carried out by Rolan et al. (1995) using dose 
titration up to maximum doses of 5.5 – 6.9 g tucaresol, in order to achieve desired effects, that is, 
15, 25 and 32.5% MOD. The PK findings were reported to be similar to the FIH study, with 
average plasma and RBC half-lives of about 10 and 8 days, respectively (Rolan et al., 1995).  
 
1.5.2.4 Clinical Pharmacodynamics 
At oral doses of 2000 – 3600 mg, tucaresol was found to result in 19 – 26% of Hb 
modification, with the peak effect (%MOD) occurring at the same time as peak whole blood 
concentrations. In addition, a linear relationship between the %MOD and RBC tucaresol to Hb 
molar ratio was observed (Rolan et al., 1993), similar to findings by Abdulmalik et al. (2005) for 
5-HMF (see section 1.6.2). Abdulmalik et al (2005) demonstrated a linear relationship between 
5-HMF-Hb-adduct, determined experimentally by a chemical assay, and nominal 5-HMF 
concentrations in sickle whole blood. 
The PK of tucaresol in 12 SCD patients was reported similar to that observed in healthy 
volunteers, but decreasing apparent (oral) clearance with dose was observed in females (Arya et 
al., 1996), suggesting some PK nonlinearity. Peak effects of 10 – 24% MOD were achieved, and 
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were shown to have anti-sickling action by reducing irreversibly sickled cell-counts. The %MOD 
and concentration of tucaresol in the SS RBC of SCD patients were found to be highly 
correlated, similar to previous findings. However, severe immuno-stimulating actions of 
tucaresol led to several adverse events, which led to termination of further development as an 
anti-sickling agent was terminated (Rolan et al., 1993; Rolan, 1995; Arya et al., 1996). 
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1.6 Second Generation AEH (SGE)  
Pharmacologically, SGE have greater OEC left-shifting action compared to the FGE: they 
are capable of resulting in a greater extent of Hb-modification (70-90%) and also exert a greater 
left-shifting effect in the p50 (Abdulmalik and Safo et al., 2005; Abdulmalik et al., 2011). The 
INN-compounds, in addition to modifying Hb by forming high O2-affinity adducts, also directly 
inhibit polymerization of deoxygenated HbS by stereo-specific interactions (Nnamani et al., 
2008). Due to this dual mode of action, they particularly strongly inhibit sickling of SS cells 
(Nnamani et al., 2008; Abdulmalik et al., 2011). This provides an advantage over the compounds 
that only inhibit sickling through the formation of high affinity Hb-adducts. 
 
1.6.1 Vanillin  
1.6.1.1 Physicochemical Characteristics 
Vanillin (4-Hydroxy-5-methoxybenzaldehyde) is a food flavoring agent, with a molecular 
weight of 152.2 Da. It has a clogP of 1.21 with an acidic pKa of 7.78. It is slightly soluble and 
predominantly unionized in the physiological pH range of 1 – 8 (SciFinder Scholar®).  
 
1.6.1.2 Investigational studies 
Vanillin, a flavoring agent used in foods, drinks and pharmaceutical products, is on the 
FDA GRAS (Generally Regarded as Safe) list, with rat LD50 values after oral administration of 
3.3 g/kg (Sigma Aldrich). Due to its low toxicity, ease of availability, and some anti-sickling 
action, it was investigated as a potential anti-sickling agent (Abraham et al., 1991). It was found 
to have moderate in-vitro anti-sickling activity compared with other aromatic aldehydes and 
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improve rheologic properties of SS cells (Zaugg 1977, Abraham et al., 1991). Abraham et al 
(1991) demonstrated vanillin incubated with whole blood (healthy and sickle) was capable of 
crossing the RBC membrane, binding with Hb (A and S), and resulting in modification to adduct. 
This adduct formation was shown to depend on the nominal concentrations of vanillin, and the 
time of incubation. 5 and 10 mM vanillin, incubated for two hours with sickle blood, resulted in 
14 – 21% modification of HbS (Abraham et al, 1991). Vanillin is known to be oxidized to 
vanillic acid in the liver, which is excreted in the urine. 
Vanillin administered to rats, by P.O., at a dose of 100 mg/kg was found to have very low 
plasma exposures and a short terminal plasma half-life of ~10 min (Zhang et al, 2004). When 
administered orally to human volunteers in an FIH study, vanillin did not show measurable 
exposure and was not found to be significantly effective (Farthing et al., 1999; Zhang et al., 
2004). The low bioavailability was assumed to be due to rapid GI metabolism (Zhang et al., 
2004). In order to overcome this issue, Zhang et al (2004) investigated MX-1520, a prodrug of 
vanillin, developed to prevent the GI degradation of vanillin, and release free vanillin in the 
systemic circulation. MX-1520 administered to Tg sickle mice either orally (137.5 and 275 
mg/kg) or intra-peritoneally (7, 14, 27.5, 55 mg/kg) was found to reduce sickling of SS cells, 
prolong the survival time for the treated mice after hypoxic challenge compared to untreated 
mice, up to a maximum of 1 hr, with some dose dependency after intra-peritoneal administration 
(Zhang et al., 2004). 
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1.6.2 5-HMF  
1.6.2.1 Physicochemical Characteristics 
5-HMF (5-Hydroxymethyl-2-furfural) is a small molecule with molecular weight 126.11 
Da and clogP -0.78. It has an acidic pKa of 12.8 and is neutral at the physiological pH range 
(SciFinder Scholar
®
). It is a polar molecule, soluble across the entire physiological pH range (54 
g/L).  
5-HMF is a decomposition product of hexose sugars and is a naturally occurring 
substance in several foods such as milk, dried fruits, juices, honey, coffee, etc. (Godfrey et al., 
1999). It is formed during cooking, heat sterilization of sugar containing products, and as an 
intermediate of the browning reaction (Maillard reaction) of amino acids and sugars. Its 
estimated daily intake is about 150 mg/day (Godfrey et al., 1999). 
 
1.6.2.2 Pre-clinical/Early Clinical Pharmacokinetics and Pharmacodynamics 
The pharmacokinetics of 5-HMF have been discussed in detail by Obied (2010). 5-HMF, 
after oral administration, was rapidly absorbed and metabolized in rats and mice, with >65% of 
the total radioactive dose recovered in the urine within 24 hrs of oral administration (Godfrey et 
al., 1999; Abdulmalik et al., 2005). At oral doses of 100 mg/kg in Tg sickle mice, 5-HMF was 
absorbed and resulted in systemic exposure sufficient to prolong survival of mice on hypoxic 
challenge (Abdulmalik et al., 2005). 5-HMF has good tissue distribution, with maximum 
radioactivity in the highly perfused elimination organs, i.e., liver and kidney (Godfrey et al., 
1999). A volume of distribution at steady-state (Vdss/Foral) of 0.45 – 0.65 l/kg has been estimated 
for 5-HMF in Tg sickle mice. The polar nature of the small molecule favors its distribution 
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through the total body water. 5-HMF binds with human serum albumin with low affinity and the 
binding of 5-HMF to plasma proteins has been considered negligible in comparison to the 
binding with Hb in RBC (Obied, 2010). 5-HMF may, however, bind to other proteins due to its 
aldehyde functional group, capable of forming (transiently covalent) Schiff base adducts. Prior et 
al. (2006) identified several metabolites for 5-HMF in humans, of which 5-hydroxymethyl-2-
furoic acid (HMFA) has been found to be most predominant; followed by 2,5-furan dicarboxylic 
acid (FDCA) and a glycine conjugate (Prior et al., 2006). Oxidative metabolism of 5-HMF is 
shown to occur in the hepatic cytosol primarily by ALDH and to a lesser extent by ADH; there is 
also evidence of ALDH-mediated metabolism of 5-HMF in RBC (Obied, 2010).   
5-HMF is currently under early clinical development (as Aes-103) as a potential 
treatment for SCD. In a Phase 1 trial, oral doses of 300 – 4000 mg were well tolerated by healthy 
volunteers (6 per dose group), with no significant toxicity observed. Peak plasma concentrations 
were achieved in 0.4 – 0.7 hr, suggesting rapid absorption, and followed by short plasma half-
lives (Stern et al., 2012). 
5-HMF has shown anti-sickling action in-vitro (see section 1.6.4), and prolonged survival 
time in Tg sickle mice on hypoxic challenge (Abdulmalik et al., 2005). 5-HMF-treated mice 
survived the severe hypoxic conditions up to 60 min (survival: 87%), while all untreated mice 
died within 15 min due to pulmonary sequestration by sickled cells (Abdulmalik et al., 2005). 
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1.6.3 Pyridine-Substituted Derivatives of Benzaldehydes (INN-compounds) 
Novel pyridyl-derivatives of substituted benzaldehydes (INN-compounds; Figure 1.2) 
stereo-specifically inhibit polymerization of deoxy-Hb, in addition to the direct inhibition of 
polymer formation by increasing the O2-binding affinity and the soluble Hb(S) fraction. This 
dual mode of action forms the molecular basis of their high anti-sickling effect in-vitro. 
(Nnamani et al, 2008; Safo et al, 2004). INN-312 (Class I; o-pyridyl substituted) and INN-298 
(Class II; m-pyridyl substituted) are two such investigational compounds with superior activity 
(Nnamani et al., 2008). INN-312 and INN-298 showed 93% and 83% change in the p50 values 
from the baseline in normal human blood, respectively, compared to INN-243 and INN-280, 
Class III p-pyridyl substituted derivatives that resulted in ∆p50 values of ~66% (Nnamani et al, 
2008).   
INN-312 and INN-298 are chemically 5-methoxy-2-(3-pyridinylmethoxy)-benzaldehyde 
and 4-methoxy-3-(2-pyridinylmethoxy)-benzaldehyde respectively, with a molecular weight of 
243.3 Da. They are relatively lipophilic, sparingly soluble compounds with clogP values of 2.1 
and 1.7, respectively, and require a solvent such as di-methyl sulfoxide (DMSO) for 
solubilization. They have basic pKa values of 4.61 and 3.98, respectively, and exist in their 
ionized form at the physiological pH of 7.4.  
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1.6.4 In-vitro anti-sickling activity 
Vanillin and 5-HMF are considered the lead compounds for the newer generation AEH, 
and have shown good anti-sickling action in-vitro. The INN-compounds are synthetic 
derivatives, and expected to have a dual mode of anti-sickling action. Figures 1.3 and 1.4 show 
the comparative plots of their in-vitro concentration-dependent increase in O2-affinity of Hb 
(∆p50%) in SS cell lysates, and subsequent inhibition of sickling, respectively.  
Among the SGE, 5-HMF and the newer INN-compounds are potentially more effective 
anti-sickling agents. The INN-compounds exert a greater degree of left-shift in the p50 and have 
greater anti-sickling action than 5-HMF and vanillin. INN-312, 2.5-fold more potent than 5-
HMF, results in a left-shift in p50 by 75%, and subsequent inhibition of sickling (in-vitro) by 
95%, at a concentration of 2 mM. On the other hand, vanillin is the least potent, resulting in a 
left-shift in p50 by 40% and minimal inhibition of sickling (10%) at high concentrations of 5 mM. 
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Figure 1.3. Comparison of the concentration-dependent relative change in p50 of HbS (from 
SS cell lysate) from the baseline, expressed as %, between the various AEH after pre-
incubation for 1 hr.  (Adapted from Abdulmalik & Safo et al., 2005; Nnamani et al., 2008; 
Safo, unpublished). 
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Figure 1.4. Comparison of the concentration-dependent inhibition of sickling of SS cells, 
expressed as %, between the various AEH. SS cells pre-incubated with the respective AEH 
for 1 hr were challenged with hypoxic conditions (4% O2) for 5 hrs and morphologically 
analyzed to determine the extent of sickling. (Adapted from Abdulmalik & Safo et al., 
2005; Nnamani et al., 2008; Safo, unpublished). 
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1.7 Systemic exposures of AEH associated with biological activity 
Intravenously administered valeresol acquired systemic exposures sufficient to result up 
to 15 %MOD at doses of 20 mg/kg (about 1400 mg for an adult with body weight of 70 kg). 
Similar extent of modification was brought about by tucaresol at an oral dose of 2000 mg with a 
similar peak plasma concentration as that for valeresol. Therefore, both compounds showed 
similar effect with similar peak exposures (Cmax). For 5-HMF, a nominal concentration of 2 mM 
(comparable to the Cmax for valeresol and tucaresol) in sickle whole blood resulted in greater than 
2-fold higher %MOD, demonstrating the greater potency of 5-HMF over FGE. The biological 
activity of the FGE was found to mimic the (calculated) RBC concentration-time profile in-vivo, 
suggesting reversible binding with Hb in the RBC.  
Figures 1.5, 1.6 and 1.7 show the systemic exposures of valeresol, tucaresol and 5-HMF 
respectively, associated with biological activity. The peak concentration (Cmax) for valeresol was 
achieved immediately post-infusion, and the maximum modification in Hb was also observed at 
the same time. %MOD values were determined from mathematical calculations from OEC 
measurements described elsewhere (Beddell et al, 1984). The average values for Cmax and 
%MOD in Figure 1.5 were determined from digitization of respective dose-dependency plots 
(Fitzharris et al, 1985). In case of tucaresol (Figure 1.6), the maximum effect (%MOD) was 
achieved at the same time as the peak concentration (Cmax) of tucaresol in whole blood for a dose 
of 3600 mg (Rolan et al., 1993). Assuming the same case for the rest of the doses, the average 
values for Cmax in whole blood were calculated from reported Cmax
plasma
 and Cmax
RBC
 values, for 
the reported corresponding maximum %MOD for oral doses of 1200 – 3600 mg (Rolan et al., 
1993). The %MOD values for 5-HMF (Figure 1.7) were extrapolated from a chemical assay for 
Hb; the modification of Hb to Hb-adduct was estimated with respect to total response for Hb, 
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using an HPLC cation exchange-UV assay for measurement of modified, and unmodified Hb 
(Abdulmalik et al, 2005). The nominal concentrations correspond to 1 – 5 mM 5-HMF, pre-
incubated with sickle whole blood for 1 hr. 
Figure 1.5 shows an increase in the maximum achievable effect with increasing systemic 
exposure (denoted as Cmax). The maximum effect achieved by the highest dose of valeresol was 
~15 %MOD. A similar peak effect can be observed for similar concentrations of valeresol and 
tucaresol (~15 %MOD with 1.2 mM). At the highest dose of tucaresol (Cmax of 1.8 mM), the 
high systemic exposure resulted in a peak effect of 23 %MOD (Figure 1.6). 5-HMF modified 
sickle Hb by 35% and 70% at nominal concentrations of 2 and 5 mM respectively, showing 
greater adduct formation than valeresol and tucaresol, respectively. 
The “transiently covalent” binding of valeresol is evident from a biphasic effect 
(%MOD)-time profile during and after the I.V. infusion of 20 mg/kg dose (Fitzharris et al., 
1985). The peak effect declined monoexponentially reflecting an apparent first-order rate of 
decline in the Hb-adduct. This rate of decline may be attributable to dissociation of valeresol 
from the Hb-adduct and, a value for this first-order reverse rate constant can be obtained from 
the reported half-life (3.1 hrs) as 0.22 hr
-1
. This in-vivo ‘rate of dissociation’ is 2.2-fold higher 
than the experimental in-vitro k-1 for 5-HMF with isolated HbA (0.107 hr
-1
) (Obied, 2010), and 
thus shows a rapidly declining effect. Similarly, the biphasic effect (%MOD)-time profile for 
tucaresol also suggests “transiently covalent” Hb-binding. The ‘rate of dissociation’ for 
tucaresol, obtained from the average reported half-life for loss of %MOD (PD t1/2 of 180 hrs) is 
0.004 hr
-1
, over 25-fold slower than that for 5-HMF. This supports the prolonged, persistent 
effect observed for tucaresol (Rolan et al, 1993). 
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Figure 1.5. Peak concentration-dependent increase in maximal effect (modification of Hb) 
for valeresol (adapted from Fitzharris et al., 1985). 
 
 
Figure 1.6. Peak concentration-dependent increase in maximal effect (modification of Hb) 
for tucaresol (adapted from Rolan et al., 1993). 
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Figure 1.7. Nominal concentration-dependent increase in maximal effect (modification of 
Hb), in-vitro, for 5-HMF (adapted from Abdulmalik and Safo et al., 2005). 
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1.8 Mechanism Based Toxicity of AEH  
According to Keidan et al. (1986), modified, high-affinity Hb is unavailable for O2 
release to tissues, but no evidence of tissue hypoxia was observed by the investigators up to 24 
hrs in homozygous SCD patients administered with valeresol. There may be an increase in heart 
rate, vasodilation and increased blood flow (observed in anesthetized dogs administered with IV 
tucaresol) at higher workloads in order to release more O2 from the high affinity Hb, to tissues 
under stress (Nicholls et al., 1989; Rolan et al., 1993; Rolan et al., 1995). There has also been 
concern of increase in blood viscosity by direct reduction in hemolysis, or compensatory 
hypoxemic stimulation of RBC formation with high affinity Hb to improve O2-delivery to the 
tissues (Fitzharris et al., 1985; Rolan et al., 1993). Hb with increased O2-affinity has been shown 
to increase to total red cell mass (erythrocytosis) as a possible compensatory mechanism to 
improve O2 delivery to the tissues, thus increasing the viscosity of blood (Wajcman and 
Galactéros, 2005). For valeresol, it was shown that in addition to inhibition of sickling, it also 
maintains the deformability of the cells during progressive deoxygenation (Fitzharris et al., 1985; 
Keidan et al., 1989) and the benefit of this effect over the increased blood viscosity has been of 
additional concern. Furthermore, the short-term increase in O2-affinity of Hb may be followed by 
rebound increase in sickling possibly due to longer survival times for the less flexible cells, and 
thus, lack of satisfactory benefit, as observed for valeresol (Keidan et al., 1986). 
 Abnormal HbS in homozygous SS cells has reduced affinity for O2 (or elevated p50) and 
undergoes polymerization, resulting in sickling, under hypoxemic conditions. The 
polymerization is thought to be a nucleation-initiated reaction, with a delay-time, and affects the 
rheological properties of the cells (Kaul et al., 1996; Stuart and Nagel, 2004). Owing to short 
transit times in the micro-circulation, compared to the delay-time in nucleation, most cells would 
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not polymerize; however, a prolonged transit time under deoxygenated conditions (venous 
capillaries) would result in nucleation and rapid sickling (Stuart and Nagel, 2004).  
 Oxygenated HbS in sickle (SS) cells is soluble and does not polymerize (Safo et al., 
2004). The reduced O2-affinity of HbS is possibly a compensatory physiological mechanism to 
improve O2-delivery to tissues. Due to the right-shifted OEC, HbS releases O2 relatively easily 
even at arterial pO2 (e.g., before reaching the capillaries). The AEH have been shown to increase 
the O2-affinity of HbS and inhibit sickling (Abdulmalik and Safo et al., 2005; Nnamani et al., 
2008). The AEH concentrations are assumed to be in equilibrium between plasma and RBC. At 
steady-state (under maintenance dosing-regimen), most RBC are expected to be treated with 
AEH, including newly formed (SS) RBC, to form high affinity Hb-adducts. The extent of 
modification may vary between cells, but owing to their strong anti-sickling effect, the cells with 
less Hb modification are expected to maintain their deformability. However, if there are some 
untreated cells circulating in the blood, due to the relatively short transit time in micro-
circulation with low pO2, and improved rheological properties of oxygenated AEH-treated RBC 
(reduced viscosity of blood), irreversible sickling is not expected to occur. In addition, complete 
sickling occurs at pO2 less than 20 mmHg (Asakura et al., 1994), which is unlikely to occur in 
the resting state; untreated cells would be anticipated to circulate in the form of ‘partially 
oxygenated sickle cells’, which are flexible and capable of passing through capillaries (Asakura 
et al., 1994; Abdulmalik and Safo et al., 2005).  
 Prolonged survival times have been shown in Tg sickle mice pre-treated with 5-HMF, 
compared with untreated mice after hypoxic challenge (Abdulmalik and Safo et al., 2005). The 
blood of 5-HMF-treated mice showed partially oxygenated sickle cells (Asakura et al., 1994; 
Abdulmalik and Safo et al., 2005). This demonstrates that despite any concern of “O2-stealing”, 
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treatment with AEH results in the desired outcome, in Tg sickle mice. Finally, in addition to 
increasing the O2-affinity of HbS, the INN-compounds directly inhibit HbS polymer formation 
by stereo-specific interactions (Nnamani et al., 2008), a mechanism not expected for further 
compromise the O2 delivery to the tissues, or result in “O2-stealing” from untreated cells. 
 For other, non-mechanism-related toxicity concerns, 5-HMF has the advantage of being a 
natural food constituent of coffee, fruit juices, etc. (Murkovic and Pichler, 2006), and is mostly 
expected to be well-tolerated at concentrations of 1.6-2 g/kg (in plums and coffee) (Murkovic 
and Pichler, 2006), thus reducing the concern of severe, unexpected toxic events at therapeutic 
doses. The INN-compounds, on the other hand, are synthetic derivatives, and would require 
additional toxicological studies during development. The toxicological findings from studies 
conducted using tucaresol as an immuno-stimulatory compound (Chen and Rhodes, 1996) would 
provide valuable information for the expected toxicities and mechanisms, to enable a better 
screening process for the newer AEH.  
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1.9 Biopharmaceutical Assessments for SGE 
The Biopharmaceutical Classification System (BCS) enables the classification of drugs 
into Classes I-IV, based on their aqueous solubility and gastrointestinal permeability, which are 
considered the major factors that govern the rate and extent of drug absorption after oral 
administration (FDA Guidance for Industry: Waiver of In Vivo Bioavailability and 
Bioequivalence Studies for Immediate- Release Solid Oral Dosage Forms Based on a 
Biopharmaceutics Classification System, 2000). A drug is considered to have high GI solubility 
when the highest dose strength is soluble in at least 250 ml of aqueous media over a pH range of 
1–7.5 at 37°C. High (apparent) GI permeability is established when the extent of absorption is   
90% of the administered dose, determined from in-vivo human mass balance or IV reference 
studies, or indirectly through in-vitro GI permeability studies using cell monolayers (FDA 
Guidance for Industry, 2000; Wu and Benet, 2005). The partition coefficient is not, by itself, a 
measure for permeability classification according to the BCS.  
Figure 1.8 shows a comparison between the calculated solubilities of 5-HMF, INN-312 
and INN-298 at varying (bio-relevant) pH (SciFinder Scholar
®
). It may be observed that 5-HMF 
is very soluble at the physiologically relevant pH range, while INN-312 and INN-298 have very 
low intrinsic solubilities, which improve at low pH due to ionization of the INN-compounds. 
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Figure 1.8. Comparison of calculated solubility between AEH at pH 1-8, in 250 ml aqueous 
media, considered to be bio-relevant. 
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1.9.1 Classification for 5-HMF  
 The calculated intrinsic solubility for 5-HMF (SciFinder Scholar
®
 software) is 54 g/l, 
over a pH range of 1 – 7.5 at 25oC. Therefore, a maximum oral dose of 13.5 g of 5-HMF would 
be expected to be soluble in 250 ml of gastrointestinal fluid assuming that the temperature (25 – 
37
o
C) will have negligible effect on its solubility. The currently studied human oral doses for 5-
HMF are 300 – 4000 mg (Stern et al., 2012), and would be expected to be readily soluble in 
gastric fluids, and thus have high GI solubility, according to BCS classification. From a mass 
balance study in mice and rats, 61–77% and 70–82% recovery of cumulative 5-HMF 
radioactivity was observed in urine of mice and rats, respectively, after oral gavage of doses 
ranging between 5–500 mg/kg (Godfrey et al., 1999). This suggests that at least 61% and 70% of 
5-HMF is orally well-absorbed. Another study showed 95 – 100% of radioactivity recovery in 
the urine of rats within 24 hours of oral and intravenous [
14
C]-5-HMF administration (0.8– 330 
mg/kg doses) (Germond et al., 1987), indicating that ≥90% of the administered 5-HMF dose is 
orally absorbed in rats.  
5-HMF has been reported to have high oral exposures in Tg sickle mice, administered 
doses of 0.5–200 mg/kg 5-HMF that were sufficient to prevent sickling (Abdulmalik et al., 
2005). Assuming similar absorption characteristics in human, 5-HMF is expected to be orally 
bioavailable, with intermediate to high GI permeability. 5-HMF administered to humans in dried 
plum juice, resulted in 46% recovery of the major metabolite, 5-hydroxymethyl furoic acid 
(HMFA) urine of healthy volunteers suggesting that at least 46% of the administered dose was 
absorbed. Therefore, 5-HMF may be considered BCS Class I (high solubility and high 
permeability) compound (from preliminary classification). 
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1.9.2 Classification for INN-312 and INN-298  
 The calculated intrinsic solubility values for INN-312 and INN-298 are 0.36 and 0.54 g/l, 
respectively, but their aqueous solubilities significantly depend on the pH (Figure 1.8) (SciFinder 
Scholar
®
). The compounds are highly soluble at a pH range of 1 – 3, but sparingly soluble 
between pH 3 – 8 (SciFinder Scholar®). A maximum oral dose of 0.09 and 0.14 g of INN-312 
and INN-298, respectively, would be expected to be soluble in 250 ml of gastric fluid (pH 1 – 8). 
The compounds cannot be correctly classified in a BCS class without information on a 
dose-prediction, but it may be expected that an oral dose lower than that for 5-HMF (1.5 g) may 
be required for either of these compounds based on their high potency and (likely) low hepatic 
extraction (see Chapter 4). Doses of 0.09 and 0.14 g of INN-312 and INN-298, respectively, 
would be expected to achieve concentrations of 1.5 – 2 mM in 250 ml gastric fluid. These are 
thought to be therapeutically relevant systemic concentrations required to result in a left-shifting 
effect in p50. So it is likely, oral doses of ~0.09 – 0.14 g, approaching the solubility limit of INN-
312 and INN-298, be administered, and therefore these compounds may be classified as likely 
‘low GI solubility’ agents.  
Partition coefficient and distribution coefficient are not, by themselves, a measure for 
permeability classification according to the BCS, but may be assumed to ‘reflect’ permeability 
for the purpose of preliminary classification. The INN-compounds can be considered lipophilic, 
based on their clogP values (see section 1.6.3) They are thus, expected to be permeable across 
membranes, especially across the intestinal mucosa at pH > 5, where the compound is more in 
the unionized form, assuming the unionized form of the compound is more readily absorbed. 
Therefore with the current information, these compounds may be (preliminarily) classified as 
likely BCS-II (low solubility, high permeability) agents (Wu and Benet, 2005). 
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1.10 Relevant Metabolic Pathways for FGE and SGE 
FGE, being aromatic aldehydes, are likely susceptible to metabolism by ALDH in the 
liver, as well as in the RBC (Inoue et al., 1979; Yoshida et al., 1998; Vasiliou et al., 2000). From 
structure function relationships, it has been shown that 2-substitution (ortho) of aromatic 
aldehydes and 2-hydroxy groups particularly had decreased apparent binding affinity for ALDH 
(Klyosov, 1996), as is the case for FGE. The two compounds may also be susceptible to other 
detoxification pathways by cytochrome P450 (CYP450) metabolism (oxidation of the side chains 
or aromatic rings, O-dealkylation, hydrolysis) or Phase 2 biotransformation reactions 
(glucuronidation or sulfation the hydroxyl-group, or glycine conjugation of the carboxylic acid 
group), in-vivo (Gonzalez and Tukey, 2006). While valeresol is known to be extensively 
metabolized compound (with fe ~ 0.01), there is insufficient information to determine the extent 
of metabolism for tucaresol, although it would also be expected to be extensively metabolized, 
owing to its lipophilic nature and susceptible groups on its molecule.  
The major metabolites of 5-HMF detected in urine (>70% of radioactive 5-HMF dose) 
are oxidation products, thought to be formed primarily by ALDH (and ADH) oxidative 
metabolism (Godfrey et al., 1999; Prior et al., 2006; Obied, 2010). 5-HMF has been shown to 
undergo oxidative metabolism by hepatic and erythrocytic ALDH (primarily) and hepatic 
alcohol dehydrogenase, ADH (to a lesser extent) (Obied, 2010) to the inactive metabolites, 
HMFA (5-hydroxy-2-methyl furoic acid) and FDCA (2,5-furan dicarboxylic acid), respectively 
(Godfrey et al., 1999).  
The relatively lipophilic INN-312 and 298, like 5-HMF, have aromatic aldehyde 
functional group responsible for their interaction with Hb, which also renders them susceptible to 
oxidation to their respective carboxylic acid by oxido-reductases such as ALDH. ALDH-
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mediated metabolism is thought to be the primary metabolic pathway for AEH, specifically due 
to its broad substrate-specificity for aromatic aldehydes, its primary role in detoxification of 
xenobiotics, and high expression in the liver (and also RBC).  
In addition to metabolism by ALDH, AEH may be susceptible to other Phase I (CYP450-
mediated oxidation, O-demethylation) metabolism followed by Phase II conjugation in-vivo. The 
most commonly found CYP enzymes in the liver are CYP3A (4), 2C (9 and 19), 1A2, 2E1, 2A6 
and 2D6 (in decreasing order of their content in the liver) (Shimada et al., 1994; Bertz and 
Granneman, 1997). CYP3A and CYP2C are known to have broad substrate specificity for drugs 
of varying sizes and polarity, while polycyclic aromatic planar hydrocarbons are commonly 
known substrates for CYP1A2 (Bertz and Granneman, 1997; Hackett, 2010). CYP2E1 is known 
to oxidize ethanol, in addition to alcohol dehydrogenase (Lieber, 2000). The benzaldehyde 
functional group of AEH (and hydroxyl-methyl group of 5-HMF) may be susceptible to 
oxidation by the CYP enzymes, and O-demethylation of the methoxy groups of INN-312 and 
298 (meta- and para-substitutions, respectively), may take place by CYP2C9 and CYP2D6, 
known to O-demethylate the aromatic drugs indomethacin and tramadol, respectively (Nakajima 
et al., 1998; Laugesen et al., 2005). 
 
1.10.1 Aldehyde Dehydrogenase 
Aldehyde dehydrogenase (ALDH) is primarily a dimeric protein with broad substrate 
specificity and is dependent on a co-factor, nicotinamide adenine dinucleotide (NAD
+
) for 
catalytic activity (Vasiliou et al., 2000). Its primary physiological function is biotransformation 
and detoxification of endogenous and exogenous aldehydes (Ambroziak & Pietruszko, 1993). It 
has a dual role:  (1) detoxification of xenobiotics, as well as endogenous aldehyde metabolites of 
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bioamines and, (2) metabolism of neurotransmitters and hormones (Ambroziak & Pietruszko, 
1993). 
The ALDH gene superfamily codes for several isozymes with different tissue expression 
and distribution, and the isozymes have specific metabolic roles, e.g., mitochondrial ALDH-2 is 
known to be responsible for the metabolism of acetaldehyde, while cytosolic ALDH-1 is 
involved in retinal oxidation to retinoic acid in the liver, and ALDH-5 present in the brain and 
pituitary is responsible for degradation of GABA (Yoshida et al., 1998; Vasiliou et al., 2000). 
ALDH is also present in the RBC, capable of oxidizing acetaldehyde, propionaldehyde and 
benzaldehyde, and is susceptible to inhibition by disulfiram (Inoue et al., 1979).   
Most ALDH isozymes are capable of aldehyde metabolism with broad substrate 
specificities for aliphatic and aromatic aldehydes, but have different substrate binding affinities 
(Km) and catalytic efficiencies (kcat) (Klyosov, 1996; Vasiliou et al., 2000). ALDH is responsible 
for degradation of therapeutic drugs like cyclophosphamide and bioactivation of organic nitrates 
(e.g., nitroglycerin) (Ambroziak & Pietruszko, 1993). The enzyme has a hydrophobic binding 
pocket; increase in hydrophobicity of the substrate results in higher ALDH binding affinity, but 
may not necessarily improve the metabolic efficiency, as in the case for ALDH-2 (Klyosov, 
1996). Mitochondrial ALDH-2 is responsible for the metabolism of exogenous aliphatic and 
aromatic aldehydes, while ALDH-1 has substrate preference for long-chain aliphatic aldehydes, 
but is inhibited by many aromatic aldehydes (Klyosov, 1996). ALDH-2 has 900-fold higher 
affinity for acetaldehyde than ALDH-1 (Km values 0.2 µM and 180 µM, respectively).  
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1.10.2 Aldehyde Oxidase 
Aldehyde oxidase (AOX) is a homo-dimeric molybdenum cofactor-containing 
flavoenzyme with broad substrate selectivity towards aromatic aldehydes and non-aldehydic 
poly-aromatic nitrogen-containing heterocyclic compounds (Obach et al., 2004; Mahro et al., 
2011; Hutzler et al., 2011). It uses flavin adenine dinucleotide (FAD) and a molybdo-pterin 
cofactor (MoCo) and molecular O2 for catalytic activity (Garattini et al., 2012).  
In humans, AOX is known to exist in a single functional form, AOX1 (Garattini et al., 
2012). It is widely distributed in tissues, with high levels in liver, lungs, GI tract, kidney and 
pancreas (Pryde et al., 2010; Garattini et al., 2012). Mice and rats and likely rabbits have four 
such isozymes, while cytosolic fractions of dogs and cats do not show hepatic AOX activity due 
to inactivation of the AOX1 gene (Johns, 1967; Garattini et al., 2012). Therefore, high 
interspecies variability in the substrate specificity and metabolic capacity of liver AOX is known 
to exist (Johns, 1967; Hutzler et al., 2011). Inter-individual variability is also observed with 
AOX activity due to genetic polymorphisms that result in increased or decreased catalytic 
activity of AOX (Garattini et al., 2012). 
AOX is known to be involved in the metabolism of drugs such as ziprasidone, among 
many others and conversion of prodrug famciclovir to penciclovir (Obach et al., 2004). It is also 
involved in metabolism of intermediate aldehyde metabolites of several drugs, such as tamoxifen 
and citalopram (Obach et al., 2004). Benzaldehyde is a known substrate for this enzyme with 
apparent Km value of 0.01 mM while that for other aldehydes such as acetaldehyde, 
propionaldehyde and o-nitrobenzaldehyde, the Km values range from 0.05 – 5 mM (Johns, 1967). 
Vanillin is known to undergo rapid oxidation to vanillic acid by the AOX contained in liver 
cytosol, which is susceptible to inhibition by disulfiram (Panoutsopoulos et al., 2004; Garattini et 
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al., 2012). The activity of AOX towards vanillin has been found to be negligible compared to 
aldehyde dehydrogenase from in-vitro studies in guinea pig liver slices (Panoutsopoulos et al., 
2004), suggesting a more predominant role of ALDH in the metabolism of benzaldehydes and 
substituted benzaldehydes, compared to AOX. Furthermore, isovanillin has also been found to be 
a potent inhibitor of AOX with IC50 of 15 μM by some researchers (Clarke et al., 1995; Obach et 
al., 2004). 
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CHAPTER 2 
2 HYPOTHESES, SPECIFIC AIMS, AND CLINICAL SIGNIFICANCE 
 
 
 
2.1 Hypotheses 
AEH are aromatic aldehydes, known to allosterically bind to Hb and form Schiff base 
adducts, which have been found to increase the O2-affinity for Hb. Their ability to form Schiff 
base adducts has been observed in both healthy and sickle blood (Abdulmalik et al. 2005; 
Nnamani et al., 2008). This mechanism of action, nevertheless, may be particularly useful for the 
case of sickle blood, containing HbS (see section 2.3 below).   
By far, knowledge on the pharmacokinetics and pharmacodynamics of the second 
generation AEH has been limited, especially for the novel INN-compounds, for which 
experimental studies have not yet been carried out. In-vitro metabolism studies for 5-HMF, the 
lead compound, suggest low affinity hepatic metabolism by cytosolic ALDH, and ADH (to a 
minor extent) in humans, with some inter-species variability among mice, rats, dogs and humans. 
In-vitro studies also show evidence of transiently covalent binding to HbA and low affinity, high 
capacity metabolism by RBC ALDH, which may be responsible for the observed short half-life 
of 5-HMF in blood in-vitro (Obied, 2010) and in-vivo, in transgenic sickle mice (Abdulmalik et 
al. 2005). Collectively, these findings suggest that AEH concentrations at the site of action are 
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determined by two concurrent kinetic processes, namely transiently covalent binding to Hb, and 
metabolism by ALDH in RBC. 
This research was design to better characterize, describe and quantitatively model the in-vitro 
PK and PD behavior of 5-HMF, the lead compound currently in clinical studies, and screen 
novel agents for possibly improved in-vitro PK/PD characteristics that may provide a basis for 
further lead optimization. Therefore, the hypotheses for the research are as follows:  
 
1) AEH are substrates for hepatic ALDH, an enzyme that selectively oxidizes (detoxifies) 
endogenous and exogenous aldehydes. Significant inter-species variability exists in the 
intrinsic ALDH metabolic efficiency for selective substrates. This ALDH-mediated hepatic 
metabolism results in hepatic first-pass effect for AEH after oral administration. 
2) AEH form transiently covalent adducts with Hb with differential binding kinetics between 
each other, and result in a time-and concentration-dependent left-shifts in p50 for Hb. This 
effect is offset by rapid, extensive extra-hepatic metabolism by ALDH in the RBC, also a 
major systemic elimination pathway for AEH.  
3) AEH in whole blood have high plasma clearance due to two concurrent mechanisms: rapid 
binding to Hb in RBC and metabolism by ALDH in RBC.  
4) The binding kinetics of AEH with normal HbA and sickle HbS are similar, as they bind to 
the α-valine amino-terminal of the two forms of Hb that differ primarily by an amino acid on 
their β-subunit. 
5) A relationship between Hb-adducts and a subsequent increase in oxygen-binding affinity of 
Hb (p50) exists, which links the disposition of AEH to their intended PD effect. A semi-
mechanistic in-vitro pharmacokinetic-pharmacodynamic (PK/PD) model for 5-HMF can thus 
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be developed, with predictive utility. The model will be able to provide information on the 
differential duration and magnitude of response, that is, the extent of 5-HMF-modified Hb as 
adduct and subsequent increase in oxygen-binding affinity of Hb (p50) for normal and sickle 
blood. 
 
2.2 Specific Aims 
The primary objective of this research is to advance a better understanding of the in-vitro PK 
and PD behavior of the different AEH. In order accomplish this objective and address the 
research questions based on hypotheses stated under section 2.1 above, the specific aims are: 
 
1) Characterize and compare the hepatic ALDH-mediated metabolism of AEH in humans, 
utilizing hepatic cytosol as a sub-cellular in-vitro model, and make predictions on the hepatic 
extraction and hepatic handling of the AEH using the in-vitro-in-vivo extrapolation (IVIVE) 
approach. 
2) Investigate the inter-species variability in ALDH substrate selectivity and metabolic 
efficiency for acetaldehyde, a selective ALDH substrate using canine, murine and rat 
(homogenized) liver cytosol models. 
3) Investigate and compare the time-course of the concentration-dependent PD effect for the 
investigational AEH in healthy human whole blood (HbA), using left-shift in p50 as a 
biomarker for the PD effect. 
4) Develop and validate (or re-validate) HPLC-UV analytical assays for AEH in various 
matrices, and develop a generic assay to enable quantitation of Hb-adducts. 
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5) Assess the in-vitro disposition of 5-HMF in plasma after incubation with healthy human 
whole blood (HbA) for varying concentrations of 5-HMF, and model the disposition kinetics 
using an appropriate PK model that describes the underlying physiological mechanisms. 
6) Characterize, assess and compare the binding kinetics of the AEH with Hb from systematic 
time- and concentration-dependency studies, using isolated HbA and HbS.  
7) Explore quantitative relationships between Hb-adduct concentrations and left-shifts in p50. 
8) Build and validate a semi-mechanistic, integrated PK/PD model from experimental in-vitro 
PK and PD data, to characterize the (time-dependent) relationship between plasma-
concentration and pharmacological effect of 5-HMF in whole blood. 
9) Assess the predictive utility of the final PK/PD model using initial sensitivity analyses for in-
vitro sickle blood.    
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2.3 Clinical Significance 
SCD affects nearly 200,000 people in the United States and European Union, and 13-20 
million people worldwide.  The pathophysiology of SCD is marked by polymerization of 
abnormal HbS, resulting in distortion (“sickling”) and loss of flexibility of RBC and vaso-
occlusion, resulting in severe pain crises and progressive multi-organ damage. Although SCD 
was the first human disorder to be described at the molecular level, clinical management options 
for acute complications are currently inadequate, and effective treatment with good safety profile 
is lacking. The chronic morbidity and early mortality associated with the disease emphasize the 
need for safer and more effective therapeutic strategies (Epstein & Bunn, 1997; Okpala et al., 
2006; Aliyu et al. 2008).  
Among different investigational approaches that target various pathophysiologic 
mechanisms in SCD for potential treatment, chemical modification of Hb by AEH is promising. 
AEH have been shown to be effective anti-sickling agents in-vitro and in-vivo, however, clinical 
development of the FGE was terminated owing to unfavorable biopharmaceutical, PK and safety 
profiles (Fitzharris et al., 1985; Keidan et al., 1986; Rhodes, 2002). Additional challenges for 
such compounds include relatively high doses required to elicit and maintain a therapeutic 
response, due to the high concentrations of Hb available for binding in blood, and potential for 
non-specific binding to other proteins that may result in toxicity concerns. 
Valeresol (BW12C), Tucaresol (589C80) and Vanillin are among the first generation, 
substituted benzaldehyde molecules that bind preferentially with amino termini of α-valine on 
the Hb molecule and show anti-sickling action (Beddell et al. 1984; White & Wootton, 1989; 
Abraham et al., 1991). Valeresol, the first AEH administered to man, resulted in modification of 
Hb to the high O2-affinity form, by 15% at IV doses of 20 mg/kg, but had a short PD effect half-
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life (Hb-modification) of 3-4 hrs following IV administration (Fitzharris et al., 1985; Keidan et 
al., 1986). Tucaresol, a potent analog with more favorable in-vivo human PK (White & Wootton, 
1989; Rolan et al, 1993; Rolan et al, 1995; Arya et al., 1996), resulted in Hb-modification up to 
16-23% at oral doses of 40-50 mg/kg, but caused immune toxicity, leading to termination of its 
further development (Rhodes, 2002). 
5-HMF, the lead compound for second generation AEH, has advantage over the first 
generation AEH as it is a naturally occurring food constituent in dried fruits, coffee, honey, etc., 
and possesses higher anti-sickling activity than the FGE (Safo et al., 2004; Murkovic and 
Pichler, 2006) at millimolar levels in blood. A double-blind, placebo-controlled, first-in-human 
study with single ascending doses assessing the safety, PK and PD of 5-HMF showed 300 – 
4000 mg doses in oral solution were well-tolerated in healthy normal subjects (Stern et al., 
2012). The terminal half-life of 5-HMF in plasma was found to be short (0.4 – 0.8 hrs), due to 
preferential partitioning into the RBC, where the half-life of free 5-HMF ranged from 1.6 –2.1 
hrs (Stern et al., 2012). These findings suggest greater partitioning of 5-HMF in RBC due to Hb-
binding, and possible metabolism in RBC by ALDH (Stern et al., 2012; Obied, 2010). Therefore, 
further investigations on the disposition mechanisms and kinetics of 5-HMF in whole blood 
would provide valuable information in its development as an anti-sickling agent. Furthermore, a 
quantitative model incorporating the various disposition mechanisms and kinetic parameters 
would enable better dose projections in addition to prediction of left-shifting effect in blood. It 
would also enable (some) differentiation of effects between normal and sickle blood, which may 
provide a basis for future design and interpretation of investigations on 5-HMF. 
The novel pyridyl derivatives of substituted benzaldehydes (INN-compounds) have greater 
anti-sickling action than 5-HMF in-vitro, especially INN-312 and INN-298 (Safo et al., 2004; 
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Murkovic and Pichler, 2006; Nnamani et al., 2008). The greater activity of these compounds may 
help reduce effective oral doses and exposure levels in humans compared to 5-HMF. Since these 
are novel synthetic derivatives, there is no available information on their in-vitro absorption, 
distribution, metabolism and elimination (ADME) behavior. This research has investigated the 
biopharmaceutical properties of INN-312 and INN-298, and made in-vitro ADME assessments 
to support pre-clinical investigations on this class of compounds. Furthermore, screening of other 
AEH will enable identification of the molecule with desired anti-sickling activity as well as 
favorable biopharmaceutical, drug metabolism and pharmacokinetic properties and safety profile 
for the treatment of SCD. 
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CHAPTER 3 
3 HPLC/UV ASSAY DEVELOPMENT AND VALIDATION FOR AEH IN VARIOUS 
MATRICES 
 
 
 
3.1 Introduction 
 
3.1.1 Assay for 5-HMF  
Analytical methods for 5-HMF in non-biological matrices reported in the literature, have 
been summarized by Obied (2010). A method has been reported by Michail et al. (2007) for 
analysis of 5-HMF concentrations in plasma using a solid phase extraction (SPE) procedure for 
sample preparation. This was adapted and further developed by Obied (2010), for quantification 
of 5-HMF in biological matrices from various species, such as plasma and red blood cell lysates 
from humans, rats, dogs and mice, and in PBS solutions. The previously developed analytical 
technique employing SPE of 5-HMF from human plasma, followed by HPLC-UV (Obied, 2010), 
was re-validated with minor changes to enable quantification of 5-HMF concentrations in human 
plasma samples and PBS solutions.  
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3.1.2 Assay for INN-compounds 
The INN-compounds are novel synthetic agents, for which literature information is 
limited. There are no reported studies for the separation and quantitation of these compounds 
from various matrices (Nnamani et al., 2008). Structurally, these compounds are pyridyl-
substituted derivatives of benzaldehyde, or benzaldehyde analogs. INN-312 belongs to Class-I 
(ortho-substituted) and INN-298 belongs to Class-II (meta-substituted) pyridyl benzaldehydes 
(Nnamani et al., 2008). The structural scaffold for these compounds is benzaldehyde; therefore, a 
literature search was performed on HPLC analytical methods for benzaldehydes in various 
matrices.  
Table 3.1 lists some analytical methods for benzaldehydes. Some studies have reported 
analytical techniques for detection of benzaldehyde as an oxidation product of benzyl alcohol, 
which is a commonly used antibacterial agent in several parenteral (IV) pharmaceutical 
formulations (Tan et al., 1991; Kashani et al., 2012). 
Coutrim et al. (1993) performed an extensive systematic analysis to evaluate the 
separation and quantitation of several low molecular mass aldehydes, including benzaldehyde, 
which was used as an internal standard, by means of their dinitrophenylhydrazone (DNPH) 
derivatives. Various stationary phases, mobile phase components, and two detection wavelengths 
were investigated. Similar studies on binary mobile phase evaluations were carried out by Ho et 
al., and have been described in detail in section 3.3.3.2. Li et al. (2004) have also reported a 
method for separation and detection of DNPH derivatives of benzaldehyde.  
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Table 3.1. Summary of several analytical methods for quantitation of benzaldehyde. 
 
 
Reference Matrix Analytical Method Stationary Phase Mobile Phase LOD/LLOQ 
LaCourse and 
Krull, 1987 
Extracts from food 
stuffs and 
beverages 
HPLC-UV (254 nm) 
and HPLC-PED 
Radial-PAK  
μBondapak CN 
(10-pm) 
40:60 MeOH/water, 0.1 M 
NaCl  
at 0.8 mL/min 
LOD: ~ 5 
ng/sample 
Chapman et al., 
1990 
Liver microsomal 
fractions 
HPLC-UV (245 nm) 
Hamilton PRP-l  
(25 cm, 10 μm) 
Two isocratic steps - 60:30 
MeOH/50 mM PIC-A 
followed by 90:10 MeOH/50 
mM PIC-A at 1 mL/min 
N/A 
Tan et al., 1991 Plasma HPLC-UV (254 nm) 
Ultrasphere  
(25 cm x 4.6 mm, 5 µm) 
~ 25:75:2.5 
ACN/water/glacial acetic acid 
at 2 mL/min 
N/A 
Ho and Kim, 2011 
(hydrazone  
derivatives)  
Standard solutions 
in ACN  
HPLC-UV (360 nm) 
Hichrome C18 column 
(250 mm×4.6 mm,5 µm) 
30:70 ACN/water –  
100:0 ACN/water and  
50:50 MeOH/water –  
100:0 MeOH /water  
at 1.5 mL/min 
N/A 
Kashani et al., 2012 
Standard solutions 
in ACN/water; 
Midazolam 
injection 
HPLC-UV (254 nm) 
Waters® Novapak C18 
(250 mm× 4.6 mm, 4μm)  
50:50 ACN/water  
at 1.2 mL/min 
LOD 10ng/mL    
LOQ 50ng/mL 
PED: photoelectrochemical detector; MeOH: methanol; ACN: acetonitrile; PIC-A: tetrabutylammonium phosphate
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Overall, the methods are fairly similar in the types of stationary and mobile phases used. 
Therefore, the HPLC/UV method by Kashani et al. (2012) was selected as a reference, and an 
HPLC/UV assay was developed and validated for separation and detection of INN-312 in neat 
solution. 
 
3.1.3 Assay for quantification of 5-HMF-HbA adduct  
Abdulmalik et al. (2005) observed a linear relationship between the extent of HbS 
modification and the degree of left-shift in p50, along with inhibition of sickling. The HbS 
modification represents the adduct formation of 5-HMF with HbS. The HbS-adduct formed was 
measured relative to the total unmodified HbS, based on semi-quantitative ion-exchange LC 
analysis of Hb. The approach has proved to be very useful for initial screening of the effect of 
AEH, however, inadequate peak resolution between the adduct and unmodified Hb limits the 
quantitative applicability of this assay, and a generic validated analytical method for accurate 
quantitation of Schiff base adducts of AEH with HbA and HbS is lacking. The objective of this 
research was to develop and validate a standardized quantitative method for analysis of time- and 
concentration-dependent binding of the various AEH with Hb (HbA and HbS). This analytical 
method would enable accurate characterization of the binding kinetics of the various AEH with 
HbA and HbS, to elucidate differences in binding with the two variants of Hb, and differences 
between affinities of the different AEH for Hb. 
Analytical methods employing GC/MS, LC/MS, HPLC-IE (ion exchange) and affinity 
chromatography have been used for detection and quantification of different types of Hb adducts, 
such as valine- and cysteine- adducts (Klenk et al., 1982; Törnqvist et al., 1986; Tannenbaum et 
al., 1993).  
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LC-MS/MS serves as a very effective technique with the greatest sensitivity and 
selectivity, enabling detection and quantification of protein fragments at very low concentrations, 
extracted from biological matrices, with short analysis-times (Yates, 1998; Mason and Liebler; 
2003; Paulsson et al., 2003). Techniques for derivatization, isolation and purification of protein 
adducts have been developed, but are extensive and require relatively long preparation time. 
Törnqvist et al. (1986) reported an N-alkyl Edman method of derivatization of the N-terminal 
valine Hb-adducts before analysis. This method involves derivatization of N-terminal valine 
adducts, further modifications and treatment by silanization, acetylation or acetonization 
followed by GC/MS or LC/MS analysis (Törnqvist et al., 1986; Paulsson et al., 2003; Davies et 
al., 2010). Tannenbaum et al. (1993) performed trypsinolysis of cysteine-adducts of Hb and 
analysis of the tryptic fragments by tandem MS. Trypsin digestion is considered to result in 
faster processing time than derivatization of the Hb-adducts (Törnqvist et al., 1986; von Stedingk 
et al., 2011). In addition to the extensive sample preparation time involved (for the purpose of a 
binding kinetic assay), the absence of stable chemical standards for Hb-adducts is a challenge. N-
carbamylated reference standards for derivatized valine-adducts have been synthesized and 
further modified and treated as mentioned above, in order to prepare standards for the Hb-
adducts (Davies et al., 2009). Additionally, the instability of the Hb-adducts may be overcome by 
stabilization using sodium borohyride, but this approach will not be useful for fully 
characterizing the binding kinetics of AEH (5-HMF) with Hb (Al-Abed et al., 1999; Davies et 
al., 2009) 
Capillary electrophoresis involves separation of large charged molecules based on their 
electrophoretic mobility, which is dependent on their charge, the viscosity, size and the strength 
of the electric field, under an applied voltage (Blanc et al., 1997). It provides greater efficiency in 
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separation of proteins, with high resolution (Blanc et al., 1997). Different variants of Hb (HbA, 
HbF, and HbS) have small differences in their charge due to amino acid substitutions that enable 
their separation by capillary electrophoresis based on their electrophoretic mobility, using buffers 
with pH greater than their isoelectric point (Chen et al., 1991). It provides a good technique for 
qualitative separation or initial screening of Hb variants, however, Cotton et al. (1999) and 
Jenkins and Ratnaike (2003) have reported reliable and accurate quantification of Hb by 
coupling with LC methods. Furthermore, difficulty in separation of Hb-adducts with high 
sensitivity, from a single Hb variant (HbA or HbS) based on their electrophoretic mobility, likely 
limits the utility of this technique for characterization and differentiation of binding kinetics of 
AEH with HbA and HbS. 
Quantitative assays for intact Hb and Hb variants have been conducted by enzyme-linked 
immunosorbant assay (ELISA) using monoclonal (mAb) or polyclonal (pAb) antibodies (e.g. 
rabbit-anti-human hemoglobin pAb) and secondary antibodies conjugated with enzyme (horse-
radish peroxidase) for colorimetric detection from an enzyme-substrate reaction (Epstein et al., 
1996; Menon et al., 2004; Woong-Shick et al., 2005). The specific antibodies developed for the 
clinical screening of various Hb variants (e.g. HbS) are based on single amino-acid substitution 
between the Hb variants (Grenett and Garver, 1980). The immunoassay technique has been 
shown to have high sensitivity and specificity in separation and determination of glycated, 
carbamylated and acetylated Hb-adducts (Weykamp et al., 1993). Specific murine mAb 
developed against glycated Hb-adduct enable measurement of the extent of glycation of Hb 
(Zeuthen et al., 1993) and pAb have been developed that recognize acetaldehyde-containing 
epitopes for assays of Hb-acetaldehyde adducts (Israel et al., 1992). Lin et al. (1993) have 
reported a technique to raise rabbit antibodies against acetaldehyde adducts with amino acid 
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residues of N-terminal of β-HbA and HbS for analysis by ELISA. Despite its sensitivity, the 
technique requires highly specific and selective antibodies against AEH adducts with Hb that are 
currently unavailable and cost-ineffective compared to real-time detection methods. 
 Cation exchange HPLC is based on the principle of charge interactions between analyte 
proteins and stationary phase (Fritz and Gjerde, 2009). A variety of columns, offering high 
resolving power and efficiency of separation, are available for different types of analyses, 
ranging from high capacity (requiring high ionic strength buffers) to low capacity, inorganic or 
polar cations to cationic biomolecules (Fritz and Gjerde, 2009). This analytical method has been 
used to readily separate and quantify various Hb from red cell lysates, as well as for qualitative 
screening of Hb variants, with good efficiency and little sample preparation time (Ou et al., 
1983; Kutlar et al., 1984; Ou and Rognerud, 1993; Riou et al., 1997). Cation exchange HPLC has 
also been the preferred method for analysis of glycated Hb, acetylated Hb and Hb-adducts with 
acetaldehyde (Turpeinen et al., 1989; Itälä et al., 1995). Furthermore, the technique enables 
kinetic analysis for binding of acetaldehyde, glucose and aspirin to Hb (Itälä et al., 1995), 
however, requires a relatively longer run-time for the ionic gradient (20 – 120 min) for good 
resolution of peaks (Kutlar et al., 1984).  
Al-Abed et al. (1999) and Al-Abed et al. (2001) reported a cation exchange LC/MS 
method for separation of acetaldehyde and glutathione adducts of Hb. This cation exchange 
method overcomes the relatively long sample preparation time involved with trypsin digestion or 
derivatization. A similar approach employing cation exchange HPLC, but with 
spectrophotometric detection at 410 nm, was followed by Abdulmalik et al. (2005) and Nnamani 
et al. (2008) to measure the extent of AEH adduct formation with sickle and normal Hb using 
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separation. This method was adapted and further developed for quantitative analysis of AEH 
adducts with Hb. 
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3.2 Methods 
 
3.2.1 Materials and Reagents 
 
1. Assay for 5-HMF in human plasma 
a. Milli-Q® water (PK/PD Laboratory, Virginia Commonwealth University) 
b. Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
c. Acetic acid, glacial, > 99% (EMD Chemicals, Billerica, MA) 
d. Tetrahydrofuran, HPLC grade (J.T. Baker, Canada) 
e. 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO) (126.11 g/mol) 
f. Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO) 
g. Human plasma in sodium heparin from a healthy female individual (BioChemed 
Services, Winchester, VA) 
 
2. Assay for 5-HMF in isolated Hb solution 
a. Milli-Q® water (PK/PD Laboratory, Virginia Commonwealth University) 
b. Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
c. Acetic acid, glacial, > 99% (EMD Chemicals, Billerica, MA) 
d. Tetrahydrofuran, HPLC grade (J.T. Baker, Canada) 
e. 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO) (126.11 g/mol) 
f. Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO) 
g. Human hemoglobin A (HbA0) lyophilized powder, ferrous stabilized (Sigma, St. 
Louis, MO) (64,677 g/mol; determined by Sigma) 
  
66 
 
h. Human sickle hemoglobin S (HbS), isolated and concentrated (11.8 g/dL; Dr. 
Martin Safo’s laboratory, Dept of Medicinal Chemistry, VCU) (64,398 g/mol; 
theoretical) 
 
3. Assay for INN-312 in neat solution and isolated HbA solution 
a. Milli-Q® water (PK/PD Laboratory, Virginia Commonwealth University) 
b. Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
c. Acetonitrile, HPLC grade (Burdick and Jackson, Morristown, NJ) 
d. INN-312 (Dr. Martin Safo’s laboratory, Department of Medicinal Chemistry, 
VCU) Batch 2 (243.26 g/mol; Purity ~85%) 
e. Dimethyl sulfoxide (DMSO), ≥ 99.9%, A.C.S. Reagent (Sigma-Aldrich, 
Milwaukee, WI) (78.13 g/mol) 
f. Human hemoglobin A (HbA0) lyophilized powder, ferrous stabilized (Sigma, St. 
Louis, MO) (64,677 g/mol; determined by Sigma) 
g. Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO) 
 
4. Assay for quantification of 5-HMF-HbA adduct 
a. Milli-Q® water (PK/PD Laboratory, Virginia Commonwealth University) 
b. Bis-Tris, HPLC grade (Sigma, St. Louis, MO) 
c. Ethylenediaminetetraacetic acid (EDTA), HPLC grade (Sigma, St. Louis, MO) 
d. Sodium chloride, HPLC grade (Sigma, St. Louis, MO) 
e. Potassium cyanide (Sigma, St. Louis, MO) 
f. Acetic acid, glacial, > 99% (EMD Chemicals, Billerica, MA) 
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g. 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO) (126.11 g/mol) 
h. Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO) 
i. INN-312 (Dr. Martin Safo’s laboratory, Department of Medicinal Chemistry, 
VCU) Batch 2 (243.26 g/mol; Purity ~85%) 
j. INN-298 (Dr. Martin Safo’s laboratory, Dept of Medicinal Chemistry, VCU) 
Batch 1 (243.26 g/mol; Purity ~85%) 
k. Dimethyl sulfoxide (DMSO), ≥ 99.9%, A.C.S. Reagent (Sigma-Aldrich, 
Milwaukee, WI) (78.13 g/mol) 
l. Human hemoglobin A (HbA0) lyophilized powder, ferrous stabilized (Sigma, St. 
Louis, MO) (64,677 g/mol; determined by Sigma) 
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3.2.2 Equipment 
  
1. Vortex (Vortex Genie 2, Fisher Scientific, Pittsburgh, PA) 
2. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA) 
3. Balance (Fisher Scientific A 250, Pittsburgh, PA) 
4. Centrifuge 5804-R (Eppendorf, Hauppauge, NY) 
5. Seal-Rite Microcentrifuge tubes, 1.5 mL (USA Scientific, Ocala, FL) 
6. pH meter (Corning, Glendale, AZ) 
7. Durapore PVDF 0.45 μm membrane filter (Millipore, Billerica, MA) 
8. Vacuum filtration apparatus (assembled, Drug Metabolism Laboratory, VCU) 
9. 10-µL, 100-µL, and 1000-µL VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA) 
10. 25-µL positive displacement pipette and corresponding pipette tips (Microman, Rainin 
Instruments, Oakland, CA). 
11. 0.5-5 mL Finnpipette (Thermo Scientific, Waltham, MA) 
12. Glass insert (150 μL) with preinstalled plastic spring (Waters, Milford, MA) 
13.  UV detector (Shimadzu, AV-10, Columbia, MA)  
14. Empower 2 software (Waters, Milford, MA) 
15. Agilent 8453 UV-visible Spectroscopy Systems (Agilent Technologies, Santa Clara, CA) 
16. Assay for 5-HMF in human plasma: 
i. Oasis HLB cartridge, 1 cc/ 30 mg (Waters, Milford, MA) 
ii. Glass shell vials with caps, 1 mL (Waters, Milford, MA) 
iii. Borosilicate glass tubes (VWR, West Chester, PA) 
iv. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA) 
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v. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA) 
vi. 717 plus autosampler (Waters, Milford, MA) 
vii. 600 Multisolvent controller (Waters, Milford, MA) 
17. Assay for 5-HMF in isolated Hb solution: 
i. Amicon® Ultra-0.5 centrifugal filter units with Ultracel-10 membrane (Millipore, 
Billerica, MA).  
ii. Forma Scientific incubator (Thermo Fisher Scientific Inc., Pittsburgh PA) 
iii. Glass shell vials with caps, 1 mL (Waters, Milford, MA) 
iv. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA) 
v. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA) 
vi. 717 plus autosampler (Waters, Milford, MA) 
vii. 600 Multisolvent controller (Waters, Milford, MA) 
18. Assay for INN-312 in neat solution and isolated HbA solution: 
i. Forma Scientific incubator (Thermo Fisher Scientific Inc., Pittsburgh PA) 
ii. Clear glass screw neck vial, with cap, 2 mL (Waters, Milford, MA) 
iii. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA) 
iv. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA) 
v. Waters 2695 Separations Module (Waters, Milford, MA) 
19. Assay for quantification of 5-HMF-HbA adduct: 
i. Forma Scientific incubator (Thermo Fisher Scientific Inc., Pittsburgh PA) 
ii. Clear glass screw neck vial, with cap, 2 mL (Waters, Milford, MA) 
iii. PolyCAT ATM weak cation exchange column, 3 μm, 4.6 mm x 35 mm, 1500 Å 
(PolyLC, Columbia, MD) 
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iv. PolyCAT ATM Javelin guard cartridge, 3 μm, 4 mm x 10 mm ( PolyLC, 
Columbia, MD) 
v. Waters 2695 Separations Module (Waters, Milford, MA) 
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3.2.3 Preparation of Solutions 
 
– Phosphate buffered saline: One tablet of phosphate buffered saline was dissolved in 200 
mL of nanopure water. This solution had a pH of 7.4, when measured by a pH meter. 
 
– Assay for 5-HMF in human plasma 
 
a. Mobile Phase  
The pre-mixed mobile phase consisted of water:MeOH:glacial acetic 
acid:tetrahydrofuran (THF) in the ratio of 92.5:6.2:1:0.3. In order to prepare 1L of 
mobile phase, 62 mL of MeOH, 10 mL of glacial acetic acid and 3 mL of THF were 
added to 925 mL of nanopure water. The mobile phase was filtered under vacuum 
using Durapore 0.45 μm membrane filter and degassed by sonication for 5 min, till 
the air bubbles escaped. 
 
b. SPE washing solution 
5% Methanol was used to wash off impurities during the SPE, after loading the 
plasma on to the cartridge. 15 mL of MeOH was added to 285 mL of nanopure water. 
 
c. SPE eluting solution 
5-HMF in plasma was eluted using 50% Methanol. 250 mL of MeOH was mixed 
with 250 mL of nanopure water. 
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d. 5-HMF standards in neat solution 
A stock solution of 20 mM 5-HMF was prepared. 12.6 mg of 5-HMF (MW 
126.11 g/mol) was dissolved in 5 mL of nanopure water. This is further diluted 
appropriately, to prepare 5-HMF standards for a calibration range of 0.3 – 634.4 μM 
(or 0.04 – 80 μg/mL). 
 
e. 5-HMF standards in plasma  
Plasma samples were diluted 1:1 with nanopure water before loading on HLB 
cartridges for SPE. 600 μL of diluted plasma was loaded on the cartridge for 
extraction. An excess (double volume) of diluted spiked plasma was prepared to 
ensure sufficient volume available for loading. As a general practice, a volume of 
standard less than 5% of the plasma volume was used to spike plasma to achieve a 
desired concentration. For this purpose, 600 μL of plasma was spiked with 30 μL of 
respective 5-HMF standards (6.5 – 13,320 μM or 0.8 – 1680 μg/mL) to achieve the 
desired concentration range of 0.3 – 634.4 μM in plasma. This spiked plasma was 
further diluted with 630 μL of nanopure water (1:1 dilution) to obtain a total volume 
of 1.26 mL of diluted spiked plasma for loading on SPE cartridges. The concentration 
of 5-HMF in diluted spiked plasma was therefore, a 2-fold dilution of that in the 
undiluted 630 μL plasma. 
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– Assay for 5-HMF in isolated Hb solution 
 
a. Mobile Phase  
The pre-mixed mobile phase consisted of water:MeOH:glacial acetic acid:THF in 
the ratio of 92.5:6.2:1:0.3. In order to prepare 1L of mobile phase, 62 mL of MeOH, 
10 mL of glacial acetic acid and 3 mL of THF were added to 925 mL of nanopure 
water. The mobile phase was filtered under vacuum and degassed by sonication for 5 
min. 
 
b. 5-HMF solutions 
A stock solution of 20 mM 5-HMF was prepared. 12.6 mg of 5-HMF (MW 
126.11 g/mol) was dissolved in 5 mL of nanopure water. This was further diluted 
appropriately, to prepare 5-HMF standards for a calibration range of 0.3 – 634.4 μM. 
 
c. HbA solution 
A solution of 125 μM HbA was prepared by re-constituting 76.8 mg of 
lyophilized isolated HbA in 9.5 mL PBS (or as required). 
 
d. HbS solution 
The concentration of isolated HbS was 11.8 g/dl (1.83 mM). A solution of 125 
μM HbS was prepared by diluting 0.65 mL of the concentrated isolated HbS in 8.85 
mL PBS (or as required). 
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– Assay for INN-312 in in neat solution and isolated HbA solution 
 
a. Mobile Phase 
The mobile phase consisted of ACN:water in the ratio of 50:50. The mobile phase 
was not pre-mixed. Two separate solvent lines, one connected to ACN and the other 
to nanopure water, were used in order to achieve 50:50 mixing of the mobile phase.  
 
b. INN-312 solutions 
A stock solution of 1 M was prepared by dissolving 12.16 mg of INN-312 (MW 
243.26 g/mol) in 50 µL of DMSO (100%). This was further diluted in PBS to obtain 
INN-312 concentrations in 0.1% DMSO. 3 µL of 1 M INN-312 was added to 3 mL 
PBS, to obtain a final concentration of 1 mM INN-312 in 0.1% DMSO. Further 2- 
fold dilutions were prepared using 0.1% DMSO/PBS. 
 
c. 0.1% DMSO/PBS 
6 µL of DMSO was added to 6 mL PBS, to prepare a solution of 0.1% DMSO for 
INN-312. 
 
d. HbA solution 
A solution of 125 μM HbA was prepared by re-constituting 76.8 mg of 
lyophilized isolated HbA in 9.5 mL PBS (or as required). 
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– Assay for quantification of 5-HMF-HbA adduct 
 
a. Mobile Phase A 
The mobile phase consisted of 40 mM Bis-Tris and 5 mM EDTA with pH 6.5. In 
order to prepare 1L of mobile phase A, 8.37 g of Bis-Tris and 1.86 g of EDTA were 
dissolved in 1000 mL of nanopure water. The pH was adjusted to 6.5 using ~750 µL 
of glacial acetic acid. 
 
b. Mobile Phase B  
The mobile phase consisted of 40 mM Bis-Tris, 5 mM EDTA and 200 mM NaCl 
with pH 6.5. In order to prepare 1L of mobile phase B, 8.37 g of Bis-Tris, 1.86 g of 
EDTA and 11.69 g NaCl were dissolved in 1000 mL of nanopure water. The pH was 
adjusted to 6.5 using ~950 µL of glacial acetic acid. 
 
c. 5-HMF solution 
A stock solution of 20 mM 5-HMF was prepared. 12.6 mg of 5-HMF (MW 
126.11 g/mol) was dissolved in 5 mL of nanopure water. This is further diluted 
appropriately to achieve desired concentrations. 
 
d. HbA solution 
Isolated human HbA0 was carefully weighed (16.2 mg; MW 64,677 g/mol) and 
dissolved in PBS pH 7.4 by gentle shaking. It was diluted appropriately with PBS to 
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achieve a concentration range of 0.08 – 250 µM HbA. The ferrous stabilized HbA is 
not expected to have significant concentrations of (ferric) methemoglobin.  
  
  
77 
 
3.2.4 Procedures 
 
3.2.4.1 Assay for 5-HMF in human plasma 
The analytical technique employing SPE of 5-HMF from human plasma, followed by 
HPLC-UV (Obied, 2010), was re-validated with changes to optimize and enable quantification of 
5-HMF concentrations in plasma samples. Modifications in the assay are shown in Table 3.2 
below.  
Aliquots of 600 µL of diluted spiked plasma (1:1 with water) were loaded on pre-
conditioned SPE cartridges. The plasma was spiked with 5-HMF standards as described in 
section 3.2.3, or nanopure water for blank spiked plasma. The SPE procedure for sample 
extraction is described in Table 3.3 below. The eluate was vortexed, and 150 µL of the eluate 
was transferred to HPLC vials for injection and HPLC-UV analysis. The analytical method is 
elucidated in Table 3.4. 
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Table 3.2. Modifications in the assay for 5-HMF in human plasma. 
 
Modification Previously validated method Newly re-validated method 
Composition of 
mobile phase 
water-MeOH-acetic acid-THF  
(93.5 : 6.2 : 1 : 0.3) 
water-MeOH-acetic acid-THF (92.5 : 6.2 : 1 : 
0.3) 
SPE procedure 
Washing of loaded SPE cartridges was 
carried out using phosphate-buffered saline, 
pH 7.4 followed by elution with 500 µL of 
50% MeOH in water.  
The minimum centrifugation speeds were 
400 rpm for the conditioning, loading and 
elution, and 700 rpm for the washing of the 
SPE cartridges. 
Washing of loaded SPE cartridges was 
carried out using 5% MeOH in water, 
followed by elution with 600 µL of 50% 
MeOH in water.  
The minimum centrifugation speeds were 500 
rpm for the conditioning, loading and elution, 
and 800 rpm for the washing of the SPE 
cartridges. 
5-HMF calibration 
range in plasma 
0.16 – 158.6 µM and ELOQ of 0.16 µM 0.3 – 634.0 µM and ELOQ of 0.3 µM 
QC levels 0.48, 15.9, 126.9 µM 0.9, 16 and 240 μM 
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Table 3.3. Sample preparation by SPE for analysis by HPLC-UV. 
 
Step Solvent 
Volume 
(mL) 
Centrifugation conditions 
Speed (RPM) Time (min) No. of times 
Conditioning 
Methanol 1 500 2 2 
Water (MQW) 1 500 2 2 
Loading 
Diluted plasma (1:1 with 
water) 
0.6 500 10 1 
Washing 5% MeOH in water 1 800 5 2 
Elution 50% MeOH in water 0.6 500 5 1 
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Table 3.4. Assay for quantitation of 5-HMF in plasma. 
 
Type of assay  HPLC-UV 
Instrumentation LC pump Waters 600E Multisolvent Delivery System 
 LC Autosampler Waters 717 Plus Autosampler 
 Detector Shimadzu 10 AV Absorbance Detector 
Columns Analytical column Zorbax Rx C18, 80 A
o, 150 mm x 4.6 mm, 5 μm (Agilent, CA) 
 Guard column C18, 12.5 mm x 4.6 mm (Agilent, CA) 
Assay conditions Mobile phase Water-MeOH-acetic acid-THF (92.5 : 6.2 : 1 : 0.3) 
 Sample preparation SPE of analyte from diluted plasma using Oasis HLB cartridges  
 Sample volume 0.15 mL of eluate from 0.6 mL of extracted plasma 
 Autosampler temperature 4 °C 
 Column temperature 25 °C 
 Flow rate 0.75 mL/minute 
 Detection UV at 285 nm 
 Injection volume 10 µL 
 Chromatographic run time 10 minutes 
 Calibration curve (CC) range 0.3 – 634 µM 
 Experimental LOQ (ELOQ) 0.3 µM 
 Quality control (QC) levels 0.9, 16 and 240 μM 
Data processing Software Empower 2 Software (Waters, MA) 
 Regression algorithm for CC Linear, weighted 1/x 
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3.2.4.2 Assay for 5-HMF in isolated Hb solution 
Aliquots of 200 μL of 5-HMF standards in PBS or Hb solution in PBS were transferred to 
Amicon® Ultra-0.5 centrifugal filter units with Ultracel-10 membrane and filtered by 
centrifugation at 14,000 rpm for 10 min at 4
o
C. The filtrate was vortexed and 100 µL of the 
filtrate was transferred to inserts in HPLC vials for injection and HPLC-UV analysis. The 
analytical method is elucidated in Table 3.4 above.  
 
3.2.4.3 Assay for INN-312 in neat solution  
A method for analysis of INN-312 in neat solution was developed and is described in 
section 3.3.3 below.  200 μL of INN-312 standards in 0.1% DMSO/PBS (buffer) were 
transferred to HPLC vials for injection. In order to develop the assay for INN-312 in Hb solution, 
aliquots of 200 μL of standards in buffer or Hb solution in buffer were transferred to Amicon® 
Ultra-0.5 centrifugal filter units with Ultracel-10 membrane and filtered by centrifugation at 
14,000 rpm for 10 min at 4
o
C. The filtrate was vortexed and 100 µL of the filtrate was 
transferred to inserts in HPLC vials for injection and HPLC-UV analysis. The analytical method 
is further elucidated under section 3.3.3. 
 
3.2.4.4 Assay for quantification of 5-HMF-HbA adduct  
A method for analysis of unmodified (total) Hb and Hb-adduct was developed and is 
described in section 3.3.4 below. 100 μL of Hb standards in PBS, or Hb incubated with 5-HMF 
at 37
o
C for varying time-periods, were transferred to HPLC vials for injection.  
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3.2.5 Data Analysis 
Chromatographic data processing was performed using Empower 2 software. Precision and 
accuracy were assessed by coefficient of variation (COV) and difference from nominal (DFN), 
respectively. The method was considered accurate and precise if the DFN and COV were less 
than 15% at each concentration level, and less than 20% at the experimental LOQ (FDA 
Guidance for Industry: Bioanalytical Method Validation Criteria). Linear regression for 3-6 
replicates was performed with a weighting factor of 1/x using JMP version 9. 
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3.3 Method Validation 
 
3.3.1 Partial Validation of Assay for 5-HMF in Human Plasma 
 
3.3.1.1 Linearity of response 
Linearity of response of 5-HMF concentrations in neat solution was demonstrated. The 
COV (n=3) was less than 2.5% for all concentrations levels and DFN (n=3) was less than 4% for 
all concentrations levels and less than 20% for the ELOQ of 0.3 µM for triplicate injections. 
Table 3.5 shows the linearity of response of the system for HPLC-UV analysis of 5-HMF in neat 
solution. 
 
3.3.1.2 Instrument reproducibility 
Instrument reproducibility was demonstrated from three independent runs with single 
injections at different time periods using three levels of 5-HMF concentrations, low, medium and 
high.  The COV and DFN (n=3) of less than 7.5% and less than 3%, respectively, and are shown 
in Table 3.6. 
 
3.3.1.3 Assay Selectivity 
The selectivity of the assay was demonstrated in order to confirm detection, separation 
and quantification 5-HMF, in the presence of other endogenous substances/impurities in the 
extracted plasma matrix. Blank plasma from a healthy individual female, and plasma spiked with 
5-HMF were treated to SPE, and analyzed by the HPLC-UV method. The assay was determined 
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to be selective for 5-HMF based on the absence of peaks in the blank plasma sample, with 
respect to the spiked plasma sample. The chromatographic peak for 5-HMF was observed at a 
retention time (tR) of 5.2 min in the spiked plasma sample. Figures 3.1 and 3.2 – 3.5 represent the 
selectivity of the assay from a blank plasma chromatogram and representative 5-HMF spiked 
plasma chromatograms for increasing 5-HMF concentrations, respectively. Further selectivity of 
the assay had been previously established using 6 different sources of human plasma (Obied, 
2010). 
 
3.3.1.4 Recovery  
The response for extracted analyte (5-HMF) from plasma samples at low, medium, and 
high concentrations (0.9, 16 and 240 μM) was compared to the response from unextracted known 
concentrations in neat solution, which represent 100% recovery of 5-HMF. Average recovery of 
5-HMF from plasma (n=3) after SPE was acceptable, with 83%, 77% and 85%, for the low, 
medium, and high concentration levels respectively (Table 3.7). These values are comparable 
with a previously reported recovery of >78% (COV of less than 4%; n=3) for all levels (Obied, 
2010). 
 
 
  
  
85 
 
Table 3.5. Demonstration of linearity of response (with precision and accuracy) for 
triplicate injections of 5-HMF in neat solution. 
 
[5-HMF] 
μM 
Response (Peak Area) 
Mean COV 
Average 
DFN% R1 R2 R3 
0.3 4151 4235 4343 4243 2% -20% 
0.6 8310 8439 8425 8391 1% -4% 
1.2 16010 16304 16256 16190 1% 0.4% 
2.5 32073 31643 31137 31618 1% 2% 
5.0 62715 63039 62785 62846 0.3% 4% 
9.9 124824 125947 124456 125076 1% 4% 
19.8 249715 249344 250897 249985 0.3% 5% 
39.7 496833 496733 500718 498095 0.5% 4% 
79.3 997054 988334 990178 991855 0.5% 4% 
158.6 1987065 1972543 1976351 1978653 0.4% 4% 
317.2 3775795 3763011 3763984 3767597 0.2% -1% 
634.4 7537650 7493799 7502029 7511159 0.3% -1% 
Weighted Slope 
   
12005 
  
Intercept 
   
1259 
  
r
2
    0.99   
 
 
Table 3.6. Instrument reproducibility for three independent runs in unicate. 
 
[5-HMF] 
μM 
Response 
Mean COV 
Average 
DFN% 
(3 separate runs in unicate) 
R1 R2 R3 
0.4 5591 5168 5247 5335 4% -2% 
16 207229 182658 206996 198961 7% 3% 
128 1587642 1413331 1630095 1543689 7% -0.3% 
Weighted Slope 12453 11071 12754 12093 
  
Intercept 768 842 205 605 
  
r
2
 0.99 0.99 0.99 0.99   
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Figure 3.1. Chromatogram for blank plasma, showing absence of impurity peaks. 
 
 
 
 
 
 
Figure 3.2. Representative chromatogram for 0.3 μM 5-HMF in plasma. 
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Figure 3.3. Representative chromatogram for 2.5 μM 5-HMF in plasma. 
 
 
 
 
 
 
 
 
Figure 3.4. Representative chromatogram for 19.8 μM 5-HMF in plasma. 
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Figure 3.5. Representative chromatogram for 317.2 μM 5-HMF in plasma. 
 
 
 
 
 
Table 3.7. Recovery of 5-HMF from plasma after SPE for low, medium and hugh 
concentrations. Response is reported as mean (n=3). 
 
[5-HMF] 
μM 
Response in Neat 
Solution 
 
(100% recovery) 
Response in Plasma 
Extract Recovery from 
plasma 
 
(dilution factor=2) 
Mean COV Mean COV Mean 
0.9 11162 1.0% 4610 5.6% 83% 
16 191801 0.3% 74272 0.4% 77% 
240 2670982 0.2% 1129750 0.2% 85% 
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3.3.1.5 Intra-run and inter-run accuracy and precision 
High within-run (intra-run) and between-run (inter-run) accuracy and precision was 
demonstrated for all 5-HMF calibration standards in plasma (in triplicate over three separate 
runs). The intra-run COV and average DFN were less than 9% and 7%, respectively, and inter-
run COV and average DFN were less than 6% and 2%, respectively (Table 3.8) 
.  
3.3.1.6 Dilution-integrity and post-preparative stability of 5-HMF 
Dilution integrity upon 50-fold dilution of 5-HMF with plasma, and post-preparative 
stability of 5-HMF at 4
o
C (in the autosampler) for 48 hrs has been previously established (Obied, 
2010).   
  
90 
 
Table 3.8.  Mean values for within-run and between-run accuracy and precision for all calibration standards in plasma (in 
triplicate over three separate runs).  
 
[5-HMF] 
μM 
Intra-run  
(response from triplicate readings) 
Inter-run  
(response from three runs with triplicate readings) 
Mean response COV DFN% Mean response COV DFN% 
0.3 1997 9% 0.2% 1990 6% -2% 
0.6 3401 6% -4% 3590 5% 2% 
1.2 6539 6% -0.2% 6478 3% -1% 
2.5 13149 2% 0.1% 12806 3% -2% 
5 25969 2% 1% 25553 2% 0.3% 
9.9 51198 1% 1% 50522 2% 1% 
19.8 102235 2% 2% 99781 4% 0.5% 
39.7 187280 1% -7% 196810 4% -1% 
79.3 419846 1% 4% 397976 5% 0.5% 
158.6 821134 1% 2% 799552 3% 1% 
317.2 1642704 1% 2% 1578058 5% -0.3% 
634.4 3152166 0.3% -2% 3161486 1% -0.1% 
Weighted Slope 5062   4989   
Intercept 475   528   
r
2
 0.99   0.99   
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3.3.1.7 Calibration Curve 
A calibration curve for 5-HMF in plasma had been previously established (Obied, 2010) 
but covers a concentration range of 0.16 – 158.9 µM 5-HMF. The objective of the partial-
validation was to further increase the calibration range in order to facilitate analysis of relatively 
high concentrations of 5-HMF in plasma, thus reducing possible dilution errors. Therefore, the 
concentration range for calibration was extended to 634.4 µM 5-HMF. The relationship between 
the UV response with increasing concentrations of 5-HMF in plasma was found to be linear 
between a concentration range of 0.31 – 634.4 µM. The calibration curve was established in this 
analytical range, by 1/x weighted linear regression of the response with respect to 5-HMF 
concentration, for three replicates. A weighting factor of 1/x was used due to the wide analytical 
range. Figure 3.6 represents a calibration curve for 5-HMF standards in plasma for three 
replicates (mean ± SD). The COV was less than 11% for all standards, and high accuracy is 
reflected from DFN values less than 6% for all standards (Table 3.9). 
The experimental LOQ (ELOQ) was determined from the lowest concentration of 5-
HMF in plasma, that could be quantified with high precision and accuracy. 0.31 µM of 5-HMF 
was established as the ELOQ, with COV of 11% and DFN of 6%. 
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Figure 3.6. Representative calibration curve for 0.31 – 634.4 μM 5-HMF in plasma (mean ± 
SD; n=3). 
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Table 3.9.  Precision and accuracy for 5-HMF calibration curve in plasma.  
[5-HMF] 
μM 
Mean Response  
Replicate measurements (n=3) 
COV DFN 
0.31 2103 11% 6% 
0.62 3658 10% 3% 
1.24 6295 5% -6% 
2.48 12851 5% -0.2% 
4.96 25718 0.4% 2% 
9.91 49697 0.4% -1% 
19.83 101467 1% 2% 
39.65 200858 0.2% 1% 
79.3 381000 1% -4% 
158.6 778381 1% -2% 
317.2 1588907 0.4% -0.01% 
634.4 3207641 0.3% 1% 
Weighted Slope 5008   
Intercept 466   
r
2
 0.99   
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3.3.2 Assay for 5-HMF in isolated Hb solution 
 
The HPLC-UV analytical method described in section 3.3.1 was used for the quantitation 
of 5-HMF in PBS solution. A descriptive summary of the method is shown in Table 3.10 with 
minor amendments in the sample preparation step.  
 
3.3.2.1 Recovery after ultrafiltration 
The Amicon® centrifugal devices consist of a loading chamber with membrane placed in 
a collection chamber, for collection of filtrate upon ultrafiltration. The devices are reported to 
have high recovery with residual volumes as low as ~30 µL after ultrafiltration. The recovery of 
5-HMF after ultrafiltration using these devices was thus investigated. The response for 5-HMF 
solutions in PBS after centrifugation and ultrafiltration was compared to the response from un-
filtered concentrations in PBS at all concentration levels (0.31 – 634.4 µM). The response from 
unfiltered solutions in PBS represent 100% recovery of 5-HMF. Average recovery of 5-HMF 
after ultrafiltration was high, and greater than 96% for all concentration levels investigated in 
unicate (Table 3.11). 
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Table 3.10. Assay for quantitation of 5-HMF in isolated Hb solution. 
 
Type of assay  HPLC-UV 
Instrumentation LC pump Waters 600E Multisolvent Delivery System 
 LC Autosampler Waters 717 Plus Autosampler 
 Detector Shimadzu 10 AV Absorbance Detector 
Columns Analytical column Zorbax Rx C18, 80 A
o, 150 mm x 4.6 mm, 5 μm (Agilent, CA) 
 Guard column C18, 12.5 mm x 4.6 mm (Agilent, CA) 
Assay conditions Mobile phase Water-MeOH-acetic acid-THF (92.5 : 6.2 : 1 : 0.3) 
 Sample preparation Ultrafiltration by centrifugation at 14000 rpm for 10 min at 4
o
C  
 Sample volume 0.10 mL of filtrate from 0.2 mL of Hb solution 
 Autosampler temperature 4 °C 
 Column temperature 25 °C 
 Flow rate 0.75 mL/minute 
 Detection UV at 285 nm 
 Injection volume 10 µL 
 Chromatographic run time 10 minutes 
 Calibration curve range 0.3 – 634 µM 
 Experimental LOQ (ELOQ) 0.3 µM 
 Quality control (QC) levels 0.9, 20 and 300 μM 
Data processing Software Empower 2 Software (Waters, MA) 
 Regression algorithm for CC Linear, weighted 1/x 
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3.3.2.2 Post-preparative stability 
The stability of 5-HMF standards prepared in PBS after storage at 4
o
C for up to 20 hrs 
and 37
o
C for up to 30 hrs was demonstrated. Table 3.12 shows good precision (COV less than 
15%) between all concentration levels of 5-HMF stored at 4
o
C for 20 hrs and 37
o
C for 30 hrs, 
and freshly prepared samples.  
 
3.3.2.3 Calibration Curve 
The relationship between the UV response with increasing concentrations of 5-HMF in 
PBS was linear between a concentration range of 0.31 – 634.4 µM. The calibration curve was 
established in this analytical range, by 1/x weighted linear regression of the response with 
respect to 5-HMF concentration, for three runs in duplicate. A weighting factor of 1/x was used 
due to the wide analytical range. Figure 3.7 represents a calibration curve for 5-HMF standards 
in PBS for three replicates, each with duplicate measurements (mean ± SD). The COV was less 
than 7% for all standards and high accuracy is reflected from DFN values less than 6% for all 
standards (Table 3.13). 
The experimental LOQ (ELOQ) determined from the lowest concentration of 5-HMF in 
PBS, that could be quantified with high precision and accuracy was 0.31 µM, with COV of 7% 
and DFN of 5%. 
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Table 3.11.  Recovery of 5-HMF after ultrafiltration of PBS solution (n=1). 
 
[5-HMF] 
μM 
Response 
Recovery 
Un-filtered Filtrate 
0.3 3336 3234 97% 
0.6 5506 5358 97% 
1.2 10711 10297 96% 
2.5 20759 20312 98% 
5.0 40277 39480 98% 
9.9 80158 79616 99% 
19.8 158289 155022 98% 
39.7 320301 310736 97% 
79.3 633973 632732 100% 
158.6 1274922 1225219 96% 
317.2 2542887 2497358 98% 
634.4 5147364 5033747 98% 
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Table 3.12.  Stability of 5-HMF in PBS standards on prolonged storage at varying 
temperatures. 
 
[5-HMF] 
μM 
Response COV 
0 hr 
 
20 hr 
4
o
C 
30 hr 
37
o
C 
20 hr 
4
o
C 
30 hr 
37
o
C 
0.3 3336 2774 2784 13% 13% 
0.6 5506 5986 4848 6% 9% 
1.2 10711 10345 8602 2% 15% 
2.5 20759 20658 18435 0.3% 8% 
5.0 40277 41150 39984 2% 1% 
9.9 80158 81655 78391 1% 2% 
19.8 158289 162844 144670 2% 6% 
39.7 320301 327374 318080 2% 0.5% 
79.3 633973 651820 618034 2% 1.8% 
158.6 1274922 1293940 1250733 1% 1.4% 
317.2 2542887 2600896 2546065 2% 0.1% 
634.4 5147364 5262901 5090008 2% 1% 
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Figure 3.7. Representative calibration curve for 0.31 – 634.4 μM 5-HMF in PBS (mean ± 
SD; three runs in duplicate). 
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Table 3.13.  Precision and accuracy for 5-HMF calibration curve in PBS.  
 
[5-HMF] Response (duplicate measurements) 
COV DFN 
μM Run 1 Run 2 Run 3 Mean 
0.31 2244 2032 2338 2205 7% 5% 
2.48 15142 14552 15819 15171 4% 5% 
9.91 59958 58327 62058 60114 3% 5% 
79.3 470193 469777 496543 478838 3% 6% 
634.4 3737136 3686221 3911608 3778322 3% 5% 
Weighted Slope 5895 5823 6176 5965 
  
Intercept 464 248 462 392 
  
r
2
 0.99 0.99 0.99 0.99   
 
  
101 
 
3.3.3 Method development for assay of INN-312 in neat solution 
 
3.3.3.1 Spectrophotometry for INN-compounds 
5-HMF is known to have maximum UV absorbance of 6.22 mM
-1
cm
-1
 at a wavelength of 
285 nm (λmax). It is this specific wavelength that enables detection and quantitation of 5-HMF 
separated from plasma and Hb solutions (see section 3.3.1 and 3.3.2). In order to develop an 
HPLC assay for the INN-compounds with UV/Vis detection method, the λmax must be known. 
Benzaldehyde, the structural scaffold for INN-compounds, is known to have a λmax of 275 nm, 
while ortho-, meta- and para-methyl benzaldehyde have λmax between 282 – 288 nm (Thiault et 
al., 2004). However, information on the absorptivity and spectra for the novel INN-compounds 
has not been studied and reported in the literature. Therefore, a complete spectrum analysis was 
performed for INN-312 and INN-298 solutions prepared in DMSO using an Agilent 8453 UV-
visible Spectroscopy System. These solutions prepared in 0.1% DMSO were corrected for 
background absorbance of 0.1% DMSO (since its λmax is ~265 nm). Figures 3.8 and 3.9 show the 
UV spectra for varying concentrations of INN-312 and INN-298 respectively.  
High absorbance in the UV region of 265 nm was observed due to the presence of 
DMSO. INN-312 was found have high specific absorbance at a λmax of 350 nm. The specific 
absorbance of INN-298 appeared to be around 305 nm but was not adequately distinguishable 
from the absorbance of DMSO.  
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The absorbance of INN-312 at 350 nm was concentration-dependent, and linear in the 
range investigated (Figure 3.10). The molar absorptivity coefficient (ε) of INN-312 was 
determined from the slope of linear regression of concentration-dependent absorbance at 350 nm, 
based on the Beer-Lambert relationship shown in Equation 3 – 1 below: 
 
                                                    
 
Where  
A: measured absorbance [AU] 
ε: molar extinction coefficient [mM-1cm-1]  
b: pathlength of the cell [1 cm] 
C: concentration of absorbing species [mM] 
 
According to this law, the slope of the (linear) relationship between measured absorbance 
at the λmax for the respective concentrations of absorbing species represents the molar extinction 
(absorptivity) coefficient, ε, for a cell with pathlength of 1 cm in the spectrophotometer. 
Since a specific λmax band could not be determined for INN-298 in DMSO due to 
inferring absorbance, additional concentrations were not tested. The absorptivity coefficient for 
INN-298 was determined from the Beer-Lambert relationship for the two concentration levels 
tested. A range for the absorptivity coefficient for INN-298 calculated by this method has been 
reported in Table 3.14, along with the values for λmax and ε for the three AEH.  
INN-312 has relatively low (about 5-fold) molar absorptivity compared to 5-HMF, while 
that for INN-298 is very high.  
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Figure 3.8. Spectrum analysis for varying concentrations of INN-312 in 0.1% DMSO. 
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Figure 3.9. Spectrum analysis for two concentrations of INN-298 in 0.1% DMSO.  
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Figure 3.10. Concentration-dependent absorbance (SD) of of INN-312 in 0.1% DMSO at 
350 nm. 
 
 
 
 
 
Table 3.14.  Molar absorptivity coefficients for AEH. 
 
AEH λmax (nm) ε (mM
-1
cm
-1
) 
5-HMF 285 6.2 
INN-312 350 1.2 
INN-298 305 (?) 8.2 – 19.8 
 
  
y = 1.21x + 0.34 
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3.3.3.2 Mobile phase optimization  
From spectrophotometry, INN-312 was determined to have a λmax in the UV/Vis region at 
350 nm. Therefore, this wavelength was selected for detection of INN-312 after HPLC 
separation. The HPLC separation method for INN-312 was developed based on the method by 
Kashani et al. (2012).  
The starting mobile phase composition was MeOH:water 50:50 followed by further 
optimization of organic phase and composition. Table 3.15 shows the effect of varying 
compositions of organic phase (MeOH) on the tR and capacity factor (k’) for INN-312. The 
reduced polarity of the mobile phase with an increased fraction of organic solvent reduces 
hydrophobic interactions between INN-312 and the stationary phase, thus resulting in more rapid 
elution, reducing its tR on the column and the k’. Similar observations were made by LaCourse 
and Krull (1987). Figure 3.11 illustrates this phenomenon for varying MeOH:water 
compositions. 
The organic phase was optimized to ACN due to optimal tR, minimum run time and 
improved peak shape. Similar observations have been reported by Ho and Kim (2011), who 
studied the relative performances of two binary mobile phases for analysis of benzaldehyde (and 
other aldehydes and ketones) in hydrazone derivative forms. Varying compositions of 
ACN/water (30:70 – 100:0) and MeOH/water (50:50 – 100:0) were evaluated based on 
resolution, relative sensitivity and tR. The relative composition of the organic phase was found to 
be a determinant factor and ACN/water was found result in more optimal elution and resolution 
compared to MeOH/water (Ho and Kim, 2011). 
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Table 3.16 shows the effect of varying compositions of ACN on the tR and k’ for INN-312. 
Different injection volumes, 5, 10 and 20 μL, were tested, and the injection volume and flow rate 
were optimized. The tR for INN-312 after method optimization was 2.9 min, with complete 
elution before 3.5 min. Therefore, the chromatographic run time was shortened to 5 min, which 
would enable analysis of several samples in a short period of time. Kashani et al. (2012) reported 
a tR for benzaldehyde using a Novapak C18 analytical column and elution by 50:50 ACN/water 
at 1.2 mL/min flow rate of 3.8 min. The comparable method and tR suggest a similar retention 
mechanism for INN-312 as benzaldehyde, also the structural scaffold for INN-312. 
A descriptive summary of the newly developed analytical assay for INN-312 is included in 
Table 3.17.  
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Table 3.15.  Capacity factor for the varying organic phase compositions (MeOH:water). 
Composition Mobile phase 
front 
tM 
(min) 
Retention time 
tR 
(min) 
Capacity factor 
k’ 
k’=tR-tM/tM 
MeOH Water 
50 50 1.43 8.90 5.2 
60 40 1.45 4.10 1.8 
70 30 1.45 2.90 1.0 
75 25 1.45 2.28 0.6 
80 20 1.45 2.07 0.4 
90 10 1.46 1.74 0.2 
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Figure 3.11. Effect of organic phase composition on the k’.  
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Table 3.16.  Capacity factor for the varying organic phase compositions (ACN:Water). 
Composition Mobile phase 
front 
tM 
(min) 
Retention time 
tR 
(min) 
Capacity factor 
k’ 
k’=tR-tM/tM 
ACN Water 
40 60 >5 >5 
 
50 50 1.30 2.94 1.3 
60 40 1.31 2.30 0.7 
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Table 3.17. Descriptive summary for newly developed assay for quantitation of INN-312 in 0.1% DMSO/PBS solution. 
 
 
Type of assay  HPLC-UV/Vis 
Instrumentation LC System Waters 2695 Separations Module (Waters, Milford, MA) 
 Detector Shimadzu 10 AV Absorbance Detector 
Columns Analytical column Zorbax Rx C18, 80 A
o, 150 mm x 4.6 mm, 5 μm (Agilent, CA) 
 Guard column C18, 12.5 mm x 4.6 mm (Agilent, CA) 
Assay conditions Mobile phase ACN:Water (50:50) 
 Autosampler temperature 4 °C 
 Column temperature 25 °C 
 Flow rate 1 mL/minute 
 Detection UV/Vis at 350 nm 
 Injection volume 10 µL 
 Chromatographic run time 5 minutes 
 Retention time 2.9 minutes 
 Calibration curve range 3.9 – 500 µM 
 Experimental LOQ (ELOQ) 3.9 µM 
 Quality control (QC) levels 10, 100 and 400 μM 
Data processing Software Empower 2 Software (Waters, MA) 
 Regression algorithm for CC Linear, weighted 1/x 
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3.3.3.3 Linearity  
A 2000-fold range of varying concentrations of INN-312 (0.5 - 1000 μM) prepared in 
0.1% DMSO was assessed for concentration-dependent increases in INN-312 response (Figure 
3.12). The relationship between the amount of INN-312 loaded on column and response was 
assessed, and determined to be linear (r
2
 = 0.99). The calibration range for INN-312 standards 
was further optimized to achieve high accuracy and precision, and is described under section 
3.3.3.5 below. 
 
3.3.3.4 Assay Selectivity 
 
Selectivity of the assay was demonstrated in order to confirm detection, separation and 
quantification of INN-312 in neat solution of 0.1% DMSO in PBS, and investigate the effect of 
(any possible) impurity peaks that may interfere with the assay. Blank solution of 0.1% DMSO 
in PBS was injected for comparison with INN-standards. The chromatographic peak for INN-
312 was observed at a tR of 2.9 min in the INN-312 standard samples, but not in the blank 
injection. Figures 3.12 and 3.13 – 3.20 represent the selectivity of the assay from a blank DMSO 
chromatogram and representative chromatograms for increasing INN-312 concentrations, 
respectively. 
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Figure 3.12. Demonstration of linear (unweighted) relationship between response and the 
amount of INN-312 loaded on column.  
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Figure 3.13. Chromatogram for blank DMSO (0.1%DMSO in PBS), showing the absence 
of impurity peaks. 
 
 
 
 
 
Figure 3.14. Representative chromatogram for 3.9 μM INN-312. 
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Figure 3.15. Representative chromatogram for 7.8 μM INN-312. 
 
 
 
 
 
 
 
Figure 3.16. Representative chromatogram for 15.6 μM INN-312. 
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Figure 3.17. Representative chromatogram for 31.3 μM INN-312. 
 
 
 
 
 
 
 
Figure 3.18. Representative chromatogram for 62.5 μM INN-312. 
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Figure 3.19. Representative chromatogram for 125 μM INN-312. 
 
 
 
 
 
Figure 3.20. Representative chromatogram for 500 μM INN-312. 
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3.3.3.5 Calibration curve  
The relationship between the UV/Vis response with increasing concentrations of INN-
312 in 0.1% DMSO was linear between a concentration range of 3.9 – 500 µM (Figure 3.21). 
The calibration curve was established in this analytical range, by 1/x weighted linear regression 
of the response with respect to INN-312 concentration, for three runs in duplicate. A weighting 
factor of 1/x was used due to the wide analytical range. Figure 3.21 represents a calibration curve 
for INN-312 in 0.1% DMSO for three replicates (mean ± SD). The COV was less than 3% for all 
standards and high accuracy of 99 – 105% is reflected from DFN values less than 5% for all 
standards except the ELOQ (Table 3.18). The ELOQ determined from the lowest concentration 
of INN-312 in 0.1% DMSO, that could be quantified with high precision and accuracy was 3.9 
µM, with COV of 2.3% and DFN of 13% (n=3) (see section 3.2.5). 
 
3.3.3.6 Accuracy  
High within-run (intra-run) and between-run (inter-run) accuracy was demonstrated for 
all INN-312 calibration standards in neat solution (in triplicate over three separate runs). The 
average intra-run DFN for triplicate readings was less than 5% for all standards except the 
ELOQ, where the DFN was 13%. The average inter-run DFN was less than 6% for all standards, 
except the ELOQ where the DFN was 19% (Table 3.19). 
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3.3.3.7 Precision  
High within-run (intra-run) and between-run (inter-run) precision was demonstrated for 
all INN-312 calibration standards in neat solution (in triplicate over three separate runs). The 
intra-run COV was less than 3% for all standards, and inter-run COV was less than 6% for all 
standards expect ELOQ (COV of 13%; Table 3.19). 
 
3.3.3.8 Post-preparative stability 
The stability of INN-312 standards prepared in 0.1% DMSO in PBS up on storage for 24 
hrs at 4
o
C and 25
o
C was demonstrated. Table 3.19 shows good precision and accuracy between 
all concentration levels of INN-312 stored at 4
o
C for 24 hrs (COV less than 3% and DFN less 
than 10%) and 25
o
C for 24 hrs (COV less than 9% and DFN less than 15%), and freshly 
prepared samples. The mean response of triplicate readings is reported for the freshly prepared 
samples in Table 3.20.  
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Figure 3.21. Representative calibration curve for 3.9 – 500 μM INN-312 in 0.1% DMSO 
(mean ± SD; n=3). 
 
 
Table 3.18.  Precision and accuracy for INN-312 calibration curve in 0.1% DMSO.  
[INN-312] 
μM 
Response (Replicate measurements) 
COV DFN 
R1 R2 R3 Mean 
3.9 4600 4717 4508 4608 2.3% 13% 
7.8 10097 10442 10714 10418 3.0% 0.1% 
15.6 22515 22489 22585 22530 0.2% -5% 
31.3 48133 48303 48361 48266 0.2% -4% 
62.5 99131 99467 99032 99210 0.2% -4% 
125 207802 208339 207688 207943 0.2% -1% 
250 424491 423986 422030 423502 0.3% -0.2% 
500 863018 861214 862753 862328 0.1% 1% 
Weighted Slope 1711 1709 1708 1709 
  
Intercept -3071 -2872 -2911 -2951 
  
r
2
 0.99 0.99 0.99 0.99   
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Table 3.19.  Mean values for within-run and between-run accuracy and precision for all INN-312 calibration standards (in 
triplicate over three separate runs). 
 
 
[INN-312] 
μM 
Intra-run 
(response from triplicate readings) 
Inter-run 
(response from three runs with triplicate readings) 
Mean response COV DFN% Mean response COV DFN% 
3.9 4608 2.3% 13% 4392 13% 19% 
7.8 10418 3.0% 0% 10127 6% 1% 
15.6 22530 0.2% -5% 22379 4% -6% 
31.3 48266 0.2% -4% 47760 5% -7% 
62.5 99210 0.2% -4% 101670 3% -5% 
125 207943 0.2% -1% 213753 3% -3% 
250 423502 0.3% 0% 442736 4% 0% 
500 862328 0.1% 1% 905320 4% 2% 
Weighted Slope 1709   1786   
Intercept -2951   -3908   
r
2
 0.99   0.99   
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Table 3.20.  Stability of INN-312 standards on 24 hr storage at varying temperatures (4
o
C 
and 25
o
C). 
 
[INN-312] 
μM 
 
Response COV DFN 
0 hr 
24 hr 24 hr 24 hr 24 hr 24 hr 24 hr 
4
o
C 37
o
C 4
o
C 37
o
C 4
o
C 37
o
C 
3.9 4608 4413 4601 3% 0.1% 10% 13% 
7.8 10418 10107 9790 2% 4% -2% -5% 
15.6 22530 21888 19860 2% 9% -7% -15% 
31.3 48266 46392 44356 3% 6% -8% -11% 
62.5 99210 97913 92384 1% 5% -6% -11% 
125 207943 204170 198841 1% 3% -3% -6% 
250 423502 418111 413217 1% 2% -1% -3% 
500 862328 857267 852614 0.4% 1% 1% 0.1% 
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3.3.4 Analytical method development for HbA and HbA-adducts with 5-HMF using 
isolated lyophilized human HbA0 
 
The Waters 2690 Alliance HPLC instrument and Shimadzu UV-Vis Spectrophotometer 
were set up for performing cation exchange chromatography (Cat-Ex LC). The cation exchange 
analytical column and guard column were conditioned appropriately by running 3-4 cycles of the 
gradient (described below). A description of the preliminary analytical method is described in 
Table 3.21. The initial gradient method was selected based on validated assays for qualitative 
separation of the different Hb variants by PolyLC (PolyLC Inc., Columbia, MD; Al-Abed et al., 
1999; Al-Abed et al., 2001). Preliminary studies were carried out to investigate the detection of 
HbA0 from isolated HbA0 solution in PBS, using Cat-Ex LC. 
 
3.3.4.1 Selectivity 
Demonstration of selectivity towards (unmodified) HbA was performed using a blank 
matrix (PBS, in the absence of HbA) and a high concentration of HbA. A major peak for HbA 
appeared at a tR of ~6 min, among other smaller peaks that may represent other conformational 
forms of Hb, which were absent in the blank injection (Figure 3.22).  
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Table 3.21.  Description of the preliminary assay for HbA (and HbA-adduct). 
 
Type of assay CATION EX-LC-UV/VIS 
LC System Waters 2695 Separations Module 
Detector Shimadzu 10 AV Absorbance Detector 
Analytical column 
 PolyCAT A
TM
 weak cation exchange column, 3 μm, 4.6 mm x 35 mm, 1500 Å (Lot # 12-112-3; 
PolyLC, Columbia, MD)  
Guard column 
PolyCAT A
TM
 Javelin guard cartridge, 3 μm, 4 mm x 10 mm (Serial # 022511-1-2; PolyLC, 
Columbia, MD) 
Detection Wavelength  410 nm 
Autosampler temperature 4 °C 
Flow rate 1.7 mL/minute 
Injection volume 10 µL 
Mobile phase 
A: 40 mM Bis-Tris, 5 mM EDTA, pH 6.5 
B: 40 mM Bis-Tris, 5 mM EDTA, 200 mM NaCl, pH 6.5 
pH adjusted to 6.5 using ~500 µL glacial acetic acid 
Degas Mode 
Off. Hb requires the presence of dissolved oxygen in the mobile phase. Mobile phases were filtered 
by vacuum prior to use. 
Elution Linear gradient of mobile phase B:  
 Minutes %B 
 0 10 
 8 40 
 15 100 
 16 10 
Chromatographic run time 18 min; Delay time for next injection = 2 min 
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3.3.4.2 Linearity in response and stability of standards 
Varying concentrations (0.4 – 250 µM; 0.03 – 16.2 mg/mL) of isolated HbA were used to 
demonstrate a concentration-dependent increase in response. An increase in response with 
increasing concentrations of HbA may be observed at tR of ~6min from Figures 3.23 – 3.27. The 
relationship between HbA response, measured as pear area and the Hb concentration was 
modeled by linear regression, with a weighting factor of 1/x.  
Furthermore, the post-preparative stability of HbA protein standards up to 70 min was 
investigated at 4
o
C, in order to confirm stability of the protein in the autosampler, due to the long 
chromatographic run-times. 
Linearity in response with high accuracy was demonstrated from an r
2
 = 0.99 and DFN 
less than 8% for all standards (Figure 3.28 and Table 3.22). Similar observations were made for 
replicate injections stored in the autosampler up to 70 min. There was high precision between the 
freshly prepared and stored standards (n=1), based on COV values of less than 1% for all 
concentration levels, except the lowest concentration (0.4 µM), which had COV of 16%. This 
demonstrates the post-preparative stability of HbA standards at 4
o
C up to 70 min. This may be 
expected as proteins are known to have stability and low activity at temperatures less than 4
o
C. 
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Figure 3.22. Representative blank chromatogram for PBS in the absence of HbA standard. 
 
 
 
Figure 3.23. Representative chromatogram for 0.4 µM HbA in PBS. 
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Figure 3.24. Representative chromatogram for 2.0 µM HbA in PBS.  
 
 
 
Figure 3.25. Representative chromatogram for 10.0 µM HbA in PBS. 
 
 
.  
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Figure 3.26. Representative chromatogram for 50.0 µM HbA in PBS.  
 
 
 
 
Figure 3.27. Representative chromatogram for 250.0 µM HbA in PBS.  
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Figure 3.28. Linear increase in mean response to HbA standard (THb) concentration 
(weighted 1/x).  
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Table 3.22.  Linear increase in response to HbA standard (THb) concentration (weighted 
1/x), and stability of the Hb samples at 4
o
C for 70 min, with high precision and accuracy.  
 
[THb] 
μM 
Response (Replicate 
measurements) 
Mean COV 
DFN% 
R1 
R2 after 70 
min 
R1 R2 Mean 
0.4 11933 9522 10728 16% 2% 2% 2% 
2 70503 69530 70017 1% -8% -7% -8% 
10 408938 405780 407359 0.5% 1% -0.3% 0.2% 
50 2143874 2171143 2157509 1% 5% 5% 5% 
125 5325044 5313617 5319330 0.2% 4% 3% 3% 
250 9990781 10120384 10055582 1% -3% -2% -3% 
Weighted Slope 41107 41460 41283 
    
Intercept -4861 -7406 -6133 
    
r
2
 0.99 0.99 0.99 
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3.3.4.3 Evaluation of two methods for Hb analysis and separation of Hb-adducts 
Preliminary separation analysis was carried out assessing separation of Hb-adducts with 
5-HMF from unmodified Hb (referred to as THb) using the cation-exchange LC method. A 
concentration of 5-HMF was selected based on the assumption that 5-HMF binds with Hb in a 
2:1 molar ratio (Safo et al., 2004), and 2-fold higher molar concentration of 5-HMF is required to 
fully bind with HbA. Therefore, 250 µM of HbA was incubated with 500 µM of 5-HMF for 70 
min based on the observed effect in sickle cell lysates (Abdulmalik et al., 2005). No significant 
peak for Hb-HMF adduct was observed, however, the approximately 34% decrease in response 
of unmodified HbA suggests conversion of the HbA to another form, limitation of the assay in 
separation and /or detection of low concentrations of Hb-adducts from unmodified HbA, and 
need for investigating higher molar ratios of 5-HMF incubated with HbA. Molar ratios of 8:1 
resulted in significant adduct formation within 70 min of pre-incubation of 5-HMF (1 mM) with 
Hb (125 µM) and could be separated from unmodified HbA by the assay, confirming the utility 
of the assay. Elution of the Hb-adduct occurs before the unmodified Hb at tR 6.3 – 6.5  min 
(Abdulmalik et al., 2005; Nnamani et al., 2008) and the appearance of a new peak was observed 
at a similar tR approximately 1 min earlier than unmodified Hb, likely representing the Hb-
adduct (see Figure 3.29). The overall positive charge on HbA is responsible for its retention on 
the polyaspartate cation-exchange column. The adduct formation decreases its retention and 
therefore, the Hb-adduct elutes faster than the unmodified Hb (Al-Abed et al., 1999; Al-Abed et 
al., 2001; PolyLC, Inc.).  
Two different gradient elution methods were assessed for optimization of separation of 
Hb-adducts with 5-HMF and Hb. The method described by PolyLC, Inc. is described in Table 
3.20. The PolyLC, Inc. method followed by Nnamani et al. (2008) was modified such that the pH 
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of mobile phase B (pH 7.5) was adjusted higher than that for mobile phase A (pH 6.5). The 
PolyLC, Inc. method described identical pH conditions (pH 6.5) for the two mobile phases. The 
two methods did not show significant differences in chromatographic separation of Hb-adducts 
from unmodified Hb at 8:1 molar ratios of 5-HMF with Hb. 
 
Figure 3.29. Cation-exchange LC chromatograms for SS cell hemolysates incubated with 5-
HMF (Abdulmalik et al., 2005). 
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3.3.4.4 Preliminary assessments for time-dependent formation of the Hb-adduct 
Obied (2010) showed time-dependent binding of 5-HMF to HbA in isolated HbA 
solution for molar fraction levels of 0.04:1, 0.3:1 and 1.8:1 5-HMF and HbA. Free 
concentrations of 5-HMF were measured, and were found to decline in a time-dependent 
manner, suggesting time-dependent binding and adduct formation with HbA (Obied, 2010). 
Therefore, preliminary assessments were made to investigate the time-dependent formation of 
Hb-adduct with 5-HMF, and ability of the assay to separate the Hb-adduct from Hb. 500 µM of 
5-HMF was incubated with 125 µM HbA (4:1 molar ratio) at 37
o
C. Aliquots were drawn at 
varying intervals from 0 – 8 hrs, and transferred to vials for injection and analysis. Figures 3.30 – 
3.38 represent the chromatograms for Hb-adducts and HbA at varying time-periods. The 
chromatographic peak for unmodified Hb has been represented as “HbA” and a new peak 
representing the adduct formation has been labeled as “Adduct”.  
A time-dependent increase in response for adduct was observed after 1 hr and up to 8 hrs, 
suggesting time-dependent binding of 5-HMF to HbA and adduct formation. Chromatographic 
peak resolution between Hb-adduct and HbA was calculated from Equation 3 – 2, which takes 
into consideration the peak width of the two species: 
 
  
  [(  )  (  ) ]
     
                                        
Where 
R: peak resolution 
(tR)A and (tR)B : retention times of the two species, i.e., Hb-adduct and HbA, respectively 
WA and WB : peak width at the base for Hb-adduct and HbA, respectively 
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Complete baseline resolution between two chromatographic peaks is achieved when R > 
1.5.  For Hb samples incubated up to 1.5 hrs, adequate peak resolution of ~1.3 was achieved. 
This was considered acceptable for quantification of Hb-adducts. However, samples incubated 
for prolonged time periods (greater than 1.5 hrs) showed significant peak overlap with poor 
baseline resolution ( < 1.0), and may be observed from Figures 3.35 – 3.38.  
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Figure 3.30. Blank chromatogram for 125 µM HbA in PBS, in absence of 5-HMF. 
 
 
 
 
 
Figure 3.31. Chromatogram after 0.25 hr incubation of 500 µM 5-HMF with 125 µM HbA 
in PBS (4:1) at 37
o
C. 
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Figure 3.32. Chromatogram after 0.5 hr incubation of 500 µM 5-HMF with 125 µM HbA in 
PBS (4:1) at 37
o
C. 
 
 
 
 
 
 
Figure 3.33. Chromatogram after 1 hr incubation of 500 µM 5-HMF with 125 µM HbA in 
PBS (4:1) at 37
o
C. A new peak for adduct may be observed. 
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Figure 3.34. Chromatogram after 1.5 hr incubation of 500 µM 5-HMF with 125 µM HbA in 
PBS (4:1) at 37
o
C. 
 
 
 
 
 
Figure 3.35. Chromatogram after 2.5 hr incubation of 500 µM 5-HMF with 125 µM HbA in 
PBS (4:1) at 37
o
C. 
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Figure 3.36. Chromatogram after 4 hr incubation of 500 µM 5-HMF with 125 µM HbA in 
PBS (4:1) at 37
o
C. 
 
 
 
 
 
 
Figure 3.37. Chromatogram after 6 hr incubation of 500 µM 5-HMF with 125 µM HbA in 
PBS (4:1) at 37
o
C. 
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Figure 3.38. Chromatogram after 8 hr incubation of 500 µM 5-HMF with 125 µM HbA in 
PBS (4:1) at 37
o
C. 
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In addition to the time-dependent increase in Hb-adduct response, a simultaneous 
appearance of additional peaks and increase in response for these unknown peaks was observed 
(Figures 3.35 – 3.38). These unknown peaks, considered possibly other conformational forms of 
HbA account for less than 20% of the total peak area in 5-HMF-incubated samples up to 1.5 hr, 
and up to 36% in 5-HMF-incubated samples from 1.5 – 8 hrs. This suggests, in addition to 
formation of the Hb-HMF adduct, other time-dependent changes in HbA may occur due to the 
presence of 5-HMF such as, incomplete binding of 5-HMF to the two alpha-globin subunits of 
Hb, conformational changes due to oxygenated state of Hb, additional binding sites on Hb (with 
valine or lysine amino acid residues), or degradation/instability of (ferrous-stabilized) HbA at 
37
o
C. Figure 3.39 shows the time-profiles for the three forms of HbA, i.e. free unmodified HbA, 
measured HbA adduct and HbA in the form of impurities, as a percent of the total peak area, and 
calculated adduct (from Equation 3 – 3 below), for comparison. While unmodified HbA levels 
declined and increase in adduct formation occurred as expected, an equally rapid increase in 
impurity peaks was also observed, limiting the assay. 
Assuming the total HbA concentration in the sample is a sum of unmodified HbA and the 
bound Hb (Hb-adduct), ignoring the appearance of impurity peaks that likely represent time-
dependent changes in HbA (or its conformational form), the % adduct formed was calculated 
from Equation 3 – 3, adapted from Abdulmalik et al. (2005). 
   
            [
                     
(                     ) (                          ) 
]                      
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This method assumes only two possible forms of Hb: unmodified Hb and Hb-adduct. It 
does not account for the presence of observed unknown peaks, possibly other conformational 
forms of Hb.  
Using this (semi-quantitative) approach, 5-HMF incubated with HbA resulted in time-
dependent formation of Hb-adduct, as a percent of the sum of unmodified Hb and Hb-adduct, up 
to 8 hrs (Figure 3.40). These results were compared with predictions for HbA adduct formation 
from binding studies, conducted by the ultrafiltration method, described in detail in Chapter 7. 
The initial rate of adduct formation is fairly comparable between the two independent 
experimental methods, supporting the mechanism of the binding reaction. It also provides some 
preliminary evidence that the method of indirect measurement of unbound 5-HMF 
concentrations in HbA solutions can be employed for characterization of the binding kinetics. 
However, the observations from Figure 3.40 cannot be further interpret due to the underlying 
assumptions for estimation of adduct formation from the calculated adduct. As it can be seen 
from Figure 3.39, the calculated Hb-adduct likely overestimates the actual Hb-adduct levels.   
Overall, this chromatographic method could not be standardized due to variable HbA 
UV/Vis absorbance, resulting in an unexpected apparent “increase” in unmodified HbA response 
with time, in addition to increased Hb-adduct formation, poor baseline separation between the 
structurally similar modified and unmodified Hb forms, and increasing appearance of multiple 
unknown peaks after 1.5 hrs. Further attempts were made for method optimization, and are 
discussed under section 3.3.4.6.  
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Figure 3.39. Time-profiles for unmodified HbA, calculated Hb-adduct, measured adduct 
and impurities as a percent of the total peak area, on incubation of 500 µM 5-HMF with 
125 µM HbA in PBS (4:1) at 37
o
C. 
 
 
 
Figure 3.40. Time-dependent Hb-adduct formation: calculated (% of modified and 
unmodified HbA) and predicted (see Chapter 7) on incubation of 500 µM 5-HMF with 125 
µM HbA in PBS (4:1) at 37
o
C. 
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3.3.4.5 Generalizability of assay 
Preliminary studies for INN-312 incubated with 125 µM HbA (at 37
o
C) at a molar 
fraction level of 2:1 for 1 hr showed rapid and extensive adduct formation with acceptable 
chromatographic peak resolution between Hb-adduct and unmodified HbA (Figure 3.41). This 
provides evidence for a greater and more rapid binding of INN-312 to Hb than 5-HMF (Nnamani 
et al, 2008). However, an additional peak, overlapping with unmodified HbA was observed, 
which was not observed when HbA was incubated with 5-HMF. The appearance of unknown 
peaks suggests some differences in the molecular reaction mechanism of INN-312 with Hb, 
compared to 5-HMF. Overall, the assay cannot serve as a generic assay, and requires separate 
validation for each respective AEH. 
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Figure 3.41. Representative chromatogram after 1 hr incubation of 250 µM INN-312 in 
DMSO with 125 µM HbA in PBS (2:1) at 37
o
C. 
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3.3.4.6 Method Optimization and Run-time Analysis 
The chromatographic run-time of 20 min is impractical to carry out time-dependent 
binding kinetic studies for 5-HMF with HbA. Therefore a run-time analysis was performed to 
improve the efficiency of the assay by shortening the run-time, and optimizing the flow rate. 
Chromatograms were carefully assessed for peak shape, resolution (between Hb-adduct and 
unmodified HbA), and unknown peaks with varying flow-rate and sequential changes in mobile 
phase gradient with shortened time. 
The run-time was shortened to 12 min from 20 min and gradient elution was optimized. 
In addition, the column temperature was optimized to 25
o
C. Furthermore, HbA standards 
prepared in plastic vials were compared with those prepared in borosilicate glass tube, 
investigating possible non-specific binding, showed similar results. The final optimized 
analytical method for Hb-adducts of Hb is described in Table 3.23 and showed good resolution 
between the respective peaks. 
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Table 3.23.  Description of the analytical assay for HbA (and HbA-adduct). 
 
Type of assay CATION EX-LC-UV/VIS 
LC System Waters 2695 Separations Module 
Detector Shimadzu 10 AV Absorbance Detector 
Analytical column 
 PolyCAT A
TM
 weak cation exchange column, 3 μm, 4.6 mm x 35 mm, 1500 Å (Lot # 12-112-3; 
PolyLC, Columbia, MD)  
Guard column 
PolyCAT A
TM
 Javelin guard cartridge, 3 μm, 4 mm x 10 mm (Serial # 022511-1-2; PolyLC, Columbia, 
MD) 
Detection Wavelength  410 nm 
Autosampler temperature 4 °C 
Column temperature 25 °C 
Flow rate 1.2 mL/min 
Injection volume 10 µL 
Mobile phase 
A: 40 mM Bis-Tris, 5 mM EDTA, pH 6.5 
B: 40 mM Bis-Tris, 5 mM EDTA, 200 mM NaCl, pH 6.5 
pH adjusted to 6.5 using ~500 µL glacial acetic acid 
Degas Mode 
Off. Hb requires the presence of dissolved oxygen in the mobile phase. Mobile phases were filtered by 
vacuum prior to use. 
Elution Linear gradient of mobile phase B:  
 Minutes %B 
 0 10 
 10 50 
 10.1 10 
Chromatographic run time 12 min 
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3.3.4.7 Stability of HbA Standards  
 
Linearity in response for HbA standards prepared in PBS was re-demonstrated using the 
newly developed method and showed to have high accuracy (DFN less than 15%) for all 
concentration levels of HbA (0.5 – 250 μM). Time-dependent stability studies were carried out 
for HbA standards on storage at 37
o
C up to 24 hours. Additionally, these would help serve as 
‘negative controls’ for quantification of time-dependent adduct formation.  
0.5 – 250 μM HbA prepared in PBS, was incubated at 37oC. Serial aliquots of 150 μL were 
drawn at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 12 hr respectively, and stored at 4
o
C in the 
autosampler for injection and analysis. The molar amount of HbA injected on column was 0.005 
– 2.5 nmoles. Storage of HbA at 37oC after 6 hr resulted in significant changes in peak shape and 
high response for unknown peaks and peak overlapping, likely due to derivatization of Hb to 
other conformational forms.  
The time-dependent response of varying amounts of HbA (0.005 – 2.5 nmol; with 
corresponding concentrations of 0.5 - 250 μM) is shown in Table 3.24. The response for HbA 
was linear with respect to amount of HbA at each time period. r
2
 values of >0.99 and high 
accuracy (DFN less than 14%) from weighted linear regression at each time period (0 – 6 hrs) 
demonstrates the linearity of response at each time period (Table 3.25). However, a significant 
time- and concentration-dependent reduction in response for HbA standards, as seen from Figure 
3.42, confirms conformational changes in the ferrous-stabilized HbA and derivatization, which 
could not be adequately captured by the analytical assay.  
The lower concentrations of HbA (0.5 – 10 μM) have the greatest degradation/ 
derivatization, in comparison with the higher concentrations (50 – 250 μM). A maximum 
reduction in peak response of 60 – 80% was observed after 4 – 6 hrs for the lowest concentration 
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level of HbA, while only 15% reduction was observed at the higher concentration levels. This 
may be explained from possible rapid formation of hemoglobin, or metHb (ferric Hb) at the 
lower concentrations, due to more handling and serial dilutions, as has been observed in 
experimental conditions (Safo et al., 2004) in comparison with the higher concentrations of HbA. 
Further evidence for this hypothesis is provided by additional unknown peaks that account for 
greater than 25% of the total peak area after 4 – 6 hrs for these lower concentrations of HbA. 
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Table 3.24.  Stability of HbA standards on storage at 37
o
C: Time-dependent change in HbA response up to 12 hrs. 
HbA 
nmol 
Response (Peak Area) after Time (hr) 
Mean COV 
0 0.25 0.5 1 1.5 2 4 6 8 – 12 
0.005 21427 22384 21228 18362 18275 16775 8416 4525 
 
16424 40% 
0.02 116367 116247 114169 109771 106054 100147 87361 70537 102582 16% 
0.1 683031 682428 682591 661146 655078 642847 592390 539259 642346 8% 
0.5 3445697 3472743 3462772 3428896 3388912 3365675 3194531 2935860 3336886 6% 
2.5 15300555 15476047 15620751 15498857 15182409 15350517 14648254 13903587 15122622 4% 
Slope 6270029 6335046 6380362 6326542 6208597 6254315 5964031 5627146 6171122  
Intercept -5352 -5434 -7424 -10682 -10228 -13755 -21329 -26212 -12858  
r
2
 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99  
 
Table 3.25.  Accuracy for HbA standards (0.005 – 2.5 nmol) at respective time periods. 
 
HbA 
nmol 
DFN% at respective time (hr) 
0 0.25 0.5 1 1.5 2 4 6 
0.005 -15% -12% -10% -8% -8% -2% -0.3% 9% 
0.02 -3% -4% -5% -5% -6% -9% -9% -14% 
0.1 10% 9% 8% 6% 7% 5% 3% 0.5% 
0.5 10% 10% 9% 9% 9% 8% 8% 5% 
2.5 -2% -2% -2% -2% -2% -2% -2% -1% 
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Figure 3.42. Time- and concentration-dependent reduction in peak response for HbA 
standards incubated at 37
o
C. 
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3.3.4.8 Comparison between forms of isolated Hb Lyophilized HbA and Purified Hb (obtained 
from Dr. Safo’s lab 
Boys et al. (2007) investigated acid-induced denaturation of Hb, derivatized as oxyHb, 
metHb and cyanomet-Hb, and found significantly different results from similar experiments 
conducted on metHb obtained commercially as lyophilized powder and freshly prepared metHb. 
Therefore, isolated HbA obtained from two sources was investigated: Lyophilized HbA supplied 
by Sigma-Aldrich (St. Louis, MO) and Concentrated HbA purified by Dr. Safo’s laboratory 
(Department of Medicinal Chemistry, VCU). The objective of the study was to investigate the 
content of metHb in the two sources of HbA, and whether the lyophilized HbA contains higher 
levels of metHb due to greater processing and further reconstitution of HbA protein. This may in 
turn, interfere with the chromatograms and peak shape for non-derivatized (ferrous) hemoglobin.  
The UV/Vis absorption spectra for the lyophilized HbA (obtained from Sigma-Aldrich) 
and concentrated Hb (obtained from the Department of Medicinal Chemistry, VCU), were 
compared for possible differences in the absorptivity. The absorption spectra were recorded for 
approximately 2 μM solutions of lyophilized HbA0 and concentrated HbA prepared in PBS (pH 
7.4) and are shown in Figure 3.43. The Soret band for metHb is at 405 nm and that for oxyHb is 
at 415 nm; other absorption maxima for oxyHb are at 541 and 577 nm (Boys et al., 2007). A shift 
in maxima to 405 nm would likely reflect higher levels of metHb (Boys et al., 2007). The Hb 
absorbance in the Soret region of 410 – 415 nm region was similar and ranged between 0.6 – 0.8 
AU for the two forms of HbA. The samples were aspirated into a co-oximeter to obtain the 
composition of Hb and the values are reported in Table 3.26. Lyophilized HbA has composition 
similar to concentrated Hb, but about 8-fold higher metHb content.  
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Figure 3.43. Absorption spectra for approximately 2 μM solutions of lyophilized HbA0 and 
concentrated HbA, prepared in PBS pH 7.4. 
 
 
 
Table 3.26.  Hb-composition analysis for concentrated HbA and lyophilized HbA. 
 
Concentrated HbA Lyophilized HbA  
Lyophilized HbA 
(100 μM) 
Total Hb (g/dL) 13.7 11.6 0.5 
Oxy-Hb (%) 96.5 87.4 86.5 
MetHb (%) 0.9 6.6 7.5 
Carboxy-Hb (%) 3.1 4.0 3.8 
Deoxy-Hb (%) -0.5 1.9 2.3 
SO2 (%) 100.5 97.5 97.5 
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It is known oxy-hemoglobin undergoes slow auto-oxidation to metHb (Misra et al., 
1972). Furthermore, a pH-dependent gradual decrease in the heterodimeric Hb species to 
monomers has also been shown (Boys et al., 2007). Therefore, incubation at 37
o
C for prolonged 
periods may result in auto-oxidation and changes in the pH of lyophilized HbA solution, 
resulting in greater formation of metHb, thus causing a time-dependent reduction in (oxy)Hb 
response (discussed in section 3.3.4.7) and high interference in the analytical assay. KCN in 
known to stabilize the ferrous (oxy) form of Hb by forming ferrocyanide and preventing 
formation of metHb (Al-Abed et al., 1999; PolyLC, Inc.). It may be used as a sample 
reconstitution solvent, and included in the mobile phase at concentrations of 2 mM (Al-Abed et 
al., 1999; PolyLC, Inc.), but did not prove useful.  
Therefore, the analytical assay for Hb-adducts was deemed unsuitable for time-dependent 
binding studies owing to the complexity of Hb fractions on prolonged storage. It may exist in 
several forms, heteroterameric, dimeric and monomeric forms, oxygentated and deoxygenated 
states, ferrous and ferric states. Additional limitations include the effects of pH on Hb, and thus, 
the chromatographic assay. Furthermore, Hb-adducts could be detected using this technique only 
at high molar fraction levels of 5-HMF and HbA, while the first (potentially) quantifiable Hb-
adduct peak was observed only after 1 – 1.5 hr of incubation with HbA. The multiple, unknown 
peaks, likely result from conformational changes of the Hb molecule (or possible degradation), 
and have high interference with the assay. Such conformational changes on the Hb molecule 
likely do not affect the binding of 5-HMF to the α-subunits of the Hb molecule and Hb-adduct 
formation. Therefore, an ultrafiltration approach was used, shown to have similar results (see 
section 2.3.4.4) to overcome the complications of the Hb assay, in order to fully characterize the 
time-dependent binding kinetics of AEH (5-HMF) to Hb (Chapter 7). 
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CHAPTER 4 
4 IN-VITRO HEPATIC OXIDATIVE METABOLISM OF AEH 
 
 
 
4.1 Introduction 
In-vitro systems have been used extensively over the years to understand and investigate 
biotransformation and metabolism of new chemical entities and drug molecules. In-vitro 
preparations of enzyme systems include isolated and purified enzymes, recombinant enzymes, 
cellular/sub-cellular fractions, and tissue slices. The use of these enzyme-expressing/containing 
systems has been of great use to investigate if the drug of interest is a substrate for certain 
enzyme systems, for comparison between the enzyme kinetic parameters for structurally similar 
drugs or different substrates in order to understand the substrate-selectivity and specificity of the 
enzyme, for studying the relative contributions of different enzyme systems in metabolizing a 
drug at physiologically relevant concentrations, for initial screening for potential drug-drug 
interactions and estimating the metabolic clearance by the enzyme (CLint) which has in-vivo 
predictive utility (Pelkonen and Turpeinen, 2007; Hallifax and Houston, 2009). It can be scaled 
or extrapolated to a physiologically meaningful metabolic clearance that may provide an insight 
on the extraction of the drug by the organ and the overall organ clearance for the drug, or used to 
establish in-vitro-in-vivo correlations for intrinsic clearance or hepatic extraction efficiency for 
drugs metabolized by specific enzyme systems. 
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Enzyme-mediated metabolic reactions can be monitored by substrate depletion, product 
formation, or co-factor consumption (for example, NAD
+
, NADP), if the reaction mechanism 
and stoichiometry is known. As a metabolic reaction progresses, substrate is depleted and 
subsequently, product is formed, either of which may be measured spectrophotometrically, by 
fluorescence, or LC techniques followed by different detection methods (UV, fluorescence, mass 
spectrometry, etc.). In order to characterize the metabolism kinetics and estimate valid metabolic 
parameters, it is essential to achieve pseudo-zero order conditions between the enzyme and 
substrate for varying initial substrate concentrations, i.e., the substrate depletion or product 
formation is linear with respect to time, and the enzyme protein concentration is in excess of the 
substrate. This can be assessed from incubation of varying concentrations of substrate for long 
time periods followed by continuous kinetic monitoring to generate progress curves. The 
concentration of product formed by the enzyme-catalyzed reaction is initially linear with time as 
the metabolic reaction progresses at a pseudo zero-order rate (initial reaction rate, obtained from 
the slope) due to steady-state approximations. When incubated for prolonged time period, the 
enzyme reaction may come to completion, represented by a plateau in product concentration, due 
to depletion of all substrate molecules that are converted to product. Such a plateau may also be 
achieved in other situations as co-factor depletion or enzyme degradation, which is independent 
of substrate concentration (Tracy and Hummel 2004). 
 It is essential to perform preliminary experiments to fully optimize the systems and 
relative concentrations of enzyme, substrate and co-factor within the system. Furthermore, as 
increasing substrate concentrations are incubated with the enzyme, the initial reaction rate 
increases to a maximum, beyond which, it does not increase further for higher substrate 
concentrations. This phenomenon is due to saturation of the enzyme. The observed initial 
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reaction rates with respect to their nominal substrate concentrations often follow a typical 
hyperbolic pattern and can be modeled by non-linear regression (Tracy and Hummel 2004).  
Enzyme-catalyzed reactions may follow typical or atypical kinetics, and the most 
commonly used model for typical kinetics is the Michaelis-Menten (MM) hyperbolic model. 
According to this model at low substrate concentrations, the initial rate of metabolism increases 
proportional to the substrate concentrations (apparent first order kinetics), and approaches a 
plateau at the maximal rate of metabolism for very high substrate concentrations due to 
saturation of the enzyme (apparent zero order kinetics). Atypical metabolism kinetics may be 
modeled, depending on the phenomenon observed, by sigmoidal kinetic model (suggesting 
autoactivation), non-asymptotic biphasic model (suggesting two or more metabolic 
sites/systems), substrate-inhibition model or heterotropic cooperativity (activation) model (Tracy 
and Hummel, 2004). 
The MM hyperbolic model provides metabolic parameters such as vmax (maximum rate of 
metabolism) and Km (affinity constant) for comparison between substrates and further 
extrapolation. Under apparent first order conditions, when the concentration of substrate is 10% 
or less of Km, the rate of metabolism is proportional to the substrate concentrations, with a 
proportionality constant, CLint. The intrinsic clearance (CLint) may also be obtained from 
vmax/Km, and is a measure of the intrinsic enzyme activity for the drug, in absence of tissue 
binding or organ flow restrictions. It provides a basis for in-vitro-in-vivo extrapolations (IVIVE). 
A four-stage approach proposed by Houston (1994) has been widely used for extrapolation of in-
vitro metabolism data to estimate in-vivo clearance for an investigational drug. The first stage 
involves the estimation of pertinent kinetic parameters such as vmax and Km and estimation of an 
in-vitro CLint. The second stage involves scaling of the in-vitro CLint to an in-vivo CLint, using 
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scaling factors such as protein concentration or cells per gram of liver, and the total liver weight. 
The third stage employs an organ (liver) model that converts the intrinsic clearance to the 
physiological metabolic pathway, accounting for the organ blood flow and unbound fraction of 
drug available for metabolism. A commonly used model for this purpose is the Wilkinson Shand 
well-stirred model for estimation of hepatic extraction (Wilkinson and Shand, 1975; Nies et al. 
1976; Pang and Rowland 1977). The final stage involves inclusion of other metabolic routes and 
other clearance mechanisms that may result in elimination of the drug from the body to predict 
the total body clearance (Houston 1994).  
AEH are new investigational compounds, and their metabolic pathways are unknown. 
Extensive literature evidence suggests oxidation of the aldehyde functional group may be a 
major metabolic pathway for 5-HMF (in addition to oxidation of the alcohol group). This has 
been shown to be mediated by ALDH and ADH enzymes respectively from in-vitro studies with 
hepatic cytosol suspensions and red blood cell lysates (Obied 2010). The INN-compounds, being 
aromatic aldehydes, may be susceptible to metabolism by ALDH in the liver, as well as the RBC 
(Inoue et al., 1979; Yoshida et al., 1998; Vasiliou et al., 2000).  
Estimating the hepatic clearance for AEH is particularly of interest because the liver is 
considered a major site of drug elimination for most compounds, and also because of its role in 
pre-systemic drug elimination (first-pass effect) for these compounds after oral administration. 
The reported affinities (Km) of isolated hepatic mitochondrial ALDH-2 for meta- and 
para-methoxy benzaldehyde, the respective structural scaffolds for INN-312 and INN-298, are 
90 and 18 nM, respectively. They are tight binding, low turnover substrates for ALDH-2 
(Klyosov, 1996).  
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The major objectives of this study were: 
1. To ascertain whether the novel AEH are substrates for hepatic ALDH, 
2. Characterize and compare their metabolic profiles,  
3. Extrapolate the extent of AEH metabolism by ALDH to the physiologically meaningful in-
vivo intrinsic clearance (CLint
in-vivo
) and apparent hepatic clearance (CLhep’), and 
4. Investigate for differences in ALDH substrate-selectivity between species and compare inter-
species metabolic efficiencies of ALDH using a model substrate. 
Commercially available homogenized hepatic cytosol (XenoTech, Lenexa, KS), as sub-
cellular model for ALDH and ADH activity contains active ALDH and ADH enzymes that are 
capable of metabolism of aldehydes and alcohols, respectively, with Km values comparable to 
those reported in literature for the isolated enzymes, and have good predictive ability for in-vivo 
metabolic clearances (Klyosov, 1996; Gupta, 2006; Obied, 2010). In addition, it has been shown 
to exhibit inter-species differences in the metabolism of primary alcohols and glycols (Gupta, 
2006) and 5-HMF (Obied, 2010).  
ALDH present in the RBC is similar to the hepatic cytosolic ALDH, utilizing NAD
+
 to 
oxidize aliphatic and aromatic aldehydes, with broad substrate specificity and relatively low 
affinity compared to mitochondrial ALDH, and is susceptible to inhibition by disulfiram (Inoue 
et al., 1979). In addition, purified ALDH from hepatic cytosol and from RBC have comparable 
affinities for propanal and cinnamaldehyde (Inoue et al., 1979; Klyosov, 1996), suggesting 
similarities in the substrate binding pocket. Therefore, the ALDH-mediated metabolism of AEH 
was investigated in the human hepatic cytosol model, to gain insight on the extent of oxidation of 
these compounds by ALDH. 
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Measurement of ALDH (and ADH)-enzyme activity can be performed with the relatively 
convenient and reproducible Warburg UV/Vis spectrophotometric method. ALDH and ADH 
enzymes catalyze the oxidation of substrates in the presence of the co-factor, NAD
+
, which is 
converted to NADH during the reaction. NAD
+
 is an essential co-factor which facilitates 
enzymatic catalysis for a variety of enzymes (Wilkinson et al., 1972; Avigad, 1978; Tottmar and 
Hellström, 1983). It is known to bind stoichiometrically with enzymes (especially 
dehydrogenases) to facilitate oxidation of endogenous and exogenous compounds, and 
generating reduced NADH in the process. NADH has an absorbance peak at 340 nm, not shown 
by the oxidized form (NAD
+
), and this serves as an advantage in the measurement of enzyme 
activity. Depending on the nature of the enzyme reaction and the enzyme involved, generation or 
depletion of NADH can be measured spectrophotometrically at 340 nm. This assumes the 
substrate does not interact in any way with NAD
+
, and the substrate, other proteins or DNA (in 
case of intact cells) do not have high intrinsic interference at 340 nm. Since the molar extinction 
coefficient for NADH is known (6.22 mM
-1
 cm
-1
), it enables the enzyme activity to be recorded 
in terms of the amount of substrate metabolized per unit time for physiological interpretation, 
unlike some chromogen-coupled assays where the enzyme activity is measured in arbitrary 
optical density (O.D.) values because of varying molar extinction coefficient values for the 
chromogens (Avigad, 1978). The relatively high molar extinction coefficient (6.22 mM
-1
 cm
-1
) 
for NADH enables measurements down to a micro-molar, and even nanomolar scale with 
adequate detection of absorbance at the low concentration of NADH generated (Kiianitsa et al., 
2003). Owing to several advantages of this assay technique, it  has been well-established and 
employed for characterization of enzymatic activity over the years (Wilkinson et al., 1972; 
Avigad, 1978; Tottmar and Hellström, 1983; Kiianitsa et al., 2003). 
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 The NADH-enzyme-assay, however, is an indirect method for measuring the extent of 
metabolism of a substrate. Difficulty in characterization of specific metabolic pathways and 
differentiation between metabolism kinetics for substrates susceptible to two or more NAD
+
-
dependent enzymes in a system are disadvantages of the NADH spectrophotometric assay. In 
such cases, apparent metabolic efficiencies have been determined and inhibition studies carried 
out to elucidate the relative contributions of each pathway (Obied, 2010). Furthermore, non-
specific NAD
+
-dependent metabolism of endogenous compounds in a system may result in time-
dependent formation of NADH and possible over-prediction of metabolic activity towards the 
substrate. The NADH spectrophotometric assay provides additional advantages such as the ease 
of conducting assay without extensive sample preparation, relatively short experimental time and 
the cost-effectiveness of the technique, compared to development and validation of a new 
experimental method for detection of respective metabolites for a substrate. 
 
 
 
.  
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4.2 Methods 
 
4.2.1 Materials and Reagents 
 
1. BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
2. Co-factor -  β-Nicotinamide adenine dinucleotide hydrate (NAD+) from yeast (Sigma, St. 
Louis, MO) (663.43 g/mol) 
3. Ethanol 200 proof, 99.5% (Sigma-Aldrich, Milwaukee, WI) (46.07 g/mol) 
4. Acetaldehyde, ACS 99% (Sigma-Aldrich, Milwaukee, WI) (44.05 g/mol) 
5. 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO) (126.11 g/mol) 
6. INN-312 (provided by Dr. Martin Safo, Department of Medicinal Chemistry, VCU) 
Batch 2 (243.26 g/mol; Purity ~85%) 
7. INN-298 (provided by Dr. Martin Safo, Department of Medicinal Chemistry, VCU) 
Batch 1 (243.26 g/mol; Purity ~85%) 
8. Vanillin ReagentPlus® 99% (Sigma, St. Louis, MO) (152.15 g/mol) 
9. Dimethyl sulfoxide (DMSO), ≥ 99.9%, A.C.S. Reagent (Sigma-Aldrich, Milwaukee, WI) 
(78.13 g/mol) 
10. Cytosol diluent – Bovine serum albumin (BSA) (Sigma, St. Louis, MO) 
11. Liver cytosol, 10 mg protein/mL (XenoTech, Lenexa, KS):  
a. Human: pooled mixed gender 
b. Canine: pooled Beagle males 
c. Rat: pooled Fischer 344 males 
d. Murine: pooled B6C3F1 males 
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4.2.2 Equipment 
 
1. 3-25 µL positive displacement pipette and corresponding pipette tips (Rainin Instruments, 
Oakland, CA). 
2. 10-100 µL and 100-1000 µL VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA). 
3. 0.5-5 mL Finnpipette (Thermo Scientific, Waltham, MA). 
4. Vortex (Vortex-Genie, VWR, West Chester, PA). 
5. Balance (Fisher Scientific A 250, Pittsburgh, PA). 
6. Synergy™ 2 multi-mode microplate reader (BioTek, Winooski, VT). 
7. Falcon assay plate, 96 reaction wells (VWR, West Chester, PA). 
8. SciFinder® (CAS  software, 2010). 
9. Scientist® Software version 2.0 (Micromath, St. Louis, MO). 
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4.2.3 Preparation of Solutions 
 
1. β-nicotinamide adenine dinucleotide (β-NAD+) co-factor solution 
22.3 mg NAD
+
 was weighed and dissolved in 3 mL Tris buffer, to prepare 11.2 mM 
stock co-factor solution. 25 µL of stock NAD
+
 was transferred to each well (of total volume 200 
µL) to obtain a final concentration of 1.4 mM NAD
+
 in the reaction mixture. 
 
2. Bovine serum albumin (BSA) cytosol diluent 
3 mg BSA was dissolved in 3 mL Tris buffer to obtain 0.1% w/v solution, and was kept 
cold during the experiment. The solution was used as a diluent only for optimization 
experiments.  
 
3. Cytosol solution  
400 µL of the stock solution (10 mg/mL) was added to 600 µL Tris buffer (or BSA 
solution in optimization experiments) to obtain a concentration of 4 mg/mL. 10 µL of this was 
transferred to each well (400 µL) to obtain a final concentration of 0.2 mg/mL cytosol. 
 
4. Solubilizing agent – DMSO in Tris buffer  
2% DMSO was prepared by addition of 0.2 mL DMSO to 9.8 mL of Tris buffer. A final 
concentration of 0.3 M DMSO was achieved in each well with INN-compound substrate-enzyme 
mixture. 
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5. Substrate solution 
Solutions of varying substrate concentrations were prepared in Tris buffer and/or 2% 
DMSO. The concentration range for ethanol, acetaldehyde and 5-HMF was selected based on 
previously reported Km values in the literature (Table 4.1) and optimized to cover concentrations 
10-fold higher and lower than the Km value. For the novel INN-compounds, the concentration 
range was optimized from preliminary experiments based on the Km for 5-HMF and initial 
investigation on a wide range of concentrations. The final concentration range for the substrates 
was limited by the assay sensitivity (NADH formation and detection at 340 nm) at the lower 
limit and their aqueous solubility, as well as high baseline absorbance at the higher 
concentrations. Table 4.2 reflects the concentration range studied for the different substrates. 
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Table 4.1. Selective Substrates. 
 
 
Substrate Reported Km Literature reference 
Ethanol 0.7 mM Gupta 2006 
Acetaldehyde 0.18 mM Klyosov 1996 
 
 
 
Table 4.2. Final concentration ranges used for substrate-dependency studies to assess MM 
kinetics. 
 
 
Substrate Concentration range 
Ethanol 0.2 – 19.8 mM 
Acetaldehyde 0.01 – 12.4 mM 
5-HMF 0.8 – 96 mM 
INN-312 0.1 – 2 mM 
INN-298 1.3 – 5 mM 
Vanillin 0.0004 – 0.1 mM 
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4.2.4 Spectrophotometric Measurement Procedure 
Enzyme activity was measured spectrophotometrically at 340 nm (λmax for NADH) over 
25 min, at 1-minute intervals, using a Synergy 2 Multi-Mode Microplate reader. The amount of 
NADH generated during the metabolic oxidative reaction was determined from the increase in 
absorbance, using the Beer-Lambert relationship below: 
 
                                                      
 
Where  
∆A: measured change in absorbance 
ε: experimental molar extinction coefficient of NADH at 340 nm  
b: pathlength of the cell 
∆C: change in concentration of NADH 
 
Blank absorbance recorded from the 96-well plate containing Tris buffer and baseline 
absorbance from varying concentrations of AEH in the absence of cytosolic protein were used 
for correction of the kinetic spectrophotometric measurements to reflect the absorbance by 
NADH generated during the metabolic reaction. 
Based on the known reaction mechanism/stoichiometry, mass balance was assessed for 
NAD
+ 
and the metabolic reaction was assumed to undergo a 1:1 interaction, i.e. for 1 mole of 
substrate depleted/product formed, 1 mole of NAD
+
 is converted to NADH. 
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4.2.5 Time- and Concentration-Dependency Studies 
A reaction mixture containing 1.4 mM β-NAD+ co-factor and varying concentrations of 
different substrate solutions was allowed to equilibrate for 10 min at 37
o
C. The metabolic 
reaction was initiated by addition of 0.2 mg protein/mL of human hepatic cytosol suspension 
(final volume in well = 0.2 mL). Enzyme activity (NAD
+
 conversion) was measured 
spectrophotometrically at 340 nm and a constant temperature of 37
°
C was maintained with slow-
stirring. The experiments were performed in triplicate. 
Initial metabolic reaction rates over 5-10 minutes were calculated using the initial linear 
slope  from progress curves (r
2
>0.97) of amount of NADH formed over time, which demonstrate 
pseudo-zero order rate of metabolism for the respective substrate concentrations.  Michaelis-
Menten (MM) curves were constructed from the initial metabolic reaction rates and fit by a 
modified MM model using non-linear regression (Scientist
® 
v.2.0) to estimate the kinetic 
parameters. 
 
      
     [ ]
    [ ]
                                       
 
 
Where  
v: observed initial metabolic reaction rate 
v0: baseline enzymatic activity (in absence of exogenous substrate)  
vmax: maximal rate of metabolism 
Km: MM affinity constant  
S: initial substrate concentration 
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For studies where self-inhibition of oxidative metabolism was observed at high substrate 
concentrations, a substrate-inhibition model was used, shown in Equation 4 – 3 below:  
 
 
      
     [ ]
  
  
[ ]
 
[ ]
  
                                      
 
 
Where  
v: observed initial metabolic reaction rate 
v0: baseline enzymatic activity (in absence of exogenous substrate)  
vmax: maximal rate of metabolism 
Km: affinity constant  
Ki: inhibition constant  
S: initial substrate concentration 
 
Goodness-of-fit was assessed by coefficient of determination (r
2
), model selection 
criterion (MSC) and residual analysis. Model suitability and appropriateness was assessed from 
the standard deviations/precision of the parameter estimates.  
Metabolic efficiency, or in-vitro intrinsic clearance (CLint
in-vitro
) was calculated from the 
equation 4-4 below. CLint
in-vitro
 for the INN-compounds was estimated from the slope of the non-
saturable apparent linear phase of the initial reaction rate vs. substrate concentration profile. 
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4.2.6 Optimization Experiments 
Optimization of the experimental technique was performed in the presence and absence 
of BSA as a cytosol diluent. For further studies, Tris buffer was used instead of BSA as the 
cytosol diluent. Varying concentrations of acetaldehyde substrate were incubated with varying 
concentrations co-factor NAD
+
 (0.7 – 2.8 mM) and cytosolic enzyme protein (0.2 – 0.4 mg/mL) 
to study the co-factor dependency and cytosolic protein-dependency. Initial optimization studies 
were also performed using varying concentrations of DMSO (0 – 2% or 0 – 0.25 M DMSO), a 
solvent used to solubilize the INN-compounds, and its effect on ADH- and ALDH-activity at 
varying concentrations, using ethanol and acetaldehyde as respective prototypical substrates. The 
effect of DMSO on substrate-dependent oxidative activity was investigated using acetaldehyde 
and 5-HMF as substrates. 
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4.2.7 Validation of the Sub-Cellular Model for ALDH (and ADH) Activity 
Time- and concentration-dependent metabolism of ethanol and acetaldehyde, known 
selective substrates for ADH and ALDH respectively, was demonstrated using human 
hepatic cytosol preparations.  
 
4.2.8 In-Vitro-In-Vivo Extrapolation 
The estimated in-vitro intrinsic clearance (CLint
in-vitro
) from the metabolic studies was 
extrapolated to in-vivo intrinsic clearance (CLint
in-vivo
) using physiological scaling variables, such 
as the total amount of cytosolic enzyme protein per gram of the liver and the liver weight. The 
in-vivo intrinsic clearance reflects the intrinsic ability of the liver to metabolize the drug via the 
specific enzyme pathway (ADH- and/or ALDH-mediated), in absence of binding or liver blood 
flow restrictions.  
In order to assess the hepatic extraction of the compound, the “well-stirred” (Wilkinson-
Shand) liver model was used. This model assumes that the liver is a single well-stirred 
compartment and the distribution equilibrium is achieved very rapidly so that drug in the venous 
blood (leaving the liver) is in equilibrium with that in the hepatocyte. The hepatic clearance is 
dependent on three biological determinants, the blood perfusion to the liver (Qhep), the inherent 
ability of the liver to eliminate the drug from the circulation (CLint
in-vivo
), and the free fraction of 
drug in blood (fu), or the fraction not bound to plasma proteins and other cellular components of 
blood (Wilkinson and Shand, 1975; Nies et al., 1976; Pang and Rowland, 1977). Any delay in 
diffusion to the hepatocytes, and effect of active transport systems are not accounted for by this 
‘perfusion-limited’ model (Yang et al., 2007). 
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The hepatic extraction ratio (ERhep), oral bioavailability (Foral) apparent hepatic clearance 
(CLhep’) for 5-HMF and INN-compounds was thus estimated from the equations below: 
 
      
           
                 
                                    
 
                                                          
 
                                                            
 
The value for fu can be determined from protein binding studies in whole blood or plasma 
to assess the free fraction of drug with in the relevant concentration range of the study. If such 
information is unavailable, as in the case of the INN-compounds, projections may be made based 
on their physicochemical properties and expected PK characteristics of the compounds.  
5-HMF is a small, polar molecule that exists primarily in its neutral species at the 
physiological pH range of 1 – 8. It is expected to have a negligible plasma protein binding. From 
HSA binding studies by Obied (2010), 5-HMF was found to undergo low affinity binding (KD 
1.5 mM) to HSA relative to binding with Hb. So, fu is considered to be about 1.0, considering the 
relatively lower concentrations of HSA compared to Hb in-vivo. However, the exact free fraction 
would need to be determined taking into account binding to Hb (in the portal vein) to estimate 
the true ERhep. So, the ERhep for 5-HMF may have been slightly over-estimated using fu = 1.0. 
For the INN-compounds, initial projections of fu were be made from a quantitative-
structure pharmacokinetic univariate relationship (QSPKR) between fu and LogD7.4 for opioids, 
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based on the hypothesis that the lipophilic INN-compounds have a similar relationship (Badri, 
2010). 
The IVIVE projections by this method were based on the following assumptions for AEH: 
1) The binding of 5-HMF to plasma proteins (and blood components) is negligible (fu ~1.0). 
The fu for the INN-compounds may be hypothetically estimated from a QSPKR univariate 
relationship between fu and LogD7.4 for opioids, assuming a similar relationship for the 
lipophilic INN-compounds (Badri, 2010). 
2) Oxidative metabolism by ALDH is the major metabolic pathway contributing toward the 
hepatic extraction and drug clearance. Therefore, the hepatic clearance estimated by this 
method is referred to as apparent CLhep (CLhep’), as it may be an underestimation of the true 
CLhep. 
3) Negligible limitations in GI solubility and permeability relative to oral absorption. The 
expected solubility and GI permeability of these AEH have been discussed in Chapter 1.  
 
 
 
Table 4.3. Physiological scaling variables for humans (Bogaards et al., 2001). 
 
 
Physiological scaling variables 
Hepatic cytosolic protein Concentration (mg/g liver) 48 
Weight of liver (g) 1,800 
Hepatic blood flow (Qhep) 1,500 
Body weight (kg) 70 
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4.3 Results 
 
4.3.1 Calibration of UV/Vis Spectrophotometer  
The Beer-Lambert law describes the light absorbed from a solution is a result of the 
chemical and physical characteristics of its contents, to the concentration of the absorbing 
medium and the length of the absorbing path. Therefore, the absorbance of light from a solution 
is directly proportional to the concentration of the absorbing species and the pathlength of the 
cell containing the solution with a proportionality constant known as the molar absorptivity. The 
reported literature value for the maximum molar absorptivity of NADH at this wavelength is 
6.22 mM
-1
cm
-1
 (Klyosov, 1996). The oxidative reaction kinetics were monitored by 
spectrophotometric measurements at 340 nm due to the formation of NADH in the human 
hepatic cytosol. In order to determine the experimental molar absorptivity of NADH, a 
calibration curve was constructed at varying NADH concentrations (0.04 – 0.5 mM) and the 
Beer-Lambert relationship was assessed. Concentrations of NADH beyond the upper range of 
the calibration curve resulted in deviations from the Beer-Lambert law due to saturation of the 
UV detector (absorbance > 3 AU). 
It may be observed from Figure 4.1, the absorbance of NADH at 340 nm is proportional 
to the concentration with a molar absorptivity coefficient of 3.59 mM
-1
cm
-1
. This is the 
experimental molar absorptivity coefficient for NADH, determined based on the UV absorbance 
reported by the Synergy™ 2 multi-mode microplate reader. It is likely, the UV absorbance 
reported by the instrument in is arbitrary units, and requires calibration; different from the 
literature reported value.  
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Figure 4.1.Calibration curve for NADH at 340 nm.  
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4.3.2 Selectivity of Assay Technique 
The selectivity of the spectrophotometric assay at 340 nm was investigated to ensure the 
increase in absorbance at 340 nm is a result of the formation of NADH during the metabolic 
oxidation reaction. Other absorbing species that may contribute to the absorbance are the 96-well 
plates made of polystyrene, Tris buffer, NAD
+
 (λmax of 259 nm), and AEH (λmax of 285 nm for 5-
HMF). In order to investigate the contribution of each of these species to the overall absorbance 
at 340 nm in detail, and demonstrate selectivity of the assay technique, the following 
experiments were performed: 
(1) two types of 96-well plates were compared for their UV-absorbance compatibility: Falcon® 
Pro-Bind™, 96-Well assay plate (VWR, West Chester, PA) and Greiner® UV-Star 96-Well 
plate (Sigma, St. Louis, MO), and  
(2) the absorptivity of NAD
+
 and 5-HMF was investigated at 340 nm.  
Absorbance by an empty assay plate and plate containing Tris buffer was measured at 
259 nm (λmax for NAD
+), 285 nm (λmax for 5-HMF) and 340 nm (λmax for NADH). Tris buffer did 
not have absorbance at 340 nm. However, it was found the Falcon® Pro-Bind™, 96-Well assay 
plate had high absorbance in the short-wavelength UV-region. Therefore, the effect of two kinds 
of 96-well plates on the NADH absorbance at 340 nm was studied, in order to reduce 
experimental errors. The Falcon® Pro-Bind™ 96-Well assay plate, and the Greiner® UV-Star 
96-Well plate known to have “UV-transparency”, or minimal UV absorption. 
Use of a UV non-compatible plate (Falcon® Pro-Bind™) resulted in an absorption 
coefficient of 3.59 ± 0.03 mM
-1
 for NADH, while the UV-compatible plate (Greiner® UV-Star) 
resulted in an absorption coefficient of 2.95 ± 0.01 mM
-1
 for NADH. Since the baseline 
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absorption of the plate was accounted for during kinetic measurements, further experiments were 
performed using the Falcon® Pro-Bind™ plates due to cost-effectiveness of the product. 
NAD
+
 solutions (0.05 – 0.5 mM) were scanned at 340 nm, in order to assess the contribution of 
its absorbance during the metabolism studies. For concentrations as high as 0.5 mM, low 
absorbance was recorded (0.02 AU). However, a relatively high concentration of NAD
+
 (1.4 
mM) was used for the metabolic experiments. Therefore, the mean absorption of several readings 
was calculated and the molar absorptivity determined for this concentration level from the Beer 
Lambert relationship (Equation 4-1). The mean absorption of 60 readings found to be 0.034 AU, 
and the calculated molar absorptivity for 1.4 mM NAD
+
 at 340 nm was found to be 0.025 mM
-1 
cm
-1
. This implies that NAD
+
 has low interference with the absorbance at 340 nm during the 
metabolism studies, in comparison with the absorbance of NADH. 
The absorbance of 5-HMF standards in absence of NAD+ or cytosolic protein at 340 nm 
was proportional to the concentration demonstrating intrinsic absorbance of 5-HMF at 340 nm 
(Figure 4.2). However, the molar absorptivity is 100-fold lower than NADH at this wavelength, 
and increases by 1.5% at the highest concentration level of 5-HMF. Therefore, a baseline 
correction of initial absorption at zero min is essential to account for the absorbance of 5-HMF, 
and further increase in absorbance owing to 5-HMF is considered negligible with respect to the 
generation of NADH from NAD
+
, as well as metabolism of 5-HMF by ALDH (and ADH). 
Vanillin was found to have high absorbance at 340 nm at concentrations as low as 0.0004 
– 0.1 mM with an absorptivity coefficient of 13.7 mM-1cm-1 (Figure 4.3), approximately 4-fold 
higher than that of NADH at 340 nm. Furthermore, Vanillin was found to be unstable on UV 
transmission up to 10 min, resulting in ~7% reduction in its molar absorptivity. Therefore, the 
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metabolism of vanillin in the human hepatic cytosol could not be characterized by the UV 
spectrophotometric assay. 
 
Figure 4.2. Absorbance of 5-HMF at 340 nm.  
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Figure 4.3. Absorbance of Vanillin at 340 nm.  
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4.3.3 Optimization of Experimental Method 
0.1% w/v BSA has been used as a cytosol diluent (Obied 2010) to stabilize the enzyme 
and/or prevent non-specific binding of enzyme protein to the sides of plastic tubes. In order to 
optimize the experimental method, the effect of 0.1% w/v BSA as a cytosol diluent was 
investigated for the metabolism studies. MM kinetic parameters were estimated for the hepatic 
cytosolic metabolism of ethanol and acetaldehyde, the prototypical substrates for ADH and 
ALDH respectively, in presence and absence of 0.1% w/v BSA as a cytosol diluent. Although 
BSA does not usually interfere with enzyme activity or expected to have UV absorbance at 340 
nm, BSA as a cytosol diluent resulted in high baseline activity in the cytosol (i.e., without 
substrate). There was significant decrease in baseline activity (vo) when Tris buffer was used as a 
cytosol diluent instead of BSA, as shown in Table 4.4. Therefore, metabolic experiments using 
hepatic cytosol were carried out using Tris buffer as a cytosol diluent.  
Co-factor and cytosol protein concentration-dependency studies were carried out using 
acetaldehyde as a prototypical substrate for ALDH in the human hepatic cytosol. Co-factor and 
cytosol protein concentration-dependency was demonstrated from Figures 4.4 and 4.5 
respectively, and MM kinetic parameter estimates are shown in Table 4.5.  
The oxidation of acetaldehyde by ALDH is facilitated by the essential co-factor NAD
+
, 
and inadequate NAD
+
 concentration would behave as rate-limiting factor in the metabolic 
reaction. The metabolic reaction rapidly reaches completion due to exhausted co-factor supply, 
and may be observed from the metabolic profile for 0.7 mM NAD
+
.  
The metabolic capacity, vmax, depends on the total concentration of enzyme and the 
catalytic activity of the enzyme. Therefore, increased cytosol protein concentration would result 
in higher vmax, as well as baseline metabolic rate, due to higher concentration of endogenous 
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substances. The intrinsic affinity of the enzyme is not significantly affected and may be observed 
from Table 4.5.  
 
 
 
Table 4.4. Effect of 0.1% w/v BSA as a cytosol diluent on the baseline metabolic activity of 
ADH and ALDH. 
 
 
Substrate 
Baseline activity (vo) (SD) 
[nmoles/min/mg] 
Presence of BSA Absence of BSA (Tris) 
Ethanol 10.0 (0.7) 1.8 (0.4) 
Acetaldehyde 9.4 (1.0) 2.4 (0.3) 
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Figure 4.4. Co-factor concentration-dependent human hepatic cytosol metabolism of 
acetaldehyde.  
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Figure 4.5. Cytosolic protein concentration-dependent metabolism of acetaldehyde.  
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Table 4.5. MM parameter estimates for co-substrate-dependency and cytosol protein 
matrix concentration-dependency study using acetaldehyde as substrate for ALDH 
(Estimate ± SD). 
 
NAD
+ 
concentration 
[mM] 
Cytosolic protein
 
concentration 
[mg/mL] 
vo 
[nmoles/min/
mg] 
vmax 
[nmol/min/
mg] 
Km 
[µM] 
r
2
 
0.7 0.2 4.9 ± 0.4 4.4 ± 0.4 10.1 ± 5.7 0.99 
1.4 0.2 2.4 ± 0.3 4.6 ± 0.4 18.2 ± 7.8 0.99 
2.8 0.2 4.4 ± 0.7 10.6 ± 0.7 30.6 ± 7.4 0.99 
1.4 0.4 5.1 ± 1.3 7.3 ± 1.4 25.8 ± 16.2 0.99 
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4.3.4 Concentration- and substrate-dependent effects of DMSO on the oxidative 
metabolism in human hepatic cytosol 
 
As discussed in Chapter 1, INN-312 and INN-298 are sparingly soluble compounds with 
low intrinsic solubilities of 0.36 g/L and 0.54 g/L (approximately 1.5-2 mM) respectively. Initial 
solubility studies were carried out using varying solvents for INN-compounds. Tris HCl and 
potassium phosphate buffers (pH 7.4 – 7.5) resulted in precipitation of INN-compounds, and use 
of a solubilizing agent was deemed necessary. Solubilizing agents such as tweens and 
polyethylene glycol have been reported as substrates for ADH, which may interfere with the 
metabolic assay, while spans are highly viscous agents, difficult to use. Therefore, in order to 
achieve adequate solubility for the metabolic studies, 2% DMSO (~0.25 M) was used as a 
solvent for both compounds. 
There has been some reported evidence of non-competitive/uncompetitive inhibition of 
ADH by DMSO in the literature (Sharkawi, 1979; Leblova and Stiborova, 1976), that may 
interfere with the oxidative kinetic profiling. In order to investigate any effects of DMSO on 
ADH and/or ALDH enzyme activity, metabolism kinetics of the prototypical ADH and ALDH 
substrates were studied in the presence of varying concentrations of DMSO (0 – 0.25 M), and the 
substrate-dependent effect of DMSO on enzyme activity was assessed using different substrates 
(ethanol, acetaldehyde and 5-HMF) prepared in varying concentrations of DMSO. The enzyme 
activity was assessed based on DMSO concentration-dependent changes in in-vitro intrinsic 
clearance (CLint
in-vitro
) for the respective substrates. 
DMSO-related effect in enzyme activity was seen, leading to large variability and 
difficulty in reliable estimation of MM kinetic parameters for ethanol metabolism. From Figure 
4.6, it may be observed that the activity of ADH in the human hepatic cytosol was almost 
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completely abolished in the presence of DMSO. The kinetics for acetaldehyde metabolism could 
be characterized in the presence of DMSO, however, nearly 10-fold reduction in ALDH-activity 
was observed with DMSO concentrations. Nearly 10-fold reduction in ALDH activity was seen 
in the presence of 0.25 M DMSO, the concentration required for solubilizing the INN 
compounds (Figure 4.7). 
Figure 4.8 represents substrate-dependent differences in human hepatic cytosolic enzyme 
activity, using 5-HMF as a substrate (for ALDH and ADH). A small reduction in activity may be 
observed for 5-HMF as a substrate. Thus, the true CLint
in-vitro
 for ALDH substrates in the presence 
of DMSO is expected to be underestimated, due to some reduction in ALDH activity.  
 
 
Figure 4.6. DMSO concentration-dependent effect on human hepatic cytosolic ADH 
enzyme activity (CLint
in-vitro
) using ethanol as a selective substrate.  
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Figure 4.7. DMSO concentration-dependent effect on human hepatic cytosolic ALDH 
enzyme activity (CLint
in-vitro
) using acetaldehyde as a selective substrate.  
 
 
 
 
 
Figure 4.8. Substrate-dependent effect of 0.25 M DMSO on human hepatic cytosolic 
ALDH/ADH enzyme activity (CLint
in-vitro
) using 5-HMF.  
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4.3.5 Validation of the Sub-Cellular Model for ALDH (and ADH) Activity 
Time- and concentration-dependent metabolism of ethanol and acetaldehyde, known 
selective substrates for ADH and ALDH, respectively, was demonstrated using human hepatic 
cytosol preparations. Figures 4.9 and 4.10 represent the typical MM kinetics of metabolism of 
ethanol and acetaldehyde by ADH and ALDH, respectively. MM kinetic parameters estimated 
were comparable with literature-reported values for ethanol metabolism by equine ADH (Gupta, 
2006) and acetaldehyde metabolism by isolated ALDH enzymes (Klyosov 1996). The parameter 
estimates are reported in Table 4.6. 
 
4.3.6 In-Vitro Hepatic Oxidative Metabolism of AEH  
The oxidative metabolism of AEH was investigated in the human hepatic cytosol. The 
AEH were found to be substrates for ALDH (and ADH for 5-HMF). Metabolism of 5-HMF 
appeared to be saturable, followed typical MM kinetics (Figure 4.11) and was fit by the modified 
MM model. On the other hand, apparent first-order (non-saturable) metabolism kinetics was 
observed for INN-312 and INN-298 at concentrations ranging from 0.1 – 5 mM, and may be 
seen from Figures 4.12 and 4.13, respectively. Due to solubility limitation at the upper 
concentration range, saturable MM kinetics could not be observed for these compounds in the 
concentration range studied and, therefore, a MM model could not be used to model the kinetics 
for these compounds. Initial MM model fitting resulted in imprecision in parameter estimation 
due to lack of observations for higher concentrations. Therefore, the apparent non-saturable 
linear kinetics were modeled by linear regression to estimate the metabolic efficiency.  
Metabolism of 5-HMF was found to proceed with relatively low efficiency, about 1000-
fold lower than that for acetaldehyde, primarily owing to low apparent enzyme affinity to ADH 
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and ALDH. The INN-compounds are also low affinity substrates for ALDH, but were found to 
have 50- and 10-fold greater CLint
in-vitro
 than 5-HMF respectively, owing to high metabolic 
capacity, thus suggesting more extensive hepatic ALDH-metabolism. Table 4.6 shows the MM 
kinetic parameters and metabolic efficiencies for the various ALDH substrates studied. The Km 
values for INN-312 and 298 reported in Table 4.6 are based on initial MM model estimates, to 
obtain a plausible estimate value for comparison.  
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Figure 4.9. Concentration-dependent metabolism of ethanol in human hepatic cytosol. The 
measured initial rates of metabolism (filled symbols) are fitted by the modified MM model 
(fitted line). Data are represented as means ± SD; n=3. 
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Figure 4.10. Concentration-dependent metabolism of acetaldehyde in human hepatic 
cytosol. The measured initial rates of metabolism (filled symbols) are fitted by the modified 
MM model (fitted line). Data are represented as means ± SD; n=3. 
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Figure 4.11. NAD
+
-dependent metabolism of 5-HMF (Mean±SD; n=3; r
2
=0.94) in the 
human hepatic cytosol. The measured initial rates of metabolism (filled symbols) are fitted 
by the modified MM model (fitted line). Data are represented as means ± SD; n=3. 
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Figure 4.12. NAD
+
-dependent metabolism of INN-312 (Mean±SD; n=3; r
2
=0.99) in the 
human hepatic cytosol. The measured initial rates of metabolism (filled symbols) are fitted 
by linear regression (fitted line). Data are represented as means ± SD; n=3. 
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Figure 4.13. NAD
+
-dependent metabolism of INN-298 (Mean±SD; n=3; r
2
=0.99) in the 
human hepatic cytosol. The measured initial rates of metabolism are fitted by linear 
regression (fitted line). Data are represented as means ± SD; n=3. 
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Table 4.6. Final MM metabolic parameter estimates (SD) for various substrates in human hepatic cytosol. 
 
Substrate 
vo 
[nmoles/min/mg] 
vmax 
[nmoles/min/mg] 
Km 
[mM] 
CLint
in-vitro
 
(µL/min/mg 
protein) 
r
2
 
Ethanol 1.8 (0.4) 7.3 (0.6) 0.8 (0.2) 9.1 (2.4) 0.99 
Acetaldehyde 2.4 (0.3) 4.6 (0.4) 0.02 (0.01) 253 (111) 0.99 
5-HMF 2.5 (0.4) 9.7 (2.4) 46.7 (28.6) 0.2 (0.1) 0.94 
INN-312 - - >25* 7.1** (0.6) 0.99 
INN-298 - - >70* 1.0** (0.2) 0.99 
* from preliminary MM modeling; **from linear regression 
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4.3.7 IVIVE  
The metabolic efficiencies reported in Table 4.6 reflect the CLint in the in-vitro hepatic 
cytosolic system. This was scaled using the IVIVE approach, in order to make predictions for the 
apparent hepatic extraction (ERhep’) and hepatic clearance (CLhep’).  
Since there is limited information available on the in-vitro ADME characteristics of the 
novel INN-compounds, plasma protein binding predictions were made for the INN-compounds 
from QSPKR studies. The INN-compounds are weak bases with pKa of 4.61 for INN-312 and 
3.98 for INN-298. At a physiological pH of 7.4 they are expected to be present primarily as 
unionized species. They are expected to bind with plasma proteins to a great extent: human 
serum albumin (HSA) is known to have a hydrophobic binding pocket that renders it to bind to 
lipophilic compounds, while α1-acid glycoprotein (AAG) is known to have a binding site for 
bases. Therefore due to their lipophilicity and basicity, the INN-compounds are expected to bind 
to HSA and/or AAG. Their free fractions were, therefore, predicted from their calculated Log P 
and Log D7.4 values using a relationship for opioids. Opioids are lipophilic (poly)-aromatic 
compounds (median and 25% – 75% range for Log D7.4: 1.64 and 0.74 – 2.47). Based on the 
univariate effect of LogD7.4 on fu for opioids, the fu values estimated for INN-compounds with 
similar (aromatic) structures and comparable lipophilicity is shown in Table 4.7. This method of 
prediction, however, does not consider possible transiently covalent “Schiff binding” of INN-
compounds to the plasma proteins. 
The INN-compounds were predicted to have relatively high plasma protein binding (> 
60%), owing to their lipophilicity and possibly basic characteristics, which may cause them to 
bind to both serum albumin, as well as AAG. 5-HMF on the other hand, is expected to have 
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negligible plasma protein binding, primarily owing to its polar (hydrophilic) structure 
(Abdulmalik et al, 2005; Obied, 2010). 
The PK projections for AEH from IVIVE, using relevant physiological scaling factors 
(Bogaards et al., 2001; Gupta, 2006; Obied, 2010) are reported in Table 4.8. Limited by the 
assumptions discussed above and elucidated in section 4.4, 5-HMF is predicted to undergo low 
first-pass hepatic extraction. The INN-compounds are efficiently metabolized by hepatic 
cytosolic ALDH but are projected to undergo binding-restricted hepatic extraction. Depending 
on their degree of plasma protein binding, low to intermediate hepatic first-pass effects are 
projected. These projections assume hepatic cytosolic ALDH is the only (primary) metabolic 
pathway for AEH, and further limitations of the extrapolation have been described in section 4.4. 
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Table 4.7. Prediction for plasma protein binding (fu
pred
) for INN-312 and 298 from QSPKR for opioids (Badri, 2010). 
 
Substrate pKa Log P LogD7.4 fu
pred 
INN-312  4.61 2.1 2.1 0.35 
INN-298  3.98 1.7 1.7 0.40 
 
 
Table 4.8. Metabolic efficiency (SD) and IVIVE values for the AEH in the human hepatic cytosol. 
 
AEH 
Km 
(mM) 
CLint
in-vitro
 
(µL/min/mg protein) 
CLint
in-vivo
 
(mL/min) 
fu 
ERhep’ 
(%) 
Foral 
(%) 
CLhep’ 
(mL/min) 
5-HMF 46.7 (28.6) 0.2 (0.1) 17 1.00 1% 99% 17 
INN-312 - 7.1 (0.6) 869 0.35 17% 83% 253 
INN-298 - 1.0 (0.2) 138 0.40 4% 96% 53 
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4.3.8 Inter-Species Comparison of ALDH Activity  
In order to explore the inter-species variability in ALDH substrate selectivity and 
metabolic efficiency for selective ALDH substrates, ALDH activity in canine, murine and rat 
liver cytosol was characterized using acetaldehyde as the prototypical substrate. This 
investigation of differences in intrinsic ALDH function or substrate specificities would help 
provide insight on, and rational explanations for possible inter-species differences in metabolism 
of the AEH.  
The methods were similar to those mentioned in section 4.2. Acetaldehyde concentrations 
(0.1 – 500 mM) were optimized for the different mammalian species from pilot experiments. 
Typical saturable MM kinetics were observed for metabolism of acetaldehyde in canine liver 
cytosol and were fit by the modified MM model. Substrate inhibition of hepatic cytosolic ALDH 
at high concentrations of acetaldehyde (>100 mM) was observed in rodents (rats and mice). 
Therefore, the metabolism of acetaldehyde by rat and mouse liver ALDH was fit by a substrate 
inhibition model, in order to account for self-inhibition at high concentrations of acetaldehyde..  
Figures 4.14 – 4.16 represent the concentration-dependent oxidative metabolism of 
acetaldehyde in canine, rat and murine liver cytosol, respectively.  
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Figure 4.14. Concentration-dependent metabolism of acetaldehyde in canine liver cytosol. 
The measured initial rates of metabolism (filled symbols) are fitted by the modified MM 
equation (fitted line). Data are represented as means ± SD; n=2, r
2
=0.99. 
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Figure 4.15. Concentration-dependent metabolism of acetaldehyde in rat liver cytosol. The 
measured initial rates of metabolism (filled symbols) are fitted by a substrate inhibition 
model (fitted line). Data are represented as means ± SD; n=2, r
2
=0.86. 
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Figure 4.16. Concentration-dependent metabolism of acetaldehyde in murine liver cytosol. 
The measured initial rates of metabolism (filled symbols) are fitted by a substrate 
inhibition model (fitted line). Data are represented as means ± SD; n=2, r
2
=0.78. 
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Table 4.9 shows the MM and substrate inhibition parameter estimates for the different 
animal species. The vo and vmax values for the substrate inhibition model were fixed based on 
experimental observations to enable precise estimation of Km and Ki values for comparison 
between species. Rat and mice hepatic cytosol showed low baseline metabolic activity in absence 
of substrate, unlike dog and human hepatic cytosol (also found to be similar), suggesting likely 
low intrinsic ALDH activity in rodents. Overall, acetaldehyde was an apparently low-affinity 
substrate for canine, rat and mouse liver cytosolic ALDH, with Km values greater than 50-fold in 
comparison with humans, resulting in poor metabolic efficiencies. The maximum metabolic 
capacity of ALDH (vmax) was similar across the species, suggesting similar expression of enzyme 
protein and/or catalytic activity of ALDH.   
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Table 4.9. Comparison of ALDH activity in the hepatic cytosol of different mammalian species, using acetaldehyde as a model 
substrate. 
 
 
Species 
vo
 
(nmol/min/mg 
protein) 
vmax 
(nmol/min/mg 
protein) 
Km 
(mM) 
Ki 
(mM) 
CLint
in-vitro
 
(µL/min/mg protein) 
Human 2.4 (0.3) 4.6 (0.4) 0.02 (0.01) - 253 (111) 
Dog 2.6 (0.3) 4.3 (0.3) 44 (13) - 0.10 (0.03) 
Rat 0.3* 3.5* 65 (16) 477 (156) 0.05 
Mouse 1.0* 6.0* 161 (43) 121 (27) 0.04 
*fixed parameters 
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4.4 Discussion and Conclusions 
 
Ethanol and acetaldehyde, selective ADH and ALDH substrates, undergo concentration-
dependent oxidative metabolism in human hepatic cytosol following MM kinetics. This 
demonstrates that human hepatic cytosol contains active ADH and ALDH enzymes, capable of 
oxidative metabolism.  
The metabolic capacity (vmax) was dependent on the co-factor (NAD
+
) and protein 
concentration, using acetaldehyde as a model (ALDH) substrate. The mechanism of ALDH 
catalysis involves formation of a tetrahedral intermediate of the enzyme, NAD
+
 and the substrate 
(Liu et al., 1997; Cobessi et al, 2000). Thus, the co-factor is essential for the metabolic reaction. 
Increasing concentrations of NAD
+
 may result in increased vmax for the substrate up to a certain 
extent, and increasing the protein content would increase the metabolic capacity within the 
system as well. Furthermore, these are not expected to significantly affect the binding affinity of 
the enzyme for the substrate, as was observed.  
The (intrinsic) baseline rate of metabolism is that observed in the absence of any 
exogenous substrate, and is directly dependent on the cytosolic protein and co-factor 
concentration. As expected, it was similar for all human hepatic cytosolic metabolism studies, 
carried out under identical experimental conditions. 
The findings from the inter-species study are in parallel with previous findings for inter-
species ALDH activity towards 5-HMF, with Km values ranging from 18-80 mM for canine and 
rodent ALDH respectively, and relatively similar vmax values between 15-28 nmol/min/mg 
protein (Obied, 2010). Canine ALDH is more efficient than rodent ALDH for acetaldehyde, as 
well as 5-HMF, owing to higher apparent affinity. Overall, for the three species, the metabolic 
efficiency for acetaldehyde is 10-fold lower than that for 5-HMF (0.36 – 0.81 µL/min/mg 
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protein, respectively), primarily due to low substrate affinity (Obied, 2010). This provides 
conclusive evidence that the ALDH function significantly varies between mammalian species, 
possibly owing to differences in enzyme protein structure, binding pocket and/or substrate 
preferences. ALDH in the animal species, unlike humans, may not be the primary or only 
enzyme metabolizing acetaldehyde. In addition to the observed inter-species differences in 
hepatic ALDH activity towards acetaldehyde and 5-HMF, similar observations have been made 
for hepatic ADH activity towards ethanol (Gupta, 2006).  Inter-species differences in the 
metabolism of primary alcohols and glycols (Gupta, 2006) and 5-HMF (Obied, 2010) have been 
shown to be primarily, owing to different substrate binding affinities. Comparable metabolic 
capacities suggest similar catalytic activity and enzyme expression across the mammalian 
species, namely rodents, dog, rabbit and humans. 
The benzaldehyde analogs (INN-compounds) are sparingly soluble compounds in aqueous 
media and require a solvent (DMSO) to remain in solution. DMSO results in substrate-dependent 
reduction in the hepatic cytosolic enzyme activity: ADH activity is nearly abolished and ALDH 
activity is reduced by 10-fold. The reduction in oxidative metabolic efficiency of 5-HMF in the 
presence of DMSO, may be primarily attributed to the abolished ADH-mediated metabolism and 
partly to the 10-fold reduction in ALDH activity. The effect on ADH activity is not considered 
relevant for INN-312 and INN-298, as they are not expected to be substrates for ADH.  
Metabolism kinetics for vanillin could not be characterized using the current assay 
technique due to interference by its high intrinsic absorbance at 340 nm and spontaneous, non-
enzymatic time-dependent degradation. The newer investigational second generation AEH are 
substrates for hepatic cytosolic ALDH (and ADH for 5-HMF). The likely reactions for 
metabolism of 5-HMF by ALDH and ADH have been suggested previously (Obied, 2010). 
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Metabolism of 5-HMF proceeds with relatively low efficiency, 1000-fold lower than that 
for acetaldehyde, primarily owing to low apparent enzyme affinity to ALDH (and ADH). 
Although INN-312 and INN-298 are low affinity substrates for ALDH, they are efficiently 
metabolized and undergo extensive hepatic ALDH-metabolism. While the apparent affinity of 
cytosolic ALDH for (aliphatic) aldehydes decreases with hydrophobicity, the catalytic efficiency 
has been shown to depend on hydrophobicity (Klyosov, 1996). Therefore, the high cytosolic 
ALDH-mediated metabolism may be explained from the hydrophobicity of the INN-compounds 
compared to 5-HMF. However, owing to binding-restrictions, and within the limitations 
discussed below, low to intermediate hepatic first pass effects (mediated by ALDH) are predicted 
for INN-312 and INN-298, similar as that for 5-HMF.  
Among orally administered FGE, tucaresol is likely a substrate for ALDH, as expected for 
AEH, owing to its aldehyde functional group, however, in-vitro metabolism studies for tucaresol 
are not reported in the literature. Its absolute bioavailability is unknown, nevertheless, it was 
found to be well-absorbed in humans at oral doses of 200 – 3600 mg, and resulted in exposures 
(with 1200 – 3600 mg doses) sufficient to modify Hb up to 15 – 23% (Rolan et al., 1993).  
In-vitro metabolism studies provide simplistic models that serve to mimic physiological 
conditions and understand the in-vivo behavior. From careful extrapolation of in-vitro (hepatic) 
metabolism data, significant information on new chemical entities may be gathered for early 
screening, such as metabolic routes, extent of hepatic extraction, oral bioavailability, metabolic 
clearance and AUCoo approximations (for a given dose). However, it is necessary to consider 
involvement of interdependent factors that account for drug absorption and elimination, for 
accurate in-vivo predictions (Lin, 1998). 
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5-HMF is thought to have good oral bioavailability in transgenic sickle mice (Abdulmalik 
et at., 2005) and this is suggested from the IVIVE prediction. However, the predictions for AEH 
depend on several experimental and physiological/pharmacokinetic factors, listed below: 
1. Characterization of the true in-vitro metabolic behavior may be masked by experimental 
limitations (especially for INN-compounds) such as: 
a. The interfering effect of DMSO on oxidative metabolic activity in the human hepatic 
cytosol: DMSO-dependent reduction in ALDH activity is likely to cause 
underestimation of the in-vitro intrinsic clearance for the INN-compounds was found 
to reduce ALDH activity, which will result in under-prediction of their in-vitro 
clearance. 
b. Relatively higher intrinsic absorbance of the INN-compounds at 340 nm compared to 
5-HMF, limits the concentration range for their metabolism kinetics study and Km 
characterization. 
c. Permeation to the hepatocytes is not accounted for, using cytosol suspension systems. 
This may not be restrictive for the lipophilic INN-compounds, but may be relevant 
consideration for the polar 5-HMF molecule. 
d. Several isozymes of ALDH are known to be present in the liver, including the hepatic 
cytosol and mitochondria, with varying substrate specificities and selectivity 
(Vasiliou et al., Pharmacology, 2000; Yoshida et al.,1998; Klyosov et al., 1996). 
ALDH-1 and ALDH-2, in the cytosol and mitochondria respectively, play a primary 
role in metabolism of endogenous aldehydes and xenobiotics. Therefore, the current 
research using pooled homogenized cytosol is a generalization of the hepatic ALDH 
activity. 
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2. Approximated in-vivo predictions for AEH depend on the following factors: 
a. ALDH is known to be ubiquitously present throughout body tissues, including liver, 
GI tract, brain, RBC, etc. (Vasiliou et al., 2000); it is likely to result in significant 
extrahepatic metabolism of AEH.  
b. ALDH is known to exist in at least 9 polymorphic forms (Vasiliou et al., 2000). This 
may result in inter-subject variability in hepatic handling, and overall exposures for 
AEH. 
c. Due to their hydrophobic structure with susceptible functional groups (especially 
INN-compounds, see Chapter 1), other metabolic routes such as AOX- and CYP-
mediated metabolism or biotransformation by phase-2 conjugation may contribute to 
the overall metabolism; therefore the predicted hepatic clearance for INN-compounds 
is likely underestimated. 
d. The efficiently metabolized INN-compounds (by ALDH) undergo binding-restricted 
hepatic extraction. Therefore pertinent (plasma) protein binding information is 
necessary to prevent over- or under-prediction of clearance.  
e. Non-specific binding to other proteins with valine or lysine amino-residues would 
also result in reduced free fractions of AEH available for metabolism.  
f. The fraction of dose in solution in the gut, and fraction of dose absorbed (entering the 
intestinal wall) are determinants of the oral bioavailability, in addition to hepatic 
extraction. Limited solubility of the INN-compounds and their likeliness as substrates 
for uptake and/or efflux transporters, may also account towards their variable 
absorption and elimination.  
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In addition to the interdependent factors mentioned above, the in-vivo predicted hepatic 
clearances for all AEH would further depend on the blood-plasma (B/P) partition ratio. The well-
stirred model for hepatic clearance relates whole blood clearance to hepatic blood flow, as the 
liver is capable of drug extraction from plasma, as well as RBC. The predicted in-vivo clearance 
values for AEH are with reference to drug levels in plasma, assuming a blood-plasma partition 
ratio of 1. However, AEH are known to bind to Hb in RBC, and expected to have B/P ratios of 
>1. Therefore, in order to estimate blood clearance from IVIVE, information on the blood-
plasma partition ratio for AEH is necessary (Yang et al., 2007; Hinderling, 1997).   
Nevertheless, this research provides backbone evidence for the INN-compounds as ALDH 
substrates. The ALDH isoform expressed in the liver cytosol and RBC is the same (ALDH-1), 
and therefore, INN-312 and INN-298 are susceptible to metabolism by ALDH in RBC. 
Benzaldehyde, their structural scaffold, has binding affinity for RBC-ALDH in the micromolar 
range, greater than that observed for 5-HMF (Inoue et al., 1979; Obied, 2010). Like 5-HMF, the 
novel benzaldehyde analogs are expected to undergo rapid metabolism in RBC, in addition to 
transient binding to hemoglobin. Furthermore, a generalized disposition model may be used to 
describe in in-vivo physiological processes driving the disposition of AEH, and has been 
described in Chapters 7 and 8, in detail. 
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CHAPTER 5 
5 IN-VITRO PHARMACODYNAMICS OF AEH IN WHOLE BLOOD 
 
 
 
5.1 Introduction 
Zaugg et al., 1977 carried out a pioneering study, screening and investigating the effects of 
29 aromatic (and aliphatic) aldehydes and other carbonyl compounds for their ability to form 
Schiff base adducts with hemoglobin. The effect of these compounds was assessed by various 
methods: the extent of chemical modification of Hb was assessed by isoelectric focusing, the 
oxygen affinities of modified RBC using p50 as a biomarker, and in-vitro anti-sickling activity 
from morphological analysis of SS cells on progressive deoxygenation conditions. The “oxygen-
binding studies” were carried out by a method called multiple-point tonometry, in which cell 
suspensions were incubated for 0.5 hr, and equilibrated with gas mixtures containing 1 – 5% O2 
(in 5% CO2). The p50 (pO2 at 50% oxygen saturation) was determined graphically from these 
measurements (Zaugg et al. 1977). It was found that the anti-sickling action of the aromatic 
aldehydes could be measured from their ability to result in a left-shift in the oxygen equilibrium 
curve (OEC), and thus, the p50. 
The use of p50 as a biomarker for the effect of these compounds has been used over several 
years (Beddell et al., 1984; Fitzharris et al., 1985; Merrett et al., 1986; White et al., 1989; 
Abraham et al., 1991; Safo et al., 2004; Abdulmalik et al., 2005; Nnamani et al., 2008). In 
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addition to p50 measurements, some studies have also reported p20 and S10 values, which are the 
pO2 resulting in 20% saturation of Hb and the SO2 at 10 mmHg pO2, respectively (Fitzharris et 
al., 1985). The method of p50 estimation for majority of these studies utilizes an instrument 
(Hemox Analyzer) that generates OEC with SO2 as a continuous function of pO2. A modified 
multi-point/three-point tonometry method of OEC measurements involves equilibration of blood 
with gas mixtures of carefully selected pO2 followed by corresponding SO2 measurements and 
modeling by nonlinear regression using the Hill model for Hb-O2 binding. This method has been 
well-validated and used for characterizing OEC right-shifting activity of investigational drugs, 
such as RSR-13, in the past (Wahr et al., 2001). 
The AEH are shown to exert a concentration-dependent left-shift in p50 (or decrease in p50) 
for Hb (HbA/HbS) after incubation up to 1 hr with Hb (Abdulmalik et al., 2005; Nnamani et al., 
2008). Abdulmalik et al (2005) showed that 5 mM 5-HMF incubated with sickle blood for 1 hr 
resulted in time-dependent decrease in newly formed sickle cells (under hypoxic conditions), and 
nearly 100% inhibition of sickling after 5 hrs. Furthermore, sickle blood pre-incubated with 5-
HMF results in greater anti-sickling action than samples without pre-incubation. These findings 
suggest evidence of a time-dependent anti-sickling effect of 5-HMF (and possibly, other AEH), 
which may also be measured using p50 as a biomarker.   
Therefore, the time-course for the concentration-dependent PD effect of the AEH in human 
whole blood (HbA) was explored by three-point tonometry (TPT) to investigate (1) the onset of 
PD effect, (2) magnitude of peak effect for each nominal concentration, (3) time to peak effect, 
(4) the duration of effect, and (5) compare these among the three AEH. These studies will 
elucidate, if any, the time- and concentration-dependent differential effects of the three AEH in 
healthy human blood.  
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5.2 Methods 
 
5.2.1 Materials and Reagents 
 
12. Heparinized whole blood from a healthy human volunteer (Female; Age: 55 yrs; Hb: 
11.5–12.0 g/dL; Hematocrit: ~37–39%)  
13. GIBCO™ Phosphate-Buffered Saline (PBS, 0.1μm filtered liquid) pH 7.2 (Invitrogen 
Corporation, Carlsbad, CA)  
14. 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO) (126.11 g/mol) 
15. INN-312 (Dr. Martin Safo’s laboratory, Dept of Medicinal Chemistry, VCU) Batch 2 
(243.26 g/mol; Purity ~85%) 
16. INN-298 (Dr. Martin Safo’s laboratory, Dept of Medicinal Chemistry, VCU) Batch 1 
(243.26 g/mol; Purity ~85%) 
17. Dimethyl sulfoxide (Sigma-Aldrich, Milwaukee, WI), 0.3-0.5% 
18. Blood-Gas Mixtures (O2 and 5.5% CO2, balanced with N2): 
a. pO2 ~5.6 mmHg  
b. pO2 ~20 mmHg  
c. pO2 ~40 mmHg  
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5.2.2 Equipment 
 
10. Centrifuge 5804-R (Eppendorf, Hauppauge, NY) 
11. Forma Scientific incubator (Thermo Fisher Scientific Inc., Pittsburgh PA) 
12. 1 mL BD™ slip-tip disposable tuberculin syringe (BD BioSciences, Franklin Lakes, NJ) 
13. IL 237 Tonometer (Instrumentation Laboratory, Lexington, MA) 
14. IL GEM® Premier™ 3000 Blood Gas Analyzer (Instrumentation Laboratory, Lexington, 
MA) 
15. IL 682 CO-Oximeter (Instrumentation Laboratory, Lexington, MA) 
16. 3-25 µL positive displacement pipette and corresponding pipette tips (Rainin Instruments, 
Oakland, CA). 
17. 10-100 µL and 100-1000 µL VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA). 
18. 0.5-5 mL Finnpipette (Thermo Scientific, Waltham, MA). 
19. Vortex (Vortex-Genie, VWR, West Chester, PA). 
20. Balance (Fisher Scientific A 250, Pittsburgh, PA). 
21. Scientist® Software version 2.0 (Micromath, St. Louis, MO). 
22. R (open source); Library: ggplot2  
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5.2.3 Preparation of Solutions 
 
 
1. 5-HMF stock solution  
1 M stock solution of 5-HMF was prepared by dissolving 126.1 mg of 5-HMF in 1 mL of 
PBS (pH 7.4). 5 – 50 μL of this stock solution were added to whole blood to achieve final 
concentrations of 0.5 – 5 mM of 5-HMF in whole blood. 
 
2. INN-312 stock solution  
1 M stock solution of INN-312 was prepared by dissolving 60.8 mg of INN-312 in 250 
μL of DMSO. 5 – 30 μL of this stock solution were added to whole blood to achieve final 
concentrations of 0.5 – 3 mM of INN-312 in up to 0.3% DMSO in whole blood. 
 
3. INN-298 stock solution  
1 M stock solution of INN-298 was prepared by dissolving 60.8 mg of INN-298 in 250 
μL of DMSO. 5 – 50 μL of this stock solution were added to whole blood to achieve final 
concentrations of 0.5 – 5 mM of INN-298 in up to 0.3% DMSO in whole blood. 
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5.2.4 Procedure 
Human whole blood obtained from a healthy volunteer was first equilibrated for 10 min 
at 37
0
C, and then incubated with AEH (0.5- 5 mM) at 37
o
C. Aliquots of 2 mL drawn at varying 
time periods (0.25-10 hrs) using a tuberculin syringe, were equilibrated in IL-287 Tonometer 
with blood-gas mixtures of three nominal pO2 of 6, 20 and 40 mmHg, for 10 min and constant 
mixing. The samples were aspirated through IL-GEM
®
 Premier™ 3000 Blood Gas Analyzer for 
measurement of actual pO2 and IL-682 Co-oximeter for measurement of the corresponding SO2, 
total Hb and hematocrit (Hct). Other variables measured by the blood-gas analyzer were pH, 
pCO2, and by the CO-oximeter were total Hb, oxygenated Hb, methemoglobin, and 
carboxyhemoglobin. 
After aspiration, the whole blood samples were centrifuged at 13,000 rpm for 2 min to 
separate the plasma from the RBC. The packed RBC and plasma samples were stored separately 
at -20
0
C for further analysis of corresponding AEH concentrations. 
 
  
  
216 
 
5.2.5 Three-Point Tonometry (TPT) 
Individual oxygen equilibrium curves (OEC) were constructed from the measured pO2 
and SO2 values at varying time points for the respective nominal concentrations of AEH using 
three-point tonometry. Three points on the OEC were selected such that the slope of the curve 
(n), and the left-shift in p50 could be adequately characterized, using pO2 values (1) close to the 
normal p50 value of ~26.7 mmHg, (2) toward the lower end and (3) the higher end of the 
equilibrium curve. Therefore, SO2 measurements were made for whole blood equilibrated with 
blood gas mixtures of pO2 of 6, 20 and 40 mmHg.  
O2-binding affinity of Hb (p50) and Hill coefficient (n) were estimated from individual 
OEC by nonlinear regression, using the Hill model for cooperative binding (Bunn & Forget, 
1986), as shown in Equation 5 – 1 below. The maximum O2-saturation of Hb is 100%. 
 
 
     
         
  
   
       
                                          
 
 
Where  
SO2: measured O2-saturation of Hb  
pO2: partial pressure of O2  
p50: O2-binding affinity of Hb 
n: Hill coefficient 
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5.2.6 Dose-Response Curves 
The peak effect for the respective AEH was measured from the peak left-shift in p50 
(∆p50) with respect to the baseline and was assessed for AEH concentration-dependency. “Dose-
Response Curves (DRC)” were constructed for the respective AEH using the sigmoidal-Emax 
model, shown in Equation 5 – 2 below. 
 
 
   
        
 
(    )    
                                        
 
Where  
E: measured peak left-shift in p50  
Emax: maximum achievable left-shift in p50 
EC50: Nominal AEH concentration at half-maximal left-shift in p50 
ϒ: sigmoidicity coefficient 
C: Nominal (starting) concentrations 
 
5.2.7 Data Analysis 
Nonlinear regression was performed using Scientist
®
 v.2.0. Goodness-of-fit was assessed 
by r
2
, MSC and residual analysis. Model suitability and appropriateness was assessed from the 
standard deviations/precision of the parameter estimates.  
Estimations for p50 and n at varying time points for respective concentrations of AEH were 
superimposed to investigate the time-course and concentration-dependency of the PD effect.   
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5.3 Results 
 
 
5.3.1 Validation of method using human whole blood 
Optimization of the TPT assay was performed using blood gas mixtures with varying pO2 
of 6 – 60 mmHg for equilibration of whole blood. The oxygen saturation of Hb was less sensitive 
to changes in pO2 beyond 40 – 50 mmHg, as may be expected from the Hill model. At pO2 levels 
of 60 mmHg, the oxygen saturation approximated the maximum, resulting in difficulty with 
precise estimation of the Hill coefficient and left shift in p50. Therefore, 40 mmHg was selected 
as the highest level of pO2 to enable characterization of the OEC for the respective AEH. 
The assay was validated from p50 measurements for whole blood stored at 37
o
C, in the 
absence of an exogenous compound (control) up to 10 hrs. The p50 and n values were stable for 
10 hrs in the absence of AEH with a mean (± SD) of 24.0±0.5 mmHg (Figure 5.1). The COVs 
for p50 and n were 2% and 9%, respectively (n=9), in the absence of exogenous AEH, 
demonstrating good reproducibility of the assay and stability of whole blood (Table 5.1). 
Therefore, any change in p50 of the whole blood incubated with AEH may thus be a result of 
their (allosteric) left-shifting effect on Hb. 
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Figure 5.1. Assay validation: Stability of whole blood and p50 values up to 10 hrs. 
 
  
20
21
22
23
24
25
26
27
0 2 4 6 8 10
p
5
0
 (
m
m
H
g)
 
Time (hr) 
Observed
Mean
SD
  
220 
 
Table 5.1. Validation of the TPT assay for 5-HMF in healthy human whole blood. The ∆p50 
and n values are reported with respect to the calculated mean. 
 
 
Time 
[hr] 
p50 
[mmHg] 
n 
∆p50 
[mmHg] 
∆n 
0 23.6 2.07 -0.4 0.23 
0.25 23.6 2.07 -0.4 0.23 
0.5 24.6 1.88 0.5 0.03 
1 23.9 1.99 -0.1 0.14 
2 24.3 1.76 0.3 -0.09 
4 25.1 1.78 1.0 -0.07 
6 23.6 1.83 -0.5 -0.02 
8 23.6 1.67 -0.4 -0.17 
10 24.1 1.58 0.0 -0.27 
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5.3.2 Effect of AEH on OECs in human whole blood 
The baseline (control) p50 values for healthy human whole blood were determined from 
measurements in the absence of exogenous compound. The baseline p50 was estimated as 
24.0±0.5 mmHg (n=9) for 5-HMF, and 25.4±0.5 (n=4) mmHg for the INN-compounds in 
presence of DMSO. All AEH resulted in concentration-dependent left-shifts in the OEC and p50, 
relative to the baseline (0 mM). Representative OECs for 5-HMF, INN-312 and INN-298, fitted 
by the Hill model, are shown in Figures 5.2, 5.3 and 5.4 respectively, for their effect between 0.5 
– 2 hrs. 
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Figure 5.2. Representative concentration-dependent left-shift in OEC of healthy human 
whole blood after incubation with 5-HMF (at 1.5 hr time point). 
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Figure 5.3. Representative concentration-dependent left-shift in OEC of HbA from healthy 
human whole blood after incubation with INN-312 (at 0.5 and 1.5 hr time points). 
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Figure 5.4. Representative concentration-dependent left-shift in OEC of HbA from healthy 
human whole blood after incubation with INN-298 (at 2 hr time point). 
 
 
 
 
 
  
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70
SO
2
 (
%
) 
PO2 (mmHg) 
0 mM
0.5 mM
1 mM
2 mM
5 mM
  
225 
 
5.3.3 Time-course of concentration-dependent effect of AEH in human whole blood 
The investigational AEH increased the O2-affinity of Hb in a time- and concentration-
dependent manner, with biphasic PD profiles. Figures 5.5, 5.6 and 5.7 show the time-course of 
PD effect with varying nominal concentrations of 5-HMF, INN-312 and INN-298 in whole 
blood, respectively. The baseline p50 (mean (SD)) is represented with the black dotted line, at 
24.0 (0.5) mmHg for 5-HMF, and 25.4 (0.5) mmHg for the INN-compounds. A downward shift 
in p50 indicates left-shift in the OEC, or increased O2-binding affinity of Hb.  
0.5 mM 5-HMF and INN-298 do not have any significant effect on p50, suggesting that at 
low concentrations, binding with Hb is not sufficient enough to cause a pharmacological effect. 
A further concentration-dependent decrease in p50 was observed for AEH, with peak left-shift 
between 0.5 – 2 hrs. Figure 5.8 shows DRC for a comparison between the concentration-
dependent peak ∆p50 by the respective AEH after 0.5 – 2 hrs of incubation with whole blood.  
The decrease in p50 is followed by a gradual recovery towards the baseline for most 5-
HMF and INN-312 nominal concentration levels. The rate of decline of the PD effect and return 
to the baseline however, is AEH- and AEH concentration-dependent. INN-312 has a rapid onset 
of action, with peak effects in 0.5 hrs, followed by signs of recovery.  On the other hand, the 
effect of INN-298 peaks at 2 hrs, and does not recover, even after 10 hrs of observation.  
The concentration-dependent left-shift in p50 by 5-HMF in whole blood containing HbA, 
is comparable with the previously recorded results in HbS hemolysates after pre-incubation of 
the samples with 5-HMF for 1 hr (Abdulmalik et al., 2005). This establishes the validity of the 
current results for preliminary interpretation in target SCD populations. 
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Figure 5.5. Time-course for the concentration-dependent PD effect of 5-HMF in human 
whole blood (containing HbA). 
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Figure 5.6. Time-course for the concentration-dependent PD effect of INN-312 in human 
whole blood (containing HbA). 
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Figure 5.7. Time-course for the concentration-dependent PD effect of INN-298 in human 
whole blood (containing HbA). 
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Figure 5.8. DRC for comparison of Peak Response Between AEH (0.5 – 2 hrs). 
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5.3.4 DRC for AEH in human whole blood 
Abdulmalik et al (2005) have reported a linear relationship between the nominal 
concentrations of 5-HMF and ∆p50 after 1 hr of incubation of HbS containing hemolysates with 
5-HMF. Therefore, the relationship between nominal AEH concentrations and peak ∆p50 (after 
0.5 – 2 hrs) was investigated and assessed.  
The relationship was fit by a sigmoidal-Emax model in order to estimate the maximum 
achievable left-shift in p50 (Emax) by the respective AEH and their EC50 values. Table 5.2 shows a 
summary of the parameter estimates (SD) for the three AEH. 
The sigmoidal-Emax model adequately describes the relationship between nominal AEH 
concentrations and peak ∆p50 with r
2
 values >0.98. The INN-compounds result in greater 
maximal left-shift in OEC (Emax), compared to 5-HMF. It may be observed, however, that the 
estimates for INN-312 have relatively less precision, owing to inadequate nominal 
concentrations investigated at the upper end (> 3 mM). Overall, the three AEH are effective at 
similar nominal concentrations of ~1.5 – 2 mM, in agreement with the proposed mechanism of 
action for these compounds (Safo et al., 2004; Nnamani et al., 2008). Figures 5.9 – 5.11 
represent the DRC for the three AEH. 
 
Table 5.2. Sigmoidal-Emax model 
 
AEH 
Estimate (SD) 
r
2
 
Emax (mmHg) EC50 (mM) ϒ 
5-HMF -18.9 (1.1) 1.5 (0.1) 3.0 (0.6) 0.99 
INN-312 -30.9 (11.6) 1.8 (0.7) 2.4 (1.1) 0.98 
INN-298 -25.5 (2.9) 1.7 (0.3) 2.0 (0.5) 0.99 
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Figure 5.9. DRC for 5-HMF (solid line) represented as maximum deltap50 (observed at 1.5 
hrs) with respect to nominal 5-HMF concentration. 
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Figure 5.10. DRC for INN-312 (solid line) represented as maximum deltap50 (observed at 
0.5 hrs) with respect to nominal INN-312 concentration. 
 
 
  
-35
-30
-25
-20
-15
-10
-5
0
0 1 2 3 4 5 6
d
e
lt
a 
p
5
0
 [
m
m
H
g]
 
Nominal concentration of INN-312 [mM] 
  
233 
 
Figure 5.11. DRC for INN-298 (solid line) represented as maximum deltap50 (observed at 2 
hrs) with respect to nominal INN-298 concentration. 
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5.3.5 Combined effect of AEH on the OEC of HbA: Trends between p50 and n 
The AEH resulted in left-shift in the OEC, causing a time-dependent decrease in p50. 
Simultaneously, a time- and concentration-dependent decrease in the Hill coefficient, n, was also 
observed, suggesting some effect on the cooperativity in the four subunits of the Hb molecule. 
Similar concentration-dependent effects on the cooperativity may be observed with FGE and 5-
HMF (Beddell et al., 1984; Abdulmalik et al., 2005). 
Therefore, the combined effect of all three AEH on the OEC (p50 and n) was investigated 
further. Moreover, it was assessed whether a left-shift in p50 (∆p50) was associated with a 
decrease in cooperativity (n). Exploratory analyses were performed investigating time-
dependency, but no significant trends were observed. Graphical plotting of data was performed 
using R (ggplot2 library). Figure 5.12 shows the combined concentration-dependent effect of the 
three AEH on p50 and n. The concentration-dependency represented by the size of the circles, 
while the three AEH are color-coded. Simple LOESS (locally weighted scatterplot smoothing, or 
local regression) is a smooth curve that may be used for scatter plot smoothing and data 
visualization. LOESS for this combined data reflects the trend between estimated p50 and n 
values. The confidence intervals for the LOESS do not have statistical significance in Figure 
5.12, but may be used for data visualization.  
All AEH result in concentration-dependent effects on both, p50 and n. A decrease in p50 
(increase in binding affinity of Hb for oxygen) was associated with a decrease in cooperativity of 
Hb with all AEH, as has been observed in the literature (Beddell et al., 1984; Abdulmalik et al., 
2005). Furthermore, the cooperativity does not decrease with further increase in oxygen binding 
affinity of Hb for respective AEH. The latter, however, may be an artifact of the method of 
estimation of p50 and n from TPT. For high concentrations of AEH, the measured SO2 for Hb was 
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nearly maximal, at the varying pO2 studied, owing to high O2 affinity of Hb. Due to this, the TPT 
method for OEC characterization did not enable precise estimation of the steepness of the slope, 
represented by n, with further decrease in p50, corresponding to increasing AEH concentrations.  
Overall, the extent of effect on OEC is dependent on AEH, with INN-312 resulting in the 
greatest effect, and 5-HMF the least.  
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Figure 5.12. Combined effect of AEH on HbA 
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5.4 Discussion and Conclusions 
As a proof-of-concept, the investigational AEH increased the O2-affinity of Hb in a time- 
and concentration-dependent manner. The biphasic time-course profiles suggest transiently 
covalent binding kinetics with Hb: rapid association and slow dissociation, subsequently 
followed by ALDH metabolism in the RBC, which corresponds to the recovery of p50 to the 
baseline over time (see Chapters 7 and 8). Despite the previously reported short half-life in blood 
(~1 hr) due to rapid ALDH-mediated metabolism in RBC (Abdulmalik, 2005; Obied, 2010), 5-
HMF binds with Hb to form a transiently covalent Schiff-base adduct, leading to peak effects 
after 1.5 hrs, and causing a prolonged in-vitro (and possibly in-vivo) PD effect. The INN-
compounds show greater degree of left-shift in p50 for prolonged duration of time, with similar 
initial concentrations as 5-HMF. Overall, the three AEH have similar potencies of ~1.5 – 2 mM 
(based on the peak effects), in agreement with the proposed mechanism of action for these 
compounds (Safo et al., 2004; Nnamani et al., 2008). 
INN-312 has a rapid onset, with peak effect achieved within 0.5 hrs. On the other hand, 
the sustained effects of INN-298, which peak at 2 hrs, but do not recover to the baseline even 
after 10 hrs of observation, may provide an advantage in chronic use of AEH in the prophylaxis 
of SCD crises, where a longer duration may be preferred over rapid onset of action. This would 
also require less frequent dosing compared to 5-HMF or INN-312. The observed differences in 
duration (time-dependency) and magnitude of effect for the three AEH suggest underlying 
differences in Hb-binding kinetics, and/or subsequent metabolic clearances in RBC (see Chapter 
7).  
Assuming the binding with Hb is reversible, the sustained left-shifting property of INN-
298 lends itself to being a preferred agent for chronic use in the treatment of SCD. However, 
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there may be a possibility of pharmacodynamic tolerance towards the long-acting INN-298 by 
compensatory OEC right-shifting mechanisms. 
A left-shift in the OEC due to increased binding affinity of Hb for oxygen is associated 
with a decrease in cooperativity of Hb with all AEH. Similar observations have been made by 
Moo-Penn et al., 1977, for a high O2-affinity Hb variant, known as Hb-Tarrant, even in the 
absence of AEH. The high oxygen affinity of Hb Tarrant has decreased cooperativity (n = 1.3) 
compared to normal HbA (n = 2.9), and the cooperativity was found to increase with addition of 
2,3-diphosphoglycerate (tested at varying pH). Moo-Penn et al. (1977) attribute these 
observations to the importance of salt bridges in the deoxy conformation of Hb. The oxygen 
affinity and cooperativity of Hb are properties that directly depend on the strength and number of 
salt bridges constraining the Hb tetramer in the deoxy form, as well as the tertiary fluctuations 
within each quaternary conformational structure (Moo-Penn et al., 1977; Safo et al., 2013). The 
AEH bind to the N-terminal αVal1, resulting in destabilization of the deoxygenated state of Hb, 
and favors the high O2-affinity form, which also has reduced cooperativity (Safo et al., 2004). 
The clinical significance of these findings for AEH, is unknown. 
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CHAPTER 6 
6 IN-VITRO DISPOSITION OF 5-HMF IN WHOLE BLOOD 
 
 
 
6.1 Introduction 
5-HMF binds transiently covalently to HbA and exerts time- and concentration-
dependent left-shifting effects on the HbA OEC in whole blood at concentrations ranging from 
0.5 – 5 mM. These in-vitro effects have been shown to decline over a period of 10 hrs, and return 
to the baseline (Chapter 5). 5-HMF is also known to undergo low affinity, high-capacity 
oxidative metabolism, most likely to HMFA, by ALDH in the RBC (Obied, 2010). The IVIVE 
predicted clearance of 5-HMF by ALDH in RBC has been found to be high (~690 mL/min) 
(Obied, 2010). It is hypothesized that the transient binding to Hb and subsequent metabolism by 
RBC-ALDH contribute significantly to the disposition of 5-HMF in whole blood, resulting in the 
observed time-dependent pharmacodynamic effects of 5-HMF, in-vitro and likely in-vivo. This 
information suggests two likely mechanisms of 5-HMF disposition in whole blood: binding to 
Hb and metabolism by ALDH. Furthermore, 5-HMF undergoes saturable binding with HbA, and 
it has been speculated that high concentrations of 5-HMF, > 4.5 – 5 mM, may result in saturation 
of the binding sites on Hb in whole blood, and may lead to nonlinear PK (Obied, 2010). 
Current clinical pharmacokinetic information on 5-HMF is limited, and inadequate to 
assess dose-dependency and elucidate the contribution of two disposition mechanisms. 5-HMF 
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has been predicted to undergo low hepatic extraction and have high oral bioavailability (Chapter 
4; Abdulmalik et al., 2005). The primary pathway for 5-HMF elimination has been projected as 
extensive extra-hepatic metabolism (in RBC) (Obied, 2010). Free 5-HMF concentrations have 
been shown to decline up to 3 hrs in healthy human blood, in-vitro,  with a half-life of 0.7 hrs in 
plasma and 1.2 hrs in whole blood for a nominal concentration 2 mM 5-HMF (Obied, 2010). 
This unique, primary disposition mechanism of 5-HMF in whole blood provides an excellent 
model for investigation of its kinetics in-vitro, and extrapolation to in-vivo conditions.  
 Characterization of the complete in-vitro “target-site disposition” of 5-HMF in plasma 
from human whole blood may thus shed some light on the kinetic behavior of 5-HMF, and also 
provide information on dose dependency. Therefore, the specific objectives of the study were to 
(1) investigate the in-vitro time- and concentration-dependent disposition kinetics of 5-HMF in 
plasma after incubation in human whole blood, (2) estimate basic PK parameters for the in-vitro 
plasma concentration-time profiles of 5-HMF, (3) assess dose-proportionality, and (4) use an 
appropriate quantitative model that adequately describes the primary mechanism(s) responsible 
for the observed disposition kinetics. 
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6.2 Methods 
 
6.2.1 Materials and Reagents 
 
19. Milli-Q® water (PK/PD Laboratory, Virginia Commonwealth University) 
20. Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
21. Acetic acid, glacial, > 99% (EMD Chemicals, Billerica, MA) 
22. Tetrahydrofuran, HPLC grade (J.T. Baker, Canada) 
23. 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO) 
24. Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO) 
25. Human plasma in sodium heparin from a healthy individual female (BioChemed 
Services, Winchester, VA) 
 
6.2.2 Equipment 
 
23. Vortex (Vortex Genie 2, Fisher Scientific, Pittsburgh, PA) 
24. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA) 
25. Balance (Fisher Scientific A 250, Pittsburgh, PA) 
26. Centrifuge 5804-R (Eppendorf, Hauppauge, NY) 
27. Seal-Rite Microcentrifuge tubes, 1.5 mL (USA Scientific, Ocala, FL) 
28. pH meter (Corning, Glendale, AZ) 
29. Durapore PVDF 0.45 μm membrane filter (Millipore, Billerica, MA) 
30. Vacuum filtration apparatus (assembled, Drug Metabolism Laboratory, VCU) 
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31. 10-µL, 100-µL, and 1000-µL VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA) 
32. 25-µL positive displacement pipette and corresponding pipette tips (Microman, Rainin 
Instruments, Oakland, CA). 
33. 0.5-5 mL Finnpipette (Thermo Scientific, Waltham, MA) 
34. Glass insert (150 µL) with preinstalled plastic spring (Waters, Milford, MA) 
35. Oasis HLB cartridge, 1 cc/ 30 mg (Waters, Milford, MA) 
36. Glass shell vials with caps, 1 mL (Waters, Milford, MA) 
37. Borosilicate glass tubes (VWR, West Chester, PA) 
38. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA) 
39. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA) 
40. 717 plus autosampler (Waters, Milford, MA) 
41. 600 Multisolvent controller (Waters, Milford, MA) 
42. UV detector (Shimadzu, AV-10, Columbia, MA)  
43. Empower 2 software (Waters, Milford, MA) 
44. Scientist® Software version 2.0 (Micromath, St. Louis, MO). 
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6.2.3 Preparation of Solutions 
 
– Phosphate buffered saline 
One tablet of phosphate buffered saline was dissolved in 200 mL of nanopure water. This 
solution has a pH of 7.4, when measured by a pH meter. 
 
– 5-HMF stock solution  
A 1 M stock solution of 5-HMF was prepared by dissolving 126.1 mg of 5-HMF in 1 mL 
of PBS (pH 7.4). 5 – 50 μL of this stock solution were added to whole blood to achieve 
final concentrations of 0.5 – 5 mM of 5-HMF in whole blood. 
 
– Mobile Phase  
The pre-mixed mobile phase consists of Water:Methanol:Glacial Acetic 
Acid:Tetrahydrofuran (THF) in the ratio of 92.5:6.2:1:0.3. In order to prepare 1L of 
mobile phase, 62 mL of methanol, 10 mL of glacial acetic acid and 3 mL of THF were 
added to 925 mL of nanopure water. The mobile phase was filtered under vacuum using 
Durapore 0.45 μm membrane filter and degassed by sonication for 5 min, till the air 
bubbles escaped. 
 
– Solid-Phase Extraction (SPE) washing solution 
5% Methanol was used to wash off impurities during the SPE, after loading the plasma 
on to the cartridge. 15 mL of methanol was added to 285 mL of nanopure water. 
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– SPE eluting solution 
5-HMF in plasma was eluted using 50% Methanol. 250 mL of methanol was mixed with 
250 mL of nanopure water. 
 
– 5-HMF standards in neat solution 
A stock solution of 20 mM 5-HMF was prepared. 12.6 mg of 5-HMF (MW 126.11 
g/mol) was dissolved in 5 mL of nanopure water. This is further diluted appropriately, to 
prepare 5-HMF standards for a calibration range of 0.3 – 634.4 μM (or 0.04 – 80 μg/mL) 
in plasma. 
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6.2.4 Procedures 
Plasma separated from whole blood, after measurements of pO2 and SO2 for estimation of 
p50 (discussed in Chapter 5), was analyzed for the corresponding 5-HMF concentrations by 
HPLC-UV. The plasma samples stored separately at -20
0
C were thawed just before analysis of 
the corresponding 5-HMF concentrations. 
As discussed in Chapter 3, 5-HMF was extracted from plasma samples by SPE. Aliquots 
of 600 µL of diluted plasma (1:1 with water) were loaded on pre-conditioned SPE cartridges. 
The 5-HMF eluate after SPE was vortexed, and 150 µL of the eluate was transferred to HPLC 
vials for injection and HPLC-UV analysis. Fresh calibration standards were prepared for the runs 
every day, and (3 × 3) quality control standards (low, medium and high levels) were maintained 
during each run. The reproducibility of the assay, including its precision and accuracy were thus 
maintained. 
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6.2.5 Non-compartmental pharmacokinetic analysis (NCA)  
The exposure metrics and PK parameters were calculated for 5-HMF using the NCA 
approach, which does not have compartmental model-based assumptions. The NCA method, 
however, does assume linear kinetics, but may also be used to assess if a drug follows nonlinear 
kinetics after ascending doses or multiple dosing (Venitz, 1997; Gabrielsson et al., 2012).  
The peak plasma concentration (Cmax) and time to peak plasma concentration (tmax) were 
determined from visual inspection of the PK data, as the highest concentration in the plasma and 
the time at which highest concentration in the plasma was measured, respectively. The total area 
under the curve (AUCoo) was determined from Equations 6 – 1 to 6 – 3 below: 
 
                                                         
 
        ∑
       
 
 (       )
 
   
                                
 
          
  
 
                                         
 
AUCtrap represents the area under the curve up to the last measured concentration and was 
calculated by the linear trapezoidal method. AUCextrap refers to the extrapolated AUC beyond the 
last measured concentration (Cn) to infinity, and must not be greater than 20% of the total 
calculated AUCoo in order to have adequate confidence in the validity of the AUCoo estimate. 
The (first-order) terminal rate constant (λ) was calculated from the slope of the log-linear 
regression of the terminal phase. The terminal phase was determined by data inspection, least 
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sum of squared residuals and goodness-of-fit after log-linear regression of the terminal phase. A 
minimum of 7 measured 5-HMF concentration points were included in the estimation of the 
terminal phase. It is desirable to have several measurements, at least up to 3 – 4 half-lives in 
order to have a reliable estimate for the terminal slope. It is known that 5-HMF has a short t1/2 in 
whole blood (~1 hr) (Abdulmalik et al., 2005; Obied 2010) and for the current studies, the 
plasma 5-HMF concentrations were measured up to 10 hrs. Therefore, a reliable estimate for the 
terminal slope could be obtained (r
2
 values > 0.90). The terminal half-life (t1/2) was determined 
from the terminal rate constant, shown in Equations 6 – 4 and 6 – 5 below. 
 
                  (      )                                 
 
     
     
 
                                           
 
The in-vitro plasma (disposition) clearance (CLplasma
in-vitro
) was estimated from the 
(initial) dose and the total area under the curve as shown below (Equation 6 – 6): 
 
        
         
    
     
                                       
 
The dose for nominal/starting concentrations of 5-HMF in human whole blood (0.5-5 
mM) was calculated based on the in-vitro experimental blood volume of 20 mL. This in-vitro 
plasma clearance was extrapolated to in-vivo plasma clearance (CLplasma
IVIVE
) for a physiological 
plasma volume of 3 L by IVIVE. 
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6.2.6 Data Analysis  
Nonlinear regression was performed when required, using Scientist
®
 v.2.0. Goodness-of-
fit statistics for the model and model suitability/appropriateness were assessed from the r
2
, MSC, 
residual analysis and precision of the parameter estimates. 
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6.3 Results 
 
6.3.1 Disposition of 5-HMF in plasma from whole blood 
The varying partial pressures of oxygen at which the whole blood was equilibrated (pO2 
of 6, 20 and 40 mmHg) did not to have an effect on the plasma concentrations (Cp) of 5-HMF, as 
may be expected. Hence, the mean Cp of 5-HMF for each nominal concentration of 0.5-5 mM in 
whole blood (n=3) were considered.  
Peak plasma concentrations were observed immediately, i.e., within 15 min of incubation 
with 5-HMF, after which the concentrations were found to decline. The mean plasma 
concentrations of 5-HMF (n=3) were found to decline from 0.25 – 10 hrs as seen from Figure 
6.1. The log-linear concentration-time profiles showed decreasing terminal slopes with respect to 
increasing nominal/starting concentration of 5-HMF (Figure 6.2). The decline of 5-HMF plasma 
concentrations over time in-vitro (plasma clearance, CLplasma
in-vitro
), is expected to occur as a 
result of two simultaneous processes, namely reversible binding with Hb in the RBC and 
irreversible metabolism by ALDH in the RBC. At lower doses, only 30% of the nominal 
concentration of 5-HMF was measured in the plasma after 15 min, the initial sample, suggesting 
rapid interactions with plasma proteins, RBC membranes, and rapid distribution of 5-HMF in to 
the RBC. At  higher doses, about 50% of the dose was measured in the plasma after the first 15 
min, showing some evidence of saturable processes.  
The relationship between the measured plasma concentrations and the effect was assessed 
for 5-HMF in whole blood. The relationship showed a counter-clockwise hysteresis, due to a lag-
time between the peak plasma concentration and the measured peak effect. This relationship may 
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be seen from Figure 6.3, and suggests a lag time, owing to distribution of 5-HMF from plasma to 
the RBC, binding with the HbA in order to exert the left-shifting effect, along with concurrent 
metabolism by RBC-ALDH. Although the relationship appears clockwise in Figure 6.3, a plot of 
the effect (actual p50 values) with respect to the plasma concentrations is shown by a counter-
clockwise hysteresis.  
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Figure 6.1. Mean (n=3) plasma concentration-time profiles for varying nominal/starting 
concentrations of 5-HMF (0.5 – 5 mM), incubated with human whole blood (containing 
HbA). 
 
 
  
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0 2 4 6 8 10 12
C
p
 (
m
M
) 
Time (hrs) 
0 mM
0.5 mM
1 mM
2 mM
3 mM
5 mM
  
252 
 
Figure 6.2. Semi-logarithmic (plasma) concentration-time profiles for varying 
nominal/starting concentrations of 5-HMF (0.5 – 5 mM), incubated with human whole 
blood containing HbA (Mean, n=3). 
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Figure 6.3. Counter-Clockwise Hysteresis between 5-HMF plasma concentrations and 
effect. 
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Noncompartmental pharmacokinetic analysis (NCA) was carried out for the plasma 
concentration-time profiles, in order to provide descriptive information on the exposure metrics 
and the pharmacokinetic parameters, such as terminal half-life of 5-HMF in the plasma, without 
employing model-based assumptions. However, the NCA assumes the drug follows linear (dose-
proportional) PK (Venitz, 1997; Gabrielsson et al., 2012). Table 6.1 provides a summary of the 
exposure metrics and PK parameters estimated from NCA for the varying nominal 
concentrations (doses) of 5-HMF. The extrapolated AUC (AUCextrap) was less than 16.5 % of the 
AUCoo for all instances, and less than 5% for 0.5 – 5 mM 5-HMF, validating the estimates from 
this method. 
The peak concentrations (Cmax) were achieved immediately, because the experimental 
design was analogous to an “IV bolus administration”. Therefore, a dose-dependent increase in 
Cmax was observed at a tmax of 0.25 hr for all doses of 5-HMF. The decreasing terminal slopes 
translated to dose-dependent t1/2 term
plasma
, which increased from 0.8 – 4 hrs for 0.5 – 5 mM of 5-
HMF.  A supra-proportional increase in AUCoo, and decline in the estimated CLplasma
in-vitro
 with 
respect to dose, was observed reflecting nonlinear kinetics and evidence of saturable 
mechanisms. Dose proportionality for 5-HMF was further assessed using a power model fit to 
the log-log-transformed AUCoo – Dose relationship (Garrett, 1985). The power model fit the data 
very well (r
2
 = 0.99) and resulted in an exponent of 2.05 (Figure 6.4), confirming the supra-
proportional relationship between AUCoo and dose, and, thus, the observed nonlinear kinetics of 
5-HMF. Figure 6.5 represents the nonlinear decline in CLplasma
in-vitro
 with respect to 5-HMF 
nominal concentration. 
The in-vitro plasma clearance estimated from dose/AUCoo was extrapolated by IVIVE to 
CLplasma
IVIVE
. Greater than 10-fold decline in the IVIVE predicted plasma clearance was observed 
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with increasing doses of 5-HMF, suggesting saturable Hb binding, and/or saturable metabolism 
by ALDH in the RBC.  
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Table 6.1. PK parameters estimated from the non-compartmental analysis for 5-HMF concentration in the plasma 
 
 
Initial nominal 
5-HMF 
concentration 
(mM) 
Dose 
(mg) 
cmax 
(mM) 
tmax 
(hr) 
AUCoo 
(mM*hr) 
t1/2 term
plasma
 
(hr) 
CLplasma
in-vitro
 
(mL/min/12 mL 
plasma) 
Predicted 
CLplasma
in-vivo
 
(mL/min) 
0.5 1.3 0.14 0.25 0.12 0.8 1.36 341 
1 2.5 0.33 0.25 0.44 0.7 0.75 188 
2 5.0 0.84 0.25 1.55 1.3 0.43 106 
3 7.6 1.62 0.25 4.61 2.3 0.22 56 
5 12.6 2.89 0.25 13.8 4.1 0.12 30 
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Figure 6.4. Assessment of dose-proportionality from the relationship between log-log-
transformed AUCoo and dose. 
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Figure 6.5. Assessment of CLplasma
in-vitro
 with nominal 5-HMF concentrations. 
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6.3.2 Modeling of nonlinear disposition clearance 
The decline of 5-HMF concentrations over time is expected to occur as a result of two 
simultaneous processes, namely reversible binding with Hb in the RBC and irreversible 
metabolism by ALDH in the RBC. The CLplasma
in-vitro
 estimated by the noncompartmental method 
has two major assumptions, i.e., clearance occurs from the central compartment with first-order 
kinetics, and the clearance is unidirectional/irreversible. Assuming rapid equilibration between 
plasma and RBC, the clearance of 5-HMF occurs from the central (blood) compartment, but is 
primarily a result of two mechanisms: reversible, bidirectional binding with Hb and (irreversible) 
unidirectional metabolism by ALDH in the RBC.  
The nonlinear, concentration-dependent CLplasma
IVIVE 
was modeled empirically using a 
sigmoidal CLmax-model (Equation 6 – 7).  
 
        
            [  (
  
(  
   )
 
   
)]                           
 
Where 
CLplasma
IVIVE
= CLplasma
in-vitro   Plasma volume (3L) 
CLmax: Maximum disposition clearance under first-order conditions (low plasma concentrations) 
Km
app
: Plasma concentration at half-maximal clearance  
n: Sigmoidicity coefficient 
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The model is analogous to a Michaelis-Menten model for clearance, however, with a 
sigmoidicity coefficient (n) for improved model prediction. 1/Y was used as a weighing factor, 
and nonlinear regression and parameter estimation was performed using Scientist® v.2.0.  
Figure 6.6 below represents the predicted CLplasma
IVIVE
 from NCA and the sigmoidal 
model fit. Table 6.2 shows the parameter estimates for the concentration-dependent CLplasma
IVIVE
 
for 5-HMF in whole blood. The model fit the data reasonably well, as observed from the 
goodness-of-fit statistics, with an r
2
 of 0.99. The sigmoidal CLmax-model with a slight 
sigmoidicity, i.e. n = 1.3 (0.2), describes the observed concentration-dependence of CLplasma
IVIVE 
very well.  The estimated CLmax (640 ± 243 mL/min), i.e., maximum possible clearance under 
first-order conditions, is comparable to the IVIVE-predicted CLRBC by RBC-ALDH of 690 
mL/min (Obied, 2010).  The estimated Km
app
 value (0.54 ± 0.29 mM) is similar to the binding 
affinity (KD) of 5-HMF for isolated HbA (0.41 ± 0.07 mM; see Chapter 7). However, the  
estimated Km
app
 value is much lower than the in-vitro Michaelis-Menten constant for ALDH (Km 
>100 mM) in RBC suspensions estimated by Obied, 2010, suggesting saturable Hb-binding as 
the more likely mechanism for the observed in-vitro nonlinear disposition kinetics of 5-HMF.  
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Figure 6.6. Nonlinear decline in IVIVE plasma clearance fit by sigmoidal-CLmax model. 
 
 
 
 
 
Table 6.2. Estimates from sigmoidal-CLmax model for 5-HMF in plasma from whole blood. 
Parameter Estimate (SD) 
CLmax (mL/min) 641 (243) 
Km
app
 (mM) 0.54 (0.29) 
n 1.34 (0.20) 
r
2
 0.99 
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6.4 Discussion and Conclusions 
5-HMF undergoes time- and concentration-dependent disposition in human whole blood.  
It undergoes rapid initial binding to plasma proteins, RBC membranes as well as rapid 
distribution into the RBC. The results confirm the existence of clearance mechanism(s) of 5-
HMF in whole blood – in-vitro.  
 Disposition of 5-HMF in whole blood is nonlinear, as evident from the decreasing 
terminal slopes with initial concentrations, supra-proportional increase in AUCoo with respect to 
dose, and a more than 10-fold decrease in predicted CLplasma
IVIVE
 with increasing nominal 
starting concentrations of 5-HMF, suggesting saturable Hb binding and/or saturable ALDH 
metabolism. At the lower nominal concentrations of 5-HMF (~Km
app
), the t1/2 term
plasma
 values are 
comparable to the IVIVE-predicted in-vivo plasma half-life of 0.7 hrs, and similar to the reported 
in-vivo half-life of the ALDH-mediated circulating metabolite (HMFA) of 1.2 hrs (Prior et al., 
2006), suggesting that the elimination clearance of 5-HMF in blood occurs primarily by RBC-
ALDH mediated oxidation. Furthermore, the CLmax estimate from the sigmoidal CLmax model, 
which describes the maximum clearance of 5-HMF in plasma under first order conditions, was 
found to be similar to the IVIVE predicted RBC clearance (by ALDH). However, this IVIVE 
estimate for CL underestimates the CLtot for 5-HMF since it does not include CLhep (by ALDH 
and other metabolic pathways), and extrahepatic clearance (likely by ALDH present in other 
tissues). From recent FIH studies, 5-HMF administered orally, at doses ranging from 300 – 4000 
mg, had high apparent CL, and suggests low Foral and/or high systemic CL, likely due to 
GI/extrahepatic metabolism (Stern et al., 2012). 
Therefore, the overall disposition clearance of 5-HMF in plasma (from blood) occurs 
through rapid, apparent first-order RBC-ALDH mediated metabolism (irreversible elimination 
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clearance), while the cause of the nonlinear disposition kinetics of 5-HMF is likely saturable Hb-
binding (reversible distribution clearance). The observed saturable binding of 5-HMF to Hb 
further explains the observed prolonged, nearly maximal PD effect of 5-HMF (discussed in 
Chapter 5) at high concentrations of 5 mM, i.e., 10-fold greater than the Km
app
 and KD values. 
The disposition of 5-HMF was further modeled by a novel “target-site drug disposition” model 
and is discussed in Chapter 8. 
The relationship between the measured 5-HMF plasma concentrations and the estimated 
∆p50 values (Chapter 5) showed a counter-clockwise hysteresis, due to a lag-time between the 
peak plasma concentration and the measured peak effect. This lag-time is due to distribution of 
5-HMF from plasma to the RBC, binding with the HbA in order to exert the left-shifting effect, 
along with concurrent metabolism by RBC-ALDH (Chapters 7 and 8).  
Similar observations of nonlinear in-vivo PK have been made for the FGE, valeresol and 
tucaresol. From clinical studies, the PK for valeresol was found to be nonlinear, while that for 
tucaresol was linear in the dose range of the study, although some nonlinear trends for tucaresol 
(decrease in CLoral for SCD females) were observed in other studies (Fitzharris et al., 1985; 
Rolan et al., 1993; Arya et al., 1996). Figures 6.7 and 6.8 represent the dose-dependent effect on 
CL, for valeresol and tucaresol, respectively (Fitzharris et al., 1985; Rolan et al., 1993). The 
CLtot for valeresol was estimated from Dose/AUCoo, where approximate AUCoo values were 
extrapolated from a plot of AUCoo against IV dose (Fitzharris et al., 1985). A 7-fold increase in 
dose results in greater than 2-fold decline in total clearance of valeresol, indicating nonlinear PK. 
The supraproportional increase in Cmax and AUCoo with IV dose and reduction in CLtot, clearly 
reflects nonlinear processes such as saturable Hb-binding and/or metabolism in RBC, which has 
been described as saturable elimination processes (Fitzharris et al., 1985). 
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The apparent (oral) plasma clearance (CLoral) was estimated for Tucaresol from 
Dose/AUCoo (Rolan et al., 1993). The apparent (oral) clearance did not change with oral doses of 
400-3600 mg, as shown in Figure 6.8. The true CLtot could not be estimated, as information on 
its oral bioavailability was unavailable; however, the systemic clearance cannot exceed CLoral. 
Rolan et al. (1993) reported linear pharmacokinetics for tucaresol in the clinical dose range (200 
– 3600 mg), but reported a dose-dependent increase in ratio of AUCoo in RBC : AUCoo in 
plasma, without change in the plasma clearance (2.1 - 2.8 mL/min). This may suggest concurrent 
RBC metabolism by ALDH, an expected clearance mechanism for AEH in blood.  
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Figure 6.7. Assessment of Dose-Proportionality for Valeresol after I.V. administration 
(adapted from Fitzharris et al., 1985). 
 
 
 
Figure 6.8. Assessment of Dose-Proportionality for Tucaresol after oral administration 
(adapted from Rolan et al., 1993). 
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Table 6.3 shows PK comparison across AEH. Valeresol an extensively metabolized 
compound, has total in-vivo clearance from whole blood between 20-45 mL/min (Fitzharris et 
al., 1985), about 10-20 fold higher than the apparent in-vivo CLoral
plasma
 for tucaresol (2.1-2.8 
mL/min) (Rolan et al., 1993), explaining why it has a shorter half-life than tucaresol. For in-vitro 
doses of 5-HMF in whole blood (1.3-12.6 mg), the plasma clearance was estimated to be 340 
mL/min (1.3 mg dose), and decreases to 30 mL/min (12.6 mg dose) respectively, declining 10-
fold with 10-fold increase in dose. The IVIVE-predicted CLplasma for 5-HMF is ~640 mL/min. 
Although it appears that 5-HMF has the highest plasma clearance, the CLtot for valeresol may 
have been underestimated by the investigators (Fitzharris et al., 1985) owing to a less-selective 
assay used for detection of plasma concentrations of valeresol (and possibly overestimation of 
parent AUCoo) (Chapter 1).  
 
Table 6.3. Comparison of PK between AEH. 
Parameters 
In-vivo studies In-vitro studies 
FGE SGE SGE 
Valeresol 
(Fitzharris et 
al., 1985) 
Tucaresol 
(Rolan et al., 
1993) 
5-HMF 
(Stern et al., 
2012) 
5-HMF 
Dose 
(mg) 
140 – 1400 
(I.V.) 
400 – 3600 
(P.O.) 
300 – 4000 
(P.O.) 
1.3 – 12.6 
(whole blood) 
Cmax 
(mM) 
0.04 – 1.2 0.1 – 1.8 0.0003 – 0.006 0.1 – 2.9 
Foral N/A Orally absorbed Orally absorbed 
Orally absorbed; likely 
low hepatic first-pass 
CLtot 
(mL/min) 
50 - 20 
2 – 3 
(CLtot/Foral) 
> 76,000 
(CLtot/Foral) 
>640 
Plasma t1/2 
(hr) 
8.5 195 – 289 0.4 – 0.8 0.8 – 4 
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A dose-dependent t1/2 of about 8-12 days was observed for tucaresol in plasma, 
suggesting nonlinear, saturable processes, likely saturable Hb-binding. Furthermore, the 
prolonged t1/2  could be a result of low apparent clearance for tucaresol (~2.4 mL/min), or 
extensive binding to and slow dissociation from proteins (plasma, RBC or tissue) (Rolan et al., 
1993). The (apparent) t1/2 for valeresol in whole blood was about 8.5 hrs (for a single dose), 
much shorter than that for tucaresol. The plasma t1/2 for 5-HMF was also relatively short, 
estimated to be 0.8-4 hrs, from in-vitro studies, and was also found to be dose-dependent. The in-
vitro findings for 5-HMF from this research are virtually identical to recent in-vivo findings in 
humans (Stern et al., 2012) (see Table 6.3). PK studies for 5-HMF in transgenic sickle mice, 
using doses of 50-200 mg/kg showed similar results; >2-fold increase in t1/2 from 0.5 to 1.5 hrs, 
for 50 – 100 mg/kg doses, respectively), however, it remained constant between 100-200 mg/mg 
doses. The terminal t1/2, nevertheless, only provides an indirect method for assessing dose-
proportionality as its estimation is sensitive to the sampling schedule (Venitz, 2010). 
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CHAPTER 7 
7 IN-VITRO BINDING KINETICS OF 5-HMF TO HBA AND HBS 
 
 
 
7.1 Introduction 
The binding of 5-HMF to HbA was found to be time-dependent, and concentration-
dependent at steady-state in isolated HbA solutions, following second-order reaction kinetics 
(Obied, 2010). As discussed in Chapter 6, 5-HMF (and other AEH) exerts a time- and 
concentration-dependent left-shift in p50 in whole blood. This provides further evidence for time- 
and likely concentration-dependent binding between 5-HMF and HbA. Abraham et al (1991) 
demonstrated a concentration- and time-dependent modification of HbS (HbS adduct measured 
by HPLC methods) for Vanillin up to 2 – 8 hrs of incubation with HbS. Abdulmalik et al (2005) 
observed concentration-dependency and some time-dependency of binding of 5-HMF with HbS 
in hemolysates. 5-HMF, pre-incubated with SS hemolysates, resulted in a greater left-shift in p50 
than non-pre-incubated samples (Abdulmalik et al 2005). Therefore, like binding to HbA, 
binding of 5-HMF to HbS is also hypothesized to have time- and concentration-dependency. 
Since it is the binding to Hb that results in the onset and duration of (observed) PD effect, in 
addition to RBC-ALDH mediated metabolism, this research was aimed to fully characterize this 
time- and concentration-dependency of 5-HMF binding to HbA and HbS, characterize the 
kinetics and estimate appropriate binding rate constants.  
  
269 
 
Attempts were made to develop a generic assay for quantification of all AEH adducts of 
Hb, in order to characterize their binding kinetics with Hb, however, the chemical assay could 
not be validated (Chapter 3). Therefore, an ultrafiltration approach that was previously used by 
Obied (2010) for preliminary binding experiments of 5-HMF to HbA, was the method of choice, 
and used to fully characterize the time- and concentration-dependency of 5-HMF binding to HbA 
and HbS. 
Obied (2010) investigated the time-dependency of 5-HMF binding with isolated HbA at 
three molar fraction levels; 0.04:1, 0.3:1 and 1.8:1 5-HMF:HbA. Individual time-dependency 
modeling was performed to estimate the forward and backward binding rate constants (k1, k-1) of 
the second-order reaction. The current research was performed to further expand the molar 
fraction levels investigated, and include levels corresponding to those in the PD and disposition 
studies (Chapters 5 and 6), to characterize the binding kinetics of 5-HMF to Hb in absence of 
metabolic ALDH. The results from these studies would provide extensive information for 
building the final PK/PD model for 5-HMF in whole blood (see Chapter 8). Additionally, new 
steady-state concentration-dependency studies will be carried out in replicate experiments, for 
better parameter estimation. 
HbS differs from HbA by a substituted amino acid on each β-subunit of HbS. 5-HMF 
however, is known to bind to the α-subunits of Hb(A/S) and may show subtle differences in 
binding kinetics between the two forms of Hb. The binding kinetics of 5-HMF with HbS have 
not been previously investigated. It is therefore of interest to investigate and characterize the 
binding kinetics of 5-HMF to HbS, and compare with HbA. Similar binding kinetics between the 
two forms may help reduce the number of in-vitro/in-vivo investigational studies required to be 
carried out on sickle blood by extrapolating results from normal whole blood.  
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INN-312 has a more rapid onset of action (left-shift in p50), suggesting differences in its 
binding kinetics compared to 5-HMF. The binding kinetics of INN-312 with Hb have not been 
previously investigated, and it is hypothesized to have rapid association with and slower 
dissociation from Hb, compared to 5-HMF. A typical aromatic aldehyde at a free concentration 
of 5 mM, capable of 50% Hb modification, is thought to have an equilibrium dissociation 
constant (KD) of 4.6 mM (Zaugg 1977).  
The primary objectives of this study were to (1) fully characterize the time-dependency 
of binding of varying concentrations of 5-HMF to normal adult Hb (HbA) and sickle Hb (HbS), 
(2) characterize the steady-state concentration-dependent binding of 5-HMF to HbA and HbS, 
(3) model the time-dependent kinetics to estimate the association (forward) and dissociation 
(backward) rate constants, k1 and k-1, respectively, and model the steady-state binding kinetics 
using an appropriate binding model to estimate the maximum binding capacity (Bmax) and 
dissociation constant (KD), and (4) compare the binding of 5-HMF with HbA and HbS. The 
secondary objectives of this study were to make predictions on the onset, peak and duration of 
Hb adduct formation, and differentiate between the two forms of Hb. Finally, the research also 
aimed to characterize the binding kinetics of INN-312 with HbA and HbS, for similar 
comparisons, and for comparison between the different AEH. 
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7.2 Methods 
 
7.2.1 Materials and Reagents 
 
26. 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO) (126.11 g/mol) 
27. Human hemoglobin A (HbA0) lyophilized powder, ferrous stabilized  (Sigma, St. Louis, 
MO) (64,677 g/mol; determined by Sigma) 
28. Human sickle hemoglobin S (HbS), isolated and concentrated (11.8 g/dL; Dr. Martin 
Safo’s laboratory, Dept of Medicinal Chemistry, VCU) (64,398 g/mol; theoretical) 
29. Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
30. Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
31. Acetic acid, glacial, > 99% (Sigma, Milwaukee, WI) 
32. Tetrahydrofuran, HPLC grade (Burdick and Jackson, Morristown, NJ) 
33. Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO) 
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7.2.2  Equipment 
 
45. Vortex (Vortex Genie 2, Fisher Scientific, Pittsburgh, PA) 
46. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA) 
47. Balance (Fisher Scientific A 250, Pittsburgh, PA) 
48. Centrifuge 5804-R (Eppendorf, Hauppauge, NY) 
49. Seal-Rite Microcentrifuge tubes, 1.5 mL (USA Scientific, Ocala, FL) 
50. pH meter (Corning, Glendale, AZ) 
51. Durapore PVDF 0.45 μm membrane filter (Millipore, Billerica, MA) 
52. Vacuum filtration apparatus (assembled, Drug Metabolism Laboratory, VCU) 
53. 10-µL, 100-µL, and 1000-µL VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA) 
54. 25-µL positive displacement pipette and corresponding pipette tips (Microman, Rainin 
Instruments, Oakland, CA). 
55. 0.5-5 mL Finnpipette (Thermo Scientific, Waltham, MA) 
56. Glass insert (150 µL) with preinstalled plastic spring (Waters, Milford, MA) 
57. Amicon® Ultra-0.5 centrifugal filter units with Ultracel-10 membrane (Millipore, 
Billerica, MA).  
58. Forma Scientific incubator (Thermo Fisher Scientific Inc., Pittsburgh PA) 
59. Glass shell vials with caps, 1 mL (Waters, Milford, MA) 
60. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA) 
61. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA) 
62. 717 plus autosampler (Waters, Milford, MA). 
63. 600 Multisolvent controller (Waters, Milford, MA). 
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64. UV detector (Shimadzu, AV-10, Columbia, MA).  
65. Empower 2 software (Waters, Milford, MA). 
66. Scientist® Software version 2.0 (Micromath, St. Louis, MO). 
 
7.2.3 Preparation of Solutions 
 
1. Phosphate buffered saline  
Phosphate buffered saline: One tablet of phosphate buffered saline was dissolved in 200 
mL of nanopure water. This solution had a pH of 7.4, when measured by a pH mete. 
 
2. Mobile Phase 
The pre-mixed mobile phase consisted of water:MeOH:glacial acetic acid:THF in the 
ratio of 92.5:6.2:1:0.3. In order to prepare 1L of mobile phase, 62 mL of MeOH, 10 mL of 
glacial acetic acid and 3 mL of THF were added to 925 mL of nanopure water. The mobile 
phase was filtered under vacuum and degassed by sonication for 5 min. 
 
3. 5-HMF standards in neat solution 
A stock solution of 20 mM 5-HMF was prepared. 12.6 mg of 5-HMF (MW 126.11 
g/mol) was dissolved in 5 mL of nanopure water. This was further diluted appropriately, to 
prepare 5-HMF standards for a calibration range of 0.3 – 634.4 μM and the QC standards. 
 
 
 
  
274 
 
4. HbA solution 
A solution of 0.125 mM HbA was prepared by re-constituting 76.8 mg of lyophilized 
isolated HbA in 9.5 mL PBS (or as required). 
 
5. HbS solution 
The concentration of isolated HbS was 11.8 g/dl (1.83 mM). A solution of 0.125 mM 
HbS was prepared by diluting 0.65 mL of the concentrated isolated HbS in 8.85 mL PBS (or 
as required). 
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7.2.4 Procedures 
Aliquots of 200 µL of serial solutions of 5-HMF in HbA and HbS, were filtered by 
centrifugation using the Amicon® Ultra-0.5 centrifugal filter units with Ultracel-10 membrane at 
14,000 RPM for 10 min at 4
o
C. Unbound 5-HMF levels were measured after incubation and 
ultrafiltration of 5-HMF in Hb protein suspensions. New calibration curves in buffer were 
established for daily analysis from freshly prepared standards, and 3 × 3 QC standards were 
maintained throughout each run. Assay reproducibility was assessed during each run. 
The specific binding of 5-HMF to Hb ([HMF]t
bound
) was determined from the measured 
nominal concentration of 5-HMF (total 5-HMF concentration at 0 min in absence of protein; 
[HMF]0) and the unbound/free concentration of 5-HMF measured in the ultrafiltrate ([HMF]t). 
Therefore,  [HMF]t
bound 
= [HMF]0 - [HMF]t. 
Non-specific binding (NSB) of 5-HMF to the centrifugal filter units (and membrane) was 
determined by analyzing 5-HMF concentrations in the filtrate after ultrafiltration of 200 μL of 
varying 5-HMF concentrations (0.3 – 634.4 μM), in the absence of Hb protein. The experiment 
was performed in unicate, and the unbound (free) concentrations of 5-HMF were measured.  
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7.2.5 Experimental design for time-dependency study 
In order to fully investigate the time-dependent binding of varying concentrations of 5-
HMF incubated with HbA and HbS, the molar fractions of 5-HMF:Hb (HbA or HbS, 
respectively) investigated are shown in Table 7.1. 
It has been shown that binding of acetaldehyde with Hb to form Hb-adducts takes at least 
20 hours (San George and Hoberman, 1986), while binding of 5-HMF with HbA takes about 24 
hours to reach equilibrium (Obied, 2010). The time-dependent binding studies were carried out 
to binding equilibrium to enable optimal estimation of initial parameter estimates for the rate 
constants (based on the method of Ge, 1997 and Obied, 2010). 
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Table 7.1. Molar fractions of 5-HMF:Hb investigated. 
 
HMF : Hb 
Molar Fraction 
HMF : Hb 
Concentration (μM) 
0.05 : 1 6.25 : 125 
0.5 : 1 62.5 : 125 
1 : 1 125 : 125 
1.5 : 1 187.5 : 125 
2 : 1 250 : 125 
4 : 1 500 : 125 
10 : 1 1250 : 125 
 
 
Each molar fraction level of 5-HMF was prepared using the following general design: 1.88 
mL of 125 μM (0.125 mM) HbA or HbS was transferred to separate tubes. Initial concentrations 
of 5-HMF were prepared from 5-HMF stock solution appropriately to achieve final 
concentrations mentioned in Table 7.1 after addition of 20 µL of each initial 5-HMF 
concentration to tubes containing HbA or HbS (total Hb-HMF volume in tube = 2 mL). Each 
concentration level of 5-HMF was incubated with Hb at 37
o
C for up to 30 hrs.  
Aliquots of 200 µL were taken at 0.5, 1, 1.5, 2, 4, 6, 10, 24 and 30 hrs and filtered by 
centrifugation using the Amicon® Ultra-0.5 centrifugal filter units with Ultracel-10 membrane at 
14,000 RPM for 10 min at 4
o
C. 5-HMF was not measured beyond the 30-hr time points due to 
instability of the Hb solution. The ultrafiltrate was injected directly onto HPLC, or diluted 10-
fold (as appropriate) with PBS before injection onto the HPLC. Nominal concentrations of 5-
HMF were measured for all experiments by adding 20 µL of varying initial concentrations to 
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achieve respective 5-HMF final concentrations in 1.88 mL of PBS (in absence of Hb) and 
ultrafiltration of the solutions.  
For binding of 5-HMF with HbA, 30-hr  time-dependency experiments were performed 
two times in unicate, except 10:1 concentration level, which was performed one time in unicate. 
Nominal concentrations of 5-HMF were not measured only in these two experiments. A third set 
of experiments were performed up to 6 hrs with dense sampling to enable better characterization 
of the initial binding reaction and estimation of the rate constants. Therefore, for binding of 5-
HMF with HbA, a total of three experiments were performed in unicate.  
For binding of 5-HMF with HbS, time-dependency experiments were performed 3 – 4 
times in unicate.  
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7.2.6 Experimental design for steady-state concentration-dependency study 
After preliminary analyses from the time-dependency studies, concentration-dependent 
steady-state binding of 0.01:1 – 10:1 HMF:HbA and 0.05:1 – 30:1 HMF:HbS was investigated. 
10 µL of appropriate initial concentrations of 5-HMF were added to 290 μL of 125 μM (0.125 
mM) HbA or HbS in order to achieve respective 5-HMF final concentrations in Hb. The total 5-
HMF-Hb solution volume in tube was maintained at 300 µL.  
Aliquots of 200 µL were taken at 24 hrs and 10 hrs for HMF-HbA and HMF-HbS, 
respectively, and filtered by centrifugation using the Amicon® Ultra-0.5 centrifugal filter units 
with Ultracel-10 membrane, at 14,000 RPM for 10 min at 4
o
C. The filtrate was injected directly 
into the HPLC, or diluted 10-fold (as appropriate) with PBS before injection to the HPLC. 
Nominal concentrations of 5-HMF were measured for each experiment by adding 10 μL of 
varying initial concentrations to achieve respective 5-HMF final concentrations in 290 μL of 
PBS (in absence of Hb) and ultrafiltration of the solutions. The experiments were performed 3 – 
4 times for replicates.  
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7.2.7 Data analysis 
The bimolecular binding reaction scheme of 5-HMF with Hb is shown in Figure 7.1 
below. 5-HMF binds with Hb reversibly, with a second order forward rate constant (k1) 
dependent on the free concentrations of both 5-HMF and Hb, to form a Schiff base adduct. The 
adduct dissociates to free 5-HMF and Hb with a first-order backward rate constant (k-1). 
 
Figure 7.1. General bimolecular binding scheme of 5-HMF to Hb. 
 
 
 
The rate of change in Hb-adduct concentration at any time,‘t’ during the time-dependent 
binding reaction was described by Equation 7 – 1 below. 
 
 [      ] 
  
 (   [    ]  [  ] )   (    [      ] )                    
 
Where [5HMF]t, [Hb]t and [Adduct]t are the concentrations of free (unbound) 5-HMF, 
free Hb and Hb-adduct  at time, t, respectively. 
Since the adduct concentrations could not be measured directly, free concentrations of 5-
HMF were measured and modeled in order to obtain estimates for the binding rate constants. The 
rate of change in free 5-HMF concentration at any time,‘t’ during the time-dependent binding 
reaction was described by Equation 7 – 2 below. 
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 [    ]
  
 (    [      ] )  (   [    ]  [  ] )                       
 
The adduct concentration was indirectly determined from the free 5-HMF concentrations 
based on Equation 7 – 3. 
 
[      ]  [    ]  [    ]                                     
 
Where [5HMF]o is the initial, nominal concentration of 5-HMF at 0 min. 
The free Hb concentration was determined from the calculated adduct concentrations 
based on Equation 7 – 4, assuming mass balance, and that the Hb in solution exists only in two 
states, the free form and as 5-HMF adduct. 
 
[  ]  [  ]  [      ]                                        
 
At binding equilibrium, the net change in rates is zero, and the rate of association is at 
steady-state with the rate of dissociation (Equation 7 – 5). 
 
   [    ]    [  ]        [      ]                              
 
The binding equilibrium constants were used to describe the steady-state condition, 
shown in Equation 7 – 6 below.  
 
  
282 
 
   
  
   
  
[      ]  
[    ]    [  ]  
 
 
  
                                 
 
Where  
KA and KD: Equilibrium association and dissociation constants respectively,  
[5HMF]eq, [Hb]eq and  [Hb-Adduct]eq: Concentrations of free (unbound) 5-HMF, free HbA, and 
Hb-adduct respectively, at equilibrium. 
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7.2.8 Modeling 
Non-linear regression was performed using Scientist
®
 v.2.0. A weighting factor of 1/Y 
was used in the final time- and concentration-dependency model due to the large concentration 
range of 5-HMF in the study. Model fits were assessed from careful visual inspection of the data. 
Goodness-of-fit statistics for the model and model suitability/appropriateness were assessed from 
the r
2
, MSC, residual analysis, precision of the parameter estimates and correlation matrix.  
 
7.2.8.1 Time-dependency studies  
Non-linear regression was performed for the time-dependent binding studies from the 
bimolecular, reversible interaction model (Obied, 2010) using Equations 7 – 1 to 7 – 4, where 
time is the independent variable and [5HMF]t, [Hb]t and [Adduct]t are the time-dependent 
variables. The initial Hb concentration (Hb0) was fixed for all models to the experimental value 
of 0.125 mM. 
The apparent first-order equilibration rate constant for the binding reaction was estimated 
when the free concentrations of 5-HMF were low, and the free Hb protein concentrations were in 
excess, such that [5-HMF] << [Hb]. In such a situation, the bimolecular reaction proceeds 
according to apparent first-order kinetics, and the decline of [5-HMF] follows an apparent first-
order equilibration process. The observed first-order equilibration rate constant (kobs) for low 
concentrations of 5-HMF was estimated from the “Sigma-minus plot” of natural logarithmic 
value for the adduct concentration yet to be formed, i.e., ln (Css-Ct) for 5-HMF with respect to 
time of incubation. This experimentally determined kobs is theoretically identical to the 
equilibration rate constant (keq), derived from the time-dependency model parameter estimates, 
as shown in Equation 7 – 7, under first-order conditions. The equilibration half-life (t1/2
eq
) for the 
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binding of 5-HMF with Hb at very low concentrations of 5-HMF and excess of Hb, is estimated 
from Equation 7 – 8.  
 
    (   [  ] )                                            
 
    
   
     
   
                                             
 
Furthermore, a dissociation half-life (t1/2
diss
) was estimated from the backward rate 
constant (k-1) estimated from Equation 7 – 9. 
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7.2.8.2 Concentration-dependency studies  
The concentration-dependent equilibrium (steady-state) binding of 5-HMF to Hb was 
modeled using the saturable hyperbolic binding model shown in Equation 7 – 10. 
 
[   ]      
     [   ]
   [   ]
                                 
 
Where  
Bmax: Maximum binding capacity of Hb for 5-HMF, and is dependent on the total amount of Hb 
and the number of binding sites on Hb. 
KD: Equilibrium dissociation constant, and provides information on the binding affinity of 5-
HMF for Hb. It depends on the forward and backward rate constants. 
[HMF]bound and [HMF] are the specifically bound and free concentrations of 5-HMF, 
respectively. 
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7.2.9 Initial Parameter Estimates 
An initial estimate for KA (and KD) was obtained from the time-dependency studies using 
Equation 7 – 6, where [5HMF]eq is the free concentration of 5-HMF measured at the time at 
which equilibrium was reached (24 hrs for HbA and 10 hrs for HbS). The [Adduct]eq was 
estimated from Equation 7 – 3.  
Initial parameter estimates for k1 and k-1 for the time-dependency model were obtained 
using the method described by Ge (1997) and Obied (2010). These initial estimates were used to 
optimize and obtain final parameter estimates after simultaneous fitting of 5-HMF concentration-
time profiles across varying nominal concentrations (molar fraction levels) of 5-HMF incubated 
with Hb. 
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7.3 Results 
 
7.3.1 Non-specific binding of 5-HMF to the centrifugal filter units 
5-HMF has been found to bind non-specifically to Amicon
®
 Ultra-4 centrifugal filter units 
with Ultracel-10 membrane with a quadratic relationship, for concentrations up to ~2 mM 
(Obied, 2010). In order to perform full characterization of time- and concentration-dependent, as 
well as steady-state binding of 5-HMF to HbA and HbS with lower sample volumes, Amicon
®
 
Ultra-0.5 centrifugal filter units were used. Therefore, the extent of non-specific binding of 5-
HMF to the Amicon
®
 Ultra-0.5 centrifugal filter units was investigated for the experimental 5-
HMF concentration range. 
Non-specific binding (NSB) was determined by analyzing 5-HMF concentrations in the 
filtrate after ultrafiltration of 200 μL of varying 5-HMF concentrations (0.3 – 634.4 μM) in PBS, 
i.e., in the absence of Hb protein. The NSB of 5-HMF to Ultra-0.5 centrifugal units was <6% for 
all concentration levels and did not depend on the free concentrations of 5-HMF (Figure 7.2).  
Therefore, the NSB of 5-HMF to Ultra-0.5 centrifugal units was considered negligible and not 
included in final assessments of specific binding of 5-HMF to Hb. 
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Figure 7.2. Non-specific binding of 5-HMF (%) to the filtration membrane for varying 5-
HMF concentrations (n=1). 
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7.3.2 Time-dependency studies for binding of 5-HMF to HbA 
5-HMF is chemically stable in PBS for up to at least 30 hrs at 37
o
C (see Chapter 3). Its 
non-specific binding to the filtration membrane was found to be negligible. When serial samples 
were incubated with HbA at 37
o
C, a decline in the free concentrations of 5-HMF was observed 
up to 30 hrs, which suggests specific binding of 5-HMF to HbA. This decline in 5-HMF 
concentrations in the presence of HbA was time- and concentration-dependent, and was found to 
approach equilibrium within 24 – 30 hrs. The individual profiles are shown in Figures 7.3 – 7.6. 
The initial decline for the lower concentrations of 5-HMF ([5-HMF] << [HbA]) was 
faster, and declined for increasing starting concentrations of 5-HMF ([5-HMF] >> [HbA]). The 
decreasing initial slopes with increasing molar fraction levels of HMF:HbA provide evidence for 
a bimolecular reaction. These observations were more evident when nominal concentrations of 
5-HMF were measured and initial dense sampling was performed.  
An average drop of ~75% was observed for free 5-HMF concentrations for the molar 
fraction level of 0.05:1 HMF:HbA after 30 hrs (Figure 7.3), while on the other hand, an average 
drop of only ~16% in free 5-HMF concentrations was seen for molar fraction level of 10:1 
HMF:HbA (Figure 7.6), suggesting saturable binding kinetics. Overall, it was observed from the 
experiments and initial simulations that the binding of 5-HMF to HbA approaches equilibrium 
by ~24 hrs.  
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Figure 7.3. Time-dependent binding of 0.05:1 HMF:HbA (0.006 mM 5-HMF in 0.125 mM 
HbA).  
 
 
Figure 7.4. Time-dependent binding of 0.5:1 (circles) and 1:1 (triangles) HMF:HbA (0.06 
mM and 0.125 mM of 5-HMF, respectively, in 0.125 mM HbA).  
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Figure 7.5. Time-dependent binding of 2:1 (squares) and 4:1 (circles) HMF:HbA (0.25 mM 
and 0.5 mM 5-HMF, respectively, in 0.125 mM HbA).  
 
 
Figure 7.6. Time-dependent binding of 10:1 (triangles) HMF:HbA (1.25 mM 5-HMF in 
0.125 mM HbA).  
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The time-dependency data was pooled and simultaneously modeled for varying molar 
fraction levels of HMF:HbA using the time-dependency model described under the Methods 
section.  
Figures 7.7 – 7.9 show the time-dependency of binding of various molar fraction levels of 
5-HMF with HbA. Figures 7.7 (linear scale) and 7.9 (semi-logarithmic scale) show the model fits 
for the pooled dataset over 30 hrs, except for the 4:1 level where data up to 6 hrs were used for 
time-dependency modeling. Figure 7.8 shows the model fits with an adjusted time scale to better 
view the initial 6-hr decline in free 5-HMF concentrations. Data points represent experimental 
measurements, and dashed lines are the fitted profiles after simultaneous modeling of the time- 
and concentration-dependent kinetics.  
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Figure 7.7. Simultaneous modeling of the time-dependency of 5-HMF binding to HbA for varying molar concentration levels 
of HMF:HbA (0.05:1 – 10:1) over 30 hrs using 0.125 mM isolated HbA. Data are shown as unbound/free 5-HMF 
concentrations over time (pooled data; n=2-4, linear scale). 
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Figure 7.8. Simultaneous modeling of the time-dependency of 5-HMF binding to HbA for varying molar concentration levels 
of HMF:HbA (0.05:1 – 10:1) over 6 hrs, with an adjusted time-scale to visualize the fit better for earlier time points (linear 
scale). 
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Figure 7.9. Modeling of the time-dependency of 5-HMF binding to HbA at varying molar concentration levels of HMF:HbA 
over 30 hrs (semi-logarithmic scale). 
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Table 7.2. Final parameter estimates (±SD) for binding of 5-HMF to HbA. 
 
Parameters Initial Estimates (Limits)* Final Estimates (SD) 
Primary k1 (mM
-1
 hr
-1
) 0.3 (0 – 1) 0.27 ± 0.03 
 k-1 (hr
-1
) 0.071 (0.05 – 0.5) 0.05 ± 0.01 
 [Hb]0 (mM) 0.125 (fixed)**  
Secondary KD (mM)  0.18 ± 0.04 
 t1/2
diss
 (hrs)  14 
 KA (mM
-1
)  5.55 ± 1.25 
 r
2
  0.99 
 MSC  4.96 
* Limits refer to the upper and lower limits constrained on the parameters for estimation; 
**Nominal [Hb]0 was fixed to the experimental value. 
 
From initial sensitivity analyses and modeling, k-1 could not be precisely estimated since 
the experiments were limited to a time period of 30 hrs. The apparent t1/2
eq
 was calculated to be 
greater than the duration of the experimental study providing evidence that the duration of the 
study may not have been sufficient to adequately characterize the dissociation of 5-HMF from 
HbA. Therefore, parameter constraints (“limits”) were set for better estimation of k-1, and an 
upper limit was set from extensive sensitivity analyses. Although k1 could be estimated precisely 
from initial modeling, broad limits were set for k1 to enable overall better parameter estimation. 
The value for nominal concentration of HbA was fixed to the experimental value of 0.125 mM. 
Table 7.2 shows the initial and final parameter estimates for k1 and k-1, and the secondary 
parameter values for KA, KD and t1/2
diss
 with their respective standard deviations. Overall, 
simultaneous weighted non-linear regression of the pooled data shows that the time- and 
concentration-dependency model fit the data quite well, with a model selection criterion (MSC) 
of 4.96 and an r
2
 of 0.99. 
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5-HMF has an apparently long half-life of dissociation from HbA of 14 hrs, which 
suggests rapid binding but slow dissociation from the HbA protein, and therefore, prolonged 
persistence of Hb-adduct. This dissociation half-life describes the half-life of dissociation of the 
Hb-adduct to free 5-HMF and HbA in absence of ALDH-metabolism in RBC (see Chapter 8). 
Table 7.3 shows a comparison of the equilibration constants and half-life estimated from 
the two methods as mentioned under section 7.2.7. The kobs was estimated from the experimental 
data under the conditions [5-HMF] << [HbA]. The keq was calculated from model estimates for 
k1 and k-1. The keq calculated from the model estimates is in 2-fold range of the experimentally 
determined kobs, and not significantly different from each other (p > 0.05). 
 
Table 7.3. Comparison of equilibration constants estimated by two different methods. 
 
Experimental Model-based 
Parameters Estimates (SD) Parameters Estimates (SD) 
kobs (hr
-1
) 0.18 ± 0.01 keq (hr
-1
) 0.08 ± 29 
t1/2
obs
 (hrs) 3.9 t1/2
eq
 (hrs) 8.2 
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7.3.3 Time-dependent binding of varying 5-HMF concentrations to HbS 
Time-dependent binding of varying concentrations of 5-HMF to HbS was performed up 
to 30 hrs in a similar way as that for HbA. However, it was found that the binding after 10 hrs 
could not be appropriately characterized. After 10 hrs of storage of HbS at 37
o
C, the protein 
suspension was found to be viscous and adhesive, most likely due to polymerization of the HbS. 
Therefore, accurate measurements could not be made for 5-HMF after 10 hrs of incubation with 
HbS. All experiments were run with simultaneous QC measurements, which confirmed that 5-
HMF is stable in solution, in absence of HbS. Therefore, the binding time-dependency of 5-HMF 
with HbS was investigated up to 10 hrs only. The individual profiles are shown in Figures 7.10 – 
7.13. 
The free concentrations of 5-HMF declined over 10 hrs with decreasing initial slopes for 
increasing molar fraction levels of HMF:HbS. An average drop of ~45% was observed for free 
5-HMF concentrations for a molar fraction level of 0.05:1 HMF:HbS (Figure 7.10), while, on the 
other hand, an average drop of ~13% in free 5-HMF concentrations was seen for a molar fraction 
level of 10:1 HMF:HbS (Figure 7.13), suggesting saturable binding, similar to the observations 
made for HbA. Overall, it was observed from the experiments and preliminary simulations that 
the binding of 5-HMF to HbS approaches equilibrium by ~10 hrs.  
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Figure 7.10. Time-dependent binding of 0.05:1 HMF:HbS (0.006 mM 5-HMF in 0.125 mM 
HbS).  
 
 
Figure 7.11. Time-dependent binding of 0.5:1 (circles) and 1:1 (triangles) HMF:HbS (0.06 
mM and 0.125 mM of 5-HMF, respectively, in 0.125 mM HbS).  
 
0.000
0.001
0.002
0.003
0.004
0.005
0.006
0.007
0 2 4 6 8 10
Fr
e
e
 [
H
M
F]
 (
m
M
) 
Time (hr) 
0.05:1
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0 2 4 6 8 10
Fr
e
e
 [
H
M
F]
 (
m
M
) 
Time (hr) 
0.5:1
1:1
  
300 
 
Figure 7.12. Time-dependent binding of 2:1 (squares) and 4:1 (circles) HMF:HbS (0.25 mM 
and 0.5 mM 5-HMF, respectively, in 0.125 mM HbS).  
 
 
Figure 7.13. Time-dependent binding of 10:1 (triangles) HMF:HbS (1.25 mM 5-HMF in 
0.125 mM HbS).  
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The time-dependency data were pooled and simultaneously modeled across varying 
molar fraction levels of HMF:HbS using the time-dependency model. Figures 7.14 and 7.15 
show the time-dependency of binding of various molar fraction levels of 5-HMF with HbS on 
linear and semi-logarithmic scales, respectively. The data points represent experimental 
measurements, and dashed lines are the fitted profiles after simultaneous modeling of the time- 
and concentration-dependent kinetics.  
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Figure 7.14. Modeling of the time-dependency of 5-HMF binding to HbS at varying molar concentration levels of HMF:HbS; 
0.05:1, 0.5:1, 1:1, 2:1, 4:1 and 10:1, using 0.125 mM isolated HbS. Serial samples were incubated at 37oC for up to 30 hrs. n=1-
3 in the pooled data for each concentration level (linear scale). 
 
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
0 2 4 6 8 10
Fr
e
e
 [
5
-H
M
F]
 (
m
M
) 
Time (hr) 
0.05:1
0.5:1
1:1
2:1
4:1
10:1
  
303 
 
Figure 7.15. Modeling of the time-dependency of 5-HMF binding to HbS at varying molar concentration levels of HMF:HbS 
over 30 hrs (semi-logarithmic scale). 
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Table 7.4. Parameter estimates for binding of 5-HMF to HbS. 
 
Parameters Initial Estimates (Limits) Final Estimates (SD) 
Primary k1 (mM
-1
 hr
-1
) 2.12 0.83 ± 0.13 
 k-1 (hr
-1
) 0.21 0.10 ± 0.04 
 [Hb]0 (mM) 0.125 (fixed)  
Secondary KD (mM)  0.13 ± 0.06 
 t1/2
diss
 (hrs)  6.6 
 KA (mM
-1
)  7.95 ± 3.58 
 r
2
  0.99 
 MSC  5.90 
 
 
Table 7.4 shows the initial and final parameter estimates for k1 and k-1, and the secondary 
parameter estimates for KA, KD and t1/2
diss
 with their respective standard deviations. Overall, 
simultaneous weighted non-linear regression of the pooled data shows that the time- and 
concentration-dependency model fit the data very well, with a model selection criterion (MSC) 
of 5.9 and an r
2
 of 0.99. 
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Table 7.5 shows a comparison of the equilibration constants and half-life estimated from 
the two methods as mentioned under section 7.2.7. The keq calculated from the model estimates 
is very similar to the experimentally determined kobs, and provides validity of the model 
parameter estimates. Overall, the equilibration between 5-HMF and HbS is relatively rapid, and 
equilibrium is achieved within ~ 10 hrs. 
5-HMF has a dissociation half-life from HbS of 7 hrs, about 2-fold lower than that with 
HbA, suggesting some intrinsic differences in the binding kinetics between HbA and HbS with 
5-HMF. 
 
 
Table 7.5. Comparison of equilibration constants estimated by two different methods. 
 
Experimental Model-based 
Parameters Estimates (SD) Parameters Estimates (SD) 
kobs (hr
-1
) 0.16 ± 0.03 keq (hr
-1
) 0.21 ± 128 
t1/2
obs
 (hrs) 4.3 t1/2
eq
 (hrs) 3.3 
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7.3.4 Comparison between initial time-dependency of binding of 5-HMF to HbA and HbS 
The initial time-dependent binding of 5-HMF to HbS was directly compared with HbA 
(Figures 7.16 – 7.20 for varying molar fraction levels). The experiments were performed in 
unicate. The free concentrations of 5-HMF show more rapid decline after 6 hrs of incubation 
with HbS, in comparison with HbA. This suggests some differences in binding kinetics, likely 
more rapid binding to HbS as compared to HbA during the time period of the study.  
5-HMF has a relatively short equilibration half-life in HbS compared with HbA. It not 
only binds with HbS rapidly to form a Schiff-base adduct, but also dissociates more rapidly from 
HbS than HbA, suggesting intrinsic differences between the binding kinetics with the two Hb 
forms. The dissociation half-life of 5-HMF from HbS was found to be shorter than that from 
HbA, suggesting potentially clinically meaningful differences in PD effect. However, due to 
limitations of the experimental design and model parameter estimation, the intrinsic differences 
could not be clearly differentiated between HbA and HbS. Overall, the two forms of Hb have 
apparent similar affinity for 5-HMF (equilibrium dissociation constant) with some differences in 
their forward and backward rates of binding (Table 7.6). The binding kinetics of 5-HMF with 
HbA and HbS are compared with those reported for glucose and HbA (Higgins, 1981) in Table 
7.6. 
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Figure 7.16. Comparative time-course of 5-HMF binding to HbA and HbS (0.05:1 
HMF:Hb) after incubation with 0.125 mM of the respective protein, separately, for up to 6 
hrs at 37
o
C (linear scale).  
 
Figure 7.17. Comparative time-course of 5-HMF binding to HbA and HbS (0.5:1 HMF:Hb) 
after incubation with 0.125 mM of the respective protein, separately, for up to 6 hrs at 
37
o
C(linear scale).  
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Figure 7.18. Comparative time-course of 5-HMF binding to HbA and HbS (1:1 HMF:Hb) 
after incubation with 0.125 mM of the respective protein, separately, for up to 6 hrs at 37
o
C 
(linear scale).  
 
 
Figure 7.19. Comparative time-course of 5-HMF binding to HbA and HbS (2:1 HMF:Hb) 
after incubation with 0.125 mM of the respective protein, separately, for up to 6 hrs at 37
o
C 
(linear scale).  
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Figure 7.20. Comparative time-course of 5-HMF binding to HbA and HbS (4:1 HMF:Hb) 
after incubation with 0.125 mM of the respective protein, separately, for up to 6 hrs at 37
o
C 
(linear scale).  
 
 
  
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0 1 2 3 4 5 6
Fr
e
e
 [
5
-H
M
F]
 (
m
M
) 
Time [hrs] 
HbA
HbS
  
310 
 
Table 7.6. Comparison of binding parameters for 5-HMF to HbA and HbS; Glucose is used 
as a literature reference. 
 
Parameter 
Estimate (SD) 
Glucose
 
(Higgins, 1981) 5HMF-HbA 5HMF-HbS 
Primary k1  (mM
-1
 hr
-1
) 0.27 (0.03) 0.83 (0.13) 0.0009 (0.0002) 
 k-1  (hr
-1
) 0.05 (0.01) 0.1 (0.04) 0.33 (0.04) 
Secondary KD (mM) 0.18 (0.04) 0.13 (0.06) 367 (91) 
 t1/2 
diss
 (hr) 13.9 6.6 - 
 t1/2 
eq
 (hr) 8.2 3.3 - 
Experimental 
(apparent first-order) 
t1/2 
obs
 (hr) 3.9 4.3 - 
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7.3.5 Concentration-dependent steady-state binding of 5-HMF to HbA and HbS 
The steady-state binding of increasing concentrations of 5-HMF with 0.125 mM HbA 
and HbS was investigated after 24 hrs and 10 hrs of incubation, respectively, in order to achieve 
binding equilibrium.  
Steady-state binding of 5-HMF to HbA was saturable with respect to increasing free 
concentrations of 5-HMF (1.25 – 1250 μM), as seen in Figure 7.21. The molar ratio of bound 5-
HMF with respect to HbA was also plotted as a function on free 5-HMF concentrations (Figure 
7.22) and modeled by the hyperbolic Bmax model.  
Steady-state binding of 5-HMF to HbS was saturable with respect to increasing free 
concentrations of 5-HMF (6.25 – 3750 μM) and fit by the Bmax model, as seen in Figure 7.23. 
The molar ratio of bound 5-HMF with respect to HbS was also plotted as a function on free 5-
HMF concentrations (Figure 7.24). 
 Overall, the steady-state Bmax model fits the data very well; the goodness-of-fit statistics 
as well as the parameter estimates are reported in Table 7.7 below. 
The steady-state molar binding of 5-HMF to HbA is approximately 1:1. From studies by 
Safo et al (2004), it is known that 5-HMF binds to two sites on the HbA molecule, i.e., to the N-
terminal valine on each α-subunit. Therefore, the molar ratio binding of 5-HMF to HbA has been 
expected to be 2:1. The steady-state molar binding of 5-HMF to HbS is approximately 2:1, 
which is as expected from X-ray crystallography studies of 5-HMF with Hb (Safo et al. 2004).  
The KD estimate for equilibrium binding of 5-HMF to HbA and HbS is very similar, as 
also suggested from the time-dependency modeling (see section 7.3.2).  
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Figure 7.21. Concentration-dependent steady-state binding of 5-HMF to isolated HbA 
(0.125 mM). Experiments were performed four times in unicate (Mean±SD). 
 
 
 
Figure 7.22. Concentration-dependent steady-state binding of 5-HMF to isolated HbA 
(0.125 mM), represented as bound moles of 5-HMF/HbA. Experiments were performed 
four times in unicate. 
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Figure 7.23. Concentration-dependent steady-state binding of 5-HMF to isolated HbS 
(0.125 mM). Experiments were performed three times in unicate (Mean±SD). 
 
 
Figure 7.24. Concentration-dependent steady-state binding of 5-HMF to isolated HbS 
(0.125 mM), represented as bound moles of 5-HMF/HbS. Experiments were performed 
three times in unicate. 
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Table 7.7. Parameter estimates (SD) for the steady-state binding of 5-HMF to HbA. 
 
Parameter 
Estimate (SD) 
Concentration (mM) Molar Ratio 
 5-HMF-HbA 5-HMF-HbS 5-HMF-HbA 5-HMF-HbS 
Bmax 0.10 (0.01) 0.23 (0.02) 0.84 (0.03) 1.72 (0.2) 
KD  (mM) 0.25 (0.04) 0.41 (0.07) 0.27 (0.03) 0.34 (0.12) 
r
2
 0.98 0.96 0.99 0.98 
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7.3.6 Predictions from time-dependency model 
The decline in free 5-HMF concentrations occurs due to saturable binding with free Hb, 
and formation of the 5-HMF-Hb adduct by a bimolecular reaction. Figures 7.25 and 7.26 show 
the predicted time-course for HbA and HbS concentrations (mM), respectively, when incubated 
with varying nominal concentrations of 5-HMF.  
The concentrations of free 5-HMF and Hb decline with time in a nonlinear exponential 
manner, while the adduct concentrations increase over a period of 30 hrs. The binding of 5-HMF 
to Hb is saturable and, therefore, at high molar fractions of 5-HMF:HbA and 5-HMF:HbS, the 
adduct formation over 30 hrs approaches ~90% of the available Hb.  
Figure 7.27 shows a comparison between the predicted time-course for HbA- and HbS-
adduct (% of HbA or HbS) - corresponding to the decline in free 5-HMF concentrations. Due to 
the intrinsic differences in the binding kinetics between HbA and HbS, it can be observed that 
the adduct formation of 5-HMF with HbA is relatively slow compared to HbS. HbS shows 
greater (~ 5 – 8%) and more rapid adduct formation with 5-HMF.  
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Figure 7.25. Predicted decline in free HbA concentrations (mM) respective 5-HMF:HbA 
concentration levels over a period of 30 hrs ([Hb]0=0.125 mM). 
 
 
Figure 7.26. Predicted decline in free HbS concentrations (mM) and formation of 5-HMF 
adduct with isolated HbS (mM) for respective 5-HMF:HbS concentration levels over a 
period of 30 hrs ([Hb]0=0.125 mM). 
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Figure 7.27. Super-imposed predicted adduct formation of 5-HMF (%) with isolated HbA 
(solid) and HbS (dashed) for varying concentration levels over a period of 30 hrs. 
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7.3.7 Non-specific binding of INN-312 to the centrifugal filter units 
In order to carry out binding studies for INN-312 with HbA and HbS for comparison 
between the two forms of Hb and with the kinetics of 5-HMF, NSB of INN-312 to the 
centrifugal unit filtration membranes was investigated. 5-HMF was found to have negligible 
binding to the regenerated cellulose membrane (section 7.3.1). 
 Varying concentrations of INN-312 (3.9 – 500 μM) were subjected to ultrafiltration, and 
INN-312 was measured in the ultrafiltrate. Mass balance was assessed from measurement of 
INN-312 in the filtrate and low volume residual INN-312 in the loading chamber, after 
ultrafiltration. The results were compared with INN-312 standards in the absence of the filtration 
membrane in the device. Table 7.8 shows mass balance assessments for INN-312 after 
ultrafiltration, represented as amounts loaded and recovered. After ultrafiltration of solutions 
with low amounts of INN-312, it could not be detected in the ultrafiltrate. For higher amounts, a 
mass-dependent loss of INN-312 was observed; 84% was unrecovered after ultrafiltration for the 
lower mass, while 60% was unrecovered at the higher end. These preliminary experiments 
suggest extensive non-specific binding of INN-312 to the regenerated cellulose membrane of the 
filtration device and is likely concentration-dependent. Therefore, further investigational 
experiments were carried out to explore if this NSB was time- and concentration-dependent. 
High concentrations of INN-312 (62.5 – 1000 μM) were stored separately with the 
filtration membrane for varying time periods (0.5 – 21 hrs). Ultrafiltration was performed (in 
separate centrifugal devices) at specific time-intervals to assess the time-dependency of NSB. 
Figure 7.28 demonstrates the time- and concentration-dependent binding of INN-312 to the 
filtration membrane. A time-dependent decline in INN-312 ultrafiltrate concentrations is 
observed, and it appears that non-specific binding equilibrium may be achieved by ~21 hrs.  
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Assuming NSB achieves steady-state by 21 hrs, steady-state concentration-dependency 
was assessed and is shown in Figure 7.29.  
NSB of INN-312 is concentration-dependent and saturable. This was further was 
modeled by the hyperbolic Bmax-model to estimate the maximum binding capacity of the 
filtration membrane/device and the affinity of the regenerated cellulose membrane for INN-312. 
The model fit the data very well (dashed line; Figure 7.29), with an r
2
 of 0.99. A high Bmax value 
(SD) of 0.79 (0.14) μM suggests high binding capacity of the membrane for INN-312. The NSB 
parameter estimates (SD) are reported in Table 7.9. The binding affinity of the membrane is also 
high; the estimated KD value of 0.06 (0.03) μM is much lower than the binding affinity of 5-
HMF for HbA and HbS. This demonstrates that INN-312 has extensive non-specific high affinity 
binding with the regenerated cellulose filtration membrane complicating its use for Hb binding 
studies.  
Similar extensive NSB for INN-312 was observed in filtration devices made of the 
hydrophilic polyethersulfone (PES) membranes as well (Pall Corporation, ThermoScientific and 
Vivasproducts, Inc.). 
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Table 7.8. Mass balance assessments for INN-312 after ultrafiltration. 
 
Amount 
loaded 
(nmol) 
Amount recovered (nmol) 
Total recovery 
(nmol) 
%lost 
 Filtrate Residual 
0.8 - - - - 
6.3 0.5 0.5 1.0 84% 
25 5.4 2.7 8.1 68% 
50 13.5 5.6 19.1 62% 
100 28.0 12.1 40.0 60% 
 
Figure 7.28. Time- and concentration-dependent non-specific binding of INN-312 to the 
regenerated cellulose filtration membrane. 
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Figure 7.29. Concentration-dependent steady-state binding (non-specific binding) of INN-
312 to the filtration membrane. 
 
 
 
Table 7.9. Parameter estimates for the steady-state binding of INN-312 to the filtration 
membrane. 
 
Parameter Estimate (SD) 
Bmax (mM) 0.79 (0.14) 
KD  (mM) 0.06 (0.03) 
r
2
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7.3.8 Leaching of INN-312 from centrifugal filter unit membrane 
Binding equilibrium of INN-312 with the filtration membrane was found to be achieved 
within 21 hrs. Therefore, pre-saturation of the membrane binding sites with INN-312 may enable 
use of this ultrafiltration method to study specific binding of INN-312 to Hb. However, form 
preliminary experiments, it was found, INN-312 binds transiently (covalently) with the filtration 
membrane, and leaches out of the membrane with washing. Therefore, the leaching of INN-312 
from the membrane after steady-state binding was investigated.  
INN-312 (62.5 – 500 μM) was incubated with the filtration membrane at 25oC up to 24 hrs. 
It was then filtered and quantified. The filtration membrane was washed with 0.1% DMSO in 
PBS up to five times, followed by quantification of INN-312 in the filtrate after each consecutive 
washing steps. The recovery of INN-312 from the membrane was assessed after multiple 
washing. Approximately 14 – 18% greater recovery was obtained after five washes of INN-312 
loaded on the device, compared to filtration alone, without washing. This suggests leaching of 
IN-312 after multiple washes and is shown in Figure 7.30. The amount of NN-312 recovered 
from each consecutive wash of the membrane is shown for three concentration levels, 125 – 100 
μM (25 – 100 nmol). INN-312 could not be detected in the ultrafiltrate after multiple washings 
for the 62.5 μM concentration level. 
It may be seen from Figure 7.30, even after 5 washes with buffer alone, INN-312 continues 
to leach from the membrane, suggesting extensive sustained NSB with relatively slow 
dissociation for the high concentrations of INN-312. 
Assuming that excess INN-312 was removed after 5 washes of membrane, and the binding 
sites of the membrane may have been adequately saturated by the pre-loaded INN-312, fresh 
INN-312 standards were loaded and quantified after ultrafiltration. Figure 7.31 shows the results 
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obtained from the investigational study. Ultrafiltration of INN-312 standards after 5 washes of 
previously saturated membrane results in higher recovery, but still shows high NSB. The line of 
identity represents the scenario in the absence of NSB; when the amount of INN-312 recovered 
from ultrafiltration is identical to that loaded on the device. Overall, despite multiple washing 
and pre-saturation, NSB of INN-312 to the filtration membrane is very high, preventing the use 
of ultrafiltration method for investigation of its binding kinetics with Hb. 
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Figure 7.30. Concentration-dependent leaching of INN-312 from the filtration membrane 
after multiple washing. 
 
 
Figure 7.31. Amount of INN-312 standard detected after pre-saturation of the membrane 
by ultrafiltration and multiple washing. 
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The effect of HbA on leaching of INN-312 from the membrane was studied to investigate 
the plausibility of competitive binding between INN-312 with HbA and the membrane. INN-312 
(125 – 100 μM) was incubated with membrane for 24 hrs and filtered, in order to pre-saturate the 
membrane sites with INN-312. HbA or blank buffer was then incubated separately with the pre-
saturated membrane up to 2 hrs to test the effect of HbA on the leaching of INN-312 from the 
membrane. Figures 7.32 – 7.35 show the time-dependent effect of HbA on leaching of INN-312 
over 2 hrs, for varying INN-312 concentrations. A small effect of HbA on leaching from the 
membrane was observed at high concentrations of INN-312, resulting in 2 – 3% lower recovery 
(and greater binding) after 2 hrs of storage of saturated membrane with HbA compared to storage 
with blank alone. This suggests that excess INN-312 or INN-312 leached from the membrane 
binds with HbA in a time-dependent manner. The complex NSB of INN-312 to the regenerated 
cellulose membrane is thus expected to interfere extensively with the intrinsic binding kinetics of 
INN-312 with Hb, as supported from the confirmatory experiments, and therefore this method 
cannot be used for characterizing the binding kinetics of INN-312 with Hb. 
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Figure 7.32. Time-dependent effect of 0.125 mM HbA on leaching of INN-312 (62.5 μM; 
12.5 nmol) from the membrane, compared to buffer. 
 
 
Figure 7.33. Time-dependent effect of 0.125 mM HbA on leaching of INN-312 (0.125 mM; 
25 nmol) from the membrane, compared to buffer. 
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Figure 7.34. Time-dependent effect of 0.125 mM HbA on leaching of INN-312 (250 μM; 50 
nmol) from the membrane, compared to buffer. 
 
 
Figure 7.35. Time-dependent effect of 0.125 mM HbA on leaching of INN-312 (500 μM; 100 
nmol) from the membrane, compared to buffer. 
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7.4 Discussion and Conclusions 
5-HMF was found to bind transiently covalently to HbA and HbS to form Schiff base 
adducts, in a time- and concentration-dependent manner. This binding is reversible and saturable, 
at physiologically relevant concentrations (1 – 2 mM). 5-HMF binds rapidly to, and dissociates 
slowly from both forms of Hb, compared to glucose, an endogenous molecule known to form 
Schiff base adducts with Hb (Higgins, 1981). 
HbS differs from normal HbA by only a single base substitution (mutation) that results in 
the substitution of the (polar) β6-glutamic acid by a neutral amino acid, valine (Bunn & Forget, 
1986). 5-HMF is known to bind to the N-terminal valine on each α-subunit of the Hb molecule, 
which is identical HbA and HbS (Safo et al., 2004). It is therefore, expected that the binding 
kinetics of 5-HMF to HbA and HbS are similar. Simultaneous time-dependency modeling 
showed relatively minor intrinsic differences between binding to, and dissociation from HbA and 
HbS (k1 = 247 ± 29 and 828 ± 128 M
-1
hr
-1
, respectively, and k-1 = 0.05 ± 0.01 and 0.1 ± 0.04 hr
-1
, 
respectively). 5-HMF has a relatively (2-fold) short t1/2
eq
 in HbS and short t1/2
diss
 from HbS, 
compared to HbA. The onset of effect with HbS is more rapid compared to HbA, due to intrinsic 
differences between the association kinetics (more rapid). A 5 – 8% greater peak effect is 
predicted for 5-HMF with HbS than HbA. However, due to experimental limitations, such as, 
limited time period of study (10 – 30 hrs), use of reconstituted lyophilized HbA and concentrated 
HbS from different sources, and model parameter estimation (k-1 for HbA), the intrinsic kinetics 
could not be fully differentiated between the two Hb forms, and overall translate to similar 
steady-state binding affinities.  
The steady-state binding affinity of 5-HMF for HbA and HbS calculated from the time-
dependency model parameter estimates is slightly lower than the experimentally determined KD 
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from the hyperbolic Bmax model. This difference may be explained by possible imprecision in 
estimation of k-1 by the time-dependency model, which drives the estimate for KD. From steady-
state concentration-dependency studies, the KD values of 5-HMF with HbA and HbS are similar; 
0.4 ± 0.07 and 0.3 ± 0.1 mM, respectively. The Km
app
 estimated from modeling of the non-linear 
clearance of 5-HMF in whole blood, was 0.5 ± 0.3 mM, similar to the KD estimate of 5-HMF 
with Hb. This provides supporting evidence of saturable Hb-binding of 5-HMF, a likely 
mechanism for the observed nonlinear kinetics of 5-HMF in human whole blood (see Chapter 6). 
Furthermore, at physiologically relevant concentrations of 1 – 2 mM (required to elicit an 
adequate left-shift in p50), the binding of 5-HMF with Hb is projected to be saturable. 
It is known that 5-HMF binds to two sites on the HbA molecule, i.e., the N-terminal valine 
on each α-subunit (Safo et al., 2004). The steady-state molar binding of 5-HMF to HbA is 
approximately 1:1, while that with HbS is approximately 2:1. This provides supporting evidence 
for X-ray crystallography studies of 5-HMF with Hb. Obied (2010) demonstrated 2:1 molar 
binding between 5-HMF and HbA from a single experimental study with duplicates. It is likely, 
due to the variability in the current steady-state concentration-dependency studies at high 5-HMF 
free concentrations, that the steady-state molar binding of 5-HMF to HbA was underestimated as 
1:1.  
INN-312, a relatively more lipophilic molecule, has high non-specific binding to 
regenerated cellulose and PES membranes, in addition to expected higher affinity for Hb. The 
non-specific binding to the cellulose membrane is time- and concentration-dependent with high 
affinity and high capacity, preventing the use of ultrafiltration techniques for investigating its 
binding kinetics with Hb. Furthermore, the binding to the membrane is transient, resulting in 
time-dependent leaching of INN-312 from the membrane, and likely competitive binding with 
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HbA, which adds further to the complexity of the nature of the non-specific binding. Although 
regenerated cellulose does not have functional groups susceptible to Schiff base adduct 
formation by the benzaldehyde group of INN-312, the unexpected extensive NSB may be due to 
hydrophobic interactions between the two chemical substances. 
The time-dependency studies provide evidence of steady-state conditions between 5-HMF 
and Hb, in absence of elimination by ALDH, in-vitro. It may be observed from Chapter 6, 
equilibrium was not attained for free 5-HMF in healthy human blood up to 10 hrs, likely due to 
concurrent metabolism by ALDH in the RBC. In absence of metabolic ALDH in the RBC, the 
binding of 5-HMF to HbA is predicted to result in sustained adduct formation up to 30 hrs.  
Similar to the known mechanism of action of 5-HMF, FGE also form Schiff-base adducts 
with the amino-terminal on the α-globin, with a slight difference: the two are bifunctional agents 
which link two α-terminal amino groups, that is, they form a Schiff-base adduct with one α-
terminal and a salt bridge with the other α-terminal, owing to the acidic group on their molecule 
(Beddell et al., 1984).  
Table 7.10 compares the binding of all AEH to Hb. Valeresol showed peak effect 
(%MOD) immediately at the end of the infusion, when peak concentrations in whole blood were 
achieved (Fitzharris et al., 1985). Similar observations were made for tucaresol, which resulted 
in peak effect at the same time as the Cmax
(whole blood)
 (Rolan et al., 1993). This is consistent with 
very rapid Hb-binding kinetics for both compounds. The “transiently covalent” binding of FGE 
is evident from a biphasic effect (%MOD)-time profiles (Fitzharris et al., 1985; Rolan et al., 
1993). The peak effect of valeresol declined monoexponentially reflecting an apparent first-order 
rate of decline in the Hb-adduct, with a half-life of about 3.1 hrs, while on the other hand, the 
effect (%MOD) half-life for tucaresol was found to be about 5-6 days (Fitzharris et al., 1985; 
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Rolan et al., 1993). This shows that valeresol in addition to rapidly binding with Hb and forming 
a Schiff-base adduct, has a relatively rapid rate of dissociation from the adduct-form, due to 
which the effect declines. For tucaresol, a rapid association with Hb is possibly followed by very 
slow dissociation from the Hb-adduct. From in-vitro binding studies, it was found that 5-HMF 
has rapid association with isolated HbA and relatively slow dissociation, with a first-order 
dissociation half-life from HbA of about 14 hrs and from HbS of about 7 hrs, intermediate 
between valeresol and tucaresol. 
This rate of decline, likely attributable to dissociation of valeresol from the Hb-adduct 
calculated from the reported PD half-life is 0.22 hr
-1
. This in-vivo ‘rate of dissociation’ is 4.5-
fold higher than the experimental in-vitro k-1 for 5-HMF with isolated HbA (0.05 hr
-1
), and thus 
shows a rapidly declining effect. The ‘rate of dissociation’ for tucaresol, obtained from the 
average reported half-life for loss of %MOD (PD t1/2 of ~180 hrs) is 0.004 hr
-1
, about 10-fold 
slower than that for 5-HMF. This supports the prolonged, persistent effect observed for tucaresol 
(Rolan et al, 1993). 
An apparent PD t1/2 estimated from the time-course of PD effect of INN-compounds 
(Chapter 5) shows they likely equilibrate and bind rapidly with Hb (especially INN-312). INN-
298 likely has a prolonged PD t1/2 (similar to tucaresol), while INN-312 and 5-HMF are likely 
intermediates between valeresol and tucaresol in terms of the PD t1/2. 
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Table 7.10. Comparison of AEH binding to Hb FGE and SGE. 
 
Parameters In-vivo studies In-vitro studies 
 
FGE SGE 
Valeresol Tucaresol 
5-HMF INN-312 INN-298 (Fitzharris et 
al., 1985) 
(Rolan et al., 
1993) 
PD t1/2 (hr) 
3 
(rats and 
humans) 
16 (rats; I.V.); 
167 (humans; 
oral) 
~4 – 6 (blood); 
(t1/2
diss
 = 14, 
isolated HbA) 
~8 – 10 >10 
k-1* 0.22 hr
-1
 0.004 hr
-1
 0.05 hr
-1
 N/A N/A 
*Apparent k-1 (rate of dissociation) determined as discussed in text 
 
AEH, being aldehydes, are capable of forming Schiff-base adducts with amino-terminals 
of other proteins as well, to form haptens (O'Brien et al., 2005). There may be concern for 
toxicity for slowly dissociating AEH (from Hb), because the bound adduct likely has (apparent) 
slow dissociation from its aldimine-linkage with proteins. Cinnamaldehyde acts as a hapten by 
forming Schiff bases with protein amino groups, resulting in allergenic hypersensitivity, while 
malonaldehyde, in addition to forming hepatotoxic haptens, also results in circulating anti-
malonaldehyde antibodies, found to correlate with severity of liver damage in alcoholic patients 
(O'Brien et al., 2005). Aldehyde-adducts are capable of resulting in the formation of anti-bodies 
in-vivo, observed in rodents and rabbits, as well as humans (Israel et al., 1992; Lin et al., 1993). 
IgE antibodies for acetaldehyde-adducts with Hb and other proteins, have been found in humans, 
resulting in hypersensitivity reactions to alcohol at high levels and in individuals with less 
functional ALDH, the acetaldehyde metabolizing enzyme (Israel et al., 1992).  
In addition to resulting in the formation of antibodies, the Hb-adducts may have other 
immuno-stimulating properties as well. Tucaresol has been shown to have immuno-stimulating 
action by forming Schiff-bases with amino-terminals on the surface of T-cells and antigen 
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presenting cells, providing co-stimulatory signals to enhance the response of T-helper 
lymphocytes (Th-cells) and CD8 cytotoxic T-cells (Tc-cells) (Arya et al., 1996; Chen and 
Rhodes, 1996). Tucaresol was also reported to form stable, slowly dissociating Schiff-base 
adducts with other plasma proteins, responsible for the long plasma half-life of 9 – 12 days 
(Rolan et al., 1993). Therefore, although these would be common concerns for any of the AEH 
which are aldehydes, the intensity and possibly duration of adverse event increases several fold if 
the compound has a tight-binding, slowly dissociating nature, as long-term non-specific binding 
could lead to in AEH accumulation at certain sites, and behave as a hypothetical ‘deep’ 
compartment (Rolan et al., 1993), resulting in chronic toxicity. 
  
  
334 
 
 
 
CHAPTER 8 
8 IN-VITRO PK/PD MODELING OF 5-HMF IN WHOLE BLOOD 
 
 
 
8.1 Introduction 
5-HMF has demonstrated unique in-vitro disposition in whole blood: It undergoes rapid 
initial binding to plasma proteins, RBC membranes as well as rapid distribution into the RBC. 
Extensive binding to Hb in the RBC and metabolism by ALDH in RBC primarily account 
towards its clearance by whole blood (Chapters 5, 6 and 7). Furthermore, the disposition follows 
nonlinear kinetics in a nominal concentration range of 0.5 – 5 mM 5-HMF, most likely due to 
saturable binding to HbA. It is this binding to Hb and formation of Hb-adduct that results in a 
left-shift in p50 of the OEC of Hb, expected to prevent RBC sickling.  
This unique disposition pattern at the target site for 5-HMF (and likely other AEH), 
namely distribution clearance by binding to HbA and elimination clearance by concurrent ALDH 
metabolism was described by a novel semi-mechanistic target-site drug disposition (TSDD) 
model. Such a model was originally used by Obied (2010), for prediction of the time-course of 5-
HMF concentrations in RBC hemolysates for nominal concentrations of 0.3 and 2 mM 5-HMF in 
whole blood, however, individual/simultaneous modeling has not been previously performed. 
 The TSDD model was further combined with newly available PD information to build an 
integrated TSDD/PD model for 5-HMF (and other AEH). A representation of the TSDD/PD 
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model scheme is shown in Figure 8.1: In whole blood, 5-HMF is assumed to rapidly equilibrate 
between plasma and RBC. Although thought to be negligible, it also undergoes rapid initial 
binding to plasma proteins (and RBC membrane), represented by a binding ratio, khsa. In RBC, 5-
HMF reversibly binds to HbA with a second order forward rate constant (k1), to form the Hb-
adduct. The Hb-adduct dissociates to free 5-HMF and Hb with a first-order backward rate 
constant (k-1). Free 5-HMF in RBC also undergoes concurrent ALDH metabolism in RBC to 
HMFA, which is represented by an apparent first-order rate constant of metabolism, kmet. The 
concentration of Hb-adduct results in a (measurable) left-shift in p50, with a relationship that is 
yet to be characterized, and is represented as E*.  
The specific aims of this research were to (1) develop a novel TSDD model for 5-HMF 
that adequately describes its disposition in blood, (2) simultaneously model the disposition of 5-
HMF in whole blood based on available data in Chapters 5 and 6, (3) investigate, characterize 
and establish the relationship between Hb-adduct concentrations and p50 from quantitative 
analyses, (4) build and develop a novel, combined TSDD/PD model for 5-HMF, with predictive 
utility in healthy blood and sickle blood, (5) simultaneously model and predict the time-course of 
5-HMF plasma concentrations and left-shift in p50, and (6) validate the model and identify key 
parameters of the TSDD/PD model that require additional information from post hoc sensitivity 
analyses.  
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Figure 8.1. Target-site drug disposition (TSDD)/PD model scheme for 5-HMF in whole blood 
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8.2 Methods 
 
8.2.1 Available PK/PD Database 
The PK/PD database was created for the simultaneous modeling of 5-HMF in whole 
blood from experimental studies: The plasma concentration-time profiles from the in-vitro whole 
blood disposition study (Chapter 6), and PD effect-time profiles of 5-HMF in whole blood 
(Chapter 5) were the primary datasets included in the final PK/PD modeling of 5-HMF. Data 
preparation and treatment was performed in Microsoft Excel.   
 
8.2.2 Model Development and Assumptions 
A novel TSDD model was built for 5-HMF in plasma from whole blood, from the current 
knowledge of its disposition mechanisms in blood, and reference was made to work by Obied 
(2010): Assuming 5-HMF undergoes rapid distribution into the RBC with rapid initial 
equilibration between the plasma and RBC, Equations 8 – 1 to 8 – 5 below were used for TSDD 
modeling of 5-HMF in whole blood. 
 
 [    ]
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 [      ] 
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 [    ]
  
 (     [    ] )                                 
 
[  ]  [  ]  [      ]                                        
 
Where  
k1 : second order forward binding rate constant 
k-1 : first-order backward rate constant 
kmet : apparent first-order metabolic rate constant (ALDH-mediated metabolism) 
[5HMF]t : measured plasma concentrations of free (unbound) 5-HMF at time, t 
[Hb]t : concentrations of free Hb at time, t 
[Adduct]t : concentrations of Hb-adduct  at time, t  
[HMFA]t : concentrations of 5-HMF metabolite (HMFA) at time, t 
 
5-HMF undergoes rapid initial binding to plasma proteins and RBC membranes (Chapter 
6). Therefore, the initial condition for 5-HMF at 0 min was expressed in the form of Equation 8 – 
5 below, while the initial concentration of Hb-adduct and 5-HMF metabolite was zero. 
 
[    ]  [    ]       [    ]                                 
 
Where  
khsa : apparent binding ratio with human serum albumin (and/or other plasma proteins and RBC 
membrane) 
[5HMF]0 : initial (nominal) concentration of 5-HMF 
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In order to link the plasma concentrations to the PD effect, the Hb-adduct concentrations 
were used for the PK/PD link model, such that, 
 
[  ]  [      ]                                            
 
Where  
CE: concentration of 5-HMF at the effect site (biophase) responsible for exerting the effect (left-
shift in p50). 
Since it is known 5-HMF forms adducts with Hb, which is responsible for its effect, in 
this scenario, the concentration responsible for the effect was assumed to be equal to the Hb-
adduct concentration.  
The PD model was developed from quantitative assessments and is described in section 
8.3. 
 
8.2.3 Initial Parameter Estimation 
The initial Hb concentration (Hb0) was fixed for all models to the physiological value. In 
whole blood studies, total Hb concentrations and the hematocrit was measured. The Hb 
concentration ranged between 13 – 16 g/dL, and hematocrit was about 46%. The Hb0 is then 
estimated as 2.0 – 2.5 mM. Based on this, and using Obied (2010) as a reference, the Hb0 was 
fixed to 2.06 mM. 
Initial estimates for k1 and k-1, for the TSDD model were obtained from 5-HMF binding 
studies with isolated HbA.  
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An initial estimate for kmet was obtained from modeling of the disposition clearance 
(Chapter 6). ALDH-mediated apparent first-order CLmax was estimated as 641 mL/min (38.5 
L/hr) in blood. Assuming 5-HMF is evenly distributed through the plasma and RBC, the volume 
of distribution (Vd) will be equivalent to the physiological blood volume (~ 6 L). However, due 
to extensive binding of 5-HMF to Hb in RBC, 6 L is likely an under-prediction of the Vd for 5-
HMF, and resulted in significant over-estimation of the kmet by this method of initial estimation. 
Therefore, the initial estimate for kmet was obtained using Obied (2010) as reference (kmet = 0.174 
hr
-1
), and from initial sensitivity analyses.  
The initial estimate for khsa was made from several initial sensitivity analyses, to account 
for the rapid initial loss of 5-HMF within 15 min of incubation with whole blood (khsa = 0 – 
0.09).  
Initial estimates for the PD model were obtained from quantitative assessments (see 
section 8.3). 
8.2.4 Data Analysis 
Model parameter optimization was performed using the simplex method, followed by 
Gauss-Newton algorithm for nonlinear regression, using Scientist® Software version 2.0 
(Micromath, St. Louis, MO). A weighting factor of 1/Y for 5-HMF concentrations (only) was 
used in the final TSDD and TSDD/PD model due to the large concentration range of 5-HMF in 
the study. Model fits were assessed from careful visual inspection of the data. Goodness-of-fit 
statistics for the model and model suitability/appropriateness were assessed from the r
2
, MSC, 
residual analysis, precision of the parameter estimates and correlation matrix.  
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8.3 Results 
 
8.3.1 Target-site drug disposition model (TSDD) 
The disposition of 5-HMF in whole blood is thought to occur due to saturable binding 
with HbA and oxidative metabolism by ALDH in the RBC. The novel TSDD model accounts for 
the observed nonlinear disposition. Figures 8.2 and 8.3 show the model fits for the disposition on 
a linear and semi-logarithmic scale, respectively, for the final/optimized model parameters. The 
semi-mechanistic model describes the data well, and the final parameter estimates are reported in 
Table 8.1. The apparent binding affinity (KD
app
) in whole blood for binding of 5-HMF to Hb was 
calculated from the k-1 and k1 estimates. A dissociation half-life (t1/2
diss
) was estimated from the 
first-order backward binding rate constant. This value describes the half-life of dissociation of 
the Hb-adduct to free 5-HMF and HbA in absence of ALDH-metabolism in RBC.  
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Figure 8.2. TSDD model fit for 5-HMF in plasma (linear scale). 
 
 
 
Figure 8.3. TSDD model fit for 5-HMF in plasma (semi-logarithmic scale). 
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Table 8.1. Final TSDD model parameter estimates for 5-HMF. 
 
Parameter Initial Estimates Final Estimates (SD) 
k1 (mM
-1
 hr
-1
) 0.274 1.25 ± 0.11 
k-1 (hr
-1
) 0.05 0.006 ± 0.004 
kmet (hr
-1
) 0.174 0.173 ± 0.016 
khsa  0 0.093 ± 0.027 
[Hb]0 (mM) 2.06 (fixed)  
KD
app
 (mM)  0.005 ± 0.003 
t1/2
diss
 (hr)  117 
r
2
  0.97 
MSC  2.4 
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Nominal concentrations of ~ 2 – 5 mM 5-HMF in whole blood are thought to be 
clinically relevant. Therefore, TSDD model predictions were made for varying nominal 
concentrations of 5-HMF (0.5 – 5 mM) in human whole blood, and are shown for 0.5, 2 and 5 
mM in Figures 8.4 – 8.6 below. It can be observed that the decline of 5-HMF concentrations in 
plasma occurs in a nonlinear fashion, with decreasing slopes for increasing nominal 
concentrations. This decline in 5-HMF occurs due to binding to Hb and concurrent ALDH 
metabolism. At lower concentrations (0.5 mM), only 6% of the nominal 5-HMF is converted to 
HMFA after 10 hrs, while 84% is bound to Hb in the form of adduct. At 10-fold higher 
concentrations (5 mM), only 41% of the nominal 5-HMF is bound to Hb, while 41% is converted 
to HMFA. This is due to the saturable binding to Hb at the high concentrations, and metabolism 
by ALDH as the primary clearance pathway for 5-HMF from blood/plasma. Furthermore, from 
these predictions, peak Hb-adduct formation is achieved within 1 – 2 hrs, similar to observations 
made in the PD studies, where the peak effect was achieved in 1 – 1.5 hrs (Chapter 5). 
On the other hand, the observed decline in PD effect and its return to the baseline 
(Chapter 5) is not predicted by the TSDD model. The TSDD model predicts sustained maximal 
Hb-adduct up to 10 hrs, with no return to the baseline. This provides initial evidence that the 
relationship between Hb-adduct concentration and observed p50 may not be linear. This 
relationship will be investigated further in the sections described below.    
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Figure 8.4. TSDD model predictions for plasma concentrations, Hb-adduct and HMFA 
concentrations for 0.5 mM 5-HMF in whole blood. 
 
 
 
Figure 8.5. TSDD model predictions for plasma concentrations, Hb-adduct and HMFA 
concentrations for 2 mM 5-HMF in whole blood. 
 
 
 
0.0
0.1
0.1
0.2
0.2
0.3
0.3
0.4
0.4
0.5
0.5
0 2 4 6 8 10
P
re
d
ic
te
d
 C
o
n
ce
n
tr
at
io
n
s 
(m
M
) 
Time (hr) 
Plasma HMF
HbHMF
Adduct
HMFA
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
0 2 4 6 8 10
P
re
d
ic
te
d
 C
o
n
ce
n
tr
at
io
n
s 
(m
M
) 
Time (hr) 
Plasma HMF
HbHMF
Adduct
HMFA
  
346 
 
Figure 8.6. TSDD model predictions for plasma concentrations, Hb-adduct and HMFA 
concentrations for 5 mM 5-HMF in whole blood. 
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Pharmacokinetic metrics such as AUCoo and CLplasma
IVIVE
 were estimated from NCA of 
the TSDD model-predicted profiles for 5-HMF. These were compared with metrics estimated by 
NCA of the observed profiles (“observed”) using model-free assumptions (see Chapter 6), as a 
method of partial-validation of the model. Dose proportionality was assessed for the TSDD 
model-predicted profiles from a power model fit for the log-log transformed AUCoo and nominal 
5-HMF dose. The AUC0-10h was calculated from TSDD model predictions, and was assumed to 
be ~AUCoo. This dose-proportionality assessment was superimposed with observed results from 
Chapter 6 for comparison (Figure 8.7). It can be seen that the power model fits are very similar 
for the TSDD model-predicted and observed log AUCoo-log dose relationships.  
The CLplasma
IVIVE
 (“predicted”) was estimated as described in Chapter 6 for the TSDD-
predicted 5-HMF profiles. Figure 8.8 shows a plot of the (TSDD) predicted versus (model-free) 
observed CLplasma
IVIVE
. The line of identity represents the scenario when the TSDD predicted 
CLplasma
IVIVE 
is identical to the observed CLplasma
IVIVE
. It can be clearly seen that the CLplasma
IVIVE
 
estimated from TSDD model predictions is very similar to the observed values, except for 0.5 
mM 5-HMF, where there is an underprediction in the CLplasma
IVIVE
 by the TSDD model. This is 
likely due to the overestimation of the AUCoo, by extrapolation, since the 5-HMF concentrations 
were not quantifiable (below the ELOQ) after 6 hrs. Overall, based on PK data only, the TSDD 
model describes the disposition of 5-HMF well. 
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Figure 8.7. Comparison between the TSDD model- and (observed) model-free dose-
proportionality from the relationship between log-log-transformed AUCoo and dose.  
 
 
 
Figure 8.8. Comparison between the TSDD-predicted CLplasma
IVIVE
 (section 8.3.1) and 
model-free-prediction CLplasma
IVIVE
  (observed) (Chapter 6). 
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8.3.2 General Strategy for TSDD/ PD (PK/PD) Model Building 
Using several key pieces of information from the quantitative analyses (section 8.3.3), 
binding studies with isolated HbA (Chapter 7), nonlinear disposition clearance model (Chapter 
6), and the TSDD model (section8.3.1), a novel, combined TSDD/PD model was built for 5-
HMF in human whole blood: The semi-mechanistic TSDD model (section 8.3.1) was linked to 
either an empiric linear PD model or sigmoidal PD model based on quantitative assessments as 
described in section 8.3.3. The overall modeling approach is described in a stepwise manner 
below: 
1. First, the TSDD model parameters (from Table 8.1) were fixed, and the parameters for the 
(linear or sigmoidal) PD model were optimized one after another from several initial 
sensitivity analyses. Only the PD data (p50 values) were fit. 
2. The next step involved inclusion of the combined PK/PD dataset. The PD model parameters 
and kmet were included in parameter optimization while leaving k1, k-1 and khsa fixed.  
3. The binding rate constants were then included in estimation one after another. 
4.  Extensive initial sensitivity analyses were carried out, and the effect of using weighting 
factor (unweighed vs. 1/Y weight for 5-HMF concentrations only) on model fits, as well as 
the effect of constraints on parameter estimates (for k1, k-1 and kmet) was explored.  
5. Goodness-of-fit statistics of the initial and final TSDD/PD model were assessed. 
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8.3.3 Quantitative Exposure-Response analysis for Hb-adduct-PD Relationship 
In order to build the PD model for 5-HMF in whole blood, various quantitative 
assessments were made to characterize the relationship between Hb-adduct concentrations and 
left-shift in p50. Abdulmalik et al. (2005) reported a linear relationship between the change in p50 
(%) and the % HbS-adduct formed in-vitro. In the current study, two relationships were 
explored: Linear and sigmoidal. 
Preliminary assessments were made to investigate the relationship between the observed 
peak ∆p50 from PD studies and the (predicted) steady-state concentration of HbA-adduct formed 
- in absence of metabolic elimination processes. The HbA-adduct concentrations were predicted 
from the time-dependency binding model (Chapter 7). Figure 8.9 shows the superimposed 
predictions of HbA-adduct concentrations and the observed peak change in p50 after 2 hrs from 
two independent studies; HbA-adduct concentrations were predicted from the binding model 
with isolated HbA, and the p50 observations were made from OEC measurements in human 
whole blood. It can be seen that the Hb-adduct concentrations and change in p50 overlay 
reasonably well, and therefore, the relationship between Hb-adduct concentrations and p50 was 
further assessed and compared with previously reported findings (Abdulmalik et al., 2005).  
Figure 8.10 shows the relationship between %Hb-adduct formed, calculated as a percent 
of total HbA (2.06 mM) and the % change in p50 from the baseline, for appropriate comparisons. 
Similar to findings by Abdulmalik et al (2005), a linear relationship is shown between the %Hb-
adduct formed with HbA and the % change in p50 from the baseline, with nearly identical slopes 
as in the study conducted in SS cells by Abdulmalik et al (2005). The similarity in observations 
between healthy HbA and sickle HbS further validates the time-dependency binding model, 
suggesting a likely linear relationship between the Hb-adduct and change in p50.   
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Figure 8.9. Superposition of predicted steady-state HbA-adduct concentrations and 
observed peak p50 shifts (after 2 hrs) for different (nominal) 5-HMF concentrations. 
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Figure 8.10. Comparison of linear relationships between Hb-adduct concentration and left-
shift in p50 across studies. 
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However, it can be seen from Figure 8.10, with comparison to Abdulmalik et al. (2005), 
the studies with human HbA blood show a positive x-intercept, suggesting no observed change 
in p50 at low Hb-adduct concentrations (< 15%). This is likely an artifact of the method of 
predictions of the Hb-adduct concentration: the Hb-adduct concentrations were predicted from a 
time-dependency model for isolated HbA, which does not account for any elimination of 5-HMF 
by ALDH-mediated metabolism. The p50 observations were made in human whole blood, and it 
was observed from the PD studies that 0.5 mM 5-HMF in human whole blood did not result in 
any significant left-shift. Therefore, while the time-dependency model predicts about 15% Hb-
adduct at a nominal 5-HMF concentration of 0.5 mM, there was no observed, corresponding left-
shift in p50. Nevertheless, the findings from these preliminary investigations for HbA are in line 
with previously reported findings for HbS. 
Therefore, further quantitative assessments were made to investigate the time-
dependency of the relationship between Hb-adduct and p50. Since the %Hb-adduct and %change 
in p50 are calculated as percent of the total Hb and percent change from the baseline, 
respectively, and only ranging from 0 – 100%, the percentage-approach was not used for any 
further characterization of the relationship. The direct relationship between HbA-adduct 
concentrations predicted by the time-dependency model and corresponding observed p50 was 
explored at different experimental time points; namely 1, 2, 4, 6, 8 and 10 hrs. Figure 8.11 shows 
the relationships over time, and Table 8.2 lists the mean slopes after individual linear regression 
at each time point over 1 – 8 hrs. It can be seen from Figure 8.11 that, overall, the linear 
relationship between Hb-adduct concentrations and p50 is similar, irrespective of time (COV of 
10%).   
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Figure 8.11. Comparative relationships between steady-state Hb-adduct concentration and 
left-shift in p50 at different time points. 
 
 
 
 
Table 8.2. Parameter estimates for the linear model with means computed for 
measurements up to 8 hrs. 
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Assuming a linear relationship exists between Hb-adduct concentrations and p50, the 
observed p50 values from the PD study were back-transformed to Hb-adduct concentrations using 
the parameters (slope and intercept) from Table 8.2, in order to explore the predicted time- and 
nominal 5-HMF concentration-dependent Hb-adduct formation for the PD studies. These 
predicted Hb-adduct concentrations for the PD studies were superimposed with Hb-adduct 
predictions from the time-dependent binding studies with isolated HbA. Figure 8.12 shows the 
superimposed time-dependency profiles for Hb-adduct predictions from binding study with 
isolated HbA and back-transformed p50 observations from PD studies for varying 5-HMF 
nominal concentrations, using the above linear relationships. 
It can be observed from Figure 8.12 that the predicted Hb-adduct in human whole blood 
peaks earlier (by ~1 hr) and follows a biphasic profile compared to that in isolated HbA solution 
that appears to be monophasic (i.e., monotonically increasing). The peak Hb-adduct 
concentrations are comparable between the two independent studies. However, the predicted Hb-
adduct concentrations in whole blood are higher than that in isolated HbA solutions, which is 
counterintuitive. Whole blood contains active ALDH enzyme, responsible for metabolism of 5-
HMF, and is expected to result in lower Hb-adduct concentration. The peak Hb-adduct 
concentration is a result of the binding and dissociation of 5-HMF from HbA, and an early peak 
in whole blood suggests more rapid association and/or dissociation (more likely), followed by 
ALDH metabolism. More importantly, the biphasic Hb-adduct predictions are consistent with 
metabolic clearance of 5-HMF in human whole blood by ALDH, while in isolated HbA 
solutions, due to absence of the elimination pathway, peak Hb-adduct concentrations are 
predicted to be maintained throughout the 10 hr time period. 
  
  
356 
 
Figure 8.12. Comparison between time-dependent Hb-adduct predictions from binding study and back-transformed p50 
observations for varying nominal 5-HMF concentrations. 
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The linear PD model may not fully describe the relationship between actual Hb-adduct 
concentrations and p50 in whole blood. However, assuming a linear relationship between Hb-
adduct concentrations and p50, the values for slope and intercept reported in Table 8.2 were used 
as initial estimates for initial PK/PD modeling using a TSDD/linear PD model.    
The rate of decline of PD effect was determined from predicted Hb-adduct concentrations 
from back-transformed p50 values with respect to time (Figure 8.13). A log-linear decline in 
predicted Hb-adduct concentrations with respect to nominal 5-HMF concentrations, with 
decreasing slopes is observed. This rate of decline of PD effect is most likely driven by ALDH-
mediated metabolism. The predicted apparent PD t1/2 for 5-HMF in human whole blood is 
between 2 – 20 hrs for 0.5 – 5 mM 5-HMF respectively (Table 8.3), however, this can only be 
interpreted with caution. This half-life is estimated from predicted Hb-adduct concentrations 
from experimentally estimated p50 values, assuming a linear relationship between the two. 
Nevertheless, this analysis helped provide initial values for kmet in the PK/PD model based on the 
apparent first-order rate of decline of predicted Hb-adduct concentrations in whole blood. 
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Figure 8.13. Rate of Decline of Predicted Hb-adduct Concentrations (semi-log scale). 
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Table 8.3. Predicted PD effect half-life from predictions of the Hb-adduct concentration, 
assuming a linear relationship between Hb-adduct concentration and p50 and log-linear 
decline. 
 
 
Nominal [HMF] 
(mM) 
Rate of decline 
(hr
-1
) 
PD effect t1/2 
(hr) 
0.5 0.352 2.0 
1 0.428 1.6 
2 0.350 2.0 
3 0.140 4.9 
5 0.035 20 
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The relationship between actual Hb-adduct concentrations and p50 was further explored: 
In Chapter 5, a sigmoidal model was used to describe the empiric relationship between the 
observed peak left-shift in p50 and the nominal/starting 5-HMF concentrations. A similar 
approach was used for developing a sigmoidal PD model and obtaining initial parameter 
estimates. The observed peak p50 was plotted with respect to predicted Hb-adduct concentrations 
after 2 hrs for the various nominal 5-HMF concentrations, and fit by a sigmoidal Emax-model, 
which was further modified to include a baseline p50 value (Equation 8 – 7). This baseline p50 
value was fixed to 24 mmHg, the experimentally observed mean baseline p50 in normal whole 
blood in absence of 5-HMF (Chapter 5).  
 
     [(
       
 
(    )     
)]                                    
Where 
E : p50 value as function of 5-HMF adduct concentrations 
E0: Baseline p50 in absence of 5-HMF 
Emax: Maximum left-shift in p50 
EC50: Hb-adduct concentration at half-maximal left-shift in p50  
ϒ: Sigmoidicity coefficient 
The sigmoidal Emax-model describes the relationship between Hb-adduct concentration 
and p50 well. Figure 8.14 shows the model fit, and Table 8.4 shows the parameter estimates from 
the sigmoidal Emax model. Assuming a sigmoidal relationship between Hb-adduct concentrations 
and p50, the PD parameter values Table 8.4 were used as initial estimates for PK/PD modeling 
using a TSDD/sigmoidal PD model. 
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Figure 8.14. Comparative relationship between predicted Hb-adduct concentration (at 2 
hrs) and peak left-shift in p50 over time fit by a sigmoidal Emax model. 
 
 
 
Table 8.4. Parameter estimates for the sigmoidal Emax model. 
Parameter Estimate (SD) 
E0 (mmHg) 24 (fixed) 
Emax (mmHg) -20.3 (2.8) 
EC50 (mM) 0.86 (0.11) 
ϒ 3.3 (1.3) 
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8.3.4 TSDD/Linear PD (PK/PD) Model 
Using the general strategy described in section 8.3.2, a TSDD/linear PD model was used to 
describe the integrated in-vitro PK/PD of 5-HMF in human whole blood. In order to overcome 
the issue of high imprecision in kmet estimates, which also resulted in high underprediction of 5-
HMF plasma concentrations for 2 – 5 mM 5-HMF in blood, an upper constraint of 0.8 hr-1 was 
enforced during modeling, from several initial assessments and Figure 8.13: assuming the 
decline of (predicted) Hb-adduct concentrations from observed p50 in whole blood is driven by 
ALDH metabolism in RBC (and also dissociation of Hb-adduct) as described in section 8.3.3, 
Figure 8.13 suggests that kmet values are likely 0.1 – 0.2 hr
-1
, and setting 0.8 hr
-1
 as an upper limit 
seems reasonable to allow for optimization of kmet within this limit. 
Figures 8.15 and 8.16 show the model fit for 5-HMF plasma concentrations (on a linear and 
semi-logarithmic scale, respectively), and Figure 8.17 shows the model fit for the PD effect of 5-
HMF in blood. The final PK/PD model parameter estimates are reported in Table 8.5. 
The initial TSDD/linear PD model and parameter estimates poorly describe the plasma 
concentrations of 5-HMF: there is significant underprediction at the higher nominal 
concentrations and overprediction at the lower nominal concentrations. The nonlinear decline in 
5-HMF plasma concentrations is also not adequately captured by this model.  
The model does adequately describe the initial increase in PD effect, but does not 
describe the return of effect to the baseline very well. The terminal portion of the PD profile is 
either overpredicted or underpredicted, depending on the nominal 5-HMF concentration. 
Therefore, since the linear PD model does not describe the differential decline in PD effect very 
well, a TSDD/sigmoidal PD model was explored.  
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Figure 8.15. TSDD/linear PD model fit for 5-HMF plasma concentrations. 
 
 
 
Figure 8.16. TSDD/linear PD model fit for 5-HMF plasma concentrations on a semi-log 
scale. 
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Figure 8.17. TSDD/linear PD model fit for 5-HMF PD effect in whole blood. 
 
 
 
Table 8.5. Parameter estimates for the TSDD/linear PD model for 5-HMF. 
 
Model Component Parameters Initial Estimates (Limits) Final Estimates (SD) 
TSDD k1 (mM
-1
 hr
-1
) 1.25 0.46 ± 0.13 
 k-1 (hr
-1
) 0.0059 0.12 ± 0.05 
 kmet (hr
-1
) 0.173 (0 – 0.8) 0.8 ± 0.4 
Fixed constants khsa  0.093 (fixed) 0.093 
 [Hb]0 (mM) 2.06 (fixed) 2.06 
Linear PD model Slope 
(mmHg/mM) 
-13.7 -14.9 ± 2.9 
 Intercept 
(mmHg) 
24 (fixed) 24 
 r
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  0.98 
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8.3.5 TSDD/Sigmoidal PD (PK/PD) Model 
A TSDD/sigmoidal PD model was developed for 5-HMF in human whole blood, using 
the general strategy mentioned in section 8.3.2. From initial modeling assessments, a high (and 
imprecisely estimated) kmet value adequately accounted for the decline in PD effect but resulted 
in significant underprediction of 5-HMF plasma concentrations. Therefore, based on several 
initial sensitivity analyses, an upper constraint of 0.3 hr
-1
 was set for optimization of kmet.  
The TSDD/sigmoidal PD model using 1/Y weight on 5-HMF plasma concentrations, with the 
final PK/PD parameter estimates, describes the in-vitro PK/PD of 5-HMF in human whole blood 
reasonably well. Figures 8.18 and 8.19 show the model fit for 5-HMF plasma concentrations (on 
a linear and semi-logarithmic scale, respectively), and Figure 8.20 shows the model fit for the PD 
effect of 5-HMF in blood. The final model parameter estimates are reported in Table 8.6. 
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Figure 8.18. TSDD/sigmoidal PD model fit for 5-HMF plasma concentrations. 
 
 
 
 
Figure 8.19. TSDD/sigmoidal PD model fit for 5-HMF plasma concentrations on a semi-log 
scale. 
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Figure 8.20. TSDD/sigmoidal PD model fit for 5-HMF PD effect in whole blood. 
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Table 8.6. Parameter estimates for the final TSDD/sigmoidal PD model for 5-HMF. 
 
Model Component Parameters Initial Estimates (Limits) Final Estimates (SD) 
TSDD k1 (mM
-1
 hr
-1
) 1.25 0.76 ± 0.26 
 k-1 (hr
-1
) 0.0059 0.49 ± 0.31 
 kmet (hr
-1
) 0.173 (0 – 0.3) 0.30 ± 0.15 
Fixed constants khsa  0.093 (fixed) 0.093 
 [Hb]0 (mM) 2.06 (fixed) 2.06 
Sigmoidal PD model E0 (mmHg) 24 (fixed) 24 
 Emax (mmHg) -20.3 -19.5 ± 1.3 
 ϒ 3.3 3.7 ± 0.5 
 EC50 (mM) 0.86 0.75 ± 0.19 
 r
2
  0.99 
 MSC  3.7 
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The TSDD/sigmoidal PD model describes the plasma concentrations of 5-HMF well at the 
higher nominal concentrations, but overpredicts at nominal concentrations below 2 mM. 
Although it is preferable that the model be able to predict all nominal concentration levels of 5-
HMF in blood, clinically, nominal concentrations of 0.5 – 1 mM are less relevant, as they are 
thought insufficient to exert the desired PD effect. There is some overprediction of plasma 
concentrations in the terminal phase for 2 mM 5-HMF, and this is likely due to the steep decline 
in observed PD effect for 2 mM 5-HMF, accounted for by the model. Regardless, it can be seen, 
overall, the model is able to predict the profiles well for nominal concentrations greater than 1 
mM, the therapeutically relevant range. 
The sigmoidal model describes the time-course of the concentration-dependent PD profile 
very well. The initial increase in effect, peak effect and decline in PD effect are described well 
by the model, with Emax values of a left-shift in p50 by -19.5 mmHg. The Hb-adduct 
concentration resulting in half-maximal effect is 0.8 (0.2) mM similar to the KD values for 5-
HMF binding to HbA (section 8.3.7), and the sigmoidal relationship is explained by a 
sigmoidicity coefficient of 3.7 (0.5). 
The terminal phase of 5-HMF plasma concentrations and return of the p50 values to baseline 
(after 1 – 2 hrs) are a result of dissociation of the Hb-adduct and subsequent ALDH- mediated 
metabolism of 5-HMF. From the current dataset, only the time-course of the p50 provides some 
indirect information on the k-1 and kmet. The time-course for measured Hb-adduct concentrations 
and HMFA will provide valuable information for the two rate constants, data for which is 
unavailable. Due to inadequate data that enables differentiation between k-1 and kmet, the two 
parameters are highly correlated. This presents a major limitation of the current dataset, and 
therefore the model. Despite this limitation, this TSDD/sigmoidal Emax-PD model was found to 
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result in the best fits for 5-HMF plasma concentrations and corresponding p50 values from visual 
and statistical assessments, and was therefore selected as the final TSDD/PD model.  
Using this model, the relationship between plasma concentrations of 5-HMF and effect was 
assessed (as described in Chapter 6). It may be seen from Figure 8.21, the counter-clockwise 
hysteresis, described in Chapter 6, is predicted by the TSDD/PD model. The lag-time in peak 
plasma concentrations and peak effect is described by the model. As the concentrations of 5-
HMF in the plasma decline, there is an increase in effect (represented by ∆p50), followed by peak 
effect, which achieves a maximum value for the higher 5-HMF nominal concentrations, and this 
is then followed by return of the effect to the baseline due to dissociation of Hb-adduct and 
subsequent ALDH-metabolism. 
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Figure 8.21. Prediction of counter-clockwise hysteresis by TSDD/sigmoidal PD model, 
superimposed with observed values (Chapter 6). 
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8.3.6 Final TSDD/PD Model Predictions 
As explained in section 8.3.5, the TSDD/sigmoidal Emax-PD model was selected as the 
final TSDD/PD model. Model predictions for concentrations of 5-HMF in plasma, free Hb, Hb-
adduct concentrations, 5-HMF metabolite concentrations and p50 values are shown in Figures 
8.22 – 8.27 for three representative concentrations of 5-HMF in human whole blood, namely 0.5, 
2 and 5 mM, assumed to be therapeutically relevant (specifically 2 – 5 mM 5-HMF). 
At low nominal 5-HMF concentrations, Hb is in excess, and the bimolecular reaction 
proceeds in an apparent first-order manner with respect to 5-HMF concentrations in plasma. 5-
HMF forms Hb-adduct which peaks in ~ 1 hr, resulting in a slight change in p50, followed by 
return to the baseline. The return to the baseline is due to dissociation of 5-HMF from HbA and 
subsequent metabolism by ALDH to its oxidative metabolite, HMFA. 5-HMF is nearly 
completely converted to HMFA within 24 hrs.  
High nominal 5-HMF concentrations such as 5 mM, result in saturation of the HbA 
binding sites, and therefore a maximal effect on p50, which is sustained for a prolonged duration 
of time, followed by return to the baseline p50 within 24 hrs, in comparison with 0.5 and 2 mM 5-
HMF.   
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Figure 8.22. TSDD/PD model predictions for concentrations of 5-HMF in plasma, free Hb, 
5-HMF–Hb-adduct and HMFA, for 0.5 mM 5-HMF in whole blood (linear scale). 
 
 
 
Figure 8.23. TSDD/PD model predictions for effect of 0.5 mM 5-HMF on p50 in whole 
blood. 
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Figure 8.24. TSDD/PD model predictions for concentrations of 5-HMF in plasma, free Hb, 
5-HMF –Hb-adduct and HMFA, for 2 mM 5-HMF in whole blood (linear scale). 
 
 
 
Figure 8.25. TSDD/PD model predictions for effect of 2 mM 5-HMF on p50 in whole blood. 
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Figure 8.26. TSDD/PD model predictions for concentrations of 5-HMF in plasma, free Hb, 
5-HMF –Hb-adduct and HMFA, for 5 mM 5-HMF in whole blood (linear scale). 
 
 
 
Figure 8.27. TSDD/PD model predictions for effect of 5 mM 5-HMF on p50 in whole blood. 
 
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
0 4 8 12 16 20 24
P
re
d
ic
te
d
 C
o
n
ce
n
tr
at
io
n
s 
(m
M
) 
Time (hr) 
Observed HMF
Plasma HMF
HbHMF Adduct
HMFA
Free Hb
0.0
5.0
10.0
15.0
20.0
25.0
30.0
0 4 8 12 16 20 24
p
5
0
 (
m
m
H
g)
 
Time (hr) 
Observed p50
p50
  
376 
 
The relationship between the predicted Hb-adduct concentrations and predicted p50 values 
was assessed. Figure 8.28 shows the underlying sigmoidal relationship between Hb-adduct and 
p50 predictions for 5-HMF. This relationship best describes the in-vitro PK/PD data for 5-HMF 
in healthy human whole blood with the available PK/PD data. 
 
 
Figure 8.28. Relationship between predicted Hb-adduct concentrations and p50. 
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8.3.7 Model comparisons 
A comparison between the binding parameters for 5-HMF with HbA estimated from four 
different models is shown in Table 8.7. The following models were compared:  
1. Steady-state binding model, used for steady-state concentration-dependency studies for 
varying 5-HMF molar fraction levels incubated with isolated HbA at 37
o
C for 24 hrs 
(Chapter 7). 
2. Time-dependency binding model, used for time-dependency studies of varying 5-HMF molar 
fraction levels incubated with isolated HbA at 37
o
C up to 30 hrs (Chapter 7). 
3. TSDD model, used for modeling of PK data, i.e., 5-HMF plasma concentrations from human 
whole blood. Varying 5-HMF nominal concentrations were incubated with human whole 
blood up to 10 hrs (Chapter 8). 
4. TSDD/sigmoidal PD model, used for PK/PD modeling of combined PK/PD data, i.e., 5-HMF 
plasma concentrations and measured effect. Varying 5-HMF nominal concentrations were 
incubated with human whole blood up to 10 hrs (Chapter 8). 
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Table 8.7. Comparative parameter estimates for the binding of 5-HMF to HbA from different models. 
 
 
Parameters Steady-State Binding Binding Model Final TSDD Model Final TSDD/PD model 
k1 (mM
-1
 hr
-1
)  0.27 ± 0.03 1.25 ± 0.11 0.76 ± 0.26 
k-1 (hr
-1
)  0.05 ± 0.01 0.006 ± 0.004 0.49 ± 0.31 
kmet (hr
-1
)   0.17 ± 0.02 0.30 ± 0.15 
[Hb]0 (mM) 0.125 0.125 2.06 2.06 
KD (mM) 0.25 ± 0.04 0.18 ± 0.04 0.005 ± 0.003 0.64 ± 0.46 
t1/2
eq
 (hrs)  8.2 4.3 1.2 
Reference  Chapter 7 Chapter 7 Chapter 8 Chapter 8 
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It is seen on Table 8.7, the estimate for forward binding with HbA is similar between the 
TSDD and TSDD/PD model for blood, however, lower in isolated HbA experiments. In whole 
blood, due to other concurrent mechanisms such as RBC membrane and plasma protein binding, 
the k1 may be overestimated to account for rapid loss of 5-HMF, compared with the true k1 from 
isolated HbA binding studies.  
Unlike k1, the estimates for k-1 vary 100-fold between the three models. Due to difficulty 
in estimation, likely due to inadequate data for selective characterization of the dissociation of 5-
HMF from HbA (after 24 hrs), constraints were set on k-1 in the binding model. The constraints 
on k-1 were lifted in the TSDD and final TSDD/PD model. Nevertheless, in the TSDD and 
TSDD/PD models, measurements up to 10 hrs are not sufficient to fully capture complete 
dissociation of 5-HMF from HbA. Furthermore, the decline in PD effect may be described by 
dissociation from HbA and subsequent metabolism by ALDH. Due to lack of sufficient data for 
differentiating between the two processes, the k-1 and kmet in the TSDD and TSDD/PD model are 
highly correlated. 
Considering the variability in the parameter estimates, the calculated KD values are 
similar across the models, except the TSDD model, where a small KD value is the result of both, 
small k-1 and greater k1 estimates. For the TSDD model, other than the loss of 5-HMF from 
plasma, there is no experimental information (on the Hb-adduct concentrations) to enable precise 
estimation of binding and metabolism parameters, while on the other hand, for the final 
TSDD/PD model, there is information on the Hb-adduct by virtue of the observed p50 profile, in 
addition to the declining 5-HMF plasma concentrations, making the TSDD/PD model parameter 
estimates more reliable than those estimated from TSDD model alone. The equilibration half-life 
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in a closed in-vitro model (binding model) is about 8 hrs (Chapter 7), while that in whole blood, 
similar to the in-vivo situation is between 1 – 4 hrs (Chapter 6). 
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8.3.8 External Validation of Model 
Attempts were made to externally validate the newly developed TSDD/PD model by 
comparing the model predictions for Hb-adduct concentrations and p50 values with literature 
reports by Abdulmalik et al (2005) for SS cells. The predicted Hb-adduct concentrations and p50 
values were transformed to % total HbA converted to Hb-adduct and % change in p50 with 
respect to the baseline (%∆p50), respectively. This plot was superimposed with findings by 
Abdulmalik et al (2005) for SS cells and is shown in Figure 8.29. Abdulmalik et al calculated the 
% change in p50 with respect to the baseline value for SS cell suspensions after incubation with 
5-HMF for 1 hr. The %Hb-adduct formed was determined from a semi-quantitative HPLC-UV 
assay with respect to the response for total Hb.  
While Abdulmalik et al reported a linear relationship between the %∆p50 and %HbS-
adduct, the TSDD/PD model shows a sigmoidal relationship exists between the two. It can be 
seen that the model predictions are in line with observations in HbS, with only slight under-
prediction, more evident at the lower %Hb-adduct. It was shown in Chapter 7 that 5-HMF binds 
with HbS more rapidly than with HbA, resulting in ~5 – 8% greater peak Hb-adduct formation. 
This may explain the slight differences between the model prediction for HbA and observations 
by Abdulmalik et al for HbS. 
For 1 mM 5-HMF, Abdulmalik et al observed a left-shift in p50 by ~16% and measured a 
corresponding HbS-adduct of 14%. This information is supported by a single observation only, 
and no further observations were made up to 30% of Hb-adduct formation. Due to lack of 
adequate data at the lower Hb-adduct concentrations, the true relationship cannot be fully 
determined for the Abdulmalik et al study. In addition, the whole blood/cell suspension systems 
used in the two studies are different, which may add to variability: the TSDD/PD model 
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predictions are for 5-HMF in healthy human whole blood containing HbA, while the Abdulmalik 
et al (2005) reports are for SS cell suspensions from homozygous SCD patients, prepared in 
Hemox buffer (pH 7.4) containing 10 mM glucose and 0.2% bovine serum albumin.  
Nevertheless, the findings are very similar, providing good external validation for the 
TSDD/PD model.  
 
 
Figure 8.29. Super-imposed measured Hb-adduct and p50 with HbS and TSDD model 
predicted Hb-adduct concentrations and p50. 
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8.3.9 Post hoc sensitivity analyses 
Post hoc model sensitivity analyses were performed to assess model stability and 
robustness, as well as to provide information of specific parameters that the model predictions is 
most sensitive to, and for which more accuracy in estimation may be required, supported by 
experimental data (Bonate, 2005). Post hoc sensitivity analyses were performed for the 
TSDD/PD model to provide valuable information on the sensitivity of the model and predicted 
profiles to changes in the parameter estimates, and parameters that require more precise 
estimation. TSDD/PD model predictions were assessed by changing various model parameters 
such as Hb0, kmet, k1, k-1, ϒ and EC50. Outcome metrics were identified to compare the various 
predictions and quantitatively assess model sensitivity. 
Parameters such as kmet, k1, k-1, ϒ and EC50 were increased and decreased by 2-fold 
relative to their final point estimate (overall-fold change in values = 4-fold), as shown in Table  
8.8, and the respective predictions of concentrations and effect are shown for 2 mM 5-HMF, as a 
representative of the therapeutically relevant concentration of 5-HMF in blood. PK metrics 
selected for sensitivity assessments were AUCoo
plasma
 and terminal t1/2, as a measure of 5-HMF 
exposures. The PD metrics (identified and) selected were peak shift in p50 (peak ∆p50) from the 
baseline (24 mmHg), as a measure of the magnitude of effect; time to peak ∆p50 (“Tmax
effect”), as 
a measure of onset of effect; and ∆p50 after 12 hrs relative to the peak ∆p50 (∆p50
12h
 % of peak 
∆p50), as a measure of the duration of effect.  
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Table 8.8. Post-hoc model sensitivity analysis for various parameter estimates. Highlighted 
parameters were increased or decreased 2-fold. 
 
Model 
Component 
Parameters 
TSDD/PD Model 
Point Estimates 
Lower/Upper 
Sensitivity Limits 
TSDD k1 (mM
-1
 hr
-1
) 0.76 0.38; 1.53 
 k-1 (hr
-1
) 0.49 0.25; 0.98 
 kmet (hr
-1
) 0.30 0.15; 0.6 
Fixed constants khsa  0.093 n/a 
 [Hb]0 (mM) 2.06 n/a 
PD E0 (mmHg) 24 n/a 
 Emax (mmHg) -19.5 n/a 
 ϒ 3.7 1.85; 7.4 
 EC50 (mM) 0.75 0.38; 1.50 
  
  
385 
 
The k1 represents the forward binding rate constant between 5-HMF and HbA. Figures 
8.30 – 8.31 and 8.32 – 8.33 show the model predictions for slow forward binding and fast 
forward binding, respectively. When the rate of association between 5-HMF and HbA is slow, 
the initial decline in 5-HMF plasma concentrations is slow; less Hb-adduct is formed and 5-HMF 
undergoes rapid and more metabolism. The low Hb-adduct concentrations result in a short 
duration of action, and return of the p50 to the baseline is achieved within about 8 – 10 hrs. On 
the other hand, a fast k1 results in a steep drop in plasma concentrations of 5-HMF in the first 2 
hrs due to rapid association with HbA. Peak Hb-adduct concentrations are achieved rapidly, and 
are greater than those from the point estimate, due to which a greater, more rapidly achieved, and 
sustained effect is seen with return to the baseline in 24 hrs. The concentration of HMFA formed 
after 24 hrs is considerably lower than that formed with slow association.  
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Figure 8.30. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for slow k1 (k1 = 
0.38 M
-1
 hr
-1
). 
 
Figure 8.31. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for slow k1 (k1 = 
0.38 M
-1
 hr
-1
). 
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Figure 8.32. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for fast k1 (k1 = 
1.53 M
-1
 hr
-1
). 
 
 
Figure 8.33. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for fast k1 (k1 = 
1.53 M
-1
 hr
-1
). 
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The k-1 represents the first-order dissociation rate constant for 5-HMF adduct with HbA. 
Figures 8.34 – 8.35 and 8.36 – 8.37 show the model predictions for slow dissociation and fast 
dissociation, respectively. Increasing k1 or decreasing k-1 and vice versa, do not change the KD, 
but have different effects on the time-course of the profiles. 
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Figure 8.34. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for slow k-1 (k-1 
= 0.25 hr
-1
). 
 
 
Figure 8.35. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for slow k-1 (k-1 
= 0.25 hr
-1
). 
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Figure 8.36. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for fast k-1 (k-1 = 
0.98 hr
-1
). 
 
 
Figure 8.37. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for fast k-1 (k-1 = 
0.98 hr
-1
). 
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The kmet represents the apparent first-order rate constant of metabolism by ALDH in the 
RBC. Changes on kmet will reflect the effect of any genetic polymorphisms or environmental 
changes on ALDH activity, and therefore, the PK/PD of 5-HMF in such individuals. Figures 8.38 
– 8.39 and 8.40 – 8.41 show the model predictions for low ALDH activity and high ALDH 
activity, respectively. For low ALDH activity, the maximum Hb-adduct concentration and peak 
effect do not vary greatly in comparison to the point estimate. However, since the elimination 
clearance of 5-HMF is reduced, the Hb-adduct concentrations are maintained longer, and a 
greater effect is maintained for prolonged period of time. The effect returns to the baseline within 
24 hrs. For high ALDH activity, 5-HMF plasma concentrations decline rapidly, and there is a 
more rapid formation of metabolite. Due to greater elimination of 5-HMF, less is available for 
binding to HbA, and therefore, the Hb-adduct concentrations are slightly lower and decline 
faster, translating to lower peak effect with rapid return to the baseline within 12 hrs. 
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Figure 8.38. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for low ALDH 
activity (kmet = 0.15 hr
-1
). 
 
 
Figure 8.39. TSDD/PD model predictions for the effect of 2 mM 5-HMF in whole blood for 
low ALDH activity (kmet = 0.15 hr
-1
). 
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Figure 8.40. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for high ALDH 
activity (kmet = 0.6 hr
-1
). 
 
 
Figure 8.41. TSDD/PD model predictions for 2 mM 5-HMF in whole blood for high ALDH 
activity (kmet = 0.6 hr
-1
). 
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The EC50 represents the concentration of Hb-adduct, resulting in half-maximal change in 
p50. A low EC50 value reflects a higher potency, and the opposite holds true. This may be of 
relevance for comparison between AEH. The Hb adducts with INN-compounds are likely to 
show greater (adduct) potency compared to 5-HMF (see Chapter 5). Figures 8.42 and 8.43 show 
the model predictions for low, and high EC50 values, respectively. The time-course and 
magnitude of the PD effect is very sensitive to the EC50 value. It is the effective Hb-adduct 
concentration that results in a change in p50. A small EC50 reflects high potency, resulting in 
rapidly achieved and sustained maximal effect for the same Hb-adduct concentrations. It does 
not affect the PK and disposition of 5-HMF since it is primarily a PD parameter, however, it 
does have a significant impact on the duration of action and return to the baseline. A large EC50 
on the other hand, reflects low potency, due to which even at high concentrations of Hb-adduct, a 
minimal change in p50 is predicted. 
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Figure 8.42. TSDD/PD model predictions for effect of 2 mM 5-HMF in whole blood for 
small EC50 (EC50 = 0.38 mM). 
 
Figure 8.43. TSDD/PD model predictions for effect of 2 mM 5-HMF in whole blood for 
higher EC50 (EC50 = 1.50 mM). 
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The sigmoidicity (Hill) coefficient (ϒ) for the Emax model determines the steepness of the 
relationship between Hb-adduct concentrations and p50. The influence of changes in this value on 
the effect of 5-HMF (and likely other AEH) was explored. Figures 8.44 and 8.45 show the model 
predictions for low, and high Hill coefficients, respectively. The Hill coefficient (ϒ) primarily 
drives the shape of the return of effect to the baseline. A large value for ϒ results in a more 
sigmoidal profile for return of effect to the baseline. The disposition does not depend on ϒ. 
However, the duration of effect depends greatly on this parameter. 
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Figure 8.44. TSDD/PD model predictions for effect of 2 mM 5-HMF in whole blood for 
small sigmoidicity coefficient (ϒ = 1.85). 
 
Figure 8.45. TSDD/PD model predictions for effect of 2 mM 5-HMF in whole blood for 
large sigmoidicity coefficient (ϒ = 7.4). 
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The effect of parameters on the outcome metrics as part of the sensitivity analyses are 
reported in Table 8.9. Fold-change in the outcome metrics are reported, with respect to a 4-fold 
change in parameter values. A cut-off of 2.0-fold change in outcome metrics was used for the 
sensitivity analyses. The relative sensitivity of the outcome metrics can be described by fold 
change in metrics divided by fold change in parameter estimate.   
It can be seen that a 4-fold change in k1 and k-1 affect plasma exposures and t1/2 to a 
similar (small) extent. The PD outcome metrics greatly depend on the estimates for both k1 and 
k-1. The estimate for k1 has an effect on peak and duration (peak ∆p50 and ∆p50
12h
 % of peak ∆p50) 
of effect, while the k-1 has a greater effect on Tmax
effect
 and significant (20-fold) effect on 
duration. The relative sensitivity of the duration of effect to k-1 estimate is 5-fold.  
 The TSDD/PD model predictions are most sensitive to changes in kmet: the PK, as well as 
PD metrics are greatly affected by a 4-fold change in kmet, demonstrating the sensitivity of the 
model to this parameter, and well as need for its more precise estimation. The relative sensitivity 
of the duration of effect to kmet estimate is 8-fold. This further elucidates, the dissociation of Hb-
adduct and metabolism to HMFA are key properties that drive the duration of effect. 
Furthermore, since there is inadequate experimental information differentiating the two 
processes, the model predictions are most sensitive to the two parameters.   
The PD model parameters do not affect plasma exposures, or t1/2 of 5-HMF; however, 
they do determine the peak and duration of effect. The EC50 and ϒ are important PD parameters 
that drive the peak and duration of PD effect: the relative sensitivity of duration is ~2-fold and 5-
fold for EC50 and ϒ, respectively. Furthermore, a 4-fold change in ϒ is more drastic in 
comparison with 4-fold change in other PK parameters, due to which a drastic change in the 
duration of effect is seen with ϒ.  
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Overall, the Tmax
effect
 is least sensitive to changes in PK and PD parameters, providing 
confirmatory evidence that the peak effect of 5-HMF is achieved in ~1.5 hrs.  
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Table 8.9. Assessment of outcome metrics from post hoc sensitivity analyses. 
 
Parameter 
-fold change 
from point 
estimates 
Outcome Metrics 
PK (plasma) PD 
AUCoo 
(mM*h) 
Terminal t1/2 
(hr) 
Peak ∆p50 
(mmHg) 
Tmax
effect 
(hr) 
∆p50
12h
 % of 
peak ∆p50 
(mmHg) 
TSDD predicted 
values  
(point estimates) 
N/A 5.3 7.8 -12.9 1.5 17 
  -fold change -fold change -fold change -fold change -fold change 
k1 4 1.2 1.7 2.2 1.3 11.4 
k-1 4 1.3 1.9 1.6 2.0 19.3 
kmet 4 3.1 2.7 1.3 1.3 32.5 
EC50 4 1.0 1.0 7.2 1.0 8.5 
ϒ 4 1.0 1.0 1.4 1.0 21.8 
        
 
  
401 
 
8.3.10 Model Simulations for HbS Blood 
The predictive utility of the TSDD/PD model was expanded to HbS and sickle blood. The 
rate constants of binding for 5-HMF with HbS have been determined in Chapter 7.  
 In order to appropriately simulate sickle blood, the Hb concentrations and baseline p50 
values were changed in addition to k1 and k-1. It is known SCD patients suffer from anemia and 
have low Hb concentrations (~8 g/dl). They also have a lowered hematocrit in blood. Therefore, 
assuming a Hb concentration of 8 g/dl (4.96 mM) in whole blood, and hematocrit of 30% in 
sickle blood, the nominal Hb concentration was fixed to 1.49 mM. The OEC of HbS in sickle 
blood are generally right-shifted and may assume values between 25 – 45 mmHg (Bunn & 
Forget, 1986). Due to high variability in baseline p50 values in sickle blood, a value of 30 mmHg 
was selected, with reference to Abdulmalik et al (2005). It was assumed that the ALDH 
metabolic activity, plasma protein binding, and PD parameters are the same in sickle blood as in 
healthy blood. With these changes (shown in Table 8.10 below), TSDD/PD model predictions 
were made for varying nominal 5-HMF concentrations in (simulated) sickle blood. The 
simulated plasma concentrations of 5-HMF, PD profile, 5-HMF-HbS-adduct concentrations, 5-
HMF metabolite concentrations and free HbS are shown in Figures 8.46 – 8.50, respectively.  
The peak effect of 5-HMF in sickle blood is predicted to occur in ~ 2 hrs (except for 5 mM 
5-HMF, which is predicted to be achieved in 1 – 1.5 hrs). The effect is sustained and more 
prolonged in sickle blood than in normal blood, likely due to slower dissociation, as expected, 
based on the sensitivity of the model to k-1 (see section 8.3.9). For 2 – 5 mM 5-HMF, the effect 
appears to return to the baseline (p50 = 30 mmHg) in over 30 hrs. Furthermore, kmet, the key 
parameter for the time-course of PD effect, was assumed to be similar between normal and sickle 
blood. Overall, the model simulations suggest more prolonged duration of action in sickle blood.  
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Table 8.10. Parameter values for TSDD/PD simulations for 5-HMF in SS blood (containing 
HbS). 
 
Parameters 
TSDD/PD Estimates 
(HbA) 
Values for HbS 
k1 (mM
-1
 hr
-1
) 0.76 0.83 
k-1 (hr
-1
) 0.49 0.1 
kmet (hr
-1
) 0.30 Same 
khsa  0.093 Same  
[Hb]0 (mM) 2.06 1.49 
E0 (mmHg) 24 30 
Emax (mmHg) -19.5 Same 
ϒ 3.7 Same 
EC50 (mM) 0.75 Same 
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Figure 8.46. TSDD/PD model predictions for 5-HMF concentrations in (simulated) sickle 
blood (containing HbS). 
 
 
Figure 8.47. TSDD/PD model predictions for effect of 5-HMF in (simulated) sickle blood. 
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Figure 8.48. TSDD/PD model predictions for 5-HMF-HbS-adduct concentrations in 
(simulated) sickle blood. 
 
 
Figure 8.49. TSDD/PD model predictions for 5-HMF metabolite in (simulated) sickle blood. 
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Figure 8.50. TSDD/PD model predictions for free HbS concentrations in the presence of 5-
HMF. 
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8.4 Discussion and Conclusions 
A novel TSDD model developed for simultaneous modeling of the disposition of 5-HMF 
in plasma from whole blood. It describes the observed nonlinear disposition of 5-HMF across 
concentrations of 0.5 – 5 mM reasonably well. The KD
app
 estimate from the TSDD model is over 
100-fold lower than the estimate from the nonlinear disposition clearance model and from the 
binding studies. This is likely due to the small value estimated for k-1 and large value for k1, and 
other binding to HSA and RBC membrane, which together result in a small KD
app
 estimate. The 
TSDD model predicts peak Hb-adduct concentrations after 1 – 2 hrs, and maximum metabolite 
concentrations within 2 hrs as well. The Hb-adduct concentrations are predicted to remain 
sustained over 10 – 24 hrs, suggesting the p50 is likely to remain left-shifted for a prolonged 
duration of time. However, this was not observed in the PD studies; therefore, a novel TSDD/PD 
model was built to include the time course of biphasic effect of 5-HMF in healthy human blood. 
Quantitative analyses showed there may be a linear relationship between Hb-adduct 
concentrations and p50. This linear relationship was similar between the different time points of 
observation, but could not adequately describe the PK and PD behavior of 5-HMF. The 
TSDD/linear PD model could capture the initial change in p50 and peak effect, but was not able 
to describe the return of the effect to the baseline without significantly underpredicting the 5-
HMF plasma concentrations.  
Therefore, a final TSDD/PD model was built for 5-HMF based on a sigmoidal relationship, 
that best describes the relationship between Hb-adduct concentrations and p50. This newly 
developed model describes the in-vitro PK and PD of 5-HMF reasonably well. The model 
predicts 5-HMF plasma concentrations well at the higher nominal concentrations (2 – 5 mM), 
but overpredicts the lower nominal concentrations, despite 1/Y weighting. This is because 
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simultaneous fitting of both 5-HMF plasma concentrations and p50 time-profiles was done, and 
the measured 5-HMF plasma concentrations were numerically lower than the observed p50 
values. Due to the wide range of values fit by the model, the lower concentrations of 5-HMF 
were likely ignored, despite 1/Y weighting used only for 5-HMF concentrations. The estimated 
KD from the estimated rate constants is similar to estimates from independent HbA binding 
studies, as well as modeling of nonlinear disposition clearance in plasma, validating the model 
and integrating the studies. The TSDD/PD model captures the observed time-course of PD effect 
well, with an Hb-adduct EC50 of 0.8 mM, responsible for half-maximal effect. Good 
superimposition between the model predictions and observations by Abdulmalik et al (2005) 
helps further validate the model and its predictive utility.      
Post hoc sensitivity analyses to assess the effect of variations in model parameter values on 
the model predictions showed the TSDD/PD model predictions are most sensitive to changes in 
kmet, the parameter describing the metabolism of 5-HMF by ALDH in RBC. As discussed in 
Chapter 6, the RBC-ALDH metabolism of 5-HMF contributes towards its elimination clearance, 
and, therefore it is expected the PK and the time-course of PD effect depend on this parameter. 
Furthermore, the model is sensitive to kmet due to inadequate data supporting the relative 
contribution of ALDH metabolism towards the overall disposition in plasma (i.e.. missing 
HMFA concentrations). 
Although k1 and k-1 affect plasma exposures in a similar (albeit inverse) manner, the 
imprecision in estimation of k-1, likely due to the short time-period of the study (10 hrs), as well 
as its high correlation with kmet, due to insufficient data supporting adequate differentiation of 
mechanisms described by the two parameters which makes it an important determinant of the 
model predictions. Furthermore, the 5-HMF-Hb-adduct is known to result in PD effect, and 
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therefore, its dissociation is likely to affect the time-course of PD effect, as suggested from the 
sensitivity analyses.  
 The PD model parameters do not affect plasma exposures, however, they greatly 
determine the peak and duration of effect. The Tmax
effect
 of 5-HMF is achieved in ~1.5 hrs, and is 
not sensitive to the various model parameters.    
 Overall, kmet and k-1 are important properties, describing mechanisms of metabolism of 5-
HMF in RBC and dissociation of 5-HMF from Hb, that determine the PK and PD of 5-HMF in 
whole blood.  
The novel TSDD/PD model also has predictive utility in sickle blood. Assuming the 
metabolic activity in sickle blood and the relationship between actual Hb-adduct concentrations 
and p50 is similar to normal blood, predictions were made to explore the disposition and PD of 5-
HMF in sickle blood using respective binding rate constants for 5-HMF with HbS, and corrected 
Hb and p50 values for sickle blood. Owing to relatively slow dissociation of 5-HMF from HbS, as 
expected, the time-course of PD effect in sickle blood likely is somewhat different from normal 
blood, with a prolonged duration of effect.  
Overall, the TSDD/PD model has predictive utility and provides valuable information on 
the disposition and effect of 5-HMF in normal blood and sickle blood. Fitzharris et al (1985) and 
Beddell et al (1984) calculated RBC concentrations of the FGE by subtracting plasma 
concentrations from whole blood concentrations and accounting for the hematocrit. The current 
research now shows strong evidence of likely over-estimation of RBC concentrations by this 
method due to concurrent ALDH metabolism in the RBC. Therefore, unlike the previously 
reported findings for AEH, the semi-mechanistic TSDD/PD model incorporates the various 
mechanisms occurring for 5-HMF (and AEH) in whole blood. However, the model does make 
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major assumptions, resulting in significant limitations. An assumption behind the model is that 
the plasma concentrations equilibrate very rapidly with RBC, and the metabolism by ALDH 
proceeds with (low affinity) apparent first-order kinetics. It is assumed that binding of 5-HMF 
with Hb forms only the Hb-adduct which is fully capable of left-shifting the p50, i.e., all types of 
adducts of 5-HMF with Hb are capable of resulting in a change in the p50.  
There is limited information on the metabolism of 5-HMF in the RBC. The decline in 
plasma concentrations is due to binding to Hb and metabolism of 5-HMF; it is difficult to truly 
differentiate between the two rate constants due to the limited data gathered and available. The 
model also does not account for any possible physiological (feedback) regulation mechanisms 
that result in right-shifting of the OEC, as a counter-effect to that of 5-HMF. Finally, it is 
assumed these findings are reflective of the in-vivo behavior of 5-HMF (and other AEH) in 
normal (and sickle) blood. 
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CHAPTER 9 
9 OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
SCD is associated with high morbidity and decreased life expectancy. Limited current 
therapeutic options for the treatment of the disease call for newer, safer and more effective 
therapies. Therapy with HU has proven that the therapeutic concept, i.e., chronically increasing 
oxygen affinity in blood (e.g., by HbF induction), can lead to favorable clinical SCD outcomes; 
however, HU’s clinical use is limited due to its clinical toxicity. Based on their similar 
mechanism of action, AEH, OEC left-shifters, are promising anti-sickling agents, and have been 
investigated for over four decades. 
FGE were tested in humans, but did not move into large scale clinical development due to 
poor biopharmaceutical properties or safety issues. The IV route of administration and the 
relatively short duration of action of valeresol without acceptable therapeutic benefit in SCD 
patients led to discontinuation of its development, while severe immuno-stimulating adverse 
events prevented further clinical studies with tucaresol. However, their essential PK/PD 
properties, e.g., binding to Hb, metabolism, etc., were never fully investigated.  
Preclinical investigations have been carried out to explore the metabolism and plasma 
protein binding of 5-HMF, the SGE lead compound. Initial studies on Hb binding and whole 
blood disposition provided information on its in-vitro human PK behavior (Obied, 2010), while 
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oral administration to transgenic sickle mice provided initial information on its in-vivo PK 
(Abdulmalik et al, 2005). However, significant gaps remained in the understanding of its kinetics 
at the target site (RBC) in normal (HbA) and sickle (HbS) blood. Furthermore, 
biopharmaceutical and in-vitro PK/PD assessments have not been previously made for the novel 
INN-compounds, SGEs which show greater in-vitro anti-sickling action than 5-HMF. 
This translational research project provides a platform of detailed investigational studies 
for the SGE, namely, 5-HMF, INN-312 and INN-298 for a more comprehensive understanding 
of their overall PK/PD properties, that can enable selection of candidates for further 
development, based on the most favorable biopharmaceutical, PK and PD properties.  
Using calculated physicochemical properties (solubility, clogP and clogDpH1-8) reported 
by SciFinder Scholar
®
, a (theoretical) BCS classification of 5-HMF, INN-312 and INN-298 was 
made: 5-HMF can be classified as BCS-I, owing to its high GI solubility and GI permeability, 
and is shown to be orally absorbed in preclinical animal species (Germond et al., 1987; Godfrey 
et al., 1999; Abdulmalik et al., 2005) and in humans (Stern et al., 2012). However, GI and 
hepatic first-pass are likely limiting its Foral. On the other hand, at their presumed clinically 
relevant doses, INN-312 and INN-298 can be classified as BCS-II (low GI solubility, high GI 
permeability) compounds. Tucaresol has low intrinsic aqueous solubility and slightly greater 
lipophilicity than the INN-compounds, and has been shown to be orally bioavailable in humans 
at high doses (~ 3.8 g; Rolan et al., 1993). However, its solubility profile differs from the INN-
compounds; it is expected to have high solubility (and permeability) in the intestinal lumen, 
unlike the INN-compounds. This tentative BCS classification of the SGE assumes the partition- 
(and distribution-) coefficients (clogP and clogDpH1-8) are reflective of the permeability across 
GIT, and suggests possible solubility-limited oral absorption for INN-312 and INN-298.  
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ALDH is thought to be one of the major metabolizing enzymes for SGE. In-vitro hepatic 
cytosolic oxidative metabolism of SGE was characterized. The SGE are substrates for hepatic 
cytosolic ALDH (and ADH for 5-HMF), as expected, due to their common aldehyde functional 
group, with differences in metabolic efficiencies, likely due to selective enzyme affinity and 
differences in hydrophobicity of the molecules. Within the limitations of IVIVE, and assuming 
hepatic cytosolic ALDH is the only (primary) metabolic pathway for AEH, low to intermediate 
(hepatic) extraction (and first-pass) is predicted for SGE. 5-HMF human in-vivo PK strongly 
indicates presence of extrahepatic (ALDH and possibly ADH) metabolism leading to high first-
pass and systemic metabolism. 
Inter-species differences in ALDH activity were investigated using acetaldehyde as a 
model substrate. ALDH activity varies significantly between mammalian species, possibly owing 
to differences in enzyme protein structure, binding pocket and/or substrate preferences. 
Differences in hepatic cytosolic ALDH- (and ADH-) mediated metabolism of 5-HMF has been 
previously shown to be due to different relative contributions of ADH and ALDH, as well as 
differences in ALDH activity among rats, mice, dogs and humans (Obied, 2010). Canine ALDH 
is more efficient than rodent ALDH for acetaldehyde, as was shown for 5-HMF, owing to higher 
apparent enzyme affinity. Inter-species differences in the metabolism of primary alcohols and 
glycols by ADH (Gupta, 2006) have also been shown to be primarily, due to differences in 
substrate binding.  
The time- and concentration-dependent in-vitro disposition of 5-HMF was characterized 
in human whole blood: 5-HMF plasma concentrations decline rapidly, confirming the existence 
of clearance mechanisms in whole blood itself. 5-HMF undergoes rapid initial binding to plasma 
proteins (and RBC membranes), as well as rapid distribution to RBC. The disposition in whole 
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blood follows nonlinear kinetics that was modeled by a sigmoidal-CLmax model. This model 
suggests the nonlinear kinetics is due to saturable Hb-binding at physiologically relevant 
concentrations. Therefore, the overall (target-site) disposition of 5-HMF in blood occurs through 
rapid, apparent first-order RBC-ALDH mediated metabolism (elimination clearance) and 
saturable Hb-binding (distribution clearance).  
Despite their metabolic clearance in the RBC for 5-HMF (and likely the INN-
compounds), all SGE demonstrated in-vitro pharmacological activity. The in-vitro time- and 
concentration-dependent PD profiling of SGE was carried out in normal whole blood (HbA); it 
shows that SGE increase the O2-affinity of Hb in a time- and concentration-dependent manner 
with biphasic time-course profiles, consistent with transiently covalent binding kinetics with Hb, 
followed by ALDH metabolism in the RBC. With respect to their peak shift in p50, the potencies 
are similar across SGE (1.5 – 1.8 mM); however, underlying differences in Hb-binding kinetics, 
and/or subsequent metabolic clearances in RBC result in differences in their respective time-
dependency. INN-compounds result in a greater degree of left-shift in p50 for prolonged duration 
of time, compared to 5-HMF.  INN-312 has a rapid onset of action, while INN-298 has sustained 
PD effects up to 10 hrs in normal whole blood.  
The findings from in-vitro disposition of 5-HMF in whole blood and the in-vitro PD 
studies for AEH suggest that Hb-binding is a major determinant of their activity. Attempts were 
made to develop a generic assay for quantification of all AEH adducts of Hb, in order to 
characterize their binding kinetics with Hb; however, the generic assay could not be validated 
due to instability of Hb in its quaternary conformational form, as well as appearance of impurity 
peaks in the chromatographic assay. Therefore, an ultrafiltration approach, that was previously 
used by Obied (2010) for preliminary binding experiments of 5-HMF to HbA, was used to fully 
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characterize the time- and concentration-dependency of 5-HMF binding to HbA and HbS. 
Unfortunately, INN-312, a more lipophilic molecule, showed transient, concentration-dependent 
non-specific binding to regenerated cellulose and PES membranes of the ultrafiltration devices, 
with high affinity and high capacity, preventing the use of the ultrafiltration assay for studying 
the binding kinetics of INN-compounds with Hb.   
However, for 5-HMF, systematic, extensive binding studies reveal, in the absence of 
metabolic ALDH in the RBC, its binding to Hb is time- and concentration-dependent, and results 
in sustained adduct formation up to 30 hrs with HbA, and ~10 hrs with HbS. The binding of 5-
HMF to Hb is rapid, with slow dissociation, compared to glucose, an endogenous molecule, 
known to also form Schiff-base adducts with Hb (Higgins, 1981). There are likely intrinsic 
differences between 5-HMF binding to, and dissociation from HbA and HbS, with more rapid 
association, and dissociation of 5-HMF from HbS. However, overall, these translate to similar 
steady-state binding affinities (see Table 9.1). 
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Table 9.1. Comparison of binding parameters (SD) for 5-HMF to HbA and HbS (from 
Chapter 7). 
 
Parameter 
Estimate (SD) 
5HMF-HbA 5HMF-HbS 
Primary 
k1  (mM
-1
 hr
-1
) 0.27 (0.03) 0.83 (0.13) 
k-1  (hr
-1
) 0.05 (0.01) 0.1 (0.04) 
Secondary 
KD (mM) 0.18 (0.04) 0.13 (0.06) 
t1/2 
diss
 (hr) 13.9 6.6 
t1/2 
eq
 (hr) 8.2 3.3 
Experimental 
(apparent first-order) 
t1/2 
obs
 (hr) 3.9 4.3 
Steady-state 
concentration-dependency 
Bmax (mM) 0.10 (0.01) 0.23 (0.02) 
Bmax 
(molar ratio) 
0.84 (0.03) 1.72 (0.2) 
KD (mM) 0.25 (0.04) 0.41 (0.07) 
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It is known that AEH bind to Hb to form Schiff-base adducts that result in left-shifting of 
the OEC. From the studies described above, a missing link of the intrinsic relationship between 
Hb-adduct concentrations and p50 shifts, remained. Therefore, this research was directed to 
investigate the relationship. While Abdulmalik et al. (2005) reported a linear relationship 
between %∆p50 and %HbS adduct formed from initial assessments, the actual underlying 
relationship between adduct concentrations and p50 was established from quantitative analyses 
and was demonstrated to be best described by a sigmoidal relationship.  
Using the information supported by the studies described above, the unique disposition of 
5-HMF at its target site was simultaneously modeled by a novel, semi-mechanistic TSDD model, 
which described the data well. Such a model was originally used by Obied (2010), for 
preliminary prediction of the time-course of 5-HMF concentrations in RBC hemolysates. The 
TSDD model was further combined with PD information, and linked to a sigmoidal PD model, 
to build an integrated TSDD/PD model for simultaneous modeling and predictions of 5-HMF in 
plasma (from disposition studies), and its effect on p50 in whole blood (from PD studies). This 
novel TSDD/PD model likely describes the disposition of AEH in whole blood. The model 
scheme is shown in Figure 9.1. The TSDD/PD model parameter estimates for 5-HMF in whole 
blood are shown in Table 9.2.   
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Figure 9.1. Scheme of the TSDD/PD model for 5-HMF in whole blood, and is the proposed 
model for all AEH. E* refers to a sigmoidal PD relationship. 
 
 
 
Table 9.2. Parameter estimates (SD) for the final TSDD/PD model for 5-HMF. 
 
Model Component Parameters Final Estimates (SD) 
TSDD 
k1 (mM
-1
 hr
-1
) 0.76 (0.26) 
k-1 (hr
-1
) 0.49 (0.31) 
kmet (hr
-1
) 0.30 (0.15) 
Fixed constants 
khsa 0.093 
[Hb]0 (mM) 2.06 
Sigmoidal PD 
E0 [mmHg] 24 
Emax [mmHg] -19.5 (1.3) 
ϒ 3.7 (0.5) 
EC50 (mM) 0.75 (0.19) 
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The model has acceptable predictive utility (see Figures 9.2 and 9.3 for 2 mM 5-HMF in 
normal whole blood), for normal and sickle blood. As demonstrated from post hoc sensitivity 
analyses, the model, however, is quite sensitive to the estimates for kmet and k-1, two parameters 
that require additional experimental data for more precision estimation. This provides an area for 
additional research in the future.  
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Figure 9.2. TSDD/PD model predictions for concentrations of 5-HMF in plasma, free Hb, 
5-HMF –Hb-adduct and 5-HMF metabolite, for 2 mM 5-HMF in whole blood (linear scale). 
 
 
 
Figure 9.3. TSDD/PD model predictions for effect of 2 mM 5-HMF on p50 in whole blood. 
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Finally, these research findings were integrated with published information and compared 
across all AEH; FGE and SGE, for their PK and PD behavior. In-vivo (human) PK/PD of 
valeresol and tucaresol (Fitzharris et al., 1985; Rolan et al., 1993; Rolan et al., 1995) were 
compared with recent in-vivo PK data for 5-HMF in humans (Stern et al., 2012), and the in-vivo 
predictions made by the current research (see Table 9.3). Trends toward PK nonlinearity were 
reported for valeresol and 5-HMF (initial studies) in humans, but not for tucaresol. This research 
provides evidence that, at physiologically relevant concentrations in plasma (2 – 5 mM), 5-HMF 
follows nonlinear PK due to saturable Hb-binding. 5-HMF has the shortest t1/2 in the plasma of 
all AEH, and the in-vitro findings from the current research are virtually identical to the recent 
findings reported in humans (Stern et al., 2012). Overall, valeresol has the shortest in-vivo PD 
effect t1/2 (or dissociation t1/2), while the t1/2 for SGE likely lie between valeresol and tucaresol. 
5-HMF and INN-312 are predicted to equilibrate and bind rapidly with Hb (from binding studies 
and PD studies, respectively), while INN-298 likely has a prolonged PD t1/2 (similar to tucaresol; 
based on PD studies). ALDH-mediated metabolism in RBC has not been previously (studied 
and) reported for FGE, although it is thought to be a major metabolic pathway for all these 
aldehyde compounds. This, and previous research (Obied, 2010) provide conclusive evidence of 
ALDH-metabolism in RBC for 5-HMF (and likely other AEH); furthermore, this metabolism is 
an important determinant of the plasma t1/2, peak effect, and duration of effect of 5-HMF (as 
predicted by the TSDD/PD model). Finally, genotypical or phenotypical variations in RBC 
ALDH activity are likely to significantly affect the PK/PD of these compounds.  
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Table 9.3. PK/PD comparison across AEH. 
Studies In-vivo findings In-vitro findings 
References 
FGE SGE SGE 
Valeresol 
(Fitzharris et al., 
1985) 
Tucaresol 
(Rolan et al., 
1993) 
5-HMF 
(Stern et al., 
2012) 
5-HMF 
(This research) 
INN-312 
(This research) 
INN-298 
(This research) 
Dose 
(mg) 
140 – 1400  
(I.V.) 
400 – 3600  
(P.O.) 
300 – 4000  
(P.O.) 
0.5 – 5 mM 
(whole blood) 
- - 
Cmax 
(mM) 
0.04 – 1.2 0.1 – 1.8 0.0003 – 0.006 
0.1 – 2.9 
(Cmax
observed
) 
- - 
Foral* N/A Orally absorbed Orally absorbed 
Orally 
absorbed; likely 
low hepatic 
ALDH first-
pass 
GI solubility-
limited 
absorption; 
likely 
low hepatic 
ALDH first-
pass 
GI solubility-
limited 
absorption; 
likely 
low hepatic 
ALDH first-
pass 
CLtot/Foral 
(mL/min) 
50 - 20 
(CLtot) 
2 – 3 > 76,000 
>640** 
(Hepatic and 
RBC ALDH) 
- - 
Plasma t1/2  
(hr) 
8.5 195 – 289 0.4 – 0.8 (plasma) 
1.6 – 2.1 (RBC) 
0.8 – 4 - - 
PD effect t1/2  
(hr) 
3 
(rats and humans) 
16 (rats; I.V.); 
167 (humans; oral) 
Not reported ~4 – 6 ~8 – 10 >10 
*Predicted for SGE from preliminary BCS assessments and in-vitro studies based on assumptions discussed in text; ** CLtot for 5-
HMF is based on IVIVE estimate (from Chapter 6). 
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SGE are predicted to undergo low hepatic extraction (by hepatic cytosolic ALDH), 
however, other metabolic pathways may significantly increase the hepatic first-pass metabolism 
effects. The ALDH metabolic efficiencies vary between SGE, and therefore, are likely to affect 
the PK of valeresol and tucaresol as well. ALDH is known to be ubiquitously present throughout 
the body (other than liver and RBC), and in addition to ALDH, FGE and the INN-compounds 
may be subject to other (oxidative/conjugation) routes of metabolism. The oral bioavailability of 
valeresol is not known since it was not investigated after oral administration. Tucaresol, on the 
other hand, was orally bioavailable in humans, and resulted in the desired OEC left-shifting 
effect in whole blood at high doses (3600 mg; ~50 mg/kg). 5-HMF has also been shown to be 
orally bioavailable to result in anti-sickling effect in Tg sickle mice at doses of 50 – 200 mg/kg; 
however, in humans, its high apparent CL likely suggests low Foral and/or high systemic CL, 
likely due to GI/extrahepatic tissue metabolism. For INN-compounds on the other hand, their 
oral bioavailability is likely limited by solubility (Table 9.3). 
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Appendix A 
Scientist ® Model Files 
 
 
1. Modified MM Kinetic Model 
 
// Michaelis-Menten kinetics  
// AP/JV 2010  
IndVars: S  
DepVars: V  
Params: Vo, VMAX, KM 
V=Vo+VMAX*S/(KM+S) 
// 
*** 
 
 
2. Substrate-Inhibition Model 
 
// Substrate-Inhibition Model  
// MB/AP/JV 2011  
IndVars: S  
DepVars: V  
Params: Vo, VMAX, KM, KI 
V=Vo+VMAX*S/(1+KM/S+S/KI) 
// 
*** 
 
 
3. Hill Model 
 
// Hill Model  
// AP/JV 2010  
IndVars: PO2  
DepVars: SO2 
Params: p50, N 
SO2=100*(PO2^N)/((p50^N)+(PO2^N)) 
// 
*** 
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4. Sigmoidal-Emax Model 
 
// Sigmoidal-Emax Model  
// AP/JV 2011  
IndVars: C  
DepVars: E 
Params: EMAX, EC50, GAMMA 
E=EMAX*(C^GAMMA)/((EC50^GAMMA)+(C^GAMMA)) 
// 
*** 
 
5. Sigmoidal-CLmax Model 
 
// Sigmoidal-CLmax Model  
// AP/JV 2012  
IndVars: C  
DepVars: CL 
Params: CLMAX, KM, N 
CL=CLMAX*(1-((C^N)/((KM^N)+(C^N)))) 
// 
*** 
 
6. Steady-State 5-HMF Concentration-Dependency Binding Model 
 
// Steady-state concentration-dependent binding model   
// AP/JV 2010  
IndVars: C  
DepVars: B  
Params: BMAX, KD 
C=BMAX*C/(KD+C) 
// 
*** 
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7. In-vitro Simultaneous Time-Dependency Binding Model for 5-HMF to Hb  
 
// In-Vitro 5-HMF Binding to Hemoglobin 
//  Version 2.0 
//  JV, AP, TO, Mar 11, 2013 
// 
//  Assuming bimolecular, reversible interaction 
//  concentrations in M 
//   k1 in M*hr-1 
//   k-1 in hr-1 
// 
IndVars: T, HMF0 
DepVars: HMF, Hb, HbHMF 
Params: k1, kmin1, Hb0 
// Diff Equations 
HMF'=kmin1*HbHMF-k1*Hb*HMF 
HbHMF'=k1*Hb*HMF-kmin1*HbHMF 
// Mass Balance 
Hb=Hb0-HbHMF 
// IC 
t=0 
HMF=k1*HMF0/k1  
HbHMF=0 
// Mathematically, HMF=HMF0; k1 was included to fix a Scientist model bug 
*** 
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8. In-vitro TMDD Model for 5-HMF in Plasma from Whole Blood 
 
// 5-HMF in Plasma 
// Version 2.0  
// JV, TO, AP May 21, 2013  
//  
// Assuming bimolecular, reversible interaction  
// concentrations in M  
// k1 in M*hr-1  
// k-1 in hr-1  
// kmet in hr-1  
// kmembrane and khsa in fractional terms  
// 
//  concentration-dependency and time-dependency 
// 
// 
IndVars: T, HMF0  
DepVars: HMF 
Params: k1, kmin1, Hb0, kmet, kmembrane, khsa  
// 
// Diff Equations 
HMF'=kmin1*HbHMF-k1*Hb*HMF-kmet*HMF  
HbHMF'=k1*Hb*HMF-kmin1*HbHMF  
HMFA'=kmet*HMF  
// Mass Balance  
Hb=Hb0-HbHMF  
// 
// IC  
t=0  
HMF=HMF0-kmembrane*HMF0-khsa*HMF0  
HbHMF=0  
HMFA=0  
***  
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9. In-vitro TMDD/linear PD Model for 5-HMF in Whole Blood 
 
// 
// In-vitro PK/linear PD Model for 5-HMF 
// 
//  A. Parikh and J. Venitz 
//  May 8, 2013 
// 
// 
IndVars: T, HMF0, HMF 
DepVars: p50 
Params: Hb0, k1, kmin1, kmet, khsa, m, c 
// 
// PK MODEL 
HMF'=kmin1*HbHMF-k1*Hb*HMF-kmet*HMF 
HbHMF'=k1*Hb*HMF-kmin1*HbHMF 
HMFA'=kmet*HMF 
// Mass Balance 
Hb=Hb0-HbHMF 
// 
//PK-PD LINK 
CE=HbHMF 
// 
// PD MODEL 
p50=m*CE+c 
// IC 
t=0 
HMF=HMF0-khsa*HMF0 
HbHMF=0 
HMFA=0 
*** 
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10. In-vitro TMDD/sigmoidal PD Model for 5-HMF in Whole Blood 
 
// 
// In-vitro PK/sigmoidal PD Model for 5-HMF 
// 
//  A. Parikh and J. Venitz 
//  May 8, 2013 
// 
// 
IndVars: T, HMF0 
DepVars: HMF, p50 
Params: Hb0, k1, kmin1, kmet, khsa, Emax, n, EC50, E0 
// 
// PK MODEL 
HMF'=kmin1*HbHMF-k1*Hb*HMF-kmet*HMF 
HbHMF'=k1*Hb*HMF-kmin1*HbHMF 
HMFA'=kmet*HMF 
// Mass Balance 
Hb=Hb0-HbHMF 
// 
//PK-PD LINK 
CE=HbHMF 
// 
// PD MODEL 
p50=E0+(Emax*CE^n/((EC50^n)+(CE^n))) 
// IC 
t=0 
HMF=HMF0-khsa*HMF0 
HbHMF=0 
HMFA=0 
*** 
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Appendix B 
Data for experimental studies 
 
Table B. 1. Measured initial rates of metabolism (SD) for NAD
+
-dependent metabolism of 
Ethanol. 
 
[Ethanol] 
(mM) 
Vi 
(nmol/min/mg 
protein) 
SD 
0.00 1.30 0.96 
0.08 3.31 0.39 
0.15 3.63 0.48 
0.31 3.78 0.65 
0.62 5.19 1.07 
1.24 5.69 0.66 
2.48 6.76 0.33 
4.95 8.73 0.27 
9.90 8.74 0.45 
19.80 9.10 0.14 
 
 
 
Table B. 2. Measured initial rates of metabolism (SD) for NAD
+
-dependent metabolism of 
Acetaldehyde. 
 
[Acetaldehyde] 
(mM) 
Vi 
(nmol/min/mg 
protein) 
SD 
0.00 2.40 1.34 
0.01 4.08 0.27 
0.02 4.85 0.17 
0.05 5.73 0.70 
0.10 5.61 0.42 
0.19 7.33 1.04 
0.39 6.61 0.06 
0.77 6.40 1.08 
1.55 6.22 0.23 
3.10 7.03 0.58 
6.19 7.50 0.27 
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Table B. 3. Measured initial rates of metabolism (SD) for NAD
+
-dependent metabolism of 
5-HMF. 
 
[5-HMF] 
(mM) 
Vi 
(nmol/min/mg 
protein) 
SD 
0.00 1.65 0.83 
0.75 2.93 0.14 
1.51 3.86 1.04 
3.01 2.33 0.92 
6.02 3.74 1.14 
12.05 4.96 0.66 
24.10 5.66 0.39 
48.19 6.99 1.16 
96.38 9.24 0.90 
 
 
 
Table B. 4. Measured initial rates of metabolism (SD) for NAD
+
-dependent metabolism of 
INN-312. 
 
[INN-312] 
(mM) 
Vi 
(nmol/min/mg 
protein) 
SD 
0.13 1.38 1.11 
0.25 6.36 1.34 
0.50 8.27 1.14 
1.00 12.59 2.98 
2.00 16.20 0.93 
 
 
Table B. 5. Measured initial rates of metabolism (SD) for NAD
+
-dependent metabolism of 
INN-298. 
 
[INN-298] 
(mM) 
Vi 
(nmol/min/mg 
protein) 
SD 
1.25 1.83 0.84 
2.50 3.61 0.41 
5.00 8.11 1.26 
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Table B. 6. Measured initial rates of metabolism (SD) for NAD
+
-dependent metabolism of 
acetaldehyde in dog liver cytosol. 
 
[Acetaldehyde] 
(mM) 
Vi 
(nmol/min/mg 
protein) 
SD 
0 2.88 0.23 
13 3.34 0.31 
20 3.79 0.36 
30 4.55 0.43 
44 4.55 0.80 
67 5.34 0.16 
100 5.76 0.77 
150 6.35 0.30 
225 6.48 0.03 
338 6.49 0.80 
506 6.08 0.37 
 
 
 
Table B. 7. Measured initial rates of metabolism (SD) for NAD
+
-dependent metabolism of 
acetaldehyde in rat liver cytosol. 
 
[Acetaldehyde] 
(mM) 
Vi 
(nmol/min/mg 
protein) 
SD 
0.0 0.52 0.35 
15.6 0.89 0.47 
31.3 1.20 0.75 
62.5 1.76 0.75 
125.0 2.78 1.58 
250.0 2.38 1.54 
500.0 1.65 0.67 
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Table B. 8. Measured initial rates of metabolism (SD) for NAD
+
-dependent metabolism of 
acetaldehyde in mouse liver cytosol. 
 
[Acetaldehyde] 
(mM) 
Vi 
(nmol/min/mg 
protein) 
SD 
0.00 1.09 0.11 
0.98 0.98 0.24 
1.95 1.10 0.03 
3.91 1.26 0.18 
7.81 1.26 0.09 
15.63 1.46 0.41 
31.25 1.45 0.51 
62.50 1.92 0.70 
100.0 2.90 0.90 
125.0 3.24 0.83 
150.0 2.86 1.87 
200.0 3.32 1.82 
250.0 2.94 0.87 
300.0 1.52 1.77 
400.0 2.08 0.21 
500.0 1.80 0.56 
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Table B. 9. Estimated p50 and n values for 0.5 mM 5-HMF by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 24.0 1.85 0.0 0.00 
0.25 23.3 2.02 -0.8 0.17 
0.5 23.3 2.01 -0.8 0.17 
1.0 24.1 1.96 0.0 0.11 
1.5 23.6 1.95 -0.4 0.10 
2.0 23.7 1.88 -0.3 0.04 
4.0 26.5 1.96 2.4 0.11 
6.0 27.0 2.02 3.0 0.17 
8.0 26.9 1.81 2.9 -0.04 
 
 
 
Table B. 10. Estimated p50 and n values for 1 mM 5-HMF by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 24.0 1.85 0.0 0.00 
0.25 21.6 1.73 -2.5 -0.12 
0.5 21.0 1.82 -3.1 -0.03 
1.0 20.4 1.66 -3.6 -0.18 
1.5 19.8 1.73 -4.2 -0.12 
2.0 20.4 1.56 -3.7 -0.29 
4.0 22.9 1.64 -1.1 -0.21 
6.0 25.9 1.76 1.9 -0.09 
8.0 22.7 1.53 -1.4 -0.32 
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Table B. 11. Estimated p50 and n values for 2 mM 5-HMF by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 24.0 1.85 0.0 0.00 
0.25 16.3 1.16 -7.7 -0.69 
0.5 15.7 1.29 -8.3 -0.56 
1.0 12.1 1.03 -11.9 -0.81 
1.5 9.9 0.88 -14.1 -0.96 
2.0 9.7 0.93 -14.4 -0.92 
4.0 13.7 0.91 -10.3 -0.93 
6.0 18.9 1.00 -5.1 -0.84 
8.0 22.3 1.03 -1.8 -0.82 
10.0 20.5 1.16 -3.5 -0.69 
 
 
 
Table B. 12. Estimated p50 and n values for 3 mM 5-HMF by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 24.0 1.85 0.0 0.00 
0.25 15.3 1.48 -8.8 -0.37 
0.5 11.9 1.43 -12.1 -0.42 
1.0 9.8 1.46 -14.2 -0.39 
1.5 8.5 1.45 -15.6 -0.40 
2.0 9.3 1.63 -14.7 -0.22 
4.0 9.8 1.52 -14.2 -0.33 
6.0 12.3 1.52 -11.8 -0.33 
8.0 14.0 1.42 -10.1 -0.43 
10.0 17.8 1.38 -6.3 -0.46 
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Table B. 13. Estimated p50 and n values for 5 mM 5-HMF by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 24.0 1.85 0.0 0.00 
0.25 12.5 1.27 -11.6 -0.58 
0.5 8.3 1.36 -15.7 -0.49 
1.0 6.5 1.50 -17.6 -0.35 
1.5 5.0 1.44 -19.1 -0.41 
2.0 4.9 1.52 -19.1 -0.33 
4.0 4.9 1.33 -19.1 -0.51 
6.0 5.5 1.21 -18.5 -0.63 
8.0 6.1 1.03 -18.0 -0.81 
10.0 8.1 1.06 -16.0 -0.79 
 
 
 
Table B. 14. Estimated p50 and n values for 5 mM 5-HMF by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 24.0 1.85 0.0 0.00 
0.25 12.5 1.27 -11.6 -0.58 
0.5 8.3 1.36 -15.7 -0.49 
1.0 6.5 1.50 -17.6 -0.35 
1.5 5.0 1.44 -19.1 -0.41 
2.0 4.9 1.52 -19.1 -0.33 
4.0 4.9 1.33 -19.1 -0.51 
6.0 5.5 1.21 -18.5 -0.63 
8.0 6.1 1.03 -18.0 -0.81 
10.0 8.1 1.06 -16.0 -0.79 
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Table B. 15. Estimated p50 and n values for 1 mM IN-312 by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 25.4 2.14 0.0 0.00 
0.5 18.5 1.32 -6.8 -0.82 
1.0 18.8 1.31 -6.5 -0.83 
1.5 19.3 1.30 -6.0 -0.85 
2.0 19.9 1.35 -5.5 -0.79 
4.0 23.0 1.27 -2.3 -0.87 
6.0 25.7 1.28 0.3 -0.87 
8.0 27.8 1.24 2.4 -0.90 
 
 
Table B. 16. Estimated p50 and n values for 1.5 mM IN-312 by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 25.4 2.14 0.0 0.00 
0.25 16.0 1.45 -9.4 -0.69 
0.5 16.1 1.61 -9.3 -0.54 
1.0 15.5 1.57 -9.9 -0.58 
1.5 15.9 1.57 -9.5 -0.58 
2.0 15.5 1.49 -9.9 -0.65 
4.0 18.1 1.51 -7.2 -0.64 
6.0 19.6 1.31 -5.8 -0.84 
8.0 21.9 1.28 -3.5 -0.87 
10.0 26.2 1.21 0.8 -0.94 
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Table B. 17. Estimated p50 and n values for 2 mM IN-312 by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 25.4 2.14 0.0 0.00 
0.25 7.3 0.86 -18.1 -1.28 
0.5 6.8 0.86 -18.6 -1.29 
1.0 7.5 0.90 -17.9 -1.25 
1.5 7.8 0.88 -17.5 -1.27 
2.0 8.1 0.89 -17.3 -1.26 
4.0 9.1 0.76 -16.3 -1.39 
6.0 11.7 0.76 -13.7 -1.39 
8.0 14.8 0.68 -10.6 -1.46 
10.0 16.9 0.71 -8.4 -1.44 
 
 
Table B. 18. Estimated p50 and n values for 3 mM IN-312 by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 25.4 2.14 0.0 0.00 
0.25 3.6 0.84 -21.8 -1.31 
0.5 2.8 0.86 -22.6 -1.28 
1.0 2.4 0.95 -23.0 -1.20 
1.5 2.1 0.94 -23.3 -1.20 
2.0 2.1 0.93 -23.3 -1.21 
4.0 3.1 0.97 -22.3 -1.17 
6.0 3.2 0.79 -22.1 -1.36 
8.0 3.6 0.67 -21.7 -1.48 
10.0 4.2 0.61 -21.1 -1.53 
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Table B. 19. Estimated p50 and n values for 0.5 mM IN-298 by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 25.4 2.14 0.0 0.00 
0.25 24.9 2.33 -0.4 0.19 
0.5 25.3 2.28 -0.1 0.13 
1.0 24.1 2.30 -1.3 0.15 
1.5 23.9 2.19 -1.4 0.05 
2.0 24.4 2.39 -1.0 0.24 
4.0 26.4 2.03 1.1 -0.12 
6.0 25.4 1.91 0.0 -0.23 
8.0 23.8 1.98 -1.6 -0.17 
10.0 21.7 2.36 -3.7 0.22 
 
 
Table B. 20. Estimated p50 and n values for 1 mM IN-298 by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 25.4 2.14 0.0 0.00 
0.25 23.2 1.71 -2.2 -0.44 
0.5 21.5 1.71 -3.9 -0.43 
1.0 18.8 1.47 -6.5 -0.67 
1.5 18.1 1.45 -7.3 -0.69 
2.0 17.4 1.41 -8.0 -0.74 
4.0 20.7 1.45 -4.7 -0.70 
6.0 20.5 1.40 -4.8 -0.74 
8.0 19.3 1.64 -6.0 -0.51 
10.0 17.4 1.63 -8.0 -0.52 
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Table B. 21. Estimated p50 and n values for 2 mM IN-298 by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 25.4 2.14 0.0 0.00 
0.25 22.0 1.46 -3.4 -0.69 
0.5 17.6 1.31 -7.8 -0.83 
1.0 13.5 1.18 -11.9 -0.96 
1.5 11.2 1.07 -14.2 -1.07 
2.0 10.9 1.09 -14.5 -1.06 
3.0 11.4 1.07 -14.0 -1.07 
4.0 13.6 1.28 -11.7 -0.87 
6.0 14.1 1.17 -11.3 -0.97 
8.0 13.7 1.26 -11.6 -0.89 
 
 
Table B. 22. Estimated p50 and n values for 5 mM IN-298 by TPT. 
 
Time 
(min) 
p50 
(mmHg) 
n 
(-)  
∆p50 
(mmHg) 
∆n 
(-)  
0 25.4 2.14 0.0 0.00 
0.25 8.9 1.03 -16.5 -1.12 
0.5 4.4 0.89 -21.0 -1.25 
1.0 2.7 1.12 -22.7 -1.02 
1.5 2.3 1.39 -23.0 -0.76 
2.0 2.4 1.71 -22.9 -0.43 
4.0 3.3 2.06 -22.0 -0.09 
6.0 2.0 1.40 -23.4 -0.74 
8.0 2.2 1.39 -23.2 -0.76 
10.0 2.0 1.16 -23.4 -0.99 
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Table B. 23. Measured 5-HMF concentrations in plasma from whole blood disposition 
study (mean). 
 
Time (hr) 
Plasma concentration of 5-HMF (mM) 
0.5 mM 
Nominal [5-
HMF] 
1 mM 
Nominal [5-
HMF] 
2 mM 
Nominal [5-
HMF] 
3 mM 
Nominal [5-
HMF] 
5 mM 
Nominal [5-
HMF] 
0.25 0.1369 0.3276 0.8369 1.6182 2.8947 
0.5 0.0905 0.2406 0.6807 1.3371 2.5103 
1.0 0.0325 0.1521 0.4481 0.9955 2.0241 
1.5 0.0075 0.0945 0.2710 0.9464 1.6456 
2.0 0.0097 0.0633 0.1945 0.6470 1.6126 
4.0 0.0017 0.0112 0.1277 0.3723 1.1370 
6.0 0.0007 0.0006 0.0527 0.2287 0.8992 
8.0 BLOQ BLOQ 0.0054 0.1345 0.6057 
10.0 n/a n/a 0.0036 0.0583 0.3874 
 
 
Table B. 24. Standard deviations (SD) for measured 5-HMF concentrations in plasma from 
whole blood disposition study. 
 
Time (hr) 
SD for Plasma concentration of 5-HMF (mM) 
0.5 mM 
Nominal [5-
HMF] 
1 mM 
Nominal [5-
HMF] 
2 mM 
Nominal [5-
HMF] 
3 mM 
Nominal [5-
HMF] 
5 mM 
Nominal [5-
HMF] 
0.25 0.0166 0.0088 0.0921 0.2135 0.1705 
0.5 0.0105 0.0140 0.1133 0.1663 0.1524 
1.0 0.0027 0.0029 0.0560 0.1877 0.1493 
1.5 0.0013 0.0026 0.0713 0.2630 0.0384 
2.0 0.0108 0.0078 0.0456 0.1685 0.0288 
4.0 0.0007 0.0040 0.0362 0.0779 0.0744 
6.0 0.0002 n/a 0.0152 0.0744 0.1899 
8.0 n/a n/a 0.0031 0.0565 0.0810 
10.0 n/a n/a n/a 0.0313 0.0529 
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Table B. 25. Pooled dataset for 5-HMF-HbA time dependency study. 
 
Time 
(hr) 
[HMF]0  
(mM) 
[HMF] 
(mM) 
0 0.006 0.006 
0 0.006 0.006 
0.5 0.006 0.006 
1 0.006 0.006 
1 0.006 0.007 
1.5 0.006 0.006 
2 0.006 0.006 
2 0.006 0.006 
4 0.006 0.005 
6 0.006 0.005 
6 0.006 0.006 
10 0.006 0.005 
24 0.006 0.005 
30 0.006 0.003 
0 0.063 0.063 
0 0.063 0.063 
0 0.063 0.063 
0.5 0.063 0.062 
1 0.063 0.062 
1 0.063 0.063 
1 0.063 0.064 
1.5 0.063 0.061 
2 0.063 0.060 
2 0.063 0.061 
2 0.063 0.062 
4 0.063 0.057 
6 0.063 0.055 
6 0.063 0.056 
6 0.063 0.058 
10 0.063 0.053 
10 0.063 0.055 
24 0.063 0.050 
24 0.063 0.042 
30 0.063 0.041 
30 0.063 0.032 
0 0.123 0.123 
0 0.125 0.125 
0 0.125 0.125 
0.5 0.123 0.123 
1 0.123 0.122 
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1 0.125 0.120 
1 0.125 0.123 
1.5 0.123 0.120 
2 0.123 0.119 
2 0.125 0.117 
2 0.125 0.121 
4 0.123 0.113 
6 0.123 0.110 
6 0.125 0.108 
6 0.125 0.112 
10 0.125 0.103 
10 0.125 0.106 
24 0.125 0.093 
24 0.125 0.088 
30 0.125 0.081 
30 0.125 0.075 
0 0.188 0.188 
0 0.188 0.188 
1 0.188 0.192 
1 0.188 0.173 
2 0.188 0.185 
2 0.188 0.168 
6 0.188 0.174 
6 0.188 0.156 
10 0.188 0.162 
10 0.188 0.150 
24 0.188 0.151 
24 0.188 0.130 
30 0.188 0.134 
30 0.188 0.114 
0 0.250 0.250 
0 0.250 0.250 
0 0.250 0.250 
0.5 0.250 0.250 
1 0.250 0.247 
1 0.250 0.246 
1 0.250 0.236 
1.5 0.250 0.239 
2 0.250 0.240 
2 0.250 0.238 
2 0.250 0.232 
4 0.250 0.228 
6 0.250 0.225 
6 0.250 0.223 
6 0.250 0.216 
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10 0.250 0.212 
10 0.250 0.208 
24 0.250 0.194 
24 0.250 0.184 
30 0.250 0.173 
30 0.250 0.166 
0 0.504 0.504 
0.5 0.504 0.505 
1 0.504 0.500 
1.5 0.504 0.496 
2 0.504 0.488 
4 0.504 0.473 
6 0.504 0.463 
0 1.186 1.186 
0.5 1.186 1.222 
1 1.186 1.191 
1.5 1.186 1.110 
2 1.186 1.099 
4 1.186 1.114 
6 1.186 1.098 
10 1.186 1.044 
24 1.186 0.988 
30 1.186 1.002 
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Table B. 26. Pooled dataset for 5-HMF-HbS time dependency study. 
 
Time 
(hr) 
[HMF]0  
(mM) 
[HMF] 
(mM) 
0 0.006 0.006 
0 0.006 0.006 
0 0.006 0.006 
0.5 0.006 0.006 
0.5 0.006 0.006 
0.5 0.006 0.006 
1 0.006 0.005 
1 0.006 0.006 
1 0.006 0.005 
1.5 0.006 0.005 
1.5 0.006 0.006 
2 0.006 0.005 
2 0.006 0.005 
2 0.006 0.005 
4 0.006 0.005 
4 0.006 0.005 
6 0.006 0.004 
6 0.006 0.005 
6 0.006 0.004 
10 0.006 0.003 
10 0.006 0.004 
0 0.061 0.061 
0 0.060 0.060 
0 0.060 0.060 
0.5 0.061 0.056 
0.5 0.060 0.059 
0.5 0.060 0.055 
1 0.061 0.055 
1 0.060 0.058 
1 0.060 0.056 
1.5 0.061 0.054 
1.5 0.060 0.056 
2 0.060 0.052 
2 0.061 0.052 
2 0.060 0.054 
4 0.061 0.047 
4 0.060 0.050 
6 0.060 0.045 
6 0.061 0.044 
6 0.060 0.047 
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10 0.060 0.041 
10 0.060 0.042 
0 0.122 0.122 
0 0.126 0.126 
0 0.121 0.121 
0.5 0.122 0.112 
0.5 0.126 0.119 
0.5 0.121 0.117 
1 0.122 0.109 
1 0.126 0.114 
1 0.121 0.113 
1.5 0.122 0.106 
1.5 0.126 0.111 
2 0.122 0.103 
2 0.126 0.108 
2 0.121 0.103 
4 0.122 0.092 
4 0.126 0.099 
6 0.122 0.088 
6 0.126 0.093 
6 0.121 0.090 
10 0.126 0.086 
10 0.121 0.084 
0 0.250 0.250 
0 0.257 0.257 
0 0.236 0.236 
0.5 0.250 0.231 
0.5 0.257 0.239 
0.5 0.236 0.224 
1 0.250 0.224 
1 0.257 0.230 
1 0.236 0.225 
1.5 0.250 0.219 
1.5 0.257 0.225 
2 0.250 0.213 
2 0.257 0.219 
2 0.236 0.205 
4 0.250 0.193 
4 0.257 0.203 
6 0.250 0.185 
6 0.257 0.190 
6 0.236 0.187 
10 0.257 0.176 
10 0.236 0.171 
0 0.508 0.508 
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0 0.468 0.468 
0.5 0.508 0.477 
0.5 0.468 0.451 
1 0.508 0.464 
1 0.468 0.454 
1.5 0.508 0.454 
2 0.508 0.443 
2 0.468 0.418 
4 0.508 0.409 
6 0.508 0.395 
6 0.468 0.384 
10 0.468 0.370 
0 1.176 1.176 
0.5 1.176 1.172 
1 1.176 1.125 
2 1.176 1.051 
6 1.176 1.042 
10 1.176 1.026 
 
  
  
462 
 
Table B. 27. Concentration-dependent steady-state binding of 5-HMF to isolated HbA 
(0.125 mM). 
 
Free [5-HMF] 
(mM) 
Specifically 
bound [5-HMF] 
(mM) 
SD  
(Specifically bound 
5-HMF) 
Specifically 
bound molar 
fraction 
0.001 0.0006 0.0008 0.00 
0.003 0.0031 0.0015 0.02 
0.046 0.0163 0.0048 0.13 
0.097 0.0278 0.0064 0.22 
0.203 0.0469 0.0134 0.38 
0.438 0.0616 0.0254 0.49 
1.163 0.0865 0.0395 0.69 
 
 
Table B. 28. Concentration-dependent steady-state binding of 5-HMF to isolated HbS 
(0.125 mM). 
 
Free [5-HMF] 
(mM) 
Specifically 
bound [5-HMF] 
(mM) 
SD 
(Specifically bound 
5-HMF) 
Specifically 
bound molar 
fraction 
0.004 0.003 0.001 0.02 
0.044 0.019 0.001 0.15 
0.084 0.043 0.009 0.35 
0.183 0.072 0.008 0.57 
0.386 0.124 0.038 0.99 
1.036 0.170 0.022 1.36 
2.190 0.149 0.053 1.19 
3.490 0.222 0.073 1.78 
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